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Anti-HCV Antibody to hepatitis C virus 
EEA European Economic Area 
EFTA European Free Trade Association 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
HBsAg Hepatitis B surface antigen 
HAV Hepatitis A virus 
HBV Hepatitis B virus 
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PWID People who inject drugs 
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Glossary 
Random  Sample selection that ensures an unbiased representation of the research population  
Non-random Any other kind of sample selection than random, often convenience sampling 
Exhaustive Fully comprehensive sample of a population 
















People with chronic HBV and/or HCV infection are at risk of serious liver disease such as liver cirrhosis and 
hepatocellular carcinoma (HCC) and remain infectious to others. Because chronic HBV and HCV infections are 
typically asymptomatic, notification data reflect national screening and testing practices and do not give accurate 
insights into the prevalence of infections. Thus, to adequately inform primary or secondary prevention efforts, 
supplementary information such as prevalence data are needed.  
ECDC conducted a systematic review of the literature published between 2005–2015, with the aim to provide 
current estimates of the prevalence of HBV and HCV in the general population and specific population subgroups in 
the EU/EEA Member States, and to identify gaps in the available information. This review is an update of a 
previous systematic review covering the period 2000–2009. 
Overview of methods  
This systematic literature review was carried out to retrieve, assess and synthesise all available data published 
between 2005 and 2015 on the prevalence of hepatitis B and C in EU/EEA countries in the general population and 
the following subgroups: blood donors, pregnant women, people who inject drugs (PWID), men who have sex with 
men (MSM), prisoners and migrants.  
A search strategy was developed and a literature search performed. Publications of interest were first screened 
based on title and abstract. The full text of all publications selected during the title and abstract screening was 
then assessed for relevance. This was followed by extracting the relevant data from the final selected publications. 
Data from each study were extracted using a predefined set of variables covering study characteristics, study 
population details, prevalence of HBV and HCV markers (HBsAg and anti-HCV antibodies), including the type of 
sample that was collected and the type of laboratory test that was used. Finally, the risk of bias was assessed for 
each study and used to categorise the included studies according to quality indicators defined in the study design.  
To assess the prevalence of HBV and HCV among blood donors, PWID and migrants, alternative sources for data 
were used. These sources were the latest Council of Europe report on national blood donor data, data from the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) database and an ECDC systematic review 
entitled ‘Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA’.  
An algorithm, which also took into account study quality, was used to develop a general population HBV and HCV 
prevalence estimate for each EU/EEA country, with the aim to estimate the current burden of chronic HBV and HCV 
in the EU/EEA.  
Overview of the results 
After a full-text screening, a total of 125 articles were considered for inclusion: 48 on the general population, 32 on 
pregnant women, 32 on prisoners, and 13 on MSM. In total, 211 prevalence data points were identified, ranging 
from 0 to 33 estimates per country.  
For HBV, estimates that were considered representative for the general population in the risk of bias assessment 
were available for 13 countries, where the prevalence ranged from 0.1% in Ireland to 4.4% in Romania. For HCV, 
prevalence estimates that were considered representative for the general population were available for 13 
countries, with the reported prevalence ranging from 0.1% (Belgium, Ireland and the Netherlands) to 5.9% (Italy).  
High-quality estimates (according to the risk of bias assessment criteria) for HBV prevalence in pregnant women 
were available for seven countries, ranging from 0.1% in Norway and Spain to 0.8% in France and Italy. Of the 15 
estimates identified for HCV prevalence among pregnant women, high-quality estimates were available for four 
countries with prevalence ranging from 0.1% in Slovenia to 0.9% in Norway.  
Estimates from eligible studies for the HBV and HCV prevalence in MSM were available for four and six countries, 
respectively. For HBV, the prevalence in MSM ranged from 0.0% in Estonia and the United Kingdom to 1.4% in 
France. The prevalence of HCV among MSM ranged from 0.0% in Italy to 4.7% in Estonia.  
HBV prevalence estimates that were considered representative for prisoners were available for 11 countries. HBV 
prevalence in prisoners ranged from 0.3% in Ireland to 25.2% in Bulgaria. HCV estimates that were considered 
representative were available for 11 countries, ranging from 4.9% in Hungary to 86.3% in Luxembourg.  
The prevalence of HBV and HCV in first-time blood donors was available for 30 countries. The prevalence of 













countries (60%) had an HBV prevalence that was below or around 0.1%. The prevalence of HCV among first-time 
blood donors ranged from 0.0% in Iceland to 2.2% in Latvia, although the Latvian estimate is not very recent 
(2003). Around a third of the countries (32%) had an HCV prevalence that was higher than 1%.  
National estimates on the prevalence of HBV in PWID were available for seven countries and ranged from 0.5% in 
Croatia, Hungary and Ireland to 6.3% in Portugal. National estimates for HCV in PWID were available for 
16 countries and ranged from 13.8% in Malta to 84.3% in Portugal.  
Estimates for the prevalence of HBV in the representative general migrant population were available for five 
countries. According to the available estimates, the prevalence of HBV in migrants varied by country or origin and 
ranged from 0.0% to 17.4%. The highest prevalence is reported among migrants from countries in south-east Asia, 
irrespective of their current country of residence. For three countries, Italy, the Netherlands and the United 
Kingdom, HCV estimates were available. The HCV prevalence in migrants ranged from 0.0% to 7.1%, with the 
highest prevalence reported among migrants from eastern Europe in Italy. 
Based on general population and blood donor estimates, the HBV prevalence in the EU/EEA as a whole is 
estimated to be 0.9% (95% CI 0.7–1.2), corresponding to almost 4.7 million HBsAg-positive cases. For HCV, the 
estimated EU/EEA prevalence is 1.1% (95% CI 0.9–1.4), corresponding to around 5.6 million anti-HCV-positive 
cases.  
Conclusions 
This systematic literature review explores the prevalence of chronic HBV and HCV infections in EU/EEA countries. 
Studies with recent data on HBV/HCV prevalence in the general population are scarce and offer only data for 
slightly more than half of the 31 countries in the EU/EEA. Studies on pregnant women and prisoners are available 
for about half of the countries, and data on the prevalence of these infections among MSM are lacking for most 
EU/EEA countries.  
The prevalence of HBV and HCV in the EU/EEA as a whole is estimated to be around 0.9 and 1.1 percent, 
respectively, with an estimated total of 4.7 million chronic HBV cases and 5.6 million HCV infected cases. These 
figures are likely to be an underestimation as a result of the inclusion of prevalence estimates among blood donors 
as a proxy for the general population in the absence of other evidence. However, when taking into account HBV 
and HCV data, the general population estimates obtained from the studies included in this review covered 
approximately 83% of the total European population, with the remaining 17% covered by blood donor estimates. 
The lack of high-quality, recent, representative, nationwide prevalence estimates, and the overall heterogeneity of 
the available studies makes it challenging to gain an overview of the current epidemiological situation in the 
EU/EEA regarding chronic viral hepatitis. For a number of EU/EEA countries, robust HBV/HCV prevalence estimates 
are needed, both for the general population and specific risk groups. Increased efforts should be made to estimate 
the burden of hepatitis B and C, for example by developing a standardised seroprevalence survey. This would also 
provide robust strategic information for policymakers and help public health authorities to design appropriate 















Hepatitis B virus (HBV) and hepatitis C virus (HCV) can cause acute and chronic hepatitis and adversely affect the 
liver. People with chronic HBV and/or HCV infection remain infectious to others and are at risk of serious liver 
disease such as liver cirrhosis or hepatocellular carcinoma (HCC) later in life [1].  
Transmission of HBV and HCV can occur via sexual, blood-blood contact or vertically (mother-to-child). There are 
several known high-risk groups for acquiring an HBV or HCV infection, these include people who require blood or 
blood products, people interned in prisons, people who inject drugs, people with multiple sexual partners, migrants 
originating from endemic regions, and new-borns from HBV or HCV chronically infected mothers (vertical 
transmission) [1] . 
The risk of developing chronic HBV infection depends on the age at infection: chronic infection results in 90% of 
infants infected at birth, in 30 to 50% of children infected between the age of one to four years, and in 1 to 10% 
of those infected at older age or as adults [2,3]. According to Schweitzer et al., an estimated 248 million people 
were chronically infected with hepatitis B worldwide in 2010 [4]. Approximately 780 000 persons die each year 
from HBV infection (650 000 from cirrhosis and liver cancer due to chronic hepatitis B infection and another 
130 000 from acute hepatitis B) [5]. 
Initial infection with HCV is frequently asymptomatic or mild (70%–90% of cases). Of those infected, 50–80% later 
develop chronic infection, and those with chronic infection can eventually develop cirrhosis (up to 50%) and liver 
cancer (1–5%) over a period of 20 to 30 years [2]. The WHO estimates 30–150 million people globally have 
chronic hepatitis C infection, and 350 000 to 500 000 people are estimated to die each year from hepatitis C-
related liver diseases [6]. 
Recently, the treatment options for HCV have greatly improved through the introduction of new drug therapies, and 
several new therapies are expected to be approved in the near future. As a result of advances in the treatment of 
chronic hepatitis B, a remission can be achieved in up to 90% of chronic hepatitis B cases [7,8]. The new direct 
acting antiviral therapy for HCV shows cure rates of over 90% [9]. 
There is a distinct geographical variation in both HBV and HCV prevalence and incidence in the EU/EEA. In parts of 
eastern and southern Europe, the prevalence of chronic infections is mostly high [10,11]. It has been estimated 
that across the EU/EFTA region almost 4.49 million people have a chronic hepatitis B virus infection [11]. In 2013, 
EU/EEA countries reported a total of 13 629 chronic HBV cases (7.4 cases per 100 000 population) to ECDC1. Data 
indicate that the most common transmission route reported was mother-to-child transmission (43.5%). For chronic 
HBV cases, ECDC notes a steep rise in the number of infections and prevalence, which seems to be related to 
changes in reporting but may also reflect increases in local testing and screening practices among key 
populations [12]. 
Across the EU/EFTA region, an estimated 5.47 million are chronically infected with hepatitis C virus [11]. EU/EEA 
countries reported a total of 31 513 HCV cases to ECDC in 2013, 15.2% of which were classified as chronic 
(3.5 cases per 100 000 population)1. The most common transmission route for chronic HCV was injecting drug use 
(77.6% of the data that included this information). For chronic HCV cases, no clear trend can be distinguished. It is 
likely that much of the variation in reported cases between countries reflects differences in testing and screening 
programmes among risk groups [13].  
Rationale for the study 
In 2011, ECDC started to coordinate EU-wide enhanced surveillance for hepatitis B and C based on annual data 
collection from EU/EEA Member States [12,13]. However, because chronic HBV and HCV infections are typically 
asymptomatic, notification data most likely do not reflect the real number of infections, but national screening and 
testing practices. It is generally felt that case-based surveillance data still do not have the robustness required to 
adequately inform primary or secondary prevention, resulting in the need for supplementary information in the 
form of prevalence data.  
Information about the prevalence of HBV and HCV can help to better describe the current situation in the EU/EEA. 
In combination with the available surveillance data, European HBV and HCV prevalence data can also be used for 
benchmarking. In addition, in the wake of new treatment options, prevalence data are relevant for estimating the 
size of the chronically infected population and those in need of treatment. The improved options for antiviral 
treatment will also improve secondary prevention of both HBV and HCV. Prevalence data can help determine if 
 
                                                                    













there is a need to target and expand screening and testing for chronic HBV and HCV infection to those population 
subgroups with the highest prevalence.  
The gold standard for assessing HBV and HCV prevalence in a population is to conduct a serosurvey on a 
randomised representative sample. In view of the costs and implementation challenges of such an exercise, a 
systematic review of existing hepatitis B and C prevalence studies is considered a robust tool to obtain up-to-date 
prevalence estimates for the EU/EEA.  
In 2009, ECDC undertook a systematic review of the literature published between 2000–2009 to obtain insights 
into HBV and HCV prevalence in EU countries. The results of this review are presented in a technical report entitled 
Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies [10,14]. 
In 2015, ECDC conducted an update (2005–2015) of the previous systematic review, with the aim to provide 
estimates of the prevalence of HBV and HCV in the general population and in specific subgroups in the EU/EEA 














2 Review methods 
A systematic literature review was carried out to retrieve, assess and synthesise all available data on the 
prevalence of hepatitis B and C in the EU/EEA published between 2005 and 2015.  
The study question was framed (see below) and a study protocol was developed. The search strategy built on the 
one used for the 2010 review [10]. After a full literature search, publications of interest were initially selected 
based on title and abstract. The full text of all publications selected during the title and abstract screening was 
then assessed for relevance. This was followed by extracting the relevant data from the selected publications and 
assessing the risk of bias for each study. All steps are described in detail below. The complete search strategy is 
described in Annex 5. 
2.1 Research question  
The objective of the review was captured in the following research question: What is the prevalence of HBsAg and 
anti-HCV in the EU/EEA countries in the general population and in the following subgroups: 
 Blood donors 
 Pregnant women 
 People who inject drugs (PWID) 
 Men who have sex with men (MSM) 
 Prisoners  
 Migrants 
Thirty-one countries were included in the review: 28 EU Member States and three EEA countries (Norway, Iceland 
and Liechtenstein). HBV and HCV prevalence were defined as the presence of HBsAg and anti-HCV in serum, saliva 
or dry blood spot samples, respectively. The definitions of the various population subgroups are shown in Table 1.  
Prevalence studies among itinerant ethnic groups, homeless people or other marginalised populations, sex workers, 
institutionalised patients in closed/fixed settings (for instance residential care homes for elderly people and 
orphanages) and returning travellers were not included in the review. The European outermost regions 
(Guadeloupe, French Guyana, Martinique and La Réunion, the Canary Islands, the Azores and Madeira) as well as 
the European overseas countries and territories (associated to Denmark, France, the Netherlands and the United 
Kingdom) were excluded. Review articles were not included in this review, as these typically do not present original 
data. However, the reference list of relevant reviews (where the disease, population, study period and setting 
matched the inclusion/exclusion criteria of this study) was checked for additional original articles not captured in 
the literature search. 




General population People living in a defined geographical area (all ages or adults only), excluding specific low-risk populations such as children 
OR  
patients attending community and primary care settings, excluding hospitalised patients 
OR 
workforce or specific professional groups (e.g. workplace screening) excluding healthcare workers and specific 
recreational/sports-related population subgroups 
Prisoners Prison inmates and people incarcerated in custodial or prison settings including youth detention centres, excluding formerly 
incarcerated populations and people in other non-custodial closed/fixed institutions (such as secure psychiatric hospitals). 
Psychiatric prison hospital inmates (i.e. people with severe mental illness that are serving custodial sentences) are included. 
MSM Men who have sex with men 
PWID People who inject drugs, including current or past injectors, injectors of non-illicit drugs such as image or performance 
enhancing drugs. Excluded are non-injecting (illicit/street) drug users with drug use that can lead to blood-borne virus 
transmission (i.e. intra-nasal). 
Pregnant women Pregnant women undergoing antenatal care screening 
Blood donors First-time blood donors (pre-screened and non-pre-screened) 
Migrants Foreign-born migrants, not including Roma and other minorities, refugees, asylum seekers and their children 
2.2 Literature search  
Original research articles were retrieved from PubMed, Embase and Cochrane Library bibliographic databases in 
March 2015. The search strategies combined the concepts of HBV and HCV with ‘prevalence’. Controlled vocabulary 
(i.e. MeSH and Emtree terms) and natural vocabulary (i.e. keywords) were used for representing the concepts in 
the search strategies. The search was limited to records published from 1 January 2005 to 12 March 2015, and no 













and to studies with regional (i.e. European) and global scope. The geographic search strategy was developed by 
ECDC and underwent one testing round with the following results: negative predictive value (NPV) of 98.4% and a 
positive predictive value (PPV) of 66.4% in Embase and NPV of 97.6% and a PPV of 65.2% in PubMed. The 
geographical search strategy was not used for searching in the Cochrane Library. Search strategies are available in 
Annex 5. 
The results of the search were transferred to an EndNote library. Duplicate records were automatically removed 
with EndNote tool. The Endnote library was then manually checked. The literature search was complemented by a 
manual search of references of relevant systematic reviews. In addition, ECDC’s National Focal Points for HBV and 
HCV were consulted in May 2015 to review and validate the selected references on general population and high-
risk group estimates for their country. They were also invited to provide additional published articles or grey 
literature. A total of 17 Member States responded by validating the list and/or providing additional references.  
Articles in all EU/EEA languages were included because ECDC could provide translations. 
To assess the prevalence of HBV and HCV among blood donors, PWID and migrants, additional sources of data 
were used. The Council of Europe and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
are specialised institutions collecting data on blood donors and PWID, respectively. It was assumed that these data 
sources were reliable and that the data were comprehensive; therefore, no estimates from the literature were used 
to determine HBV and HCV prevalence in PWID and blood donors. Moreover, data on blood donors are often not 
reported in the literature, as was shown in the previous review [10]. Data on HBV and HCV prevalence among 
migrants in the EU/EEA were taken from a recent ECDC review on this topic [154] to avoid duplication.  
The following three additional sources of data were used: 
 For first-time blood donors: Council of Europe national blood donor data, 2014 report [15] 
 For PWID: European Monitoring Centre for Drugs and Drug Addiction database on HBV and HCV prevalence 
in PWID [16] [17] 
 For migrants: ECDC systematic review ‘Epidemiological assessment of hepatitis B and C among migrants in 
the EU/EEA’ [154] 
2.3 Eligibility criteria and selection process 
All records identified during the search were screened by title and abstract. Inclusion and exclusion criteria 
(Table 2) were developed in an iterative process involving all team members from both ECDC and RIVM. Two 
reviewers reviewed a random selection of five percent of the retrieved articles by title and abstract – in accordance 
with a predefined set of inclusion criteria – which resulted in an insufficient level of concordance (>10% 
disagreement). Inclusion criteria definitions were perfected and during a second round of parallel screening the 
two reviewers achieved a high level of concordance (>95%), after which the screening was continued separately. 
In cases of uncertainty about inclusion or exclusion, the reviewers consulted each other for a second opinion. 
Disagreements were resolved by consultation with a third team member.  
Table 2. Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Articles published in 2005 or later 
reporting data from populations sampled 
in 2000 or later, including studies with 
data collection ending after 2000 
(irrespective of start date) 
Articles falling outside the specified sampling period or publication date range 
Articles reporting data from one or more 
EU/EEA Member States and/or any of their 
regions/districts 
Articles reporting data on non EU/EEA countries only 
Articles reporting HBsAg/anti-HCV 
prevalence rates in humans 
Articles not reporting data on HBsAg/anti-HCV prevalence or DNA/RNA or if virological markers tested 
for were not specified  
 
Article reporting only self-reported (i.e. unconfirmed) HBsAg/anti-HCV prevalence 
Articles reporting data from the general 
population and/or key subgroups (Table 1) 
Articles reporting data on specific high-risk groups only (Table 3)  
 Articles reporting modelled data only 
Articles reporting only data from a study not conducted in humans, environmental studies, technology 
assessments (studies on diagnostic and/or laboratory methods) 
Opinion papers, editorials, guidelines or recommendations, perspectives, and correspondence articles, 
systematic reviews or meta-analyses 
Articles reporting data on the general population or pregnant women in countries with a population of 
>5 million inhabitants, but with a sample size <100 participants or with a sample size <50 participants 














After completion of the title and abstract screening, full-text publications were obtained using the libraries of RIVM, 
the Public Health Service Rotterdam-Rijnmond, and ECDC. Each reviewer individually screened the full texts of the 
selected references. Disagreement of selected full texts was resolved with mutual consent. If authors could not 
agree upon the issue, the reviewers consulted each other for a second opinion. Disagreements were resolved by 
consultation with a third team member. When a study was not considered relevant, the reason for exclusion was 
recorded in the data extraction file (Microsoft Excel). If more than one exclusion criteria was applicable, only one 
criterion was used to categorise the article.  
Table 3. List and definition of high-risk groups excluded from the systematic review  
Population category Definition 
Acute/chronic liver disease patients Patients with acute or chronic liver disease  
In-/outpatients Patients in healthcare settings (as opposed to primary care), hospital care settings and emergency 
departments, including specific diagnosis-related populations such as lichen planus patients, 
lymphoma/leukaemia and all cancer patients, haemodialysis patients, and any other 
immunocompromised patients, including people living with HIV 
Haemophiliacs Haemophiliacs, recipients of blood products and organ transplant recipients  
Healthcare workers Healthcare services staff, including both healthcare professionals and support staff 
Military Military recruits 
Children2 Children aged 0–17 years 
2.4 Data extraction 
Data extraction was performed simultaneously with the full text screening. Relevant data were extracted from each 
included article and immediately recorded in the data extraction file (Microsoft Excel).  
The unit for data extraction was not article, but study. A study was defined as a report of prevalence data on HBV 
or HCV for a defined population group, in a defined country, over a discrete period of time. According to this 
definition, a single article may include more than one study (e.g. comparing the same population over time; 
comparing different populations; reporting HBV and HCV prevalence). Studies published in more than one article 
were extracted only once, and the first publication was used as reference. Data from each study were extracted 
using a predefined set of variables covering: study characteristics, study population details, prevalence of HBV and 
HCV markers, including the type of sample collected and the laboratory test used. The complete list of variables is 
provided in Annex 6. 
2.5 Assessment of quality and risk of bias  
Each original article reporting the results of a prevalence study included in the analysis was evaluated for its quality 
based on a framework for making summary assessments of the risk of bias. The framework was developed ad hoc 
to assess the risk of selection bias, to determine the level of representativeness of the target population, and to 
judge the robustness of the estimates provided by the included studies. The framework was piloted, reassessed 
with the project team, and refined through a consensus-building approach. Four different frameworks were 
proposed to accommodate the differences between seroprevalence studies with regard to study design and 
sampling approaches toward different populations.  
The risk of bias was not assessed for data on blood donors, PWID and migrants. Data for blood donors were 
obtained from the Council of Europe report, which collects annual data on national blood donations in Member 
States. For PWID no, or very limited, data were available to assess the risk of bias, and the study characteristics 
available are presented alongside the prevalence estimates.  
In a review on HBV and HCV seroprevalence in migrants [154], the quality of individual studies was not assessed. 
This review, however, only contains those studies on migrants that were considered representative for the general 
migrant population. Criteria include sample size and study population. Studies on high-risk groups such as 
refugees, for example, were not included in the current review. The results of the assessment of the risk of bias for 
all included articles and populations is provided in Annex 4. 
 
                                                                    
2 Studies reporting seroprevalence of HBV or HCV in children only were excluded because they were not considered to be 














The following four domains were considered as possible sources of selection bias in general population studies: 
 Age 
 Gender 
 Sampling method and response rate 
 Population coverage (i.e. the population covered by the sampling design in geographic/demographic terms) 
Points were given for representativeness or a lower risk of bias in each domain (Table 4). A total score for risk of 
bias was calculated by adding up the scores in all four domains, resulting in a score of between 0 and 6. The 
highest score indicates the lowest risk of bias. 
Table 4: Framework for assessing risk of bias: general population 
Domain Scores and description 
Age 0 1 
Clear age bias (towards children for example), not representative for 
general population; no information on age 
No clear bias in age profile of respondents; 
representative for general population age distribution 
Gender 0 1 
Clear bias in gender; no information to suggest representativeness 
for general population 
No clear bias in gender distribution of subjects; could 
be considered representative if information is limited 
Sampling method 0 – Non-random or non-exhaustive 
1 – Exhaustive or random and <60% response rate or no info 
2 – Exhaustive or random and >60% response rate 
Population coverage 0 – Single centre/local; 1 – Multi-centre/local or regional; 2 – Multi-centre/national 
Pregnant women 
The following two domains were considered as potential sources of selection bias in studies on pregnant women: 
 Sampling method; response rate not included due to lack of denominator data  
 Population coverage (i.e. the population covered by the sampling design in geographic/demographic terms). 
Points were given for representativeness or a lower risk of bias in each domain (Table 5). A score for the combined 
risk of bias was calculated (0 to 3), with a score of 3 indicating the lowest risk of bias.  
Table 5: Framework for assessing risk of bias: pregnant women 
Domain Scores and description 
Sampling method 0 1 
Non-random or non-exhaustive Exhaustive or random 
Population coverage 0 – Single centre/local; 1 – Multi-centre/local or regional; 2 – Multi-centre/national 
MSM 
Only the domain ‘sampling venue coverage’ was included in the framework for assessing the risk of bias in studies 
on MSM (Table 6). Studies that took samples from multiple venue types were rates as having a lower risk of bias 
than studies that only explored single venues or multiple venues of the same type. Studies were assigned zero to 2 
points, with a score of 2 indicating the lowest risk of bias.  
Table 6: Framework for assessing risk of bias: MSM 
Domain Scores and description 
Sampling venue coverage 0 – Single venue; 1 – Multi-centre/single venue type; 2 – Multi-centre/multi-venue type 
Prisoners 
The following five domains were considered as potential sources of selection bias for studies in prisoners: 
 Age 
 Gender 
 Proportion of PWID (or used as a selection criterion) 
 Sampling method  
 Population coverage (i.e. the population covered by the sampling design in geographic/demographic terms) 
Points were given for representativeness or a lower risk of bias in each domain (Table 7). A score for the combined 













Table 7: Framework for assessing risk of bias: prisoners 
Domain Scores and description 
Age 0 1 
Clear age bias (i.e. among juvenile offenders only); no information No clear bias in age profile of subjects 
Gender 0 1 
Clear bias in gender; no information No clear bias in gender distribution of subjects; 
could be considered representative if 
information is limited 
% PWID 0 1 
Exclusively among PWID/former PWID prisoners PWID not used to select subjects; no bias 
toward PWID 
Sampling method 0 1 
Non-random or non-exhaustive Exhaustive or random 
Population coverage 0 – Single centre/local; 1 – Multi-centre/local or regional; 2 – Multi-centre/national 
2.6 Data analyses  
General approach 
All available estimates were rounded to one decimal point. Weighted or standardised prevalence estimates, if 
available, were preferred over unweighted or crude estimates. Confidence intervals (CI) of 95% were calculated 
using the Fisher exact method, unless already reported.  
Based on the score from the assessment of the bias risk in the four population groups, an algorithm for data 
inclusion in the analysis was developed. Studies with higher quality (see criteria below) were included in the 
comparative analysis. HBV and HCV prevalence estimates from all eligible studies (i.e. all data points) are 
presented in the overview tables (Annex 2) and the country profiles (Annex 3). 
General population 
General population estimates were reported separately for adults and children where possible, and estimates for 
adults were included in the analysis. Studies in the general population with a score for risk of bias greater or equal 
to 4 (higher quality) were pooled. When there was a difference greater than 1% between higher quality estimates, 
regional estimates were reported separately. 
HBV and HCV prevalence maps of Europe were produced for the general population, representing data from higher 
quality studies. Countries for which no studies with a score of 4 or more were available were shaded grey or 
labelled ‘no data’. Maps were produced with EMMA, the ECDC Mapping and Multi-Layer Analysis tool. Countries in 
the prevalence map were categorised based on the following ranges: <0.5%, 0.5–1%, 1–2%, 2–8%.  
All higher quality estimates (risk of bias score ≥4) retrieved for each country for the general population were 
presented in a forest plot. Separate forest plots were prepared for HBV and HCV infections using Microsoft Excel. 
The parameters displayed in each forest plot are country, sampling period, prevalence estimate, and 95% CI.  
Pregnant women 
HBV and HCV prevalence estimates obtained from studies in pregnant women with a risk of bias score greater or 
equal to 2 were considered of higher quality and pooled (when possible). Higher quality estimates were presented 
in separate forest plots for HBV and HCV infections. The parameters displayed in each forest plot are country, 
sampling period, prevalence estimate, and 95% CI.  
First-time blood donors 
A summary table with HBV and HCV estimates for first-time blood donors was created by using data from the latest 
Council of Europe report (2011 data) [15]. For countries with no data reported in the latest report, data from the 
most recent previous Council of Europe report were used. For the following countries, older data were used: 
Austria (2010), Poland (2010), Slovenia (2009), Sweden (2009), Cyprus (2008), Portugal (2006), Latvia (2003). 
The number of first-time blood donors, the number of HBV cases, and the number of HCV cases were retrieved 
and shown in a table.  
European HBV/HCV prevalence estimates 
In order to estimate the current burden of chronic hepatitis B and C in the EU/EEA, an algorithm based on study 
quality was used to estimate the prevalence of HBV and HCV in the general population of each EU/EEA country. 
General population crude estimates and blood donor data identified in this review were combined using the 













country, it was used to determine the HBV and HCV prevalence in that country. If there was no higher quality 
estimate available, general population estimates with a lower quality were pooled (when possible) and used as an 
estimate of a country’s HBV and HCV prevalence. If no general population prevalence estimates were available, 
data on the prevalence of HBV and HCV in blood donors were used as a prevalence measure for the country. To 
determine the total number of HBV and HCV cases in each country, Eurostat 2014 data were used; the total 
population size was multiplied by the estimated prevalence in each country. 
MSM 
No prevalence estimates were pooled because the number of eligible studies among MSM was small and had a 
higher risk of bias. All retrieved estimates, irrespective of the risk of bias score, are presented in a forest plot. 
Separate forest plots were prepared for HBV and HCV prevalence using Microsoft Excel. The parameters shown in 
the forest plots are country, sampling period, prevalence estimate and 95% CI.  
Prisoners 
HBV and HCV prevalence estimates obtained from studies with a risk of bias score greater or equal to 3 and in 
adult populations were considered of higher quality and pooled when possible. All higher quality estimates for 
prisoners are presented in a forest plot. Separate forest plots were prepared for HBV and HCV infections using 
Microsoft Excel. The parameters displayed in each forest plot are country, sampling period, prevalence estimate, 
and 95% CI. Estimates for adult and juvenile populations are shown separately. 
PWID 
A summary table with HBV and HCV prevalence estimates among PWID was created using EMCDDA data. The 
most recent available data were downloaded from the EMCDDA website [16,17]. National and subnational 
prevalence estimates were retrieved. The summary table includes sampling period, sample size, national 
prevalence estimates, and 95% CI.  
Migrants 
Migrant data from the ECDC systematic review ‘Epidemiological assessment of hepatitis B and C among migrants in 
the EU/EEA’ were used [154]. Only HBC and HCV prevalence estimates for foreign-born first generation migrants 
obtained from studies with a sample size of >100 were included. When multiple estimates (by country of origin) 
were available from a Member State, results were pooled. A summary table of all estimates (alphabetically by 
Member State) was prepared. The table includes country of origin, sampling period, sample size, prevalence 
and CI.  
Country profiles 
All country-specific HBV and HCV prevalence estimates retrieved from eligible studies are presented in country 
profiles which include: 
 Summary tables with details of all included studies and an assessment of the related risk of bias for HBV 
and HCV 
 Forest plots summarising HBV and HCV prevalence estimates from all eligible studies for all relevant 
population groups, including blood donors and migrants.  
HBV and HCV prevalence estimates for PWID were reported separately due to heterogeneity of the data, for 














3 Review results  
3.1 Systematic literature search 
The literature search identified 9 379 articles, 142 of which were selected – based on title and abstract – for the 
‘general population’ category. The title and abstract screening yielded 50 articles for the category ‘pregnant 
women’, 17 for ‘MSM’, and 57 for ‘prisoners’. A manual search and Member State consultation yielded additional 
articles for the categories ‘general population’ (9), ‘prisoners’ (7), ‘pregnant women’ (5), and ‘MSM’ (3).  
Of the 284 full-text articles retrieved (three publications were unavailable), 148 were on the general population, 61 
on prisoners (three articles unavailable), 55 on pregnant women, and 20 on MSM. After the full-text screening, the 
number of eligible articles was further reduced: 48 articles on the general population were considered eligible; 32 
on pregnant women; 32 on prisoners; and 13 on MSM.  
Some publications reported both HBV and HCV prevalence, and one publication reported results from multiple 
countries. PRISMA3 flowcharts with the results of the literature search are presented in Annex 1. 
The number of prevalence estimates per country for HBV and HCV are presented in Table 8 per population group. 
Estimates derived from EMCDDA data (HBV and HCV in PWID), the Council of Europe report (HBV and HCV in first-
time blood donors) and the ECDC epidemiological assessment of hepatitis B and C among migrants in the EU/EEA 
(HBV and HCV in migrants) are not included in this table.  
For a total of 15 countries, no recent estimates for HBV and HCV prevalence in the general population were 
available. For the following subpopulations, HBV/HCV prevalence estimates were not available for a number of 
countires: pregnant women (HBV: 20 countries, HCV: 23 countries), MSM (HBV: 27, HCV: 24), and prisoners 
(HBV/HCV: 12). 
Table 8. Number of identified estimates for the prevalence of hepatitis B (HBsAg) and hepatitis C 














Austria 0 0 0 0 0 1 0 0 1 
Belgium 3 0 0 0 1 0 0 0 4 
Bulgaria 0 0 0 1 0 0 0 3 4 
Croatia 2 0 1 3 2 0 2 3 13 
Republic of Cyprus 0 0 0 0 0 0 0 0 0 
Czech Republic 5 0 0 0 0 0 0 0 5 
Denmark 0 2 0 0 0 0 0 0 2 
Estonia 0 0 2 0 0 0 2 0 4 
Finland 0 0 0 1 0 0 0 1 2 
France 2 2 1 1 3 0 1 7 17 
Germany 3 2 0 0 3 0 0 4 12 
Greece 2 6 0 0 1 1 0 0 10 
Hungary 1 0 0 1 1 0 0 1 4 
Iceland 0 0 0 0 0 0 0 0 0 
Ireland 4 1 0 1 1 3 0 1 11 
Italy 10 2 0 1 14 3 1 2 33 
Latvia 0 0 0 0 1 0 0 0 1 
Liechtenstein 0 0 0 0 0 0 0 0 0 
Lithuania 0 0 0 0 4 0 0 0 4 
Luxembourg 0 0 0 1 0 0 0 1 2 
Malta 0 0 0 0 0 0 0 0 0 
Netherlands 2 3 0 0 3 1 2 0 11 
Norway 0 1 0 0 0 1 0 0 2 
Poland 2 0 0 0 3 0 0 0 5 
Portugal 0 0 0 1 0 0 0 2 3 
Romania 4 0 0 1 1 0 0 0 6 
Slovakia 3 2 0 0 1 0 0 0 6 
Slovenia 0 0 0 0 0 4 0 0 4 
Spain 6 3 0 1 4 1 0 13 28 
 
                                                                    


























Sweden 0 0 0 0 0 0 1 0 1 
United Kingdom 1 3 2 2 2 0 2 5 17 
Total estimates 50 27 6 15 45 15 11 43 212 
Countries with 
estimates 
16 11 4 12 16 8 7 12 27 
3.2 Prevalence of chronic HBV and HCV infections 
General population 
Fifty estimates for the prevalence of HBV in the general population were obtained from eligible studies; for HCV, 45 
estimates were retrieved. A summary of these estimates with additional information on study characteristics and 
population is given in Tables A5 and A6 (Annex 2). The articles used for estimating the prevalence per country in 
Figures 1a and 1b are marked with asterisks in Tables A5 and A6. The forest plots in Figures 2 and 3 show all 
higher quality, pooled or standardised estimates for the general population for HBV and HCV. 
Of the 50 prevalence estimates for HBV, representative estimates for the general population (risk of bias score ≥ 4) 
were available for 13 countries: Belgium, Croatia, the Czech Republic, France, Germany, Greece, Hungary, Ireland, 
Italy, the Netherlands, Romania, Slovakia and Spain (Figure 1a). The number of estimates available per country 
ranged from one estimate for Hungary and the United Kingdom to 10 estimates for Italy. For HBV, the prevalence 
in the general population ranged from 0.1% in Ireland to 4.4% in Romania (Figure 2). Greece and Romania 
account for the highest HBV prevalence, 3.3% and 4.4% respectively, while the vast majority of countries have an 
HBV prevalence around or below 1%. The most recent estimate for Greece is much higher than the prevalence 
range of 0.0%–2.1% reported in the previous review [10]. However, the most recent estimate is completely based 
on population data from Crete only because no nation-wide estimate for Greek was available for this review. 
Several higher quality prevalence estimates were available for Italy which, when pooled, resulted in an HBV 
prevalence of 0.7%. However, single study prevalence estimates ranged from 0.5% in the region of Apulia, 
southern Italy, to 5.8% in the province of Bergamo, northern Italy, thus showing a high heterogeneity in the 
available estimates of HBV prevalence (Annex 2 Table A5 and Annex 3).  
HCV prevalence estimates that were considered representative for the general population (risk of bias score ≥ 4) 
were available for 13 countries: Belgium, Croatia, France, Germany, Greece, Hungary, Ireland, Italy, the 
Netherlands, Latvia, Romania, Slovakia and Spain (Figure 1b). The number of estimates available varied between 
one estimate (Belgium, Greece, Hungary, Ireland, Latvia, Romania and Slovakia) and 14 estimates for Italy. The 
HCV prevalence in the general population reported ranged from 0.1% in Belgium, Ireland and the Netherlands to 
5.9% in Italy (Figure 3). Countries with a relatively high HCV prevalence were Romania (3.2%), Greece (2.2%), 
Latvia (2.4%) and Slovakia (2.0%). For Greece, the present estimate is based on population data from Crete. Italy 
and Spain had the largest number of prevalence estimates available. Spain had one higher quality estimate, which 
reported an HCV prevalence of 1.1%, as shown in Figure 2. The other estimates show a range from 0.4% in 
Barcelona to 0.6% in the working population of Murcia and Madrid to 1.5% in multiple GP offices around Barcelona 
(Annex 2, Table A6; Annex 3). The highest prevalence estimate for Spain (1.5%) shows a very large confidence 











































Figure 2. HBsAg in the adult general population: prevalence estimates and CIs from studies with a 
lower risk of bias (risk of bias score ≥ 4), EU/EEA, 2005–2015 
 
Legend: Country, prevalence estimate (95% CI) and sample size (N) 
Standardised estimates were used for Belgium and the Czech Republic 
Pooled estimates were used for Germany, Italy and Spain 
Figure 3. Anti-HCV in the adult general population: prevalence estimates and CIs from studies with a 
lower risk of bias (risk of bias score ≥ 4), EU/EEA, 2005–2015  
 
Legend: Country, prevalence estimate (95% CI) and sample size (N) 
Pooled estimates were used for Germany and Italy 
Pregnant women 
Twenty-seven estimates on HBV prevalence in pregnant women were retrieved from eligible studies; for the same 
group, 15 estimates on HCV prevalence could be found. A summary of these estimates with information on study 
characteristics and population is presented in Tables A7 and A8 (Annex 2). The forest plots in Figures 4 and 5 show 
all higher quality, standardised or pooled estimates with regard to pregnant women in the EU/EEA. 
Higher quality estimates (risk of bias score ≥2) for HBV prevalence were available for seven countries, ranging 
from 0.1% in Norway and Spain to 0.8% in France and Italy (Figure 4). Pooled estimates were available for four 
countries. For nine countries, more than one estimate was available, with Greece having the highest number of 













2008). HBV prevalence in these years changed from 0.3% in 2006 and 2007 to 0.4% in 2008 (Annex 2, Table A7; 
Annex 3).  
Of the 15 estimates identified for HCV prevalence among pregnant women, higher quality estimates (risk of bias 
score ≥2) were available for four countries: Slovenia, Spain, Italy and Norway, with prevalence ranging from 0.1% 
in Slovenia to 0.9% in Norway (Figure 5). For Slovenia, several estimates were available (2003, 2009 and 2013), 
which could be pooled (Figure 5). HCV prevalence among pregnant women in Slovenia in 2003 was 0.2%, while 
2009 and 2013 estimates show HCV prevalence at 0.1% (Annex 2, Table A8; and Annex 3). 
Figure 4. HBsAg in pregnant women: prevalence estimates and CIs from studies with a lower risk of 
bias (risk of bias score ≥2), EU/EEA, 2005–2015  
 
Legend: Country, prevalence estimate (95% CI) and sample size (N) 
Pooled estimates were used for Denmark, Italy, the Netherlands and the United Kingdom 
Figure 5. Anti-HCV in pregnant women: Prevalence estimates and CIs from studies with a lower risk 
of bias (risk of bias score ≥2), EU/EEA, 2005–2015  
 
Legend: Country, prevalence estimate (95% CI) and sample size (N) 
First-time blood donors 
The prevalence of HBsAg and anti-HCV in first-time blood donors by country was available for 30 countries and is 
presented in Table 9. A comprehensive table of the data is shown in Table A9 in Annex 2. For Latvia and Portugal, 
no details were available on the absolute number of positive HBV or HCV cases and first-time blood donors, and no 
95% Confidence Intervals (95% CI) could be calculated.  
The prevalence of HBV among first-time blood donors ranged from 0.0% in Finland and Luxembourg to 3.2% in 
Bulgaria. Most countries (60%) had an HBV prevalence that was below or around 0.1%. 
The prevalence of HCV among first-time blood donors ranged from 0.0% in Iceland to 2.2% in Latvia, although the 
latter is the least recent estimate (2003), and is presented in Table 9. Most countries had an HCV prevalence below 













Table 9. Prevalence of HBsAg and anti-HCV in first-time blood donors, EU/EEA, source: Council of 
Europe, 2011* 
Country Prevalence of HBsAg (95% CI)a Prevalence of anti-HCV (95% CI)a Council of Europe Report  
Austria  0.099% (0.072–0.132) 0.039% (0.023–0.061) 2010 
Belgium 0.077% (0.055–0.104) 0.039% (0.024–0.060) 2011 
Bulgaria 3.224% (3.039–3.418) 0.342% (0.282–0.410) 2011 
Croatia 0.233% (0.142–0.359) 0.140% (0.072–0.244) 2011 
Cyprus  0.441% (0.270 –0.681) 0.221% (0.106–0.405) 2008 
Czech Republic  0.059% (0.040–0.085) 0.216% (0.177–0.261) 2011 
Denmark 0.016% (0.004–0.040) 0.016% (0.004–0.040) 2011 
Estonia 0.267% (0.128–0.490) 0.959% (0.673–1.326) 2011 
Finland 0.000% (0.000–0.019) 0.025% (0.008–0.059) 2011 
Franceb 0.070% (0.062–0.079) 0.034% (0.028–0.040) 2011 
Germany 0.116% (0.107–0.126) 0.062% (0.055–0.069) 2011 
Greece  1.374% (1.280–1.473) 1.202% (1.114–1.295) 2011 
Hungary  0.009% (0.003–0.021) 0.159% (0.128–0.195) 2011 
Iceland 0.072% (0.002–0.398) 0.000% (0.000–0.264) 2011 
Ireland  0.039% (0.013–0.090) 0.008% (0.000–0.043) 2011 
Italy  0.168% (0.155–0.181) 0.094% (0.085–0.104) 2011 
Latviac 1.127% 2.170% 2003 
Liechtenstein  - - n/a 
Lithuania 0.560% (0.468–0.665) 1.537% (1.382–1.704) 2011 
Luxembourg 0.000% (0.000–0.406) 0.221% (0.027–0.794) 2011 
Malta 0.174% (0.047–0.445) 0.043% (0.001–0.242) 2011 
Netherlands 0.034% (0.018–0.060) 0.020% (0.008–0.041) 2011 
Norway 0.028% (0.009–0.065) 0.033% (0.012–0.073) 2011 
Poland  0.450% (0.425–0.476) 0.742% (0.710–0.775) 2010 
Portugal  0.094% 0.165% 2006 
Romania  3.078% (2.965–3.195) 0.590% (0.541–0.643) 2011 
Slovakia 0.072% (0.048–0.104) 0.025% (0.012–0.046) 2011 
Slovenia  0.087% (0.043–0.155) 0.016% (0.002–0.057) 2009 
Spain  0.168% (0.152–0.185) 0.099% (0.086–0.112) 2011 
Sweden  0.043% (0.026–0.065) 0.059% (0.040–0.085) 2009 
United Kingdom 0.038% (0.030–0.047) 0.037% (0.030–0.047) 2011 
* Adapted from Tables 1 and 7.1, Council of Europe Report 2011 [15] 
a Calculated using the Fisher exact method for 95% CI when data on number of cases were available 
b France: The French blood service is composed of the French National Blood Service (EFS) (17 blood centres) and the French 
Army Transfusion Service (CTSA) with one blood centre. Data of both organisations are reported.  
c Latvia: After 2002, only data on HIV were presented; no HBV/HCV data were available 
European HBV/HCV prevalence estimates 
An overview of the estimates and data used for each country can be found in Table A10 in Annex 2. Based on 
general population and blood donor estimates to determine the current burden of chronic HBV, the HBV prevalence 
in the EU/EEA as a whole is estimated to be 0.9% (95% CI 0.7–1.2), corresponding to almost 4.7 million HBV 
HBsAg-positive cases. The United Kingdom has the highest estimated number of HBV cases (1 093 240). This 
assessment, however, is based on a lower quality prevalence estimate (Table A10, Annex 2). Romania also has a 
high estimated number of HBV cases (877 682), and Spain, France and Italy all have around 400 000 to 500 000 
HBV cases. For both Finland and Luxembourg, zero HBV cases were computed because only blood donor 
prevalence estimates were available. 
For HCV, the estimated EU/EEA prevalence is 1.1% (95% CI 0.9–1.4), corresponding to around 5.6 million anti-
HCV-positive cases. Italy has the highest estimated number of HCV cases (2 510 324), with the next highest 
number of cases being 771 762 for Poland (based on a lower quality estimate). France, Romania, Spain and the 
United Kingdom all have around 350 000 to 450 000 estimated HCV cases. For Iceland, no HCV cases were 














For the prevalence of HBV/HCV in MSM, 6 (HBV) and 11 (HCV) estimates were obtained from eligible studies. All 
estimates are included in the forest plots (Figures 6 and 7) to compensate for the low number of studies and the 
overall lack of good-quality studies, which are all based on convenience sampling. A summary of these estimates 
with information on study characteristics and population is given in Tables A11 and A12 (Annex 2).  
For HBV, the prevalence in MSM ranged from 0.0% in Estonia and the United Kingdom to 1.4% in France. Multiple 
estimates were only available for Estonia and the United Kingdom; however, the single estimates for Croatia and 
France were of higher quality (Figure 6). The Estonian estimates were from different sampling periods; in 2013, 
the reported HBV prevalence was 0.0% and in 2014–2015, reported prevalence was at 0.1%. Both estimates, 
however, do have a large confidence interval, ranging from 0.0% to 8.2% for the 2013 estimate and from 0.0% to 
5.6% for the 2014–2015 estimate. 
The prevalence of HCV among MSM ranged from 0.0% in Italy to 4.7% in Estonia. For Croatia, Estonia, the 
Netherlands and the United Kingdom multiple estimates were available  (Figure 7). Most countries show an HCV 
prevalence below or around 2%, with the exception of Estonia and Croatia (2.9%). Estonia has two divergent 
estimates for HCV prevalence in MSM: one from 2013, reporting a 4.7% prevalence, and one from 2014–2015, 
reporting a 1.8% prevalence. The highest estimate (4.7%) also shows a very large confidence interval, ranging 
from 0.6% to 15.8%.  
Figure 6. HBsAg in MSM: prevalence estimates and CIs from all included studies, EU/EEA, 2005–2015 
 
Legend: Country, prevalence estimate (95% CI) and sample size (N) 
Figure 7. Anti-HCV in MSM: prevalence estimates and CIs from all included studies, EU/EEA, 2005–
2015 
 














Eligible studies yielded 15 estimates for HBV prevalence in prisoners and 43 estimates for HCV prevalence in the 
same population group. HBV and HCV prevalence estimates for 11 countries based on higher quality studies (risk 
of bias score ≥3) are presented in Figures 8 and 9. A summary of all estimates with information on the study 
characteristics and population is given in Tables A13 and A14 (Annex 2).  
HBV prevalence estimates that were considered representative for prisoners were available for 11 countries: 
Bulgaria, Croatia, Finland, France, Hungary, Ireland, Italy, Luxembourg, Portugal, Spain and the United Kingdom. 
The only countries with multiple estimates were Croatia (3) and the United Kingdom (2), as shown in Annex 2: 
Table A14. For HBV, the prevalence in prisoners ranged from 0.3% in Ireland to 25.2% in Bulgaria (Figure 8). 
Countries with high HBV prevalence were Portugal (10.8%), Luxembourg (7.0%) and Italy (6.7%). For Croatia, 
estimates obtained over different sampling periods were available, consistently reporting an HBV prevalence of 
1.3% in prisoners (Annex 2: Table A13, Annex 3). 
HCV estimates that were considered representative were available for 11 countries, ranging from 4.9% in Hungary 
to 86.3% in Luxembourg (Figure 9). Pooled estimates were available for five countries. Overall, multiple estimates 
were available for eight countries, with Spain having the highest number of estimates (13). For Spain, consecutive 
estimates were available for HCV in prisoners (2000–2009). The HCV prevalence in these years changed from 
44.9% in 2000 to 25.3% in 2009, showing a decrease in prevalence over time and, combined with other estimates, 
resulted in a pooled estimate of 20.3% (Annex 2: Table A14, Annex 3).  
Figure 8. HBsAg in prisoners: prevalence estimates and CIs from all included studies, EU/EEA, 2005–
2015 
 
Legend: Country, prevalence estimate (95% CI) and sample size (N) 













Figure 9. Anti-HCV in prisoners: prevalence estimates and CIs from all included studies, EU/EEA, 
2005–2015  
 
Legend: Country, prevalence estimate (95% CI) and sample size (N) 
* Pooled estimates were used for Bulgaria, Croatia, France and the United Kingdom 
PWID 
The prevalence of HBsAg and anti-HCV in PWID is presented in Table 10 by country. Comprehensive tables of the 
PWID data including regional estimates are shown in Tables A15 and A16 in Annex 2.  
National estimates on HBV were available for seven countries: Croatia, Cyprus, Greece, Hungary, Ireland, Latvia 
and Portugal. The national prevalence estimates of HBV ranged from 0.5% in Croatia, Hungary and Ireland to 
6.3% in Portugal.  
National estimates for HCV were available for 16 countries: Austria, Croatia, Cyprus, the Czech Republic, Denmark, 
Finland, Greece, Hungary, Ireland, Italy, Latvia, Malta, Norway, Portugal, Slovenia and the United Kingdom. 
National prevalence estimates of HCV in PWID ranged from 13.8% in Malta to 84.3% in Portugal.  
Table 10. Prevalence of HBsAg and anti-HCV in PWID, EU/EEA, 2007–2013  
Country Year Sample sizea Prevalence of HBsAg (95% CIb) Year Sample sizea Prevalence of anti-HCV (95% CIb) 
Austria - - - 2013 48 31.3% (18.7–46.3) 
Croatia 2007 200 0.5% (0.0–2.8) 2007 200 44% (37.0–51.2) 
Cyprus 2013 82 6.1% (2.0–13.7) 2013 82 47.6% (36.4–58.9) 
Czech Republic - - - 2013 1 889 14.6% (13.1–16.3) 
Denmark - - - 2008 223 52.5% (45.7–59.2) 
Finland - - - 2009 682 60.5% (56.8–64.3) 
Greecec 2013 1,337 3.0% (2.2–4.1) 2013 1 309 68.1% (65.5 -70.6) 
Hungary 2011 664 0.5% (0.1–1.3) 2011 652 24.1% (20.8–27.6) 
Ireland 2010 200 0.5% (0.0–2.8) 2010 200 41.5% (34.6–48.7) 
Italyd - - - 2010 743 60.5% (56.8–64.0) 
Latviae 2013 562 2.1% (1.1–3.7) 2013 522 70.1% (66.0–74.0) 
Malta  - - - 2013 109 13.8% (7.9–21.7) 
Norway - 
 
- 2013 6 342 63.0% (61.8–64.2) 
Portugal 2013 399 6.3% (4.1–9.1) 2013 414 84.3% (80.4–87.7) 
Slovenia - - - 2009 112 32.1% (23.6–41.6) 
United Kingdomf - - - 2013 3 144 49.1% (47.4–50.9) 
Source: EMCDD, adapted from table INF 114 and INF-111, EMCDDA [16, 17] 
a Samples with sample size under N = 10 were excluded. 
b Calculated using the Fisher exact method for 95% CI. 
c Greece: Two national estimates were pooled. 
d Italy: Data collection system was changed. Up to 2011, aggregated data were collected. Detailed data became available in 
2012. Data from 2012 and later are therefore are not comparable with previous years. 
e Latvia: Status for ‘IDUs’ changed from unknown to ‘ever IDUs’ after 2011. 














The prevalence of HBsAg and anti-HCV in the representative general migrant population is presented in Table 11. 
Comprehensive tables of the HBV and HCV migrant data are shown in Tables A17 and A18 in Annex 2. Estimates 
were available for five countries: Greece, Italy, the Netherlands, Norway and the United Kingdom. Studies from the 
Netherlands and the United Kingdom reported HBV prevalence estimates among several migrant groups by country 
of origin. According to the available estimates, the prevalence of HBV ranged from 0.0% to 17.4% in migrants. The 
highest prevalence is reported among migrants from countries in south-east Asia, irrespective of their current 
country of residence [ECDC report, in press].  
For three countries, Italy, the Netherlands and the United Kingdom, HCV estimates were available. Studies from the 
Netherlands and the United Kingdom reported HCV prevalence estimates for a variety of migrant groups by country 
of origin. The anti-HCV prevalence in migrants ranged from 0.0% to 7.1%, with the highest prevalence reported 
among migrants from Eastern Europe in Italy [ECDC report, in press]. 
Table 11. Prevalence of HBsAg and anti-HCV in migrants by country/region of origin, EU/EEA, 1998–
2011  
Country Country of origin Sampling 
period 
Prevalence of 
HBsAg (95% CI) 
Country of birth Sampling 
period 
Prevalence of anti-
HCV (95% CI) 
Greece Former Soviet Union 1998–2006 4.3% (2.7–6.6) Former Soviet Union - - 
Italy Asia 1999–2009 0.0% (0.0–3.2) Asia 1999–2009 3.5% (1.0–8.7) 
Italy Eastern Europe 1999–2009 3.3% (1.3–6.7) Eastern Europe 1999–2009 7.1% (4.0–11.5) 
Italy Sub-Saharan Africa 1999–2009 8.1% (7.0–9.3) Sub-Saharan Africa 1999–2009 2.5% (1.9 –3.2) 
Netherlands Countries with >2% HBV 
prevalencea 
2006–2007 2.2% (1.0–4.2) Countries with >2% 
HBV prevalencea 
- - 
Netherlands Afghanistan 2011 2.0% (0.8–4.4) Afghanistan 2011 1.0% (0.2–3.0) 
Netherlands Cape Verde 2004 0.0% (0.0–24.7) Cape Verde 2004 0.0% (0.0–24.7) 
Netherlands China and Hong Kong 2009 9.7% (7.8–11.8) China and Hong Kong - - 
Netherlands Dutch Antilles 2004 2.6% (0.1–13.8) Dutch Antilles 2004 2.6% (0.1–13.8) 
Netherlands Egypt 2004 1.1% (0.4–2.5) Egypt 2004 2.4% (1.2–4.2) 
Netherlands Former Soviet Union 2011 0.0% (0.0–5.5) Former Soviet Union 2011 3.1% (0.4–10.7) 
Netherlands Iran 2011 0.7% (0.0–3.6) Iran 2011 0.7% (0.0–3.6) 
Netherlands Iraq 2011 0.7% (0.1–2.5) Iraq 2011 0.3% (0.0–1.9) 
Netherlands Morocco 2004 0.4% (0.0–2.2) Morocco 2003–2009 0.4% (0.0–2.2) 
Netherlands Morocco 2004 0.0% (0.0–8.0) Morocco 2006–2007 2.8% (0.1–14.5) 
Netherlands Morocco - - Morocco 2004 2.5% (0.1–13.2) 
Netherlands Non-western ethnicity - - Non-western ethnicity 2003–2009 0.7% (0.2–1.5) 
Netherlands Non-western ethnicity - - Non-western ethnicity 2006–2007 2.3% (1.1–4.1) 
Netherlands Other non-western ethnicity - - Other non-western 
ethnicity 
2003–2009 1.8% (0.4–5.2) 
Netherlands Other non-western ethnicity - - Other non-western 
ethnicity 
2006–2007 1.9% (0.8–3.8) 
Netherlands Suriname 2004 0.0% (0.0–6.4) Suriname 2004 1.8% (0.0–9.4) 
Netherlands Suriname - - Suriname 2003–2009 3.0% (0.4–10.5) 
Netherlands Suriname - - Suriname 2006–2007 2.0% (0.2–6.9) 
Netherlands Turkey 2004 4.9% (2.8–8.0) Turkey 2003–2009 0.0% (0.0–1.2) 
Netherlands Turkey 2009 3.1% (1.8–5.0) Turkey 2006–2007 0.0% (0.0–5.5) 
Netherlands Turkey 2004 1.9% (0.0–9.9) Turkey 2004 0.0% (0.0–7.5) 
Netherlands Turkey - - Turkey 2009 0.4% (0.0–1.3) 
Netherlands Vietnam 2011 9.5% (5.0–16.0) Vietnam 2011 1.6% (0.2–5.6) 
Norway Pakistan 2009 1.3% (0.3–3.9) Pakistan - - 
United Kingdom Bangladesh n/s 0.5% (0.0–2.6) Bangladesh n/s 0.0% (0.0–1.8) 
United Kingdom Bangladesh n/s 1.5% (0.8–2.7) Bangladesh n/s 0.6% (0.2–1.4) 
United Kingdom China (including Hong Kong) n/s 8.9% (6.5–11.9) China (including Hong 
Kong) 
- - 
United Kingdom India 2009–2010 0.0% (0.0–2.7) India n/s 0.2% (0.0–0.6) 
United Kingdom India n/s 0.1% (0.0–0.5) India 2009–2010 2.9% (0.8 –7.3) 
United Kingdom Other south-Asian countriesb n/s 5.3% (0.1–26.0) Other South Asianb n/s 0.0% (0.0–17.6) 
United Kingdom Other south-Asian countriesb 2009–2010 4.0% (1.1–9.8) Other South Asianb 2009–2010 2.0% (0.2–7.0) 
United Kingdom Other south-east Asian 
countriesc 


















Pakistan n/s 3.2% (1.3–6.4) Pakistan n/s 1.8% (0.5–4.5) 
United Kingdom Pakistan 2009–2010 0.8% (0.3–1.6) Pakistan 2009–2010 3.1% (2.0–4.4) 
United Kingdom Pakistan n/s 1.8% (1.3–2.4) Pakistan n/s 2.7% (2.1–3.4) 
United Kingdom Vietnam n/s 17.4% (5.0–38.8) Vietnam - - 
Source: ECDC, adapted from ‘Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA’ [154]. 
a Countries with >2% HBV prevalence: medium or high HBV-endemic countries 
b South-Asian countries other than Pakistan, India and Bangladesh 















This systematic literature review aims to collect, assess and collate the available evidence on the prevalence of HBV 
and HCV in the general population and six population subgroups in EU/EEA countries, and to identify gaps in the 
currently available evidence.  
There was widespread heterogeneity in the identified studies, which limited comparability. In order to identify 
representative estimates for the general population and other target populations in each EU/EEA country, the risk 
of bias was assessed for each study. Preference was given to the higher quality studies; however, corresponding 
higher quality estimates were not available for many countries. Limited geographical coverage in studies was also a 
frequent issue; regional or local estimates were more regularly available than national estimates.  
General population, pregnant women, and first-time blood 
donors 
Based on the data extracted from the literature reviewed in this study, the prevalence of HBV and HCV infections in 
the general population varied widely between EU/EEA countries. Countries in the eastern and southern part of the 
EU/EEA generally had a higher HBV and HCV prevalence than countries in the northern and western parts.  
HBV prevalence ranged from 0.1% in Ireland to 4.4% in Romania. Comparing these percentages with the 
estimates presented in the previous report [10], no clear pattern is discernible. For nine countries, HBV prevalence 
estimates were available in both reports. Although no statistical analysis of differences was performed, it was 
observed that HBV prevalence in Belgium and Ireland remained the same, while HBV prevalence has increased in 
Greece, Italy, Slovakia and the Netherlands. A decrease in HBV prevalence was found in Germany, Romania and 
Spain. A possible explanation for the increase in prevalence estimates in Greece is the limited geographical 
coverage of the studies included in this review: the current HBV prevalence estimate of 3.3% for Greece, which is 
higher than the one in the previous review (0.0%–2.1%), refers to the population of Crete only. No national 
estimate for Greece was available for the publication period in this review. Schweitzer et al. [4] estimated that 
Greece has a national HBsAg prevalence of 0.97%. Heterogeneity between studies was high between Italian 
studies; single-study prevalence estimates showed a wide range in HBV prevalence (0.5%–5.8%). However, the 
available higher quality studies from Italy reported consistent prevalence estimates. In the Netherlands, the 
increase in chronic HBV prevalence (from 0.1% in 1996 to 0.2% in 2007) is reportedly related to demographic 
changes over time resulting in an increase in the proportion of the population born in HBV-endemic countries [18].  
The anti-HCV prevalence in this report ranges from 0.1% in Belgium, Ireland and the Netherlands to 5.9% in Italy. 
A comparison of HCV prevalence for the nine countries with higher quality HCV estimates in both reports suggests 
that prevalence is decreasing in half of the countries. Notable exceptions are Greece, where an increase is 
observed, and Belgium and Germany, where the prevalence stays the same. For Greece, however, the restricted 
geographical coverage (Crete) of the current estimate limits the generalisability of this finding. For Italy, the 
geographical coverage of the HCV estimates also influences the current findings. In the previous report [10], Italy 
had a geographical gradient for HCV, with higher prevalence in the southern regions, as compared to central and 
northern Italy. Similarly, the studies included in this review showed a high heterogeneity, although no clear north-
to-south gradient was found. However, some estimates for HCV in Italy had a local geographical coverage and the 
investigated communities were in a region that was considered hyperendemic for HCV [19], which might have 
skewed the overall prevalence estimate. It is noteworthy that in this study, HCV prevalence among people older 
than 50 years (27.6%) was considerably higher than in younger people (3.0%) [19]. 
In pregnant women, the HBV and HCV prevalence estimates were higher when compared to the general population 
in nearly all countries. This is consistent with the results of the 2009 report [10]. A possible explanation may be 
found in the contribution of migrants, who are often underrepresented in general population studies but 
overrepresented among pregnant women. Italy and Spain are the exceptions, where the HBV and HCV prevalence 
estimate for pregnant women showed a lower prevalence than the estimate for the general population. This likely 
reflects the impact of the early start of universal HBV vaccination programmes in these countries [20] as well as 
the lower seroprevalence levels observed in young adults as compared to older age groups [19]. 
HBV and HCV prevalence in first-time blood donors can generally be regarded as the lower limit of the prevalence 
estimate in the general population; however, pre-selection of blood donors, where implemented, makes them an 
unrepresentative sample of the general population. The data in this review also show that the HBV and HCV 
prevalence in first-time blood donors is lower than in the general population for all countries, although some 
confidence intervals overlap. Nonetheless, using blood donor or pregnant women data as a proxy for HBV and HCV 
prevalence estimates for the general population is not optimal. 
The prevalence of HBV and HCV in the EU/EEA as a whole is estimated to be around 0.9 and 1.1 percent, 













figures are likely to be an underestimation as a result of inclusion of prevalence estimates among blood donors as 
proxy for the general population in the absence of other evidence. However, when taking into account both HBV 
and HCV data, general population estimates, obtained from included studies, accounted for approximately 83% of 
the total European population, with the remaining 17% covered by blood donor estimates. 
High-risk populations 
The heterogeneity and lack of comparability between identified studies was particularly noticeable for high-risk 
populations.  
For MSM, very few prevalence estimates were available. This lack of studies in many countries raises the question 
whether MSM are considered to be a key group in these countries. When comparing HBV prevalence among MSM 
to that of the general population in countries where both estimates were available, HBV prevalence was higher in 
France, and lower in Estonia and the United Kingdom. For HCV, all countries showed a higher prevalence among 
MSM except for France, where HVC prevalence in the general population was higher. Estonia was one of the 
countries with more than one prevalence estimate available for both infections, but the studies had very small 
sample sizes and do not necessarily report a prevalence representative of the situation in the MSM community in 
the country. A higher HCV prevalence among MSM is often seen in HIV-positive men [21], but studies conducted 
among HIV-positive people were not included in this review (Table 3).  
In all countries, the prevalence estimates of HBV and HCV were higher among PWID than in the general 
population, and in all countries, PWID had the highest HCV prevalence. This can be expected, as intravenous drug 
use is one of the most important risk factors for HCV infection. The prevalence of anti-HCV among PWID was 
considerably higher than that of HBsAg in all countries that provided data on both types of infections among PWID. 
This may be explained by the relatively low risk of developing chronic HBV infection when the infection is acquired 
as an adolescent or adult through injecting drug use [3]. 
The HBV and HCV estimates among prisoners were higher than in the general population in all countries. For HCV, 
and to a lesser extent for HBV, this is related to overrepresentation of PWID among prisoners. Longitudinal data 
from Spain showed that the anti-HCV prevalence in prisoners declined from 45% in 2000 to 25% in 2009. Similar 
to what was observed among PWID, in countries that supplied data for both types of infections, the prevalence of 
HCV among prisoners was higher than that of HBV. Nevertheless, prisoners showed the highest HBV prevalence for 
all countries. A possible explanation for the relatively high prevalence of chronic HBV in prisoners is the 
overrepresentation of foreign-born people in the prison population [22].  
The number of HBV and/or HCV prevalence studies in migrants is limited. Available data from the ECDC systematic 
review ‘Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA’ [154] shows that in nearly 
all countries and ethnic groups the estimated prevalence of both HBV and HCV is higher among migrants compared 
with the general population. The only exception is Italy, where the estimated general population HCV prevalence is 
higher than the prevalence found in migrants groups, with the caveats discussed above. 
Gaps in evidence at EU/EEA level 
In the 2009 systematic review, estimates for the general population were identified for 13 countries, for both HBV 
and HCV prevalence [10]. For this review, estimates were identified for a total of 15 countries with available HBV 
prevalence estimates in the general population and for a total of 16 countries with available HCV estimates. For 
some countries that were included in the previous report no general population prevalence studies were available 
for inclusion in this review, namely Cyprus, the Czech Republic, Denmark, Finland and Sweden for HBV prevalence, 
and Bulgaria, the Czech Republic and Sweden for HCV prevalence. This is mainly due to the selected time frame  
(articles published between 2005 and 2015) and shows the lack of recent prevalence data for some countries.  
Other than perhaps the population size of the country, no clear geographical distribution across the EU can be 
observed in the availability of (higher quality) estimates in any of the targeted population groups. For one country, 
Liechtenstein, no information about HBV and HCV prevalence was available for any of the population groups. For 
Cyprus, Iceland and Malta, only prevalence data on first-time blood donors were available and for five countries, 
only lower quality estimates were available: Austria, Estonia, Lithuania, Poland and Sweden. However, Estonia and 
Sweden were two of the few countries that reported HBV and HCV prevalence in MSM.  
When comparing countries that have at least one higher quality estimate for HBV in the general population with 
countries for which no estimates are available, the countries with higher quality estimates appear to have a slightly 
lower prevalence (and more studies with random sampling). There are more studies on countries with higher 
quality estimates for HCV in the general population than for HBV. Some of the countries for which no higher quality 
estimates are available have well-designed studies but these studies often only cover a geographically limited 













and public health priority agendas may contribute to the availability of recent and higher quality HBV and HCV 
estimates at the national or subnational levels. 
Other gaps in the available evidence are the lack of recent data on blood donors (for seven countries no data were 
available in the 2011 Council of Europe report) and the large number of countries without data on the prevalence 
of HBV and HCV infections among PWID. In addition, the general lack of good prevalence data for MSM is 
problematic. The included MSM studies usually had small sample sizes, resulting in reported estimates with large 
confidence intervals. A few more estimates were available for HCV prevalence in MSM compared to HBV, but data 
were still far from comprehensive. Generally, the overall lack of available estimates, lack of comparability and poor 
geographical representativeness of studies show that there is still a need for further research.  
Strengths and limitations 
This literature review builds on and expands previous work conducted by ECDC to provide an overview of the 
current situation with respect to HBV and HCV prevalence in the EU/EEA, both in the general population and 
among high-risk groups. It was limited to studies published after 2004 to better reflect recent developments but 
this restriction potentially excludes relevant data. The risk of bias was assessed for each study by using a pre-
defined methodology to mitigate the impact of differences in study design and conduct (e.g. study population 
selection and sampling, different laboratory tests, and sample types), but comparisons of the prevalence estimates 
across countries should still be made with caution.  
Instead of focussing on trends over time and differences between genders, this review compared absolute 
differences between the current and previous estimates [10]. According to Schweitzer et al., western European 
countries showed a consistently low HBV prevalence over time, while in a few countries in eastern Europe a 
tendency towards an increasing HBV prevalence became noticeable [4].  
This report explores anti-HCV prevalence, as opposed to HCV RNA, the marker of HCV chronic infection. Although 
the information on HBV DNA and HCV RNA prevalence was also extracted, nucleic acid amplification confirmatory 
testing was performed or reported in too few studies to warrant an analysis of this indicator: information about 
DNA or RNA confirmation was available for only 8% of HBV studies and 33% of HCV studies on the general 
population.  
A round of data validation with Member States provided additional information and further supplemented the 
evidence base. Despite that, the use of a geographical string and single reviewer screener may still have resulted 
in incomplete identification of the evidence base. 
For PWID, first-time blood donors and migrants, other data sources were used rather than studies identified in this 
systematic review. For migrants, prevalence data were derived from ‘Epidemiological assessment of hepatitis B and 
C among migrants in the EU/EEA’ [154]. For blood donors, recent national prevalence estimates were available for 
most countries. 
Estimates were pooled using source data on the number of cases and denominators, rather than the prevalence 
estimates. More weight was given to the studies with a larger sample size in pooled estimates. No estimates were 
pooled among heterogeneous populations. The recalculation of the CIs using the conservative Fischer’s exact 
method has standardised the data across estimates and improved transparency of calculation. Furthermore, no 














5 Conclusions  
This systematic literature review shows the diversity in the prevalence of chronic HBV and HCV infections. The 
availability of studies with relatively recent data on the prevalence in the general population is limited: data were 
available for slightly more than half of the 31 countries in the EU/EEA. For pregnant women and prisoners, studies 
were found for 40–50% of all EU/EEA countries. Data on the prevalence of HBV and HCV infections among MSM 
were lacking for most of the countries.  
The lack of higher quality, recent, nationwide prevalence estimates, and the overall heterogeneity of the available 
studies makes it challenging to provide an EU/EEA overview of the current epidemiological situation of chronic viral 
hepatitis. Nevertheless, in this review, we were able to estimate the prevalence of HBV and HCV in the EU/EEA as a 
whole at around 1 percent, with an estimated total of 10.3 million HBV and HCV cases. More robust prevalence 
estimates are needed to gain further insights into the size of the populations with chronic hepatitis B or C 
infections, both with regard to the general population in the different EU/EEA countries and in specific risk groups. 
This information can then be used to better target primary and secondary prevention measures (e.g. screening and 
linkage to care of at-risk populations to identify patients with chronic hepatitis B and C who can benefit from new 
treatment options) and evaluate these measures.  
Overall, countries in the eastern and southern part of the EU/EEA had a higher HBV and HCV prevalence than 
countries in the northern and western parts. Some countries with information based on general population studies, 
show evidence of a relatively low HBV/HCV prevalence in the general population, which stands in stark contrast 
with high prevalence in high-risk groups, mostly migrants, PWID, and prisoners. PWID remain at high risk for HCV 
infection, with high prevalence rates reported for most countries.  
In all, prevalence in first-time blood donors was lower than that in the general population, while prevalence in 
pregnant women was slightly higher. The observed increase over time in the prevalence of chronic HBV in some 
countries indicates that it is important to maintain hepatitis B prevention and control high on the public health 
agenda.  
Data on the prevalence of chronic viral hepatitis are unavailable for many countries; better surveillance and 
monitoring and further research are needed to provide reliable and comprehensive strategic information for 
policymakers who design and implement secondary prevention programmes for HBV and HCV infections in the 
EU/EEA. In the meantime, this report may provide a useful overview of what data are available with regard to 
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Annex 1. PRISMA chart of identified citations 
Figure A1. PRISMA flow diagram for the systematic review of prevalence of HBsAg and anti-HCV in 
the EU/EEA: general population 
 
 
Table A1. Reasons for exclusion: publications on the general population  
Reasons for exclusion 
Notification or incident data; no prevalence data 33 
Irrelevant and/or unspecified virological markers 2 
Self-reported serological status; unclear confirmation of serological status 6 
Duplicate reference/data 2 
No original data (commentary, erratum, guidelines, etc.) 7 
Conference abstract but full paper has been published 6 
Review article 4 
Population bias; no clear general population estimate 29 
Modelled data only 3 
Date range 6 
Sample size too small 2 
Total 100 
 
12 379 records retrieved prior to deduplication 
Medline (Pubmed): 4 541 
Embase: 7 801 
Cochrane Library: 37 
9 379 records after deduplication 
Records excluded based on title and/or 
abstract (n = 9 237) 
Full-text articles assessed for eligibility  
(n = 151).  Three articles are unavailable (as 
of 1 June 2015) 
Full-text articles excluded, with reasons  
(n = 100) 
Studies included in qualitative 
synthesis (n = 48)  
Records included for full text screening  
(n = 142)  
List of articles not in English, 
Dutch, French or German 
requiring translation (n = 16) 
Articles added from other 
population groups/sources; 
Member State additions  













Figure A2. PRISMA flow diagram for the systematic review of prevalence of HBsAg and anti-HCV in 
the EU/EEA: pregnant women 
 
 
Table A2. Reasons for exclusion: publications on pregnant women  
Reasons for exclusion 
Notification or incident data; no prevalence data 6 
Irrelevant and/or unspecified virological markers 1 
Duplicate reference/data 5 
Conference abstract but full paper has been published 2 
Population bias; no clear general population estimate 8 
Date range 1 
Total 23 
 
12 379 records retrieved prior to 
deduplication 
Medline (Pubmed): 4 541 
Embase: 7 801 
Cochrane Library: 37 
9,379 records after deduplication 
Records excluded based on title 
and/or abstract (n = 9 329) 
Full-text articles assessed for 
eligibility (n = 55)  
Full-text articles excluded, with 
reasons (n = 23) 
Studies included in qualitative 
synthesis (n = 32) 
Records included for full text 
screening (n = 50)  
List of articles not in 
English, Dutch, French or 
German requiring 
translation (n = 8) 
Articles added in from 
other population 
groups/sources or Member 
State additions  













Figure A3. PRISMA flow diagram for the systematic review of prevalence of HBsAg and anti-HCV in 
the EU/EEA: MSM 
 
 
Table A3. Reasons for exclusion: publications on MSM  
Reasons for Exclusion 
Notification or incident data; no prevalence data 3 
Irrelevant and/or unspecified virological markers 2 
Self-reported serological status 1 
Duplicate reference/data 1 
Total 7 
 
12 379 records retrieved prior to deduplication 
Medline (Pubmed): 4 541 
Embase: 7 801 
Cochrane Library: 37 
9 379 records after deduplication 
Records excluded based on title and/or 
abstract (n = 9 362) 
Full-text articles assessed for eligibility  
(n = 20)  
Full-text articles excluded, with reasons  
(n = 7) 
Studies included in qualitative 
synthesis  
(n = 13) 
Records included for full text screening  
(n = 17)  
List of articles not in English, 
Dutch, French or German 
requiring translation (n = 1) 
Member State additions  













Figure A4. PRISMA flow diagram for the systematic review of prevalence of HBsAg and anti-HCV in 
the EU/EEA: prisoners 
 
Table A4. Reasons for exclusion: publications on prisoners  
Reasons for Exclusion 
Notification or incident data; no prevalence data 4 
Irrelevant and/or unspecified virological markers 1 
Self-reported serological status; unclear confirmation of serological status 3 
Duplicate reference/data 6 
No original data (commentary, erratum, guidelines, etc.) 4 
Conference abstract but full paper has been published 1 
Review article 2 
Population bias; no clear general population estimate 6 
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Embase: 7 801 
Cochrane Library: 37 
 
9 379 records after deduplication 
 
Records excluded based on title and/or 
abstract (n = 9 322) 
Full-text articles assessed for eligibility  
(n = 64); three are unavailable  
(as of 1 June 2015) 
 
Full-text articles excluded,  
with reasons  
(n = 29) 
Studies included in qualitative 
synthesis (n = 32)  
 
Records included for full text screening 
(n = 57)  
List of articles not in English, 
Dutch, French or German 
requiring translation (n = 11) 
 
Articles added in from other 
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Member State additions  














Annex 2. Prevalence of chronic HBV and HCV 
infections 
Table A5. Prevalence of HBsAg in the general population, EU/EEA countries  
Country 















Belgium* Quoilin (2007) (23) Regional 2002 Random Region of 
Flanders 
Standardised Standardised 0.7% (0.5–0.8) 
Belgium Quoilin (2007) (23) Regional 2002 Random Region of 
Flanders 
0 to >65 1,830 0.7% (0.4–1.2) 
Belgium Nardone (2009) (24) N/R 2002–2003 Convenience Residual lab 
samples 
representative 
of location and 
gender  
1 to 15 1,175 0.7% (0.3–1.3) 
Belgium Nardone (2009) (24) N/R 2002–2003 Convenience Residual lab 
samples 
representative 
of location and 
gender 
16 to 39 321 0.6% (0.1–2.2) 
Croatia* Vilibic-Cavlek 
(2014) (25) 






20% of regions 
20 to 80 2,009 0.7% (0.4–1.2) 
Croatia Burek (2010) (26) Multi-centre 2005–2007 N/R Multi-centre 
study of staff in 
20 prisons 
(10.9% of all 
prison staff) 
N/R 259 2.3% (0.9–5.0) 
Czech 
Republic* 
Nardone (2009) (24) N/R 2001 Random  Standardised Standardised 0.6% 
Czech Republic Nardone (2009) (24) N/R 2001 Random  16 to >40 
years 
1,669 0.4% (0.1–0.8) 
Czech Republic Nardone (2009) (24) N/R 2001 Random  1 to 15 years 975 0.3% (0.1–0.9) 
Czech Republic Nardone (2009) (24) N/R 2001 Random  16 to 39 
years 
1,148 0.2% (0.0–0.6) 
Czech Republic Nardone (2009) (24) N/R 2001 Random  >40 years 521 0.8% (0.2–2.0) 






18 to 80 18,230 0.7% (0.5–0.9) 
France Bottero (2014) (28) Multi-centre 2010–2011 Convenience Multi-centre 
screening study 
in Paris region 
includes 
multiple risk 
groups such as 
migrants and 
PWID 
Mean age 33 3,929 2.2% (1.7–2.7) 
Germany# Poethko-Müller 
(2013) (29) 
National 2008–2011 Random  National 
coverage, 
DEGS1 study 
18 to 79 7,047 0.3% (0.2–0.6) 




18 to 65, 
mean age 
39.4 
2,256 0.7% (0.4–1.1) 
Germany Wolffram (2015) (31)  Regional 2012–2013 Convenience Check-up 35+ 
attendees 
(mid-life health 





21,008 0.5% (0.4–0.6) 
Germany* Pooled  Pooled 2002; 
2008–2011 
Pooled Pooled Pooled 9,303 0.4% (0.3–0.5) 
Greece* Drositis (2013) (32) Regional 2006–2010 Random Adult residents 
of Arkalochori, 
a province in 






























Greece Dounias (2005) (33) Local 1999–2001 Convenience Municipal solid 
waste workers 
Mean age 42 159 7.5% (4.0–12.8) 
Hungary* Treso (2012) (34) National 2007–2009 Convenience Prison staff 21 to 60 1,066 0.4% (0.1–1.0) 
Ireland* Talento (2010) (35) National 1992–2009 Exhaustive Living and 
deceased solid 
organ donors 
N/R 1,478 0.1% (0.0–0.4) 
Ireland Nardone (2009) (24) N/R 2003 Convenience Residual lab 
samples 
representative 
of location and 
gender  
1 to 15 877 0.0% (0.0–0.9) 
Ireland Nardone (2009) (24) N/R 2003 Convenience Residual lab 
samples 
representative 
of location and 
gender  
16 to >40  1,658 0.1% (0.0–0.4) 
Ireland Nardone (2009) (24) N/R 2003 Convenience Residual lab 
samples 
representative 
of location and 
gender  
16 to 39 1,194 0.1% (0.0–0.5) 
Ireland Nardone (2009) (24) N/R 2003 Convenience Residual lab 
samples 
representative 
of location and 
gender  
>40 464 0.2% (0.0–1.2) 
Italy# Cozzolongo (2009) 
(36) 
Local 2005–2007 Random  GP records in 
Bari, Apuglia 
18 to 93 
Mean age 47 
2,195 0.5% (0.3–1.0) 
Italy# Pendino (2005) (37) Local 2002–2003 Random  Census data 
from Cittanova, 
Calabria 
12 to 95 1,645 0.8% (0.4–1.3) 
Italy# Floreani (2006) (38) Local 2001 Random  Residents of 
Arsita (Central 
Italy) 
>8 142 0.7% (0.0–3.9) 





1 to 50 1,071 2.0% (1.2–3.0) 
Italy Fabris (2008) (40) Local 2002 Exhaustive  Vicenza, north-










965 1.0% (0.5–1.9) 
Italy Del Corno (2006) 
(41) 




20 to 70 2,829 5.8% (5.0–6.7) 





30 to 60 3,207 0.6% (0.4–1.0) 
Italy De Paschale (2012) 
(43) 







22,758 2.1% (2.0–2.3) 
Italy Da Villa (2007) (44) Local 2006 N/R Cohort in 
Afragola, 
Naples  
6 to 58 1,540 0.9% (0.5–1.5) 
Italy Squeri (2006) (45) Local 2005 Convenience Municipal solid 
waste workers 
20 to 68 327 4.0% (2.1–6.7) 
Italy* Pooled Pooled 2001; 
2002–2003; 
2005–2007 
Pooled Pooled Pooled 3,982 0.7% (0.4–1.0) 






























Netherlands Veldhuijzen (2009) 
(53) 




18 to 65 284 0.7% (0.1–2.5) 










3,826 1.1% (0.8–1.5) 






N/R 4,774 0.9% (0.7–1.2) 
Romania* Gheorghe (2013) 
(48) 




18 to 69 13,127 4.4% (4.0–4.8) 
Romania Nardone (2009) (24) N/R 2002 Convenience Residual lab 
samples 
representative 
of location and 
gender  
1 to 15  630 5.1% (3.5–7.1) 
Romania Nardone (2009) (24) N/R 2002 Convenience Residual lab 
samples 
representative 
of location and 
gender  
16 to >40 629 6.2% (4.4–8.4) 
Romania Nardone (2009) (24) N/R 2002 Convenience Residual lab 
samples 
representative 
of location and 
gender  
16 to 39 276 7.6% (4.8–11.4) 
Romania Nardone (2009) (24) N/R 2002 Convenience Residual lab 
samples 
representative 
of location and 
gender  
>40 353 5.1% (3.0–7.9) 
Slovakia Nardone (2009) (24) National 2002 Random 
 
1 to 15  1,623 0.1% (0.0–0.4) 
Slovakia* Nardone (2009) (24) National 2002 Random   16 to >40 1,946 1.1% (0.7–1.6) 
Slovakia Nardone (2009) (24) National 2002 Random   16 to 39 1,270 0.9% (0.4–1.5) 
Slovakia Nardone (2009) (24) National 2002 Random   >40 676 1.5% (0.7–2.7) 
Spain# Pedraza-Flechas 
(2014) (49) 









16 to 80 3,695 0.7% (0.5–1.0) 
Spain# Lopez-Izquierdo 
(2007) (50) 





on health card 
N/R 364 0.0% (0.0–1.0) 






15 to >65 1,296 1.4% (0.8 –2.2) 
Spain Salleras (2007) (51) Regional 2002 Random  Two stage 
cluster sample 
from schools 
5 to >65 2,620 0.7% (0.4–1.1) 
 
                                                                    
4 PIENTER 2 project: second research project on the protection against infectious diseases offered by the national immunisation 

































Spain Salleras (2007) (51) Regional 2002 Random  Two stage 
cluster sample 
from schools in 
Catalonia 
5 to 14 1,324 0.0% (0.0–0.3) 
Spain Calleja-Panero 
(2013) (52) 
Multi-centre 2007–2010 Convenience Study in Murcia 







42 5,017 0.7% (0.5–1.0) 
Spain* Pooled Pooled 2002; 
2003; 
2008–2009 
Pooled Pooled Pooled 5,355 0.8% (0.6–1.1) 









N/R 3,910 1.7% (1.3–2.2) 
# Estimates used for pooled estimate 
* Estimates presented in Figure 1a (prevalence map) 

















Belgium* Quoilin (2007) 
(23) 
Regional 2002 Random Region of Flanders 0 to >65 1,830 0.1% (0.0–0.4) 




N/R Multi-centre study of staff in 20 
prisons (10.9% of all prison 
staff) 





Convenience Multi-centre study of patients 
attending a medical check-up. 
Covers 20% of regions 
20 to 80 1,930 0.9% (0.6–1.5) 
France* Meffre (2010) 
(27) 
National 2004 Random  National sample obtained via 
primary health care insurance 
units 





Mixed Underprivileged populations 
sampled via primary care 
services. Includes a small 
number of homeless people 
(n=89) and former/active PWID 
(n=16) 
18 to >60 944 4.7% (3.4–6.2) 
France Poynard 
(2009) (56) 
Multi-centre N/R Convenience Attendees of social security 
health centres 






Random  National coverage. DEGS1 study 18 to 79 7,047 0.3% (0.1–0.5) 
Germany# Huetter 
(2014) (30) 
Local 2002 Random  Residents of Leutkirch, 
southern Germany 
18 to 65, 
mean age 
39.4 





Convenience Check-up 35+ attendees (mid-




21,008 1.0% (0.8–1.1) 
Germany* Pooled Pooled 2002; 
2008–
2011 





Random  Adult residents of Arkalochori, a 
province in Crete 
Mean age 52 876 2.2% (1.3–3.4) 









Exhaustive Living and deceased solid organ 
donors 

































Random  GP records in Bari, Apuglia 18 to 93, 
mean age 
47 





Random  Census data from Cittanova, 
Calabria 
12 to 95 1,645 6.5% (5.4–7.8) 
Italy# Floreani 
(2006) (38) 
Local 2001 Random  Residents of Arsita (Central 
Italy) 
>8 697 10.2% (8.0–
12.7) 
Italy# Petti (2006) 
(57) 
Local N/R Random  GP registration. Local coverage >25 289 16.3% (12.2–
21.0) 
Italy Petti (2006) 
(57) 
Local N/R Random  GP registration. Local coverage 25-49 133 3.0% (0.8–7.5) 
Italy Petti (2006) 
(57) 
Local N/R Random  GP registration. Local coverage >50 156 27.6% (20.7–
35.3) 




Convenience Milan. Hospital (2 points in one 
location), STI clinics (n=1) and 
GPs (n=6) 
>18 4,507 0.6% (0.4–0.9) 
Italy Guadagnino 
(2013) (59) 
Local 2010 Random  Study in a small town in 
Calabria 
>18 1,012 5.7% (4.4–7.4) 
Italy Fabris (2008) 
(40) 
Local 2002 Exhaustive Vicenza, north-east Italy. A 
broken sewer pipe prompted 
HAV vaccination. Subjects were 
also tested for HBV/HCV 
Mean age 
42.1 





Convenience Naples. Residual sera from 
primary care tests 
19 to 65 1,972 8.2% (7.0–9.5) 
Italy Del Corno 
(2006) (41) 
Local N/R Random  Four towns in Isola Bergamasca 
(northern Italy) 
20 to 70 960 4.7% (3.4–6.2) 
Italy Dazzani 
(2009) (42) 
Local 2008 Convenience Survey of residents in 
Bagnacavallo (Emilia-Romagna) 
30 to 60 3,207 1.1% (0.8–1.5) 




Convenience Hospital lab samples from 




425 4.7% (2.9–7.2) 
Italy Squeri (2006) 
(45) 
Local 2005 Convenience Municipal solid waste workers 20 to 68 327 0.9% (0.2–2.7) 
Italy* Pooled Pooled N/R Pooled  Pooled Pooled 4,826 5.9% (5.2–6.6) 
Latvia* Tolmane 
(2011) (61) 
National 2008 Random  GP registration 18 to 94 1,459 2.4% (1.7–3.3) 





2010 Convenience Shopping centre attendees 
(62% female) 
N/R 1,514 2.4% (1.7–3.4) 









  2.8% 
 





2010 Convenience Shopping centre attendees 
(62% female) 
Standardised   2.8% 
  
  










  2.9% 
  
  




Random  National study (PIENTER 2) 15 to 79 4,046 0.1% (0.0–0.2) 
Netherlands Veldhuijzen 
(2009) (53) 
Local 2004 Random  Rotterdam municipal population 
register 
18 to 65 284 1.1% (0.2–3.1) 
Netherlands Slavenburg 
(2008) (67) 
Regional 2006 Convenience GP attendees in Arnhem and 
Nijmegen who had blood taken 
as part of clinical work up 
N/R 2,200 0.2% (0.1–0.5) 
Poland Hartleb 
(2012) (46) 
National N/R Exhaustive  Study among elderly 
population. Sample from 
national population register 
>65, mean 
age 79.4 
3,826 2.9% (2.4–3.5) 




Convenience Consecutive patients in a GP 
outpatient clinic. 65.4% female 





Convenience Retrospective study among 
deceased potential blood 
donors. Regional in scope. 75% 
male 





Random  National cross-sectional 
population survey  
18 to 69 13,146 3.2% (2.9–3.6) 
Slovakia* Schreter 
(2007) (64) 




Regional 2003 Random  Study in Valladolid. Stratified 
random sampling based on 
health card 

































Random  Multi-centre study of invitation-
based screening via GP 
registers in Barcelona 
20 to 90, 
mean age 
50.6 





Convenience Multi-centre study of screening 
via flyers and posters in GP 
offices in Barcelona 
Mean age 
51.2 






Convenience Study in Murcia and Madrid of 
working population at yearly 
insurance check-up. 73% male. 







Exhaustive Patients undergoing Assisted 
Reproductive Treatment at Guy 
& St Thomas Hospital, London 





Regional 2000 Convenience Residual serum samples from 
Public Health and National 
Health Service Laboratories in 
England and Wales for routine 
diagnostic examination 
>16 5,068 1.2% (0.9–1.5) 
# Estimates used for pooled estimate 
* Estimates presented in Figure 1b (prevalence map) 

















Denmark# Moller (2014) 
(69) 
National 2013 Exhaustive National antenatal screening 
programme 
N/R 60,977 0.3% (0.2–0.3) 




Exhaustive National antenatal screening 
programme 
N/R 140,376 0.3% (0.2–0.3) 
Denmark Pooled Pooled 2005–
2007; 
2013 




National 2011 N/R ELFE cohort study, national 
sample 
25 to 34, 
mean age 
30 
N/R 0.8% (0.6–1.1) 
France Braillon (2010) 
(72) 
Regional 2006 Random  Regional coverage. Lookback 
study design 










Exhaustive Antenatal screening in Leutkirch 
hospitals, southern Germany 
N/R 15,873 0.8% (0.7–1.0) 
Greece Papaevangelou 
(2006) (75) 
National 2003 Exhaustive National antenatal screening 
programme 





Exhaustive Antenatal screening attendees Mean age 
27.2 





Exhaustive Antenatal screening non-
attendees screened post-partum 
Mean age 
26.6 





Exhaustive Consecutive women delivering 
at the ObGyn department 





Exhaustive Antenatal screening at Thriassio 
General Hospital 
N/R 2,188 0.0% (0.0–0.3) 
Greece Betsas (2006) 
(79) 
Local 2004 Exhaustive Attendees of the University of 










Exhaustive Antenatal screening lab data 
from Galway hospital 
N/R 24,008 0.2% (0.2–0.4) 




Exhaustive  Multi-centre study in 41 
hospitals across 13 regions 
14 to 53 16,858 0.9% (0.7–1.0) 




Exhaustive  Regional study. One-third 
migrant women. 
>17 10,093 0.8% (0.6–1.0) 









Exhaustive  Multi-centre study in all 
hospitals and delivery rooms in 
northern Norway 
16 to 44, 
mean age 
29.3 
1,668 0.1% (0.0–0.3) 




Convenience Residual serum samples from 
regional departments of clinical 
microbiology, eastern Slovakia 

































Convenience Residual serum samples from 
nine regional departments of 
clinical microbiology, eastern 
Slovakia 
N/R 10,739 2.3% (2.1–2.6) 






Regional antenatal screening 
programme 





Convenience Study in a hospital and a health 
centre in Madrid 
19 to 49, 
mean age 
30 





Exhaustive Single centre study. 8.4% 
migrants 
N/R 4,169 0.6% (0.4–0.9) 
Netherlands# Op de Coul 
(2011) (89) 
National 2006 Exhaustive National antenatal screening 
programme 
N/R 186,137 0.3% (0.3–0.4) 
Netherlands# Op de Coul 
(2011) (89) 
National 2007 Exhaustive National antenatal screening 
programme 
N/R 190,140 0.3% (0.3–0.3) 
Netherlands# Op de Coul 
(2011) (89) 
National 2008 Exhaustive National antenatal screening 
programme 
N/R 185,941 0.4% (0.4–0.4) 
Netherlands Pooled Pooled 2006–
2008 










Exhaustive Antenatal screening from four 
laboratories (covering 60% of 
Scottish population) 







Exhaustive Antenatal screening in four 
London hospitals 
15 to 46, 
mean age 
29 





Local 2003 N/R Antenatal screening at Guy & St 
Thomas Hospital, London 





Pooled Pooled Pooled 167,398 0.5% (0.4–0.5) 
# Estimates used for pooled estimate  























Local 2009–2011 Exhaustive Universal antenatal 
screening at Vienna 
University Hospital 




Local 2005–2007 Exhaustive Antenatal screening at 
Thriassio General Hospital 
N/R 2,188 1.3% (0.9–
1.8) 
Ireland Lambert (2013) 
(93) 
Local 2007–2008 Exhaustive  Antenatal care attendees 
of Rotunda hospital 
N/R 8,976 0.9% (0.7–
1.1) 
Ireland Martyn (2011) 
(94) 
Local 2006 Exhaustive Deliveries at a single 
hospital 
N/R 4,666 1.4% (1.1–
1.8) 
Ireland Martyn (2011) 
(94) 
Local 2007 Exhaustive Deliveries at a single 
hospital 
N/R 9,222 0.7% (0.6–
0.9) 
Italy Ruffini (2014) 
(82) 
Regional 2011–2012 Exhaustive  Regional study. One third 
migrant women 




Local 1996–2001 Exhaustive  All deliveries at the 
hospital in Palma 
N/R 13,025 0.8% (0.7–
1.0) 
Italy Lagana (2015) 
(96) 
Local 2003–2013 Convenience Outpatient clinic 
attendees, mostly migrant 
women 




Regional 2003–2004 Exhaustive  Multi-centre study in all 
hospitals and delivery 
rooms in northern Norway 







National 2013 Exhaustive Residual sera from 
antenatal screening 




National 2009 Exhaustive Residual sera from 
antenatal screening 




National 2003 Exhaustive Residual sera from 
antenatal screening 




National 2003, 2009 
& 2013 
Exhaustive Residual sera from 
antenatal screening 






2012 Random  HIV- women screened in 
six regions 
N/R 8,555 0.2% (0.1–
0.3) 
Netherlands Urbanus (2011) 
(99) 
Local 2003 Random  Antenatal screening in 
Amsterdam, 64% non-
Dutch 



























Prevalence of HBsAg 
(95% CI)a 






Austria  46 18 46,603 0.099% (0.072–0.132) 0.039% (0.023–0.061) 2010 
Belgium 41 21 53,524 0.077% (0.055–0.104) 0.039% (0.024–0.060) 2011 
Bulgaria 1,095 116 33,961 3.224% (3.039 –3.418) 0.342% (0.282–0.410) 2011 
Croatia 20 12 8,599 0.233% (0.142–0.359) 0.140% (0.072–0.244) 2011 
Republic of Cyprus  20 10 4,532 0.441% (0.270 –0.681) 0.221% (0.106–0.405) 2008 
Czech Republic  29 106 49,122 0.059% (0.040–0.085) 0.216% (0.177–0.261) 2011 
Denmark 4 4 25,647 0.016% (0.004–0.040) 0.016% (0.004–0.040) 2011 
Estonia 10 36 3,752 0.267% (0.128–0.490) 0.959% (0.673–1.326) 2011 
Finland 0 5 19,775 0.000% (0.000–0.019) 0.025% (0.008–0.059) 2011 
Franceb 257 124 365,593 0.070% (0.062–0.079) 0.034% (0.028–0.040) 2011 
Germany 631 336 542,542 0.116% (0.107–0.126) 0.062% (0.055–0.069) 2011 
Greece  783 685 57 000 1.374% (1.280 –1.473) 1.202% (1.114–1.295) 2011 
Hungary  5 90 56,632 0.009% (0.003 –0.021) 0.159% (0.128–0.195) 2011 
Iceland 1 0 1,398 0.072% (0.002–0.398) 0.000% (0.000–0.264) 2011 
Ireland  5 1 12,900 0.039% (0.013–0.090) 0.008% (0.000–0.043) 2011 
Italy  663 372 394,910 0.168% (0.155–0.181) 0.094% (0.085–0.104) 2011 
Latviac - - - 1.127% 2.170% 2003 
Liechtenstein  - - - - - N/A 
Lithuania 129 354 23,034 0.560% (0.468–0.665) 1.537% (1.382–1.704) 2011 
Luxembourg 0 2 907 0.000% (0.000–0.406) 0.221% (0.027–0.794) 2011 
Malta 4 1 2,300 0.174% (0.047–0.445) 0.043% (0.001–0.242) 2011 
Netherlands 12 7 35,166 0.034% (0.018–0.060) 0.020% (0.008–0.041) 2011 
Norway 5 6 17,940 0.028% (0.009–0.065) 0.033% (0.012–0.073) 2011 
Poland  1,225 2,021 272,310 0.450% (0.425–0.476) 0.742% (0.710–0.775) 2010 
Portugal  - - - 0.094% 0.165% 2006 
Romania  2,711 520 88,066 3.078% (2.965–3.195) 0.590% (0.541–0.643) 2011 
Slovakia 29 10 40,140 0.072% (0.048–0.104) 0.025% (0.012–0.046) 2011 
Slovenia  11 2 12,677  0.087% (0.043–0.155) 0.016% (0.002–0.057) 2009 
Spain  391 230 232,893 0.168% (0.152–0.185) 0.099% (0.086–0.112) 2011 
Sweden  21 29 49,071  0.043% (0.026–0.065) 0.059% (0.040–0.085) 2009 
United Kingdom 82 81 216,083 0.038% (0.030–0.047) 0.037% (0.030–0.047) 2011 
a Calculated using the Fisher exact method for 95% CI, provided that case numbers were available 
b France: The French blood service is composed of the French National Blood Service (EFS) (17 blood centres) and the French 
Army Transfusion Service (CTSA) with one blood centre. Data of both organisations are reported. .  
c Latvia: Since 2003 only data on HIV have been presented and no data are available on HBV/HCV.  



























































































































Liechtenstein  37,129 - - - - - - 






















































Total 512,318,382 0.9% (0.7–1.2) 4,675,959 1.1% (0.9–1.4) 5,574,391 - - 
* Eurostat 2014 
** Retroactively computed 95% CI from reported prevalence and sample size 
*** No sample size reported  
























among MSM in Zagreb 




N/S 2013 Convenience Online survey with free, 
anonymous STI screening 









Online survey with free, 
anonymous STI screening 







Multi-centre 2009 Convenience Screening offered in 14 bars, 
saunas and 'backrooms'  












Local 2001–2003 Exhaustive Retrospective analysis of 
samples from all new clients of 
Edinburgh STI clinic 












































among MSM in Zagreb 
N/R 360 2.5% (1.1–4.7) 
Estonia Rüütel 
(2015a) (101) 
N/S 2013 Convenience Online survey with free, 
anonymous STI screening 
18 to 67, 
mean age 
33 







Online survey with free, 
anonymous STI screening 
14 to 68, 
mean age 
30 
113 1.8% (0.2–6.2) 
France Sauvage 
(2015) (103) 
Multi-centre 2009 Convenience Screening offered in 14 bars, 
saunas and 'backrooms'  
>18 876 1.0% (0.5–1.9) 
Italy Di Benedetto 
(2012) (107) 
Local 2010 Convenience Men living in Sicily for more than 
six months, recruited via internet 
and in gay bars 
18 to 56, 
mean age 
30 





Convenience Attendees of a Stockholm STI 
clinic 
16 to 82, 
mean age 
33 
1,008 0.6% (0.2–1.3) 




Convenience Cohort study in Amsterdam Mean age 
31.8 
1,836 1.3% (0.8–1.9) 
Netherlands Van Rooijen 
(2013) (110) 
Local 2007 Convenience STI clinic attendees opting out 
of HIV testing 





Local 2008 Convenience Multi-centre study in gay bars, 
saunas and clubs 







Convenience STI clinic attendees N/R 3,395 1.6% (1.2–2.0) 

















Bulgaria Popov (2012) 
(113) 








Convenience Multi-centre study in 20 
prisons. Sample includes PWID 
32 to 70 3,348 1.3% (0.9–1.7) 




Convenience Multi-centre study in 20 
prisons. Sample includes PWID 
16 to 18 140 1.4% (0.2–5.1) 




Convenience Multi-centre study in 20 
prisons. Sample of men only 
N/R 3,160 1.3% (0.9–1.8) 
Croatia Pooled Pooled 2004–
2007 
Pooled Pooled Pooled 6,508 1.3% (1.0–1.6) 
Finland Viitanen 
(2011) (115) 
National 2006 Mixed 
methods 
National coverage 16 to 69 383 0.5% (0.1–1.9) 




Exhaustive Two maisons d'arret in 
Clermont-Ferrand and Riom. 
97% male 
25 to 39, 
mean age 30 
347 0.6% (0.1–2.1) 




Exhaustive All inmates 21 to 60 4,894 1.5% (1.2–1.8) 
Ireland Drummond 
(2014) (117) 
National 2011 Random  National coverage–all adult 
inmates (sentenced and 
remand) 





Convenience Multi-centre study in eight 
prisons. Mixed gender, includes 
PWID 
Mean age 36 973 6.7% (5.2–8.4) 
Luxembourg Removille 
(2011) (119) 
Multi-centre 2005 Convenience Multi-centre study in two 
prisons. Population of problem 
drug users (not all PWID) 





Exhaustive  Study in regional prison of 
Coimbra. Includes PWID  























Local 2012 Exhaustive  Implementation of routine 
testing in a maximum security 
psychiatric hospital 



































Convenience Study in a London prison 
among participants of TB 
screening 





Pooled Pooled Pooled 640 1.6% (0.8–2.9) 
# Estimates used for the pooled estimate 

















Bulgaria# Popov (2013) 
(125) 
Multi-centre N/R Convenience Five adult prisons and one 
juvenile facility 
N/R 658 28.6% (25.1–
32.2) 
Bulgaria# Popov (2010) 
(126) 
Multi-centre N/R Convenience Five adult prisons and one 
juvenile facility 
N/R 498 24.7% (21.0–
28.7) 
Bulgaria Popov (2012) 
(113) 






Bulgaria Pooled Pooled N/R Pooled Pooled Pooled 1,156 26.3% (23.5–
29.3) 




Convenience Multi-centre study in 20 
prisons. Sample includes PWID 
32 to 70 3,348 12.5% (11.4–
13.7) 




Convenience Multi-centre study in 20 
prisons. Sample includes men 
and women. 24% PWID 
N/R 3,348 14.2% (13.0–
15.4) 




Convenience Multi-centre study in 20 
prisons. Sample includes PWID 
16 to 18 140 4.3% (1.6–9.1) 
Croatia Pooled  Pooled 2004–
2007 
Pooled Pooled Pooled 6,696 13.3% (12.5–
14.2) 
Finland Viitanen (2011) 
(115) 
National 2006 Mixed 
methods 
National coverage 16 to 69 383 45.8% (40.8–
51.0) 
France# Semaille (2013) 
(127) 
National 2010 Random  Stratified samping by facility 
characteristics. Prisoners 
randomly sampled 
18 to >50 1,876 4.8% (3.9–5.9) 
France# Remy (2006) 
(128) 
Multi-centre 2003 Other Multi-centre study. Prisons 
asked to report screening 
practices, number of cases and 
capacity 
N/R 31,215 6.8% (6.5–7.1) 
France# Remy (2006) 
(128) 
Multi-centre 2000 Other Multi-centre study. Prisons 
asked to report screening 
practices, number of cases and 
capacity 
N/R 27,245 6.0% (5.8–6.3) 




Exhaustive Two maisons d'arret in 
Clermont-Ferrand and Riom. 
97% male 
25 to 39, 
mean age 30 
342 4.7% (2.7–7.5) 




Exhaustive Multi-centre study involving all 
inmates. Unspecified facilities 
N/R 1,720 6.5% (5.4–7.8) 




Convenience Screening study. Testing 
offered due to multiple risk 
factors or on inmates request. 
93% male 
Mean age 28 5,957 5.2% (4.6–5.8) 








442 3.8% (2.3–6.1) 
France Pooled Pooled 2000–
2013 
Pooled Pooled Pooled 68,797 6.3% (6.1–6.5) 
Germany Meyer (2007) 
(132) 
Local 2002 Exhaustive  Largest German juvenile 
prison. All new inmates offered 
screening 
>16 1,125 8.6% (7.0–10.4) 




Exhaustive  Multi-centre study. All new 
inmates who had ever used 
illicit drugs (nasal or IV) 
offered screening 
N/R 173 83.2% (76.8–
88.5) 
Germany Karakaya and 
Stark (2009) 
(134) 
Local N/R Convenience Single prison study (Berlin). 
Females only, >90% PWID 
22 to 47, 
mean age 31 
106 84.9% (76.6–
91.1) 
Germany Karakaya and 
Stark (2009) 
(134) 
Local N/R Convenience Single prison study (Berlin). 
Males only, >90% PWID 
23 to 47, 
mean age 31 
48 77.1% (62.7–
88.0) 




Exhaustive All inmates 21 to 60 4,894 4.9% (4.3–5.6) 




































Convenience Multi-centre study in eight 
prisons. Mixed gender. 
Includes PWID 
Mean age 36 973 38.0% (35.0–
41.2) 




Convenience Male inmates in Secondigliano 
prison, Naples 




Multi-centre 2005 Convenience Multi-centre study in two 
prisons. Population of problem 
drug users (not all PWID) 






Exhaustive  Study in regional prison of 
Coimbra. Includes PWID  





Portugal Barros (2008) 
(136) 
Local 2005 N/R Inmates of largest female 
prison (57% of all female 
inmates). 96.5% PWID 














National 2009 Other Data from the National Centre 
for Prison Health Co-ordination  




National 2008 Other Data from the National Centre 
for Prison Health Co-ordination  





National 2007 Other Data from the National Centre 
for Prison Health Co-ordination  





National 2006 Other Data from the National Centre 
for Prison Health Co-ordination  





National 2005 Other Data from the National Centre 
for Prison Health Co-ordination  





National 2004 Other Data from the National Centre 
for Prison Health Co-ordination  





National 2003 Other Data from the National Centre 
for Prison Health Co-ordination  





National 2002 Other Data from the National Centre 
for Prison Health Co-ordination  





National 2001 Other Data from the National Centre 
for Prison Health Co-ordination  




(2010) (137)  
National 2000 Other Data from the National Centre 
for Prison Health Co-ordination  






Convenience Hospitalized prisoners in the 
province of Valencia 
17 to 74 2,332 14.7% (13.3–
16.2) 
Spain# Murcia (2009) 
(139) 
Local 2001 Exhaustive Single prison study in Alicante 
involving all inmates 
N/R 730 38.2% (34.7–
41.9) 
Spain Pooled  Pooled 2000–
2009 








Exhaustive  Multi-centre study in all 14 
prisons in Scotland including 
females and juvenile inmates. 
32% history of IDU. 5% female 









Local 2012 Exhaustive  Implementation of routine 
testing in a maximum security 
psychiatric hospital 







Convenience Study in a London prison 
among participants of TB 
screening 







Convenience STI clinic attendees in a 
medium security male prison in 
Oxfordshire 






Local N/R Convenience STI clinic attendees in a young 
offenders institute 
16 to 21, 
mean age 19 



















# Estimates used for the pooled estimate  
Table A15. Prevalence of HBsAg in PWID, EU/EEA countries [16] 
Country 
National data Regional dataa 









Austria -  - - - Vienna 2013 2.7% 




Bulgaria -  - - - Sofia 2013 4.5% 
Croatia 2007 200 
 





Cyprus 2013 82 6.1% (2.0–
13.7) 
DT DTC - - - 
Estonia -  - - - Tallinn 2013 4% 
Germany -  - - - Berlin & Essen 2011 0.3%–1.5% 
Greecef 2013 1,337 3.0% (2.2–4.1) DT DTC; LTS; 





Hungary 2011 664 0.5% (0.1–1.3) SP DTC, NSP Six counties 2013 2.2% 
Ireland 2010 200 0.5% (0.0–2.8) SP PRI - 
  
Latvia 2013 562 2.1% (1.1–3.7) DT NSP Seven cities 2013 2.9% 
Netherlan
ds 
-  - - - Amsterdam 2012 0% 
Norway -  - - - Oslo 2012 0.9% 
Poland -  - - - Gdansk & 
Krakow 
2009 2.5%–3.8% 




- - - 
Romania -  - - - Bucharest 2009 4.7% 
Slovakia -  - - - Bratislava 2013 2.6% 
United 
Kingdom 
-  - - - Wales 2013 0.7% 
a Various study designs and settings included 
b Samples with sample size under N = 10 were excluded 
c Calculated using the Fisher exact method for 95% CI 
d Study design: DT = diagnostic testing; SP = specific prevalence study (UAT = unlinked anonymous testing); RDS = respondent-
driven sampling; SR = prevalence study based on self-reported test results 
e Setting: ANT = antenatal clinics; ARR = arrests; DEM = drug emergencies; DTC = drug treatment centres*; GPS = general 
practitioners; HTC = HIV testing centres; LTS = low-threshold services; NSP = needle exchanges; ODD = overdose deaths; OHC 
= other hospital or clinics; OTH = other; STI = STI clinics; STR = street; PHL = public health laboratories; PRI = prisons; IDUnk 
= IDU status not known** 
f Greece: two national estimates were pooled 
 
* Having health problems is one selection criterion for admission to drug treatment in some countries or cities (Greece, Portugal, 
and Rome); due to long waiting lists or special programmes for infected IDUs, this may result in upward bias of prevalence. 
** Data sources with no information on injecting status were excluded if possible because of the possible severe underestimation 
of prevalence in injectors.   
Some of these data sources were included if samples were large or provided trends over time, in which case it is indicated that 














Table A16. Prevalence of anti-HCV in PWID, EU/EEA countries [17] 
 
Country 





HCV (95% CIc) 













Bulgaria - - - - - Sofia 2013 62.7% 





Cyprus 2013 82 47.6% (36.4–58.9) DT DTC - - - 
Czech 
Republic 
2013 1,889 14.6% (13.1–16.3) DT NSP - - - 
Denmark 2008 223 52.5% (45.7–59.2) SP (UAT) ODD, 3 sites - - - 
Estonia - - - - - Tallinn 2013 90.2% 




Germany - - - - - Essen & Berlin 2011 56.0%–71.6% 









Hungary 2011 652 24.1% (20.8–27.6) SP DTC; NSP Eight counties 2013 31.9% 
Ireland 2010 200 41.5% (34.6–48.7) SP PRI - - - 





Latviah 2013 522 70.1% (66.0–74.0) DT NSP Riga 2011 81.5% 
Lithuania - - - - 
 
Vilnius 2012 27.6% 
Malta  2013 109 13.8% (7.9–21.7) DT DTC; HTC; PHL; 
STI; ANT; OHC 
- - - 
Nether-
lands 
- - - -  Amsterdam 2013 39.3% 
Norway 2013 6,342 63.0% (61.8–64.2) SP DTC Oslo 2012 63.8% 
Poland 




Portugal 2013 414 84.3% (80.4–87.7) DT DTC (drug 
free/detox, only 
Outpatient) 
- - - 
Romania - - - - - Bucharest 2009 82.9% 
Slovakia  - - - - - Bratislava 2013 36.2% 
Slovenia 2009 112 32.1% (23.6–41.6) DT DTC - - - 


















a Various study designs and settings included 
b Samples with sample size under N = 10 were excluded 
c Calculated using Fisher method for 95% CI 
d Study design: DT = diagnostic testing; SP = specific prevalence study (UAT = unlinked anonymous testing); RDS = 













e Setting: ANT = antenatal clinics; ARR = arrests; DEM = drug emergencies; DTC = drug treatment centres*; GPS = general 
practitioners; HTC = HIV testing centres; LTS = low-threshold services; NSP = needle exchanges; ODD = overdose deaths; OHC 
= other hospital or clinics; OTH = other; STI = STI clinics; STR = street; PHL = public health laboratories; PRI = prisons; IDUnk 
= IDU status not known** 
f Greece: two national estimates were pooled 
g Italy: Data collection system was changed. Aggregated data were collected before 2012, and since then individual detailed data 
are available. In that sense, data are not comparable with previous years 
h Latvia: IDUs status changed from unknown to ever IDUs after 2011 
i United Kingdom: Data collection for Scotland is not following calendar year, but tax year (i.e. from April 201x to March 201x) 
* Having health problems is one selection criterion for admission to drug treatment in some countries or cities (Greece, Portugal, 
Rome), due to long waiting lists or special programmes for infected IDUs, this may result in upward bias of prevalence. 
** Data sources with no information on injecting status were excluded if possible because of the possible severe underestimation 
of prevalence in injectors.  
Some of these data sources were included if samples were large or provided trends over time, in which case it is indicated that 
injecting status is unknown and that prevalence among injectors may be underestimated. 
Table A17. Prevalence of HBsAg in migrants by country/region of origin, EU/EEA  
Country Country of origin 







Prevalence of HBsAg 
(95% CI) 
Greece Former Soviet Union Zacharakis (2009) (143) 1998–2006 RS 463 4.3% (2.7–6.6) 
Italy Asia Stornaiuolo (2014) (144) 1999–2009 OS  115 0.0% (0.0–3.2) 
Italy Eastern Europe Stornaiuolo (2014) (144) 1999–2009 OS 211 3.3% (1.3–6.7) 
Italy Sub-Saharan Africa Stornaiuolo (2014) (144) 1999–2009 OS 2,198 8.1% (7.0–9.3) 
Netherlands Countries with >2% HBV 
prevalenceb 
Hahné (2011) (18) 2006–2007 RS 406 2.2% (1.0–4.2) 
Netherlands Afghanistan Richter (2014) (145) 2011 IBS  293 2.0% (0.8–4.4) 
Netherlands Cape Verde Veldhuijzen (2009) (53) 2004 RS  13 0.0% (0.0–24.7) 
Netherlands China and Hong Kong Veldhuijzen (2012) (146) 2009 OS 849 9.7% (7.8–11.8) 
Netherlands Dutch Antilles Veldhuijzen (2009) (53) 2004 RS  38 2.6% (0.1–13.8) 
Netherlands Egypt Zuure (2013) (147) 2004 CBS  465 1.1% (0.4–2.5) 
Netherlands Former Soviet Union Richter (2014) (145) 2011 IBS 65 0.0% (0.0–5.5) 
Netherlands Iran Richter (2014) (145) 2011 IBS 153 0.7% (0.0–3.6) 
Netherlands Iraq Richter (2014) (145) 2011 IBS 290 0.7% (0.1–2.5) 
Netherlands Morocco Baaten (2007) (148) 2004 RS 261 0.4% (0.0–2.2) 
Netherlands Morocco Veldhuijzen (2009) (53) 2004 RS 44 0.0% (0.0–8.0) 
Netherlands Suriname Veldhuijzen (2009) (53) 2004 RS 56 0.0% (0.0–6.4) 
Netherlands Turkey Baaten (2007) (148) 2004 RS 304 4.9% (2.8–8.0) 
Netherlands Turkey Richter (2011) (149) 2009 CBS 544 3.1% (1.8–5.0) 
Netherlands Turkey Veldhuijzen (2009) (53) 2004 RS 54 1.9% (0.0–9.9) 
Netherlands Vietnam Richter (2014) (145) 2011 CBS 126 9.5% (5.0–16.0) 
Norway Pakistan Bjerke (2010) (150) 2009 RS 224 1.3% (0.3–3.9) 
United Kingdom Bangladesh McPherson (2013) (151) n/s CBS 208 0.5% (0.0–2.6) 
United Kingdom Bangladesh Uddin (2010) (152) n/s CBS 726 1.5% (0.8–2.7) 
United Kingdom China (including Hong Kong) McPherson (2013) (151) n/s CBS 470 8.9% (6.5–11.9) 
United Kingdom India O'Leary (2010) (153) 2009–2010 CBS 137 0.0% (0.0–2.7) 
United Kingdom India Uddin (2010) (152) n/s CBS 1,197 0.1% (0.0–0.5) 
United Kingdom Other south Asian countriesc McPherson (2013) (151) n/s CBS 19 5.3% (0.1–26.0) 
United Kingdom Other south Asian countriesc O'Leary (2010) (153) 2009–2010 CBS 101 4.0% (1.1–9.8) 
United Kingdom Other south-east Asian 
countriesd 
McPherson (2013) (151) n/s CBS 38 5.3% (0.6–17.7) 
United Kingdom Pakistan McPherson (2013) (151) n/s CBS 222 3.2% (1.3–6.4) 
United Kingdom Pakistan O'Leary (2010) (153) 2009–2010 CBS 882 0.8% (0.3–1.6) 
United Kingdom Pakistan Uddin (2010) (152) n/s CBS 2,458 1.8% (1.3–2.4) 
United Kingdom Vietnam McPherson (2013) (151) n/s CBS 23 17.4% (5.0–38.8) 
Source: ECDC; adapted from ‘Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA’ [in press]  
a Study design: RS = random sample, OS = outreach screening, CBS = community-based screening, IBS = invitation-based 
screening 
b Countries with >2% HBV prevalence: medium or high HBV-endemic countries 
c South Asian countries other than Pakistan, India and Bangladesh 













Table A18. Prevalence of anti-HCV in migrants, by country/region of origin, EU/EEA 
Country Country of birth 








Prevalence of anti-HCV 
(95% CI) 
Italy Asia Stornaiuolo (2014) (144) 1999–2009 OS 115 3.5% (1.0–8.7) 
Italy Eastern Europe Stornaiuolo (2014) (144) 1999–2009 OS 211 7.1% (4.0–11.5) 
Italy Sub-Saharan Africa Stornaiuolo (2014) (144) 1999–2009 OS 2,198 2.5% (1.9 –3.2) 
Netherlands Afghanistan Richter (2014) (145) 2011 IBS  293 1.0% (0.2–3.0) 
Netherlands Cape Verde Veldhuijzen (2009) (53) 2004 RS 13 0.0% (0.0–24.7) 
Netherlands Dutch Antilles Veldhuijzen (2009) (53) 2004 RS 38 2.6% (0.1–13.8) 
Netherlands Egypt Zuure (2013) (147) 2004 CBS  465 2.4% (1.2–4.2) 
Netherlands Former Soviet Union Richter (2014) (145) 2011 IBS 65 3.1% (0.4–10.7) 
Netherlands Iran Richter (2014) (145) 2011 IBS 153 0.7% (0.0–3.6) 
Netherlands Iraq Richter (2014) (145) 2011 IBS 290 0.3% (0.0–1.9) 
Netherlands Morocco Urbanus (2011) (99) 2003–2009 RS 255 0.4% (0.0–2.2) 
Netherlands Morocco Urbanus (2011) (99) 2006–2007 RS 36 2.8% (0.1–14.5) 
Netherlands Morocco Veldhuijzen (2009) (53) 2004 RS 40 2.5% (0.1–13.2) 
Netherlands Non-western ethnicity Urbanus (2011) (99) 2003–2009 RS 764 0.7% (0.2–1.5) 
Netherlands Non-western ethnicity Urbanus (2011) (99) 2006–2007 RS 442 2.3% (1.1–4.1) 
Netherlands Other non-western 
ethnicity 
Urbanus (2011) (99) 2003–2009 RS 165 1.8% (0.4–5.2) 
Netherlands Other non-western 
ethnicity 
Urbanus (2011) (99) 2006–2007 RS 374 1.9% (0.8–3.8) 
Netherlands Suriname Veldhuijzen (2009) (53) 2004 RS 57 1.8% (0.0–9.4) 
Netherlands Suriname Urbanus (2011) (99) 2003–2009 RS 66 3.0% (0.4–10.5) 
Netherlands Suriname Urbanus (2011) (99) 2006–2007 RS 102 2.0% (0.2–6.9) 
Netherlands Turkey Urbanus (2011) (99) 2003–2009 RS 309 0.0% (0.0–1.2) 
Netherlands Turkey Urbanus (2011) (99) 2006–2007 RS 65 0.0% (0.0–5.5) 
Netherlands Turkey Veldhuijzen (2009) (53) 2004 RS 47 0.0% (0.0–7.5) 
Netherlands Turkey Richter (2011) (149) 2009 CBS 544 0.4% (0.0–1.3) 
Netherlands Vietnam Richter (2014) (145) 2011 CBS 126 1.6% (0.2–5.6) 
United Kingdom Bangladesh McPherson (2013) (151) n/s CBS 208 0.0% (0.0–1.8) 
United Kingdom Bangladesh Uddin (2010) (152) n/s CBS 726 0.6% (0.2–1.4) 
United Kingdom India Uddin (2010) (152) n/s CBS 1,197 0.2% (0.0–0.6) 
United Kingdom India O'Leary (2010) (153) 2009–2010 CBS 137 2.9% (0.8 –7.3) 
United Kingdom Other south Asian 
countriesb 
McPherson (2013) (151) n/s CBS 19 0.0% (0.0–17.6) 
United Kingdom Other south Asian 
countriesb 
O'Leary (2010) (153) 2009–2010 CBS 101 2.0% (0.2–7.0) 
United Kingdom Pakistan McPherson (2013) (151) n/s CBS 222 1.8% (0.5–4.5) 
United Kingdom Pakistan O'Leary (2010) (153) 2009–2010 CBS 882 3.1% (2.0–4.4) 
United Kingdom Pakistan Uddin (2010) (152) n/s CBS 2,458 2.7% (2.1–3.4) 
Source: ECDC. Adapted from ‘Epidemiological assessment of hepatitis B and C among migrants in the EU/EEA’ [in press] 
a Study design: RS = random sample, OS = outreach screening, CBS = community-based screening, IBS = invitation-based 
screening 














Annex 3. Country profiles 
3.1 Austria 
HbsAg prevalence  
Author 












Council of Europe First-time blood 
donors 
2010 N/A 46,603 N/A N/A N/A 
 
Author (year of publication) Sampling period Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 














Sampling description Age range 
Diab-Elschahawi et al. (2013) Pregnant women 2009–2011 1 4,222 Exhaustive Universal antenatal 
screening at Vienna 
University Hospital 
18 to 43 
Council of Europe First-time blood 
donors 
2010 N/A 46,603 N/A N/A N/A 
 










Diab-Elschahawi et al. (2013) 2009–2011 1.7% (1.4–2.2) 4,222 
First-time blood donors 
Council of Europe 2010 0.0% (0.02–0.06) 46,603 






Testing settings and sample size  
(if available) 
Estimated prevalence range 
EMCDDA 2013 HBsAg Drug treatment, harm reduction and low-threshold 
services in Vienna. N=N/A 
2.7% (no CI available) 















3.2 Belgium  
HbsAg prevalence  
Author 










Sampling description Age range 
Quoilin et al. (2007) General 
population 
2002 4 Standardised Random Region of Flanders Standardised 
Quoilin et al. (2007) General 
population 
2002 4 1,830 Random Region of Flanders 0 to >65 
Nardone et al. (2009) General 
population 
2002–2003 3 321 Convenience Residual lab samples 
representative of 
location and gender  
16 to 39 
Nardone et al. (2009) General 
population 
2002–2003 3  
1,175 
Convenience Residual lab samples 
representative of 
location and gender  
1 to 15 
Council of Europe First-time blood 
donors 
2011 N/A 53,524 N/A N/A N/A 
 




Estimate (95% CI) 
Sample 
size 
Forest plot of estimates and 95% CI 
General population  
 
Quoilin et al. (2007) 2002 0.7% (0.5–0.8) Standardised 
Quoilin et al. (2007) 2002 0.7% (0.4–1.2) 1,830 
Nardone et al. (2009) 2002–2003 0.6% (0.1–2.2) 321 
General population – children 
Nardone et al. (2009) 2002–2003 0.7% (0.3–1.3) 1,175 
First-time blood donors 
Council of Europe 2011 0.08% (0.05–0.1) 53,524 
Anti-HCV prevalence 
Author (year of publication) Population 
Sampling 
period 






Sampling description Age range 
Quoilin et al. (2007) General 
population 
2002 4 1,830 Random Region of Flanders 0 to >65 
Council of Europe First-time blood 
donors 
2011 N/A 53,524 N/A N/A N/A 
 
Author (year of publication) 
Sampling 
period 
Estimate (95% CI) Sample size Forest plot of estimate and 95% CI 
General population  
 
Quoilin et al. (2007) 2002 0.1% (0.0–0.4) 1,830 
First-time blood donors 
Council of Europe 2011 0.04% (0.02–0.06) 53,524 






Testing settings and sample size  
(if available) 
Estimated prevalence range  
(no CI available) 
EMCDDA 2013 HBsAg Drug treatment services in Antwerp and the Flanders 
region. N=N/A 
0.0% to 1.58% 
EMCDDA 2013 Anti-HCV Drug treatment and harm reduction services in 
Antwerp and the Flanders region. N=N/A 
















HbsAg prevalence  
Author 










Sampling description Age range 
Popov et al. (2012) Prisoners 
(juveniles) 
2010 3 258 Convenience Study in two juvenile 
facilities 
N/R 
Council of Europe First-time blood 
donors 






Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 
Prisoners  
 
Popov et al. 
(2012) 
2010 25.2% (20.0-31.0) 258 
 
First-time blood donors 
Council of 
Europe 
2011 3.22% (3.04–3.42) 33,961 
Anti-HCV prevalence  
Author 









Sampling description Age range 
Pooled estimates Prisoners N/A N/A 1,156 Pooled Pooled Pooled 
Popov el al (2013) Prisoners N/R 5 658 Convenience Four adult prisons and one 
juvenile facility 
N/R 
Popov el al (2010) Prisoners N/R 5 498 Convenience Four adult prisons and one 
juvenile facility 
N/R 
Popov et al. (2012) Prisoners 2010 3 258 Convenience Study in two juvenile 
detention facilities 
N/R 
Council of Europe First-time blood 
donors 
2011 N/A 33,961 N/A N/A N/A 
 
Author  







Forest plot of estimates and 95% CI 
Prisoners  
 
Pooled estimates N/A 26.9% 
(24.4-29.6) 
1,156 
Popov el al (2013) N/R 28.6% 
 (15.2-32.2) 
658 
Popov el al (2010) N/R 24.75  
(21.0-28.7) 
498 
Popov et al. (2012) 2010 20.5%  
(15.8-26.0) 
258 
First-time blood donors 
Council of Europe 2011 0.34% 
 (0.28–0.41) 
33,961 






Testing settings and sample size  
(if available) 
Estimate (CI not available) 
EMCDDA 2013 HBsAg Street-based testing of ever injectors in Sofia. N=N/A 4.5% 






























Vilibic-Cavlek et al. (2014) General 
population 
2010–2011 4 2,009 Convenience Multi-centre study 
of patients 
attending a check-
up. Covers 20% of 
regions 
20 to 80 
Burek et al. (2010) General 
population 
2005–2007 3 259 N/R Multi-centre study 
of staff in 20 
prisons (10.9% of 
all prison staff) 
N/R 
Bozicevic et al. (2009) MSM 2006 2 360 Respondent-
driven 
Zagreb N/R 
Pooled estimate Prisoners 2004–
2007 
N/A 6,508 Pooled Pooled Pooled 
Burek et al. (2010) Prisoners 2005–2007 5 3,348 Convenience Multi-centre study 
in 20 prisons. 
Sample includes 
PWID 
32 to 70 
Burek et al. (2009) Prisoners 2004–2006 4 3,160 Convenience Multi-centre study 
in 20 prisons. 
Sample of men only 
N/R 
Burek et al. (2010) Prisoners 2005–2007 4 140 Convenience Multi-centre study 
in 20 prisons. 
Sample includes 
PWID 
16 to 18 
Council of Europe First-time 
blood donors 
2011 N/A 8,599 N/A N/A N/A 
 








Forest plot of estimates and 95% CI 
General population  
 
Vilibic-Cavlek et al. (2014) 2010–2011 0.8% (0.4–1.2) 2,009 
Burek et al. (2010) 2005–2007 2.3% (0.9–5.0) 259 
MSM 
Bozicevic et al. (2009) 2006 0.6% (0.1–2.0) 360 
Prisoners 
Pooled estimate 2004–2007 1.3% (1.0–1.6) 6,508 
Burek et al. (2010) 2005–2007 1.3% (0.9–1.7) 3,348 
Burek et al. (2009) 2004–2006 1.3% (0.9–1.8) 3,160 
Burek et al. (2010) 2005–2007 1.4% (0.2–5.1) 140 
First-time blood donors 
Council of Europe 2011 0.23% (0.14–0.36) 8,599 
Anti-HCV prevalence 
Author  















Vilibic-Cavlek et al. (2014) General 
population 
2010–2011 4 1,930 Convenience Multi-centre study of 
patients attending a check-
up. Covers 20% of regions 
20 to 80 
Burek et al. (2010) General 
population 
2005–2007 3 259 N/R Multi-centre study of staff 
in 20 prisons (10.9% of all 
prison staff) 
N/R 





























Bozicevic et al. (2009) MSM 2006 2 360 Respondent-
driven 
Zagreb N/R 
Pooled estimates Prisoners 2004–
2007 
N/A 6,696 Pooled Pooled Pooled 
Burek et al. (2010) Prisoners 2005–2007 5 3,348 Convenience Multi-centre study in 20 
prisons. Sample includes 
PWID 
32 to 70 
Burek et al. (2009) Prisoners 2004–2006 5 3,348 Convenience Multi-centre study in 20 
prisons. Sample includes 
men and women. 24% 
PWID 
N/R 
Burek et al. (2010) Prisoners 2005–2007 4 140 Convenience Multi-centre study in 20 
prisons. Sample includes 
PWID 
16 to 18 
Council of Europe First-time blood 
donors 
2011 N/A 8,599 N/A N/A N/A 
 
Author 







Forest plot of estimates and 95% CI 
General population  
 
Vilibic-Cavlek et al. (2014) 2010–2011 0.9%  
(0.6–1.5) 
1,930 




Cavlek et al. (2009) 2003–2006 2.9%  
(1.1–6.3) 
205 









Burek et al. (2010) 2005–2007 12.5%  
(11.4-13.7) 
3,348 
Burek et al. (2009) 2004–2006 14.2%  
(13.0-15.4) 
3,348 
Burek et al. (2010) 2005–2007 4.3% 
(1.6–9.1) 
140 
First-time blood donors 
Council of Europe 2011 0.14%  
(0.07–0.24) 
8,599 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2007 HBsAg National sample of ever injectors from prisons. N=200 0.5% (0.0%–2.8%) 
















HbsAg prevalence  
Author 













Council of Europe First-time blood 
donors 
2008 N/A 4,532 N/A N/A N/A 
 
Author (year of publication) 
Sampling 
period 
Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 
Council of Europe 2008 0.44% (0.27–0.68) 4,532 
 
Anti-HCV prevalence  
Author 












Council of Europe First-time blood 
donors 
2008 N/A 4,532 N/A N/A N/A 
 
Author (year of publication) 
Sampling 
period 
Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 
Council of Europe 2011 0.23% (0.11–0.41) 4,532 
 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2013 HBsAg National sample of ever injectors from drug treatment 
services. N=82 
6.1% (2.0%–13.7%) 
EMCDDA 2013 Anti-HCV National sample of ever injectors from drug treatment 
services. N=82 
47.6% (36.4%–58.9%) 
3.6 Czech Republic 
HbsAg prevalence  
Author 














Nardone et al. (2009) General 
population 
2001 4 Standardised N/R N/R Standardised 
Nardone et al. (2009) General 
population 
2001 4 975 Random N/R 1 to 15  
Nardone et al. (2009) General 
population 
2001 4 1148 Random N/R 16 to 39  
Nardone et al. (2009) General 
population 
2001 4 521 Random N/R >40  
Nardone et al. (2009) General 
population 
2001 4 1669 Random N/R 16 to >40 
Council of Europe First-time 
blood donors 





















Forest plot of estimates and 95% CI 
General population  
 
Nardone et al. (2009) 2001 0.6% Standard-
ised 
Nardone et al. (2009) 2001 0.3%  
(0.1–0.9) 
975 
Nardone et al. (2009) 2001 0.2%  
(0.0–0.6) 
1148 
Nardone et al. (2009) 2001 0.8%  
(0.2–2.0) 
521 
Nardone et al. (2009) 2001 0.4%  
(0.1–0.8) 
1669 
First-time blood donors 
Council of Europe 2011 0.06% 
(0.04–0.08) 
49122 
Anti-HCV prevalence  
Author 










Sampling description Age range 
Council of Europe First-time blood 
donors 
2011 N/A 49122 N/A N/A N/A 
HBsAg and anti-HCV prevalence: PWID 
Author (year of publication) Sampling period Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 









Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2013 Anti-HCV Needle exchanges, N=1,889 14.6% (13.1%–16.3%) 















HbsAg prevalence  
Author 









Sampling description Age range 




N/A 201,353 Pooled Pooled Pooled 
Moller et al. (2014) Pregnant 
women 
2013 3 60,977 Exhaustive National antenatal 
screening programme 
N/R 
Harder et al. (2011) Pregnant 
women 
2005–2007 3 140,376 Exhaustive National antenatal 
screening programme 
N/R 
Council of Europe First-time blood 
donors 
2011 N/A 25,647 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 
Pregnant women  
 





Moller et al. (2014) 2013 0.3%  
(0.2–0.3) 
60,977 
Harder et al. (2011) 2005–2007 0.3%  
(0.2–0.3) 
140,376 
First-time blood donors 
Council of Europe 2011 0.02%  
(0.0–0.04) 
25,647 
Anti-HCV prevalence  
Author 













Council of Europe First-time blood 
donors 
2011 N/A 25,647 N/A N/A N/A 
 
Author (year of publication) 
Sampling 
period 
Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 
Council of Europe 2011 0.02% (0.0–0.04) 25,647 
 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2008 Anti-HCV Overdose deaths (multi-site (N=3) study of post-mortem 
blood). N=223 
52.5% (45.7%–59.2%) 















HbsAg prevalence  
Author 










Sampling description Age range 
Rüütel et al. (2015a) MSM 2013 1 43 Convenience Online survey with free, 
anonymous STI screening 
18 to 67, 
mean age 33 
Rüütel et al. (2015b) MSM 2014–2015 1 97 Respondent-
driven 
Online survey with free, 
anonymous STI screening 
14 to 68, 
mean age 30 
Council of Europe First-time blood 
donors 
2011 N/A 3,752 N/A N/A N/A 
 











Rüütel et al. (2015a) 2013 0.0%  
(0.0–8.2) 
43 
Rüütel et al. (2015b) 2014–2015 1.0%  
(0.0–5.6) 
97 
First-time blood donors 
Council of Europe 2011 0.27% 
(0.13–0.49) 
3,752 
Anti-HCV prevalence  
Author 









Sampling description Age range 
Rüütel et al. (2015a) MSM 2013 1 43 Convenience Online survey with free, 
anonymous STI screening 
18 to 67, mean 
age 33 
Rüütel et al. (2015b) MSM 2014–2015 1 97 Respondent-
driven 
Online survey with free, 
anonymous STI screening 
14 to 68, mean 
age 30 
Council of Europe First-time 
blood donors 
2011 N/A 3,752 N/A N/A N/A 
 











Rüütel et al. (2015a) 2013 4.7%  
(0.6-15.8) 
43 
Rüütel et al. (2015b) 2014–2015 1.8%  
(0.2–6.3) 
97 
First-time blood donors 
Council of Europe 2011 0.96% 
(0.67–1.33) 
3,752 






Testing settings and sample size  
(if available) 
Estimate (CI not available) 
EMCDDA 2013 HBsAg Single centre study of current injectors in a harm reduction 
service in Tallinn. N=N/A 
4.0% 
EMCDDA 2013 Anti-HCV Single centre study of current injectors in a harm reduction 

















HbsAg prevalence  
Author 









Sampling description Age range 
Viitanen et al. (2011) Prisoners  2006 6 383 Mixed methods National coverage 16 to 69 
Council of Europe First-time blood 
donors 
2011 N/A 19,775 N/A N/A N/A 
 











Viitanen et al. (2011) 2006 0.5%  
(0.1–1.9) 
383 
First-time blood donors 
Council of Europe 2011 0.0% (0.0–
0.02) 
19,775 
Anti-HCV prevalence  
Author 









Sampling description Age range 
Viitanen et al. (2011) Prisoners  2006 6 383 Mixed methods National coverage 16 to 69 
Council of Europe First-time blood 
donors 
2011 N/A 19,775 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 
Prisoners  
 
Viitanen et al. (2011) 2006 45.8% 
(40.8-51.0) 
383 
First-time blood donors 
Council of Europe 2011 0.03% 
(0.01–0.06) 
19,775 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2009 Anti-HCV National (multi-centre, N=9) study in harm reduction services. 
Sample of current injectors. N=682 
60.5% (56.8%–64.3%) 















HbsAg prevalence  
Author 










Sampling description Age range 
Meffre et al. (2010) General 
population 
2004 4 18,230 Random  National sample obtained via 
primary health care insurance 
units 
18 to 80 
Bottero et al. (2014) General 
population 
2010–2011 3 3,929 Convenience Multi-centre screening study in 
Paris region includes multiple 
risk groups such as migrants 
and PWID 
Mean age 33 
Richaud-Eyraud et al. 
(2015) 
Pregnant women 2011 2 N/R N/R ELFE cohort study. National 
sample 
25 to 34, 
mean age 30 
Braillon et al. (2010) Pregnant women 2006 1 1,112 Random  Regional coverage. 
Retrospective study design 
Mean age 29 
Sauvage et al. (2015) MSM 2009 2 876 Convenience Screening offered in 14 bars, 
saunas and 'backrooms'  
>18 
Abergel et al. (2014) Prisoners  2012–2013 5 347 Exhaustive Two maisons d'arret in 
Clermont-Ferrand and Riom. 
97% male 
25 to 39, 
mean age 30 
Council of Europe First-time blood 
donors 
2011 N/A 365593 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 
General population  
 
Meffre et al. (2010) 2004 0.7% (0.5–0.9) 18,230 
Bottero et al. (2014) 2010–2011 2.2% (1.7–2.7) 3,929 
Pregnant women 
Richaud-Eyraud et al. (2015) 2011 0.8% (0.6–1.1) N/R 
Braillon et al. (2010) 2006 0.2% (0.0–0.7) 1,112 
MSM 
Sauvage et al. (2015) 2009 1.4% (0.7–2.4) 876 
Prisoners  
Abergel et al. (2014) 2012–2013 0.6% (0.1–2.1) 347 
First-time blood donors 
Council of Europe 2011 0.07% (0.06–0.08) 365,593 
Anti-HCV prevalence  
Author 











Sampling description Age range 
Meffre et al. (2010) General 
population 
2004 4 18,230 Random  National sample obtained via 
primary health care 
insurance units 
18 to 80 
Sahajian et al. (2007) General 
population 
2003–2004 3 944 Mixed Underprivileged populations 
sampled via primary care 
services. Includes a small 
number of homeless people 
(n=89) and former/active 
PWID (n=16) 
18 to >60 
Poynard et al. (2009) General 
population 
N/R 2 7,463 Convenience Attendees of social security 
health centres 
>40 
Sauvage et al. (2015) MSM 2009 2 876 Convenience Screening offered in 14 bars, 
saunas and 'backrooms'  
>18 
Pooled estimates Prisoners  2000–2013 N/A 68,797 N/A Pooled Pooled 
Semaille et al. (2013) Prisoners 2010 6 1,876 Random  Stratified sampling by facility 
characteristics. Prisoners 
randomly sampled 
18 to >50 
Remy (2006) Prisoners 2003 6 31,215 Other Multi-centre study. Prisons 
asked to report screening 
practices, number of cases 
and capacity 
N/R 
Remy (2006) Prisoners 2000 6 27,245 Other Multi-centre study. Prisons 
asked to report screening 



























Sampling description Age range 
Abergel et al. (2014) Prisoners 2012–2013 5 342 Exhaustive Two maisons d'arret in 
Clermont-Ferrand and Riom. 
97% male 
25 to 39, 
mean age 30 
Vergniol et al. (2014) Prisoners 2012–2013 4 1,720 Exhaustive Multi-centre study involving 
all inmates. Unspecified 
facilities 
N/R 
Roux et al. (2014) Prisoners 2004–2010 4 5,957 Convenience Screening study. Testing 
offered due to multiple risk 
factors or on inmates 
request. 93% male 
Mean age 28 
Verneuil et al. (2009) Prisoners 2000–2003 3 442 Random  Study in a remand centre in 
Caen 
Mean age 29.7 
Council of Europe First-time blood 
donors 
2011 N/A 365,593 N/A N/A N/A 
 
Author  





Sample size Forest plot of estimates and 95% CI 
General population  
 
Meffre et al. (2010) 2004 0.8%  
(0.7–1.1) 
18,230 
Sahajian et al. (2007) 2003–2004 4.7% 
 (3.4–6.2) 
944 














Semaille et al. (2013) 2010 4.8%  
(3.9–5.9) 
1,876 
Remy (2006) 2003 6.8%  
(6.6–7.1) 
31,215 
Remy (2006) 2000 6.0%  
(5.8–6.3) 
27,245 
Abergel et al. (2014) 2012–2013 4.7%  
(2.7–7.5) 
342 
Vergniol et al. (2014) 2012–2013 6.5%  
(5.4–7.8) 
1,720 
Roux et al. (2014) 2004–2010 5.2%  
(4.6–5.8) 
5,957 
Verneuil et al. (2009) 2000–2003 3.9%  
(2.3–6.1) 
442 
First-time blood donors 


















HbsAg prevalence  
Author 










Sampling description Age range 
Pooled estimates General 
population  
N/A N/A 9,303 Pooled Pooled Pooled 




2008–2011 5 7,047 Random  National coverage. DEGS1 
study 
18 to 79 
Huetter et al. (2014) General 
population 
2002 4 2,256 Random  Residents of Leutkirch, 
south Germany 
18 to 65, 
mean 39.4 
Wolffram et al. (2015) General 
population 
2012–2013 2 21,008 Convenience ‘Check-up 35+' attendees 
(mid-life health check) in 
North Rhine-Westphalia 
Mean age 57.5 
Lobstein et al. (2011) Pregnant 
women  
2006–2010 1 8,193 Exhaustive Deliveries in one hospital N/R 




2001–2008 1 15,873 Exhaustive Antenatal screening in 
Leutkirch hospitals, south 
Germany 
N/R 
Council of Europe First-time 
blood donors 
2011 N/A 542,542 N/A N/A N/A 
 





Sample size Forest plot of estimates and 95% CI 
General population  
 
Pooled N/A 0.4%  
(0.3–0.5) 
9,303 
Poethko-Müller et al. (2013) 2008–2011 0.3%  
(0.2–0.6) 
7,047 
Huetter et al. (2014) 2002 0.7%  
(0.4–1.1) 
2,256 




Lobstein et al. (2011) 2006–2010 0.5%  
(0.4–0.6) 
8,193 
Alba-Alejandre et al. (2008) 2001–2008 0.8%  
(0.7–1.0) 
15,873 
First-time blood donors 
Council of Europe 2011 0.12% 
(0.11–0.13) 
542,542 
Anti-HCV prevalence  
Author 











Sampling description Age range 
Pooled estimates General 
population 
N/A N/A 9,303 Pooled Pooled Pooled 




2008–2011 5 7,047 Random  National coverage. DEGS1 
study 
18 to 79 
Huetter et al. (2014) General 
population 
2002 4 2,256 Random  Residents of Leutkirch, 
southern Germany 
18 to 65, 
mean 39.4 
Wolffram et al. (2015) General 
population 
2012–2013 2 21,008 Convenience ‘Check-up 35+' attendees 




Meyer (2007) Prisoners 
(juveniles) 
2002 3 1,125 Exhaustive  Largest German juvenile 
prison. All new inmates 
offered screening 
>16 
Stark et al. (2006) Prisoners  1998–2001 2 173 Exhaustive  Multi-centre study. All new 
inmates who had ever used 
illicit drugs (nasal or IV) 
offered screening 
N/R 
Karakaya and Stark 
(2009) 
Prisoners N/R 1 106 Convenience Single prison study (Berlin). 
Females only, >90% PWID 
22 to 47, 
mean age 31 
Karakaya and Stark 
(2009) 
Prisoners N/R 1 48 Convenience Single prison study (Berlin). 
Males only, >90% PWID 
23 to 47, 
mean age 31 
Council of Europe First-time blood 
donors 






















Forest plot of estimates and 95% CI 
General population  
 





2008–2011 0.3%  
(0.1–0.5) 
7,047 
Huetter et al. 
(2014) 
2002 0.6%  
(0.3–1.0)  
2,256 
Wolffram et al.  
(2015) 





Meyer (2007) 2002 8.6%  
(7.1–10.4) 
1,125 
Stark et al. (2006) 1998–2001 83.2% 
(76.8–88.5) 
173 











First-time blood donors 










Testing settings and sample size  
(if available) 
Estimate (CI not available) 
EMCDDA 2011 HBsAg Four low-threshold services in Berlin and Essen. Sample of 
current injectors. N=N/A 
0.3% to 1.5% 
EMCDDA 2011 Anti-HCV Four low-threshold services in Berlin and Essen. Sample of 
current injectors. N=N/A 
















HbsAg prevalence  
Author 










Sampling description Age range 
Drositis et al. (2013) General 
population 
2006–2010 4 876 Random (87% 
response) 
Adult residents of 
Arkalochori, Crete 
Mean age 52 
Dounias et al. (2005) General 
population 
1999–2001 1 159 Convenience Municipal solid waste 
workers 
Mean age 42 




2003 3 3,384 Exhaustive National antenatal 
screening programme 
N/R 




2009–2011 1 1,304 Exhaustive Antenatal screening 
attendees 
Mean age 27.2 




2009–2011 1 1 000 Exhaustive Antenatal screening non-
attendees screened post-
partum 
Mean age 26.6 
Elefsiniotis et al. (2010) Pregnant 
women 
2008–2009 1 1,826 Exhaustive Consecutive women 
delivering at the Ob/Gyn 
dept. 
N/R 
Kafkoula et al. (2009) Pregnant 
women 
2005–2007 1 2,188 Exhaustive Antenatal screening at 
Thriassio General Hospital 
N/R 
Betsas et al. (2006) Pregnant 
women 
2004 1 544 Exhaustive Attendees of the University 
of Thessaloniki antenatal 
clinic 
Mean age 32.3 
(Greek-born); 
27.1 (migrant) 
Council of Europe First-time 
blood donors 
2011 N/A 57 000 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 
General population  
 
 
Drositis et al. (2013) 2006–2010 3.3% 
(2.2–4.7) 
876 




Papaevangelou et al. (2006) 2003 2.9% 
(2.4–3.5) 
3,384 
Karatapanis et al. (2012) 2009–2011 1.2%  
(0.7–1.9) 
1,304 
Karatapanis et al. (2012) 2009–2011 5.3%  
(4.0–6.9) 
1,000 
Elefsiniotis et al. (2010) 2008–2009 3.8% 
(3.0–4.8) 
1,826 
Kafkoula et al. (2009) 2005–2007 0.1%  
(0.0–0.3) 
2,188 
Betsas et al. (2006) 2004 3.5% 
(2.1–5.4) 
544 
First-time blood donors 

















Drositis et al. (2013) General 
population 
2006–2010 4 876 Random (87% 
response) 
Adult residents of 
Arkalochori, Crete 
Mean age 52 




Council of Europe First-time blood 
donors 















Anti-HCV prevalence  








Forest plot of estimates and 95% CI 
General population  
 




Kafkoula et al. (2009) 2005–2007 1.3%  
(0.9–1.8) 
2,188 
First-time blood donors 
Council of Europe 2011 1.2%  
(1.11–1.29) 
57,000 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2013 HBsAg National sample from ever injectors sampled from various 
services and settings N=1,337 
3.0% (2.2%–4.1%) 
EMCDDA 2013 Anti-HCV National sample from ever injectors sampled from various 
services and settings N=1,309 
68.1% (65.5%–70.6%) 
HBsAg prevalence: migrants 
Country of birth 







Estimate (95% CI) 
Former Soviet 
Union 
Zacharakis (2009) 1998–2006 Random sero-survey in Thrace via mobile 
units across the city 
















HbsAg prevalence  
Author 













Treso et al. (2012) General population 2007–2009 4 1,066 Convenience Prison staff 21 to 60 
Treso et al. (2012) Prisoners  2007–2009 6 4,894 Exhaustive All inmates 21 to 60 
Council of Europe First-time blood 
donors 
2011 N/A 56,632 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 
General population  
 
 




Treso et al. (2012) 2007–2009 1.5%  
(1.2–1.9) 
4,894 
First-time blood donors 
Council of Europe 2011 0.01% 
(0.0–0.02) 
56,632 
Anti-HCV prevalence  
Author 












Treso et al. (2012) General 
population 
2007–2009 4 1,066 Convenience Prison staff 21 to 60 
Treso et al. (2012) Prisoners  2007–2009 6 4,894 Exhaustive All inmates 21 to 60 
Council of Europe First-time blood 
donors 
2011 N/A 56,632 N/A N/A N/A 
 






Sample size Forest plot of estimates and 95% CI 
General population  
 
Treso et al. (2012) 2007–2009 0.5% (0.2–1.1) 1,066 
Prisoners  
Treso et al. (2012) 2007–2009 4.9% (4.3–5.6) 4,894 
First-time blood donors 
Council of Europe 2011 0.16% (0.13–0.2) 56,632 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2011 HBsAg National sample from ever injectors sampled from drug 
treatment and harm reduction services N=664 
0.45% (0%–1.3%) 
EMCDDA 2011 Anti-HCV National sample from ever injectors sampled from drug 

















HbsAg prevalence  
Author 












Council of Europe First-time blood 
donors 
2011 N/A 1,398 N/A N/A N/A 
 
Author (year of publication) 
Sampling 
period 
Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 
Council of Europe 2011 0.07% (0.0–0.4) 1,398 
 
Anti-HCV prevalence  
Author 












Council of Europe First-time blood 
donors 
2011 N/A 1,398 N/A N/A N/A 
 
Author (year of publication) 
Sampling 
period 
Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 



















HbsAg prevalence  
Author 









Sampling description Age range 
Talento et al. (2010) General 
population  
1992–2009 6 1,478 Exhaustive Living and deceased solid 
organ donors 
N/R 
Nardone et al. (2009) General 
population 
2003 3 1,658 Convenience Residual lab samples 
representative of location 
and gender  
16 to >40  
Nardone et al. (2009) General 
population 
2003 3 1,194 Convenience Residual lab samples 
representative of location 
and gender  
16 to 39 
Nardone et al. (2009) General 
population 
2003 3 464 Convenience Residual lab samples 
representative of location 
and gender  
>40 
Nardone et al. (2009) General 
population 
2003 3 877 Convenience Residual lab samples 
representative of location 
and gender  
1 to 15 
O'Connell et al. (2010) Pregnant 
women 
2004–2009 1 24,008 Exhaustive Antenatal screening lab data 
from Galway hospital 
N/R 
Drummond et al. 
(2014) 
Prisoners 2011 6 777 Random 
(49.5% 
response) 
National coverage. All adult 
inmates (sentenced and 
remand) 
Mean age 31 
Council of Europe First-time 
blood donors 
2011 N/A 12,900 N/A N/A N/A 
 




Estimate (95% CI) 
Sample 
size 
Forest plot of estimates and 95% CI 
General population  
 
Talento et al. (2010) 1992–2009 0.1% (0.0–0.4) 1,478 
Nardone et al. (2009) 2003 0.1% (0.0–0.4) 1,658 
Nardone et al. (2009) 2003 0.1% (0.0–0.5) 1,194 
Nardone et al. (2009) 2003 0.2% (0.0–1.2) 464 
Nardone et al. (2009) 2003 0.0% (0.0–0.4) 877 
Pregnant women 
O'Connell et al. (2010) 2004–2009 0.2% (0.2–0.3) 24,008 
Prisoners  
Drummond et al. (2014) 2011 0.3% (0.0–0.9) 777 
First-time blood donors 
Council of Europe 2011 0.04% (0.01–0.09) 12,900 
Anti-HCV prevalence  
Author 









Sampling description Age range 
Talento et al. (2010) General 
population 
1992–2009 6 1,478 Exhaustive Living and deceased solid 
organ donors 
N/R 
Lambert et al. (2013) Pregnant 
women 
2007–2008 1 8,976 Exhaustive 
(98.4% 
coverage) 
Antenatal care attendees of 
Rotunda hospital 
N/R 
Martyn et al. (2011) Pregnant 
women 
2006 1 4,666 Exhaustive Deliveries at a single hospital N/R 
Martyn et al. (2011) Pregnant 
women 
2007 1 9,222 Exhaustive Deliveries at a single hospital N/R 
Drummond et al. 
(2014) 
Prisoners 2011 6 777 Random (50% 
response) 
National coverage. All adult 
inmates (sentenced and 
remand) 
Mean age 31 
Council of Europe First-time 
blood donors 















(year of publication) 
Sampling 
period 
Estimate (95% CI) 
Sample 
size 
Forest plot of estimates and 95% CI 
General population  
 
Talento et al. (2010) 1992–2009 0.1% (0.0–0.4) 1,478 
Pregnant women 
Lambert et al. (2013) 2007–2008 0.9% (0.7–1.1) 8,976 
Martyn et al. (2011) 2007 0.7% (0.6–0.9) 9,222 
Martyn et al. (2011) 2006 1.4% (1.1–1.8) 4,666 
Prisoners 
Drummond et al. (2014) 2011 12.9% (10.6-15.4) 777 
First-time blood donors 
Council of Europe 2011 0.01% (0.0–0.04) 12,900 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2010 HBsAg National sample from ever injectors sampled from the prison 
population N=200 
0.5% (0%–2.8%) 


















HbsAg prevalence  
Author 










Sampling description Age range 
Pooled estimate General 
population 
N/R N/A 3,982 Pooled Pooled Pooled 




2005–2007 5 2,195 Random  GP records in Bari, Apuglia 18 to 93, mean 
age 47 
Pendino et al. (2005) General 
population 
2002–2003 4 1,645 Random  Census data from 
Cittanova, Calabria 
12 to 95 
Floreani et al. (2006) General 
population 
2001 4 142 Random  Residents of Arsita (central 
Italy) 
>8 
Boccalini et al. (2013) General 
population 
2009 3 1,071 Convenience Residual blood samples 
from 0.05% of residents in 
Tuscany 
1 to 50 
Fabris et al. (2008) General 
population 
2002 3 965 Exhaustive  Vicenza, north east Italy. A 
broken sewer pipe 
prompted HAV vaccination. 
Subjects were also tested 
for HBV/HCV 
Mean age 42.1 
Del Corno et al. (2006) General 
population 
N/R 3 2,829 Random  Four towns in Isola 
Bergamasca (north Italy) 
20 to 70 
Dazzani et al. (2009) General 
population 
2008 2 3,207 Convenience Survey of residents in 
Bagnacavallo (Emilia-
Romagna) 
30 to 60 




2007–2008 2 22,758 Convenience Hospital lab samples from 
Legnano Hospital in 
northern Italy 
Mean age 51.4 
Da Villa et al. (2007) General 
population 
2006 2 1,540 N/R Cohort in Afragola, Naples  6 to 58 
Squeri et al. (2006) General 
population 
2005 1 327 Convenience Municipal solid waste 
workers 
20 to 68 
Pooled estimate Pregnant 
women 
N/A N/A 26,951 Pooled Pooled Pooled 
Spada et al. (2014) Pregnant women 2008–2009 3 16,858 Exhaustive  Multi-centre study: 41 
hospitals in 13 regions 
14 to 53 
Ruffini et al. (2014) Pregnant women 2011–2012 2 10,093 Exhaustive 
(99% 
response) 
Regional study. One third 
migrants. 
>17 
Babudieri et al. (2005) Prisoners 2001–2002 4 973 Convenience Multi-centre study in eight 
prisons. Mixed gender. 
Includes PWID 
Mean age 36 
Council of Europe First-time blood 
donors 



















Sample size Forest plot of estimates and 95% CI 
General population  
 
Pooled N/R 0.7% 
(0.4–1.0) 
3,982 
Cozzolongo et al. (2009) 2005–2007 0.6%  
(0.3–1.0) 
2,195 
Pendino et al. (2005) 2002–2003 0.8%  
(0.4–1.4) 
1,645 
Floreani et al. (2006) 2001 0.7%  
(0.0–3.9) 
142 
Boccalini et al. (2013) 2009 2.0%  
(1.2–3.0) 
1,071 
Fabris et al. (2008) 2002 1.0%  
(0.5–1.9) 
965 
Del Corno et al. (2006) N/R 5.8%  
(5.0–6.7) 
2,829 
Dazzani et al. (2009) 2008 0.6%  
(0.4–1.0) 
3,207 
De Paschale et al. (2012) 2007–2008 2.1%  
(2.0–2.3) 
22,758 
Da Villa et al. (2007) 2006 0.9%  
(0.5–1.5) 
1,540 




Pooled N/A 0.8% 
(0.7–1.0) 
26,951 
Spada et al. (2014) 2008–2009 0.9%  
(0.7–1.0) 
16,858 




Babudieri et al. (2005) 2001–2002 6.7% 
(5.2–8.4) 
973 
First-time blood donors 

















Anti-HCV prevalence  
Author 










Sampling description Age range 
Pooled  General 
population 
N/R N/A 4,826 Pooled Pooled Pooled 




2005–2007 5 2,195 Random  GP records in Bari, Apuglia 18 to 93, mean 
age 47 
Pendino et al. (2005) General 
population 
2002–2003 4 1,645 Random  Census data from 
Cittanova, Calabria 
12 to 95 
Floreani et al. (2006) General 
population 
2001 4 697 Random  Residents of Arsita (central 
Italy) 
>8 
Petti et al. (2006) General 
population 
N/R 4 289 Random  GP registration. Local 
coverage 
>25 to >50 
Petti et al. (2006) General 
population 
N/R 4 133 Random  GP registration. Local 
coverage 
25-49 
Petti et al. (2006) General 
population 
N/R 4 156 Random  GP registration. Local 
coverage 
>50 
Del Corno et al. (2006) General 
population 
N/R 3 960 Random  Four towns in Isola 
Bergamasca (Northern 
Italy) 
20 to 70 
Parisi et al. (2014) General 
population 
2011–2014 3 4,507 Convenience Milan. One hospital, one 
STI clinic and six GPs 
>18 




2010 3 1,012 Random  Study in a small town in 
Calabria 
>18 
Fabris et al. (2008) General 
population 
2002 3 965 Exhaustive Vicenza, northeast Italy. A 
broken sewer pipe 
prompted HAV 
vaccination. Subjects were 
also tested for HBV/HCV 
Mean age 42.1 
Montella et al. (2005) General 
population 
2000–2002 3 1,972 Convenience Naples. Residual sera from 
primary care tests 
19 to 65 
Dazzani et al. (2009) General 
population 
2008 2 3,207 Convenience Survey of residents in 
Bagnacavallo (Emilia-
Romagna) 
30 to 60 




2007–2008 2 425 Convenience Hospital lab samples from 
Legnano Hospital (north 
Italy) 
Mean age 51.4 
Picardi et al. (2007) General 
population 
2000–2002 2 2,025 Convenience Patients undergoing (non-
liver related) surgery 
4 to 100 
Squeri et al. (2006) General 
population 
2005 1 327 Convenience Municipal solid waste 
workers 
20 to 68 
Ruffini et al. (2014) Pregnant women 2011–2012 2 9,977 Exhaustive  Regional study. One third 
migrants. 
>17 
Veronesi et al. (2007) Pregnant women 1996–2001 1 13,025 Exhaustive  All deliveries at the 
hospital in Palma 
N/R 
Lagana et al. (2015) Pregnant women 2003–2013 0 320 Convenience Outpatient clinic 
attendees, mostly migrant 
women 
N/R 
Di Benedetto et al. 
(2012) 
MSM 2010 2 74 Convenience Men living in Sicily for 
more than 6 months 
recruited via internet and 
in gay bars 
18 to 56, mean 
age 30 
Babudieri et al. (2005) Prisoners 2001–2002 4 973 Convenience Multi-centre study in eight 
prisons. Mixed gender. 
Includes PWID 
Mean age 36 




Council of Europe First-time blood 
donors 














Author (year of publication) Sampling period Estimate (95% CI) 
Sample 
size 
Forest plot of estimates and 95% CI 
General population  
 
Pooled  N/R 5.9% (5.2–6.6) 4,826 
Cozzolongo et al. (2009) 2005–2007 2.6% (2.0–3.4) 2,195 
Pendino et al. (2005) 2002–2003 6.5% (5.4–7.8) 1,645 
Floreani et al. (2006) 2001 10.2% (8.0-12.7) 697 
Petti et al. (2006) N/R 16.3% (12.2–21.0) 289 
Petti et al. (2006) N/R 3.0% (0.8–7.5) 133 
Petti et al. (2006) N/R 27.6% (20.7–35.3) 156 
Del Corno et al. (2006) N/R 4.7% (3.4–6.2) 960 
Parisi et al. (2014) 2011–2014 0.6% (0.4–0.9) 4,507 
Guadagnino et al. (2013) 2010 5.7% (4.4–7.4) 1,012 
Fabris et al. (2008) 2002 2.6% (1.7–3.8) 965 
Montella et al. (2005) 2000–2002 8.2% (7.0–9.5) 1,972 
Dazzani et al. (2009) 2008 1.1% (0.8–1.5) 3,207 
De Paschale et al. (2012) 2007–2008 4.7% (2.9–7.2) 425 
Picardi et al. (2007) 2000–2002 4.6% (3.7–5.6) 2,025 
Squeri et al. (2006) 2005 0.9% (0.2–2.7) 327 
Pregnant women 
Ruffini et al. (2014) 2011–2012 0.4% (0.3–0.6) 9,977 
Veronesi et al. (2007) 1996–2001 0.8% (0.7–1.0) 13,025 
Lagana et al. (2015) 2003–2013 0.9% (0.2–2.7) 320 
MSM 
Di Benedetto et al. (2012) 2010 0.0% (0.0–4.9) 74 
Prisoners 
Babudieri et al. (2005) 2001–2002 38.0% (35.0-41.1) 973 
Montella et al. (2005) 2000–2002 37.4% (33.3-41.7) 524 
First-time blood donors 
Council of Europe 2011 0.09% (0.08–0.1) 394,910 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2010 Anti-HCV National sample from drug treatment services N=743 60.5% (56.8%–64.0%) 
* No data on HBsAg available 
HBsAg prevalence: migrants 









Estimate (95% CI) 
Asia Stornaiuolo (2014) 1999–2009 Outreach and opportunistic screening 
(convenience sampling) in Castelvolturno, 
Caserta  
115 0.0% (0.0%–3.2%) 
Eastern Europe Stornaiuolo (2014) 1999–2009 Outreach and opportunistic screening 
(convenience sampling) in Castelvolturno, 
Caserta  
211 3.3% (1.3%–6.7%) 
Sub-Saharan 
Africa 
Stornaiuolo (2014) 1999–2009 Outreach and opportunistic screening 
(convenience sampling) in Castelvolturno, 
Caserta  
2,198 8.1% (7.0%–9.3%) 
Anti-HCV prevalence: migrants 









Estimate (95% CI) 
Asia Stornaiuolo (2014) 1999–2009 Outreach and opportunistic screening 
(convenience sampling) in Castelvolturno, 
Caserta  
115 3.5% (1.0%–8.7%) 
Eastern Europe Stornaiuolo (2014) 1999–2009 Outreach and opportunistic screening 
(convenience sampling) in Castelvolturno, 
Caserta  
211 7.1% (4.0%–11.5%) 
Sub-Saharan 
Africa 
Stornaiuolo (2014) 1999–2009 Outreach and opportunistic screening 
(convenience sampling) in Castelvolturno, 
Caserta  














HbsAg prevalence  
Author 












Council of Europe First-time blood 
donors 
2003 N/A 1.127 N/A N/A N/A 
 
Author (year of publication) 
Sampling 
period 
Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 
Council of Europe 2003 2.17% 1,127 
 
Anti-HCV prevalence  
Author 












Tolmane et al. (2011) General population 2008 6 1,459 Random  GP registration 18 to 94 
Council of Europe First-time blood 
donors 
2005 N/A 2,170 N/A N/A N/A 
 





Sample size Forest plot of estimates and 95% CI 
General population  
 
 
Tolmane et al. (2011) 2008 2.4% (1.7–3.3) 1,459 
First-time blood donors 
Council of Europe 2005 1.13% 2,170 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2013 HBsAg National sample from harm reduction services N=562 2.1% (1.1%–3.7%) 
















HbsAg prevalence  
Author 












Council of Europe First-time blood 
donors 
2011 N/A 23,034 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 




Anti-HCV prevalence  
Author 














Liakina et al. (2012) General 
population 
2010 2 1,514 Convenience Shopping centres 




Liakina et al. (2012) General 
population 
2010 2 Mean Convenience Shopping centres 





Liakina et al. (2012) General 
population 
2010 2 Standardised 
(a) 
Convenience Shopping centres 






Liakina et al. (2012) General 
population 
2010 2 Standardised 
(b) 
Convenience Shopping centres 






Council of Europe First-time 
blood donors 
2011 N/A 23,034 N/A N/A N/A 
 




Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 
General population  
 
Liakina et al. (2012) 2010 2.4% (1.7–3.4) 1,514 
Liakina et al. (2012) 2010 2.8% Mean 
Liakina et al. (2012) 2010 2.8% Standardised (a) 
Liakina et al. (2012) 2010 2.9% Standardised (b) 
First-time blood donors 
Council of Europe 2011 1.54% (1.38–1.70) 23,034 






Testing settings and sample size  
(if available) 
Estimate (CI not available) 


















HbsAg prevalence  
Author 









Sampling description Age range 
Removille et al. (2011) Prisoners  2005 4 115 Convenience Multi-centre study in the two 
prisons. Population of 
problem drug users (not all 
PWID) 
N/R 
Council of Europe  First-time 
blood donors 
2011  N/A 907 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 
Prisoners  
 
Removille et al. (2011) 2005 7.0% (3.0-13.3) 115 
First-time blood donors 
Council of Europe  2011  0.0% (0.0–0.4) 907 
Anti-HCV prevalence  
Author 












Removille et al. (2011) Prisoners  2005 4 124 Convenience Multi-centre study in the two 
prisons. Population of 
problem drug users (not all 
PWID) 
N/R 
Council of Europe  First-time blood 
donors 
2011  N/A 907 N/A N/A N/A 
 













Removille et al. (2011) 2005 86.3%  
(79.0-91.8) 
124 
First-time blood donors 




















HbsAg prevalence  
Author 












Council of Europe First-time blood 
donors 
2011 N/A 17,940 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 




Anti-HCV prevalence  
Author 












Council of Europe First-time blood 
donors 
2011 N/A 17,940 N/A N/A N/A 
 
Author (year of publication) 
Sampling 
period 
Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 










Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2013 Anti-HCV National sample from ever injectors sampled from various 
settings and services, N=109 
13.8% (7.9%–21.7%) 















HbsAg prevalence  
Author 









Sampling description Age range 
Hahné et al. (2012) General 
population 
2006–2007 5 6,246 Random  National study (PIENTER 2) >18 months 




2004 3 284 Random  Rotterdam municipal 
population register 
18 to 65 
Pooled estimate Pregnant 
women 
2006–2008 N/A 562,218 Exhaustive National antenatal 
screening programme 
N/R 
Op de Coul et al. 
(2011) 
Pregnant women 2006 3 186,137 Exhaustive National antenatal screening 
programme 
N/R 
Op de Coul et al. 
(2011) 
Pregnant women 2007 3 190,140 Exhaustive National antenatal screening 
programme 
N/R 
Op de Coul et al. 
(2011) 
Pregnant women 2008 3 185,941 Exhaustive National antenatal screening 
programme 
N/R 
Council of Europe First-time blood 
donors 
2011 N/A 35,166 N/A N/A N/A 
 
Author  
(year of publication) 
Sampling 
period 
Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 
General population  
 
Hahné et al. (2012) 2006–2007 0.2% (0.1–0.4) 6,246 
Veldhuijzen et al. 
(2009) 
2004 0.7% (0.1–2.5) 284 
Pregnant women 
Pooled 2006–2008 0.3% (0.3–0.4) 562,218 
Op de Coul et al. 
(2011) 
2006 0.3% (0.3–0.4) 186,137 
Op de Coul et al. 
(2011) 
2007 0.3% (0.3–0.3) 190,140 
Op de Coul et al. 
(2011) 
2008 0.4% (0.4–0.4) 185,941 
First-time blood donors 
Council of Europe 2011 0.03% (0.02–0.06) 35,166 
Anti-HCV prevalence  
Author 









Sampling description Age range 
Vriend et al. (2013) General 
population 
2006–2007 5 4,046 Random  National study (PIENTER 2) 15 to 79 




2004 3 284 Random  Rotterdam municipal 
population register 
18 to 65 




2006 2 2,200 Convenience GP attendees in Arnhem 
and Nijmegen who had 
blood taken as part of 
clinical work up 
N/R 




van de Laar et al. 
(2007) 
MSM 1984–2003 2 1,836 Convenience Cohort study in Amsterdam Mean age 
31.8 
Van Rooijen et al. 
(2013) 
MSM 2007 1 450 Convenience STI clinic attendees opting 
out of HIV testing 
N/R 
Council of Europe First-time blood 
donors 














Author (year of publication) 
Sampling 
period 
Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 
General population  
 
Vriend et al. (2013) 2006–2007 0.1% (0.0–0.2) 4,046 
Veldhuijzen et al. (2009) 2004 1.1% (0.2–3.1) 284 
Slavenburg et al. (2008) 2006 0.2% (0.1–0.5) 2,200 
Pregnant women 
Urbanus et al. (2011) 2003 0.3% (0.2–0.5) 4,563 
MSM 
van de Laar et al. (2007) 1984–2003 1.3% (0.8–1.9) 1,836 
Van Rooijen et al. (2013) 2007 0.7% (0.1–1.9) 450 
First-time blood donors 
Council of Europe 2011 0.02% (0.01–0.04) 35,166 






Testing settings and sample size  
(if available) 
Estimate  
(CI not available) 
EMCDDA 2012 HBsAg Drug treatment services (in Amsterdam) N=N/A 0%  
EMCDDA 2013 Anti-HCV Drug treatment services (in Amsterdam) N=N/A 39.3% 
HBsAg prevalence: migrants 









Estimate (95% CI) 
>2% HBV 
prevalence 
Hahné (2011) 2006–2007 Random national sero-prevalence study 
(PIENTER 2). (32% response). Adults only 
406 2.2% (1.0%–4.2%) 
Afghanistan Richter (2014) 2011 Invitation-based screening via municipal register 
in Arnhem. Educational meeting with free onsite 
serological screening. (30% response) 
293 2.0% (0.8%–4.4%) 
Cape Verde Veldhuijzen (2009) 2004 Random sample using municipal register (16% 
response) 
13 0% (0%–24.7%) 
China (including 
Hong Kong) 
Veldhuijzen (2012) 2009 Outreach screening in various social/civic 
centres in Rotterdam 
849 9.7% (7.8%–11.8%) 
Dutch Antilles Veldhuijzen (2009) 2004 Random sample using municipal register (16% 
response) 
38 2.6% (0.1%–13.8%) 
Egypt Zuure (2013) 2004 Community-based screening in Amsterdam 465 1.1% (0.4%–2.5%) 
Former Soviet 
Union 
Richter (2014) 2011 Invitation-based screening via municipal register 
in Arnhem. Educational meeting with free onsite 
serological screening. (30% response) 
65 0% (0%–5.5%) 
Iran Richter (2014) 2011 Invitation-based screening via municipal register 
in Arnhem. Educational meeting with free onsite 
serological screening. (30% response) 
153 0.7% (0%–3.6%) 
Iraq Richter (2014) 2011 Invitation-based screening via municipal register 
in Arnhem. Educational meeting with free onsite 
serological screening. (30% response) 
290 0.7% (0.1%–2.5%) 
Morocco Baaten (2007) 2004 Random sample of the general population of 
Amsterdam. Response N/R 
261 0.4% (0%–2.2%) 
Morocco Veldhuijzen (2009) 2004 Random sample using municipal register (16% 
response) 
44 0% (0%–8.0%) 
Morocco Pooled Pooled Veldhuijzen (2009) and Baaten (2007)  305 0.3% (0%–1.8%) 
Suriname Veldhuijzen (2009) 2004 Random sample using municipal register (16% 
response) 
56 0% (0%–6.4%) 
Turkey Baaten (2007) 2004 Random sample of the general population of 
Amsterdam. Response N/R 
304 4.9% (2.8%–8.0%) 
Turkey Richter (2011) 2009 Community-based screening in Arnhem 
(convenience sample) 
544 3.1% (1.8%–5.0%) 
Turkey Veldhuijzen (2009) 2004 Random sample using municipal register (16% 
response) 
54 1.9% (0.0%–9.9%) 
Turkey Pooled Pooled Veldhuijzen (2009), Baaten (2007) and 
Richter (2011) 






















Estimate (95% CI) 
Vietnam Richter (2014) 2011 Community-based screening in Arnhem 
(convenience sample) 
126 9.5% (5.0%–16.0%) 
Anti-HCV prevalence: migrants 
Country of birth 







Estimate (95% CI) 
Afghanistan Richter (2014) 2011 Invitation-based screening via municipal register 
in Arnhem. Educational meeting with free onsite 
serological screening. 30% response 
293 1.0% (0.2%–3.0%) 
Cape Verde Veldhuijzen 
(2009) 
2004 Random sample using municipal register (16% 
response) 
13 0% (0%–24.7%) 
Dutch Antilles Veldhuijzen 
(2009) 
2004 Random sample using municipal register (16% 
response) 
38 2.6% (0.1%–13.8%) 
Egypt Zuure (2013) 2004 Community-based screening in Amsterdam 465 2.4% (1.2%–4.2%) 
Former Soviet 
Union 
Richter (2014) 2011 Invitation-based screening via municipal register 
in Arnhem. Educational meeting with free onsite 
serological screening. 30% response 
65 3.1% (0.4%–10.7%) 
Iran Richter (2014) 2011 Invitation-based screening via municipal register 
in Arnhem. Educational meeting with free onsite 
serological screening. 30% response 
153 0.7% (0%–3.6%) 
Iraq Richter (2014) 2011 Invitation-based screening via municipal register 
in Arnhem. Educational meeting with free onsite 
serological screening. 30% response 
290 0.3% (0%–1.9%) 
Morocco Urbanus (2011) 2003–2009 Random sample of health survey respondents in 
Amsterdam 
255 0.4% (0%–2.2%) 
Morocco Urbanus (2011) 2006–2007 Selection from random national population 
sample (PIENTER 2). Response 36% 
36 2.8% (0.1%–14.5%) 
Morocco Veldhuijzen 
(2009) 
2004 Random sample using municipal register (16% 
response) 
40 2.5% (0.1%–13.2%) 
Morocco Pooled Pooled Veldhuijzen (2009) and Urbanus (2011) 331 0.9% (0.2%–2.6%) 
non-western 
ethnicity 
Urbanus (2011) 2003–2009 Random sample of health survey respondents in 
Amsterdam 
764 0.7% (0.2%–1.5%) 
non-western 
ethnicity 
Urbanus (2011) 2006–2007 Selection from random national population 
sample (PIENTER 2). Response 36% 
442 2.3% (1.1%–4.1%) 
non-western 
ethnicity 
Pooled Pooled Urbanus (2011) 1,206 1.2% (0.7%–2.0%) 
Other non-
Western ethnicity 
Urbanus (2011) 2003–2009 Random sample of health survey respondents in 
Amsterdam 
165 1.8% (0.4%–5.2%) 
Other non-
Western ethnicity 
Urbanus (2011) 2006–2007 Selection from random national population 
sample (PIENTER 2). Response 36% 




Pooled Pooled Urbanus (2011) 539 1.9% (0.9%–3.4%) 
Suriname Veldhuijzen 
(2009) 
2004 Random sample using municipal register (16% 
response) 
57 1.8% (0%–9.4%) 
Suriname Urbanus (2011) 2003–2009 Random sample of health survey respondents in 
Amsterdam 
66 3.0% (0.4%–10.5%) 
Suriname Urbanus (2011) 2006–2007 Selection from random national population 
sample (PIENTER 2). Response 36% 
102 2.0% (0.2%–6.9%) 
Suriname Pooled Pooled Veldhuijzen (2009) and Urbanus (2011) 225 2.2% (0.7%–5.1%) 
Turkey Urbanus (2011) 2003–2009 Random sample of health survey respondents in 
Amsterdam 
309 0% (0%–1.2%) 
Turkey Urbanus (2011) 2006–2007 Selection from random national population 
sample (PIENTER 2). Response 36% 
65 0% (0%–5.5%) 
Turkey Veldhuijzen 
(2009) 
2004 Random sample using municipal register (16% 
response) 
47 0% (0%–7.5%) 
Turkey Richter (2011) 2009 Community-based screening in Arnhem 
(convenience sample) 
544 0.4% (0%–1.3%) 
Turkey Pooled Pooled Veldhuijzen (2009), Richter (2011) and 
Urbanus (2011) 
965 0.2% (0%–0.7%) 
Vietnam Richter (2014) 2011 Community-based screening in Arnhem 
(convenience sample) 













3.22 Norway  
HbsAg prevalence  
Author 









Sampling description Age range 
Kristiansen et al. 
(2009) 
Pregnant women 2003–2004 2 1,668 Exhaustive  Multi-centre study in all 
hospitals and delivery rooms 
in north Norway 
16 to 44, 
mean age 
29.3 
Council of Europe First-time blood 
donors 
2011 N/A 17,940 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 
Pregnant women  
 
Kristiansen et al. (2009) 2003–2004 0.1% (0.0–0.3) 1,668 
First-time blood donors 
Council of Europe 2011 0.03% (0.01–0.07) 17,940 
Anti-HCV prevalence  
Author 










Sampling description Age range 




2003–2004 2 1,668 Exhaustive  Multi-centre study in all 
hospitals and delivery rooms 
in north Norway 
16 to 44, mean 
age 29.3 
Council of Europe First-time blood 
donors 
2011 N/A 17,940 N/A N/A N/A 
 
 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2012 HBsAg Harm reduction and low-threshold services in Oslo. Current 
injectors only. N=N/A 
0.91 (no CI available) 
EMCDDA 2013 Anti-HCV National sample of current injectors in drug treatment 
services N=6,342 
63.0% (61.8%–64.2%) 
HBsAg prevalence: migrants 
Country of birth 







Estimate (95% CI) 
Pakistan Bjerke (2010) 2009 Random sample of antenatal screening attendees 
and husbands in Oslo 
224 1.3% (0.3%–3.9%) 
 
  
Author (year of publication) 
Sampling 
period 
Estimate (95% CI) 
Sample 
size 
Forest plot of estimates and 95% CI 
Pregnant women  
 
Kristiansen et al. (2009) 2003–2004 0.9% (0.5–1.5) 1,668 
First-time blood donors 














HbsAg prevalence  
Author 









Sampling description Age range 
Hartleb et al. (2012) General 
population 
N/R 3 3,826 Exhaustive  Study among elderly 





Pszenny (2012) General 
population 
2000–2008 1 4,774 Convenience Retrospective study among 
deceased potential blood 
donors. Regional in scope. 
75% male 
N/R 
Council of Europe First-time blood 
donors 
2010 N/A 272,310 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 
General population  
 
Hartleb et al. (2012) N/R 1.1%  
(0.8–1.5) 
3,826 
Pszenny (2012) 2000–2008 0.9%  
(0.7–1.2) 
4,774 
First-time blood donors 
Council of Europe 2010 0.45%  
(0.43–0.48) 
272,310 
Anti-HCV prevalence  
Author 









Sampling description Age range 
Hartleb et al. (2012) General 
population 
N/R 3 3,826 Exhaustive  Study among elderly 





Flisiak et al. (2011) General 
population 
2009–2010 2 1,203 Convenience Consecutive patients in a 
GP outpatient clinic. 
65.4% female 
Mean age 45 
Pszenny (2012) General 
population 
2000–2008 1 4,733 Convenience Retrospective study among 
deceased potential blood 
donors. Regional in scope. 
75% male 
N/R 
Council of Europe First-time blood 
donors 
2010 N/A 272,310 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 
General population  
 
Hartleb et al. (2012) N/R 2.9% (2.4–3.5) 3,826 
Flisiak et al. (2011) 2009–2010 0.9% (0.5–1.6) 1,203 
Pszenny (2012) 2000–2008 2.6% (2.2–3.1) 4,733 
First-time blood donors 
Council of Europe 2010 0.74% (0.71–0.78) 272,310 






Testing settings and sample size  
(if available) 
Estimate (range) 
EMCDDA 2009 HBsAg Two low-threshold services, one in Gdansk and one in Krakow 
N=N/A 
2.5% to 3.8% 
EMCDDA 2009 Anti-HCV Two low-threshold services, one in Gdansk and one in Krakow 
N=N/A 














HbsAg prevalence  
Author 









Sampling description Age range 
Marques et al. (2011) Prisoners 2007–2008 4 151 Exhaustive  Study in regional prison of 
Coimbra. Includes PWID  
19 to 75, 
mean age 
34.1 
Council of Europe First-time blood 
donors 
2006 N/A N/R N/A N/A N/A 
 
Author (year of publication) 
Sampling 
period 
Estimate (95% CI) 
Sample 
size 
Forest plot of estimates and 95% CI 
Prisoners  
 
Marques et al. (2011) 2007–2008 0.7% (0.0–3.6) 151 
First-time blood donors 
Council of Europe 2006 0.09% N/R 
 
Anti-HCV prevalence  
Author 









Sampling description Age range 
Marques et al. (2011) Prisoners 2007–2008 4 151 Exhaustive Study in regional prison of 
Coimbra. Includes PWID  
19 to 75, 
mean age 
34.1 
Barros et al. (2008) Prisoners 2005 2 445 N/R Inmates of largest female 
prison (57% of all female 
inmates). 97% PWID 
N/R 
Council of Europe First-time blood 
donors 







Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 
Prisoners  
 
Marques et al. (2011) 2007–2008 34.4% (26.9-42.6) 151 
Barros et al. (2008) 2005 10.8% (8.1-14.1) 445 
First-time blood donors 
Council of Europe 2006 0.17% N/R 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2013 HBsAg Drug treatment services, national coverage, N=399 6.3% (4.1%–9.1%) 
















HbsAg prevalence  
Author 









Sampling description Age range 
Gheorghe et al. (2013) General 
population 
2006–2008 6 13,127 Random  National cross-sectional 
population survey  
18 to 69 
Nardone et al. (2009) General 
population 
2002 3 629 Convenience Residual lab samples 
representative of location 
and gender  
16 to >40 
Nardone et al. (2009) General 
population 
2002 3 276 Convenience Residual lab samples 
representative of location 
and gender  
16 to 39 
Nardone et al. (2009) General 
population 
2002 3 353 Convenience Residual lab samples 
representative of location 
and gender  
>40 
Nardone et al. (2009) General 
population 
2002 3 630 Convenience Residual lab samples 
representative of location 
and gender  
1 to 15 
Nazare (2011) Prisoners  2007–2010 1 197 Convenience Single prison screening 
study 
N/R 
Council of Europe First-time blood 
donors 
2011 N/A 88,066 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 
General population  
 
Gheorghe et al. (2013) 2006–2008 4.4% (4.0–4.8) 13,127 
Nardone et al. (2009) 2002 6.2% (4.5–8.4) 629 
Nardone et al. (2009) 2002 7.6% (4.8-11.4) 276 
Nardone et al. (2009) 2002 5.1% (3.1–7.9) 353 
Nardone et al. (2009) 2002 5.1% (3.5–7.1) 630 
Prisoners 
Nazare (2011) 2007–2010 10.7% (6.7-15.8) 197 
First-time blood donors 
Council of Europe 2011 3.08% (2.97–3.19) 88,066 
Anti-HCV prevalence  
Author 









Sampling description Age range 
Gheorghe et al. (2010) General 
population 
2006–2008 6 13,146 Random (75% 
response) 
National cross-sectional 
population survey  
18 to 69 
Council of Europe First-time blood 
donors 
2011 N/A 88,066 N/A N/A N/A 
 





Sample size Forest plot of estimates and 95% CI 
General population  
 
Gheorghe et al. (2010) 2006–2008 3.2% (2.9–3.6) 13,146 
First-time blood donors 



















Testing settings and sample size  
(if available) 
Estimate (CI not available) 
EMCDDA 2009 HBsAg Street-based testing (one site) in Bucharest  
N=N/A 
4.7%  


















HbsAg prevalence  
Author 









Sampling description Age range 
Nardone et al. (2009) General 
population 
2002 4 1,946 Random National population survey 16 to >40 
Nardone et al. (2009) General 
population 
2002 4 1,270 Random National population survey 16 to 39 
Nardone et al. (2009) General 
population 
2002 4 676 Random National population survey >40 
Nardone et al. (2009) General 
population 
2002 4 1,623 Random National population survey 1 to 15 
Kristian et al. (2013) Pregnant 
women 
2008–2009 1 13,798 Convenience Residual serum samples 




Kristian et al. (2010) Pregnant 
women 
2000–2004 1 10,739 Convenience Residual serum samples 




Council of Europe First-time 
blood donors 
2011 N/A 40,140 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 
General population  
 
 
Nardone et al. (2009) 2002 1.1% (0.7–1.6) 1,946 
Nardone et al. (2009) 2002 0.9% (0.4–1.5) 1,270 
Nardone et al. (2009) 2002 1.5% (0.7–2.7) 676 
Nardone et al. (2009) 2002 0.1% (0.0–0.4) 1,623 
Pregnant women 
Kristian et al. (2013) 2008–2009 2.1% (1.9–2.4) 13,798 
Kristian et al. (2010) 2000–2004 2.3% (2.1–2.6) 10,739 
First-time blood donors 
Council of Europe 2011 0.07% (0.05–0.1) 40,140 
Anti-HCV prevalence  
Author 









Sampling description Age range 
Schreter et al. (2007) General 
population 
2002 6 2,124 Random Residual serum samples 15 to 69 
Council of Europe First-time blood 
donors 





















Forest plot of estimates and 95% CI 
General population  
 
Schreter et al. (2007) 2002 2.0% (1.4–2.7) 2,124 
First-time blood donors 
Council of Europe 2011 0.02% (0.01–0.05) 40,140 






Testing settings and sample size  
(if available) 
Estimate (CI not available) 
EMCDDA 2013 HBsAg Drug treatment services in Bratislava  
N=N/A 
2.56%  


















HbsAg prevalence  
Author 









Sampling description Age range 
Council of Europe  First-time blood 
donors 
2009  N/A 12,677 N/A N/A N/A 
 







Forest plot of estimates and 95% CI 




Anti-HCV prevalence  
Author 









Sampling description Age range 
Kopilovic et al. (2015) Pregnant women 2013 3 9,574 Exhaustive Residual sera from 
antenatal screening 
N/R 
Kopilovic et al. (2015) Pregnant women 2009 3 8,064 Exhaustive Residual sera from 
antenatal screening 
N/R 
Kopilovic et al. (2015) Pregnant women 2003 3 7,281 Exhaustive Residual sera from 
antenatal screening 
N/R 
Kopilovic et al. (2015) Pregnant women 2003, 2009 & 
2013 
3 24,919 Exhaustive Residual sera from 
antenatal screening 
N/R 
Council of Europe  First-time blood 
donors 
2009 N/A 12,677 N/A N/A N/A 
 
Author  
(year of publication) 
Sampling period Estimate (95% CI) 
Sample 
size 




Kopilovic et al. (2015) 2013 0.1% (0.1–0.2) 9,574 
Kopilovic et al. (2015) 2009 0.1% (0.0–0.2) 8,064 
Kopilovic et al. (2015) 2003 0.2% (0.1–0.3) 7,281 
Kopilovic et al. (2015) 2003, 2009 & 2013 0.1% (0.1–0.2) 24,919 
First-time blood donors 
Council of Europe 2009 0.02% (0.0–0.06) 12,677 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2013 Anti-HCV Ever injected population sampled from drug treatment 
centres nationally N=112 
32.1% (23.6%–41.6%) 















HbsAg prevalence  
Author 











Sampling description Age range 
Pooled estimate General 
population 
Pooled Pooled 5,355 Pooled Pooled Pooled 




2008–2009 5 3,695 Random  Attendees of blood extraction 
centres in region of Madrid. 
Bi-stage, cluster stratified 
sampling 
16 to 80 




2003 5 364 Random  Study in Valladolid. Stratified 
random sampling based on 
health card 
N/R 
Salleras et al. (2007) General 
population 
2002 4 1,296 Random  Two stage cluster sample 
from municipal electoral 
registers in Catalonia 
15 to >65 
Salleras et al. (2007) General 
population 
2002 3 2,620 Random  Two stage cluster sample 
from schools and municipal 
electoral registers in Catalonia 
5 to >65 
Salleras et al. (2007) General 
population 
2002 3 1,324 Random  Two stage cluster sample 
from schools in Catalonia 
5 to 14 




2007–2010 2 5,017 Convenience Study in Murcia and Madrid of 
working population at yearly 
insurance check-up. 73% 
male. 
42 
Salleras et al. (2009) Pregnant women 2008–2009 2 1,534 Random/Exhaustive Regional antenatal screening 
programme 
15 to 49  
Lopez-Fabal et al. 
(2013) 
Pregnant women 2007–2010 1 6,939 Convenience Study in a hospital and a 
health centre in Madrid 
19 to 49, 
mean age 30 
Sampedro et al. (2010) Pregnant women 2007–2008 1 4,169 Exhaustive Single centre study. 8.4% 
migrants 
N/R 
Garcia-Guerrero et al. 
(2010) 
Prisoners 2008 6 N/R Random  Multi-centre study in 18 
prisons across Spain 
Mean age 35.7 
Council of Europe First-time blood 
donors 














Author (year of publication) 
Sampling 
period 
Estimate (95% CI) 
Sample 
size 
Forest plot of estimates and 95% CI 
General population  
 
Pooled Pooled 0.8% (0.6–1.1) 5,355 
Pedraza-Flechas et al. (2014) 2008–2009 0.7% (0.5–1.0) 3,695 
Lopez-Izquierdo et al. (2007) 2003 0.0% (0.0–1.0) 364 
Salleras et al. (2007) 2002 1.4% (0.8–2.2) 1,296 
Salleras et al. (2007) 2002 0.7% (0.4–1.1) 2,620 
Salleras et al. (2007) 2002 0.0% (0.0–0.3) 1,324 
Calleja-Panero et al. (2013) 2007–2010 0.7% (0.5–1.0) 5,017 
Pregnant women 
Salleras et al. (2009) 2008–2009 0.1% (0.0–0.5) 1,534 
Lopez-Fabal et al. (2013) 2007–2010 0.9% (0.7–1.1) 6,939 
Sampedro et al. (2010) 2007–2008 0.7% (0.4–0.9) 4,169 
Prisoners 
Garcia-Guerrero et al. (2010) 2008 2.6% (0.8–4.5) N/R 
First-time blood donors 
Council of Europe 2011 0.17% (0.15–0.19) 232,893 
Anti-HCV prevalence  
Author 










Sampling description Age range 




2003 5 364 Random  Study in Valladolid. Stratified 
random sampling based on 
health card 
N/R 
Caballeria et al. (2014) General 
population 
2010–2011 3 238 Random  Multi-centre study of 
invitation-based screening 
via GP registers in Barcelona 
20 to 90, 
mean age 
50.6 
Caballeria et al. (2014) General 
population 
2010–2011 2 69 Convenience Multi-centre study of 
screening via flyers and 








2007–2010 2 5,017 Convenience Study in Murcia and Madrid 
of working population at 
yearly insurance check-up. 
73% male. 
42 
Seisdedos et al. (2011) Pregnant women 2012 3 8,555 Random 
(response N/R) 
HIV-negative women 
screened in six regions 
N/R 
Pooled estimates Prisoners 2000–2009 N/A 3,062 Pooled Pooled Pooled 
Garcia-Guerrero et al. 
(2010) 
Prisoners 2008 6 N/R Random (92% 
response) 
Multi-centre study in 18 





Prisoners 2009 5 N/R Other Data from the National 





Prisoners 2008 5 N/R Other Data from the National 





Prisoners 2007 5 N/R Other Data from the National 





Prisoners 2006 5 N/R Other Data from the National 





Prisoners 2005 5 N/R Other Data from the National 
Centre for Prison Health Co-
ordination  
N/R 
























Sampling description Age range 




Prisoners 2003 5 N/R Other Data from the National 





Prisoners 2002 5 N/R Other Data from the National 





Prisoners 2001 5 N/R Other Data from the National 





Prisoners 2000 5 N/R Other Data from the National 
Centre for Prison Health Co-
ordination  
N/R 
Abad-Perez et al. 
(2011) 
Prisoners 2000–2009 4 2,332 Convenience Hospitalized prisoners in the 
province of Valencia 
17 to 74 
Murcia et al. (2009) Prisoners 2001 4 730 Exhaustive Single prison study in 
Alicante involving all inmates 
N/R 
Council of Europe First-time blood 
donors 






















Forest plot of estimates and 95% CI 
General population  
 
Lopez-Izquierdo et al. 
(2007) 
2003 1.1%  
(0.3–2.8) 
364 
Caballeria et al. (2014) 2010–2011 0.4%  
(0.0–2.3) 
238 
Caballeria et al. (2014) 2010–2011 1.5%  
(0.0–7.8) 
69 
Calleja-Panero et al. 
(2013) 










Pooled 2000–2009 20.3% 
(18.9-21.8) 
3,062 
Garcia-Guerrero et al. 
(2010) 





2009 25,3% N/R 
Hernandez-Fernandez 
(2010) 
2008 27,0% N/R 
Hernandez-Fernandez 
(2010) 
2007 29,0% N/R 
Hernandez-Fernandez 
(2010) 
2006 30,0% N/R 
Hernandez-Fernandez 
(2010) 
2005 33,0% N/R 
Hernandez-Fernandez 
(2010) 
2004 37,2% N/R 
Hernandez-Fernandez 
(2010) 
2003 37,8% N/R 
Hernandez-Fernandez 
(2010) 
2002 38,9% N/R 
Hernandez-Fernandez 
(2010) 
2001 42,9% N/R 
Hernandez-Fernandez 
(2010) 
2000 44,9% N/R 
Abad-Perez et al. (2011) 2000–2009 14.7%  
(13.3-16.2) 
2,332 




First-time blood donors 


















HbsAg prevalence  
Author 













Council of Europe First-time blood 
donors 
2009 N/A 49,071 N/A N/A N/A 
 
Author (year of publication) 
Sampling 
period 
Estimate (95% CI) Sample size Forest plot of estimates and 95% CI 
Council of Europe 2009 0.04% (0.02–0.06) 49,071 
 
Anti-HCV prevalence  
Author 









Sampling description Age range 
Blaxhult et al. (2013) MSM 2012–2013 1 1,008 Convenience Attendees of a Stockholm 
STI clinic 
16 to 82, 
mean age 33 
Council of Europe First-time blood 
donors 
2009 N/A 49,071 N/A N/A N/A 
 





Sample size Forest plot of estimates and 95% CI 
MSM  
 




First-time blood donors 
Council of Europe 2009 0.06%  
(0.04–0.08) 
49,071 






Testing settings and sample size  
(if available) 
Estimate (CI not available) 
EMCDDA 2013 Anti-HCV Ever injected prison population (multi-venue study in 
Stockholm) N=N/A 
96.8% 














3.30 United Kingdom 
HbsAg prevalence  
Author 













Pepas et al. (2011)  General 
population 




Treatment at Guy & 
St Thomas Hospital, 
London 
N/R 
Pooled estimate  Pregnant 
women 
Pooled Pooled 167,398 Pooled Pooled Pooled 
Schnier et al. (2014)  Pregnant 
women 
2009–2010 2 129,171 Exhaustive Antenatal screening 
from four 
laboratories 
(covering 60% of 
Scottish population) 
15 to 44 
Godbole et al. (2013)  Pregnant 
women 
2007–2010 2 38,227 Exhaustive Antenatal screening 
in four London 
hospitals 
15 to 46, 
mean age 29 
Pepas et al. (2011)  Pregnant 
women 
2003 1 25,082 N/R Antenatal screening 
at Guy & St Thomas 
Hospital, London 
N/R 
Roy et al. (2008)  MSM 2001 1 81 Convenience STI clinic samples N/R 
Roy et al. (2008)  MSM 2001 1 27 Convenience STI clinic samples <25 years 
Roy et al. (2008)  MSM 2001 1 54 Convenience STI clinic samples >25 years 
McMillan (2006)  MSM 2001–2003 0 575 Exhaustive Retrospective 
analysis of samples 
from all new clients 
of Edinburgh STI 
clinic 
15 to 64, 
mean age 29 
Pooled estimate  Prisoners 2010–2013 N/A 640 Pooled Pooled Pooled 
Mortlock et al. (2013)  Prisoners 2012 4 129 Exhaustive Implementation of 




Ferenando et al. 
(2014) 
 Prisoners 2011–2013 3 511 Convenience Study in a London 
prison among 
participants of TB 
screening 
N/R 
Council of Europe  First-time 
blood donors 






















Forest plot of estimates and 95% CI 
General population  
 
Pepas et al. (2011) 2007–2009 1.7% (1.3–2.2) 3,910 
 
Pregnant women 
Pooled Pooled 0.5% (0.4–
0.5) 
167,398 
Schnier et al. (2014) 2009–2010 0.3% (0.3–0.3) 129,171 
Godbole et al. (2013) 2007–2010 1.1% (1.0–1.2) 38,227 
Pepas et al. (2011) 2003 1.4% (1.3–1.6) 25,082 
 
MSM 
Roy et al. (2008) 2001 0.0% (0.0–4.5) 81 
Roy et al. (2008) 2001 0.0% (0.0-12.8) 27 
Roy et al. (2008) 2001 0.0% (0.0–6.6) 54 
McMillan (2006) 2001–2003 1.0% (0.4–2.3) 575 
 
Prisoners  
Pooled 2010–2013 1.6% (0.8–
2.9) 
640 
Mortlock et al. (2013) 2012 0.0% (0.0–2.8) 129 
Ferenando et al. 
(2014) 
2011–2013 2.0% (0.9–3.6) 511 
First-time blood donors 
Council of Europe 2011 0.04% (0.03–
0.05) 
216,083 
Anti-HCV prevalence  
Author 









Sampling description Age range 
Pepas et al. (2011) General 
population 
2007–2009 3 3,953 Exhaustive Patients undergoing 
Assisted Reproductive 
Treatment at Guy & St 
Thomas Hospital, London 
N/R 
Balogun et al. (2009) General 
population 
2000 3 5,068 Convenience Residual serum samples 
from Public Health and 
National Health Service 
Laboratories in England 
and Wales for routine 
diagnostic examination 
>16 
Price et al. (2013) MSM 2008 2 1,121 Convenience Multi-centre study in gay 
bars, saunas and clubs 
16 to 51 
Donson et al. (2012) MSM 2009–2011 0 3,395 Convenience STI clinic attendees N/R 
Pooled estimate Prisoners 2010–2013 N/A 5,450 Pooled Pooled Pooled 
Taylor et al. (2013) Prisoners 2010–2011 6 4,810 Exhaustive Multi-centre study in all 
14 prisons in Scotland 
including females and 
juvenile inmates. 32% 
history of IDU. 5% female 
<20 to >40, 
mean age 
32.4 
Mortlock et al. (2013) Prisoners 2012 4 129 Exhaustive  Implementation of routine 




Ferenando et al. 
(2014) 
Prisoners 2011–2013 3 511 Convenience Study in a London prison 
among participants of TB 
screening 
N/R 
Duncan et al. (2013) Prisoners 2010–2011 2 118 Convenience STI clinic attendees in a 
medium security male 
prison in Oxford 
N/R 
Samuel et al. (2013) Prisoners N/R 2 79 Convenience STI clinic attendees in a 
young offenders institute 
16 to 21, 
mean age 19 
Council of Europe First-time blood 
donors 















(year of publication) 
Sampling 
period 
Estimate (95% CI) 
Sample 
size 
Forest plot of estimates and 95% CI 
General population  
 
Pepas et al. (2011) 2007–2009 0.4% (0.3–0.7) 3,953 
Balogun et al. (2009) 2000 1.2% (0.9–1.5) 5,068 
MSM 
Price et al. (2013) 2008 2.1% (1.4–3.2) 1,121 
Donson et al. (2012) 2009–2011 1.6% (1.2–2.0) 3,395 
Prisoners 
Pooled 2010–2013 17.4% (16.4-18.4) 5,450 
Taylor et al. (2013) 2010–2011 19.2% (18.1–20.3) 4,810 
Mortlock et al. (2013) 2012 2.3% (0.5–6.7) 129 
Ferenando et al. 
(2014) 
2011–2013 4.3% (2.7–6.5) 511 
Duncan et al. (2013) 2010–2011 11.0% (6.0-18.1) 118 
Samuel et al. (2013) N/R 1.3% (0.0–6.9) 79 
First-time blood donors 
Council of Europe 2011 0.04% (0.03–0.05) 216,083 






Testing settings and sample size  
(if available) 
Estimate (95% CI) 
EMCDDA 2013 HBsAg Low threshold drug treatment and harm reduction services (in 
Wales) N=N/A 
0.72% (no CI available) 
EMCDDA 2013 Anti-HCV Low threshold drug treatment and harm reduction services 
(nationwide) N=3,144 
49.1% (47.4%–50.8%) 
HBsAg prevalence: migrants 
Country of birth 
Author  






Estimate (95% CI) 
Bangladesh Uddin (2010) n/s Community-based screening in various 
cities in England (convenience sample) 
726 1.5% (0.8%–2.7%) 
Bangladesh Pooled Pooled McPherson (2013) and Uddin 
(2010) 
934 1.3% (0.7% –2.2%) 
China (including 
Hong Kong) 
McPherson (2013) n/s Community-based screening in north-
eastern England (convenience sample) 
470 8.9% (6.5%–11.9%) 
India O'Leary (2010) 2009–2010 Community-based screening in Glasgow 
(convenience sample) 
137 0% (0%–2.7%) 
India Uddin (2010) n/s Community-based screening in various 
cities in England (convenience sample) 
1,197 0.1% (0%–0.5%) 
India Pooled Pooled Uddin (2010) and O'Leary (2010) 1,334 0.1% (0%- 0.4%) 
Other South Asian McPherson (2013) n/s Community-based screening in north-
eastern England (convenience sample) 
19 5.3% (0.1%–26.0%) 
Other South Asian O'Leary (2010) 2009–2010 Community-based screening in Glasgow 
(convenience sample) 
101 4.0% (1.1%–9.8%) 
Other South 
Asian 
Pooled Pooled McPherson (2013) and O'Leary 
(2010) 
120 4.2% (1.4%–9.5%) 
Other South East 
Asian 
McPherson (2013) n/s Community-based screening in north-
eastern England (convenience sample) 
38 5.3% (0.6%–17.7%) 
Pakistan McPherson (2013) n/s Community-based screening in north-
eastern England (convenience sample) 
222 3.2% (1.3%–6.4%) 
Pakistan O'Leary (2010) 2009–2010 Community-based screening in Glasgow 
(convenience sample) 
882 0.8% (0.3%–1.6%) 
Pakistan Uddin (2010) n/s Community-based screening in various 
cities in England (convenience sample) 
2,458 1.8% (1.3%–2.4%) 
Pakistan Pooled Pooled McPherson (2013), Uddin (2010) 
and O'Leary (2010) 
3,562 1.6% (1.2%–2.1%) 
Vietnam McPherson (2013) n/s Community-based screening in north-
eastern England (convenience sample) 













Anti-HCV prevalence: migrants 






Estimate (95% CI) 
Bangladesh McPherson (2013) n/s Community-based screening in north-
eastern England (convenience sample) 
208 0% (0%–1.8%) 
Bangladesh Uddin (2010) n/s Community-based screening in various cities 
in England (convenience sample) 
726 0.6% (0.2%–1.4%) 
Bangladesh Pooled Pooled McPherson (2013) and Uddin (2010) 934 0.4% (0.1%–1.1%) 
India Uddin (2010) n/s Community-based screening in various cities 
in England (convenience sample) 
1,197 0.2% (0%–0.6%) 
India O'Leary (2010) 2009–2010 Community-based screening in Glasgow 
(convenience sample) 
137 2.9% (0.8%–7.3%) 
India Pooled Pooled Uddin (2010) and O'Leary (2010) 1,334 0.4% (0.2%–1.0%) 
Other South 
Asian 
McPherson (2013) n/s Community-based screening in north-
eastern England (convenience sample) 
19 0% (0%–17.6%) 
Other South 
Asian 
O'Leary (2010) 2009–2010 Community-based screening in Glasgow 
(convenience sample) 
101 2.0% (0.2%–7.0%) 
Other South 
Asian 
Pooled Pooled McPherson (2013) and O'Leary (2010) 120 1.7% (0.2%–5.9%) 
Pakistan McPherson (2013) n/s Community-based screening in north-
eastern England (convenience sample) 
222 1.8% (0.5%–4.5%) 
Pakistan O'Leary (2010) 2009–2010 Community-based screening in Glasgow 
(convenience sample) 
882 3.1% (2.0%–4.4%) 
Pakistan Uddin (2010) n/s Community-based screening in various cities 
in England (convenience sample) 
2,458 2.7% (2.1%–3.4%) 
Pakistan Pooled Pooled McPherson (2013), Uddin (2010) and 
O'Leary (2010) 















Annex 4. Risk of bias assessment 
Table A16. Results of the risk of bias assessment and characteristics of the general population 
studies included in the HBV and HCV prevalence analysis 
Study characteristics Risk of bias assessment 
Authors Publication 
Year 
Virus Country Age bias 
(0 or 1) 
Gender bias  
(0 or 1) 
Sampling 
method 
(0, 1 or 2) 
Population 
coverage 




Quoilin 2007 Both Belgium 1 1 1 1 4 
Nardone  2009 HBV Belgium 0 1 0 2 3 
Vilibic-Cavlek  2014 Both Croatia 1 1 0 2 4 
Burek   2010 Both Croatia 1 0 1 1 3 
Nardone  2009 HBV Czech Republic 0 1 1 2 4 
Meffre  2010 Both France 1 1 1 2 5 
Sahajian  2007 HCV France 1 1 0 1 3 
Bottero  2014 HBV France 1 1 0 1 3 
Poynard  2009 HCV France 0 1 0 1 2 
Huetter  2014 Both Germany 1 1 2 0 4 
Poethko-Müller  2013 Both Germany 1 1 1 2 5 
Wolffram  2015 Both Germany 0 1 0 1 2 
Dounias  2005 HBV Greece 1 0 0 0 1 
Drositis  2013 Both Greece: Crete 1 1 2 0 4 
Treso  2012 Both Hungary 1 1 0 2 4 
Nardone  2009 HBV Ireland 0 1 0 2 3 
Talento  2010 Both Ireland 1 1 2 2 6 
Floreani  2006 Both Italy 1 1 2 0 4 
Fabris  2008 Both Italy 1 1 1 0 3 
Squeri  2006 Both Italy 1 0 0 0 1 
Da Villa  2007 HBV Italy 1 1 0 0 2 
Dazzani  2009 Both Italy 1 1 0 0 2 
Boccalini  2013 HBV Italy 1 1 0 1 3 
Guadagnino  2013 HCV Italy 1 1 1 0 3 
Montella  2005 HCV Italy 1 1 0 1 3 
Pendino  2005 Both Italy 1 1 2 0 4 
Cozzolongo  2009 Both Italy 1 1 2 1 5 
De Paschale  2012 Both Italy 1 1 0 0 2 
Parisi  2014 HCV Italy 1 1 0 1 3 
Petti  2006 HCV Italy 1 1 2 0 4 
Petti  2006 HCV Italy 1 1 2 0 4 
Petti  2006 HCV Italy 1 1 2 0 4 
Giacomoni  2010 Both Italy 0 1 0 0 1 
Del Corno  2006 Both Italy 1 1 1 0 3 
Tolmane  2011 HCV Latvia 1 1 2 2 6 
Liakina  2012 HCV Lithuania 0 0 0 2 2 
Pszenny 2012 Both Poland 0 0 0 1 1 
Flisiak  2011 HCV Poland 1 0 0 1 2 
Hartleb  2012 Both Poland 0 1 1 2 4 
Nardone  2009 HBV Romania 0 1 0 2 3 
Gheorghe   2013 HBV Romania 1 1 2 2 6 
Gheorghe  2010 HCV  Romania 1 1 2 2 6 
Nardone  2009 HBV Slovakia 0 1 1 2 4 
Schreter  2007 HCV Slovakia 1 1 2 2 6 
Salleras  2007 HBV Spain 0 1 2 0 3 
Salleras  2007 HBV Spain 1 1 2 0 4 
Salleras  2007 HBV Spain 0 1 2 0 3 
Lopez-
Izquierdo  
2007 Both Spain 1 1 2 0 5 
Calleja-Panero  2013 Both Spain 0 1 0 1 2 
Pedraza-
Flechas  













Study characteristics Risk of bias assessment 
Caballeria  2014 HCV Spain 1 1 1 0 3 
Caballeria  2014 HCV Spain 1 1 0 0 2 
Veldhuijzen  2009 Both Netherlands 1 1 1 0 3 
Slavenburg   2008 HCV Netherlands 1 1 0 0 2 
Hahné  2012 HBV Netherlands 1 1 1 2 5 
Vriend  2013 HCV Netherlands 1 1 1 2 5 
Pepas  2011 Both UK: England 0 1 2 0 3 
Balogun  2009 HCV UK: England 
and Wales 
1 1 0 1 3 
 
Table A17. Results of the risk of bias assessment and characteristics of the studies in pregnant 
women included in the HBV and HCV prevalence analysis 
Study characteristics Risk of bias assessment 
Authors Publication 
year 
Virus Country Sampling method  
(0 or 1) 
Population 
coverage 




Diab-Elschahawi  2013 HCV Austria 1 0 1 
Moller  2014 HBV Denmark 1 2 3 
Harder  2011 HBV Denmark 1 2 3 
Braillon  2010 HBV France 1 0 1 
Richaud-Eyraud  2015 HBV France 1 1 2 
Alba-Alejandre  2009 HBV Germany 1 0 1 
Lobstein  2011 HBV Germany 1 0 1 
Papaevangelou  2006 HBV Greece 1 2 3 
Betsas  2006 HBV Greece 1 0 1 
Kafkoula  2009 Both Greece 1 0 1 
Elefsiniotis  2010 HBV Greece 1 0 1 
Karatapanis  2012 HBV Greece 1 0 1 
Karatapanis  2012 HBV Greece 1 0 1 
Martyn  2011 HCV Ireland 1 0 1 
Martyn  2011 HCV Ireland 1 0 1 
O'Connell  2010 HBV Ireland 1 0 1 
Lambert  2013 HCV Ireland 1 0 1 
Veronesi  2007 HCV Italy 1 0 1 
Lagana  2015 Both Italy 0 0 0 
Spada  2011 HBV Italy 1 2 3 
Ruffini  2014 HBV Italy 1 1 2 
Ruffini  2014 HCV Italy 1 1 2 
Kristiansen  2009 HBV Norway 1 1 2 
Kristian  2010 HBV Slovakia 0 1 1 
Kristian  2013 HBV Slovakia 0 1 1 
Kopilovic  2015 HCV Slovenia 1 2 3 
Kopilovic  2015 HCV Slovenia 1 2 3 
Kopilovic  2015 HCV Slovenia 1 2 3 
Kopilovic  2015 HCV Slovenia 1 2 3 
Kopilovic  2015 HCV Slovenia 1 2 3 
Lopez-Fabal  2013 HBV Spain 0 1 1 
Seisdedos  2011 HCV Spain 1 2 3 
Sampedro  2010 HBV Spain 1 0 1 
Salleras  2009 HBV Spain 1 1 2 
Op de Coul  2011 HBV Netherlands 1 2 3 
Op de Coul  2011 HBV Netherlands 1 2 3 
Op de Coul  2011 HBV Netherlands 1 2 3 
Urbanus  2011 HCV Netherlands 1 0 1 
Pepas  2011 Both UK, England 1 0 1 
Godbole  2013 HBV UK, England 1 1 2 














Table A18. Results of the risk of bias assessment and characteristics of the MSM studies included in 
the HBV and HCV prevalence analysis. 
Study characteristics Risk of bias assessment 
Authors Publication year Virus Country Population 
coverage 




Bozicevic   2009 Both Croatia 2 2 
Cavlek  2009 HCV Croatia 2 2 
Rüütel  2015 Both Estonia 1 1 
Rüütel  2015 Both Estonia 1 1 
Sauvage  2015 Both France 2 2 
Di Benedetto   2012 HCV Italy 2 2 
Blaxhult  2013 HCV Sweden 1 1 
Van Rooijen  2013 HCV Netherlands 1 1 
van de Laar  2007 HCV Netherlands 2 2 
Price  2013 HCV UK, England 2 2 
Donson  2012 HCV UK, England 0 0 
Roy  2008 HBV UK, Scotland 1 1 
Roy  2008 HBV UK, Scotland 1 1 
Roy  2008 HBV UK, Scotland 1 1 
McMillan 2006 HBV UK, Scotland 0 0 
 
Table A19. Results of the risk of bias assessment and characteristics of the prisoner studies included 
in the HBV and HCV prevalence analysis 
Study characteristics Risk of bias assessment 
Authors Publication 
year 
Virus Country Age bias 
(0 or 1) 
Gender 
bias 
(0 or 1) 
PWID bias  
(0 or 1) 
Sampling 
method  
(0 or 1) 
Population 
coverage  




Popov  2012 Both Bulgaria 0 1 1 0 1 3 
Popov  2013 Both Bulgaria 1 1 1 0 2 5 
Popov  2010 Both Bulgaria 1 1 1 0 2 5 
Burek  2009 HBV Croatia 1 0 1 1 1 4 
Burek  2009 HCV Croatia 1 1 1 1 1 5 
Burek   2010 Both Croatia 1 1 1 0 2 5 
Burek   2010 Both Croatia 0 1 1 0 2 4 
Viitanen  2011 Both Finland 1 1 1 1 2 6 
Remy 2006 HCV France 1 1 1 1 2 6 
Verneuil  2009 Both France 1 0 1 1 0 3 
Remy 2006 HCV France 1 1 1 1 2 6 
Roux  2014 HCV France 1 1 1 0 1 4 
Semaille  2013 HCV France 1 1 1 1 2 6 
Vergniol  2014 Both France 1 0 1 1 1 4 
Abergel  2014 Both France 1 1 1 1 1 5 
Stark  2006 Both Germany 1 0 0 0 1 2 
Meyer 2007 HCV Germany 0 1 1 1 0 3 
Karakaya & Stark 2009 Both Germany 1 0 0 0 0 1 
Karakaya & Stark 2009 Both Germany 1 0 0 0 0 1 
Treso  2012 Both Hungary 1 1 1 1 2 6 
Drummond  2014 Both Ireland 1 1 1 1 2 6 
Montella  2005 HCV Italy 1 0 1 0 0 2 
Babudieri  2005 Both Italy  1 1 1 0 1 4 
Removille  2011 Both Luxembourg 1 1 0 0 2 4 
Barros  2008 HCV Portugal 1 0 0 1 0 2 
Marques  2011 Both Portugal 1 1 1 1 0 4 
Narare C 2011 HBV Romania 0 0 0 0 1 1 
Murcia  2009 HCV Spain 1 1 0 1 0 3 
Garcia-Guerrero  2010 Both Spain 1 1 1 1 2 6 
Hernandez-
Fernandez  
2010 HCV Spain 1 1 0 1 2 5 
Hernandez-
Fernandez  













Study characteristics Risk of bias assessment 
Hernandez-
Fernandez  
2010 HCV Spain 1 1 0 1 2 5 
Hernandez-
Fernandez  
2010 HCV Spain 1 1 0 1 2 5 
Hernandez-
Fernandez  
2010 HCV Spain 1 1 0 1 2 5 
Hernandez-
Fernandez  
2010 HCV Spain 1 1 0 1 2 5 
Hernandez-
Fernandez  
2010 HCV Spain 1 1 0 1 2 5 
Hernandez-
Fernandez  
2010 HCV Spain 1 1 0 1 2 5 
Hernandez-
Fernandez  
2010 HCV Spain 1 1 0 1 2 5 
Hernandez-
Fernandez  
2010 HCV Spain 1 1 0 1 2 5 
Abad-Perez   2011 HCV Spain 1 1 0 1 1 4 
Duncan  2013 HCV UK, England 1 0 1 0 0 2 
Ferenando  2014 Both UK, England 1 1 1 0 0 3 
Mortlock  2013 Both UK, England 1 1 1 1 0 4 
Samuel  2013 HCV UK, England 0 1 1 0 0 2 
Taylor  2013 HCV UK, 
Scotland 















Annex 5. Search strategy  
5.1 Pubmed search 
Date of the search: 16/03/2015 
Language limit: no limits 
Date limits: from 2005 to 2015 




#4 Search #1 AND #2 AND #3 10461 
#5 Search #1 AND #2 AND #3 Filters: Publication date from 2005/01/01 4541 
#3 Search "hepatitis B"[MeSH Terms] OR "hepatitis c"[MeSH Terms] OR "Hepatitis B virus"[Mesh] OR "hepacivirus"[Mesh] OR 
"hepatitis b"[TIAB] OR "hepatitis c"[TIAB] OR hepaciviru*[TIAB] OR "hbv"[TIAB] OR "hcv"[TIAB] OR "hbsag"[TIAB] OR "hbs 
ag"[TIAB] OR "hepatitis b surface antigens"[MeSH Terms] OR “Australia Antigen”[TIAB] OR “Australia Antigens”[TIAB] OR 
"hepatitis c antibodies"[MeSH Terms] OR "Hepatitis C Antigens"[Mesh] OR "Hepatitis B Antibodies"[Mesh] 
135899 
#2 Search "Prevalence"[Mesh] OR prevalence*[TIAB] OR "Population Surveillance"[Mesh] OR "Seroepidemiologic 
Studies"[Mesh:NoExp] OR prevalence*[TIAB] OR seroepidemiolog*[TIAB] OR "sero epidemiologic"[TIAB] OR "sero 
epidemiological"[TIAB] OR "sero epidemiology"[TIAB] OR serosurvey*[TIAB] OR serolog*[TI] OR epidemiolog*[TI] OR 
surveillance[TI] 
643490 
#1 Search (((("United kingdom"[ad] OR Britain[ad] OR British[ad] OR (England[ad] NOT ("New England"[ad])) OR English[ad] 
OR Scotland[ad] OR Scottish[ad] OR Wales[ad] OR Welsh[ad] OR "Northen Ireland"[ad] OR London[ad] OR "East 
midlands"[ad] OR "West midlands"[ad] OR Yorkshire[ad] OR "East Anglia"[ad] OR Bedfordshire[ad] OR Hertfordshire[ad] OR 
Essex[ad] OR Peterborough[ad] OR Cambridgeshire[ad] OR Norfolk[ad] OR Suffolk[ad] OR Luton[ad] OR Bedford[ad] OR 
"Southend on sea"[ad] OR Thurrock[ad] OR Derbyshire[ad] OR Nottinghamshire[ad] OR Leicestershire[ad] OR Rutland[ad] 
OR Northamptonshire[ad] OR Lincolnshire[ad] OR Derby[ad] OR Leicester[ad] OR Northamptonshire[ad] OR Nottingham[ad] 
OR Northumberland[ad] OR "Tyne and Wear"[ad] OR "Tees Valley"[ad] OR "Durham"[ad] OR Darlington[ad] OR 
Hartlepool[ad] OR "Stockton on tees"[ad] OR Northumberland[ad] OR Teesside[ad] OR Sunderland[ad] OR Tyneside[ad] OR 
Cumbria[ad] OR Cheshire[ad] OR Manchester[ad] OR Lancashire[ad] OR Merseyside[ad] OR (Blackburn[ad] AND 
Darwen[ad]) OR Blackpool[ad] OR Chester[ad] OR Liverpool[ad] OR Sefton[ad] OR Warrington[ad] OR Wirral[ad] OR 
Berkshire[ad] OR Buckinghamshire[ad] OR Oxfordshire[ad] OR Hampshire[ad] OR "Isle of Wight"[ad] OR Kent[ad] OR 
Surrey[ad] OR Sussex[ad] OR (Brighton[ad] AND Hove[ad]) OR Medway[ad] OR "Milton keynes"[ad] OR Portsmouth[ad] OR 
Southampton[ad] OR Devon[ad] OR Dorset[ad] OR Somerset[ad] OR Gloucestershire[ad] OR Wiltshire[ad] OR Bristol[ad] 
OR Bath[ad] OR Bournemouth[ad] OR Poole[ad] OR Bristol[ad] OR Plymouth[ad] OR Swindon[ad] OR Torbay[ad] OR 
Herefordshire[ad] OR Worcestershire[ad] OR Warwickshire[ad] OR Shropshire[ad] OR Staffordshire[ad] OR Birmingham[ad] 
OR Coventry[ad] OR Dudley[ad] OR Sandwell[ad] OR Shropshire[ad] OR Solihull[ad] OR "stoke on trent"[ad] OR Telford[ad] 
OR Wrekin[ad] OR Walsall[ad] OR Warwickshire[ad] OR Wolverhampton[ad] OR Worcestershire[ad] OR Barnsley[ad] OR 
Doncaster[ad] OR Rotherham[ad] OR Bradford[ad] OR Calderdale[ad] OR Kirklees[ad] OR Kingston[ad] OR Leeds[ad] OR 
Sheffield[ad] OR Wakefield[ad] OR (York[ad] NOT ("New York"[ad])) OR Antrim[ad] OR Ards[ad] OR Armagh[ad] OR 
Ballymena[ad] OR Ballymoney[ad] OR Banbridge[ad] OR Carrickfergus[ad] OR Castlereagh[ad] OR Coleraine[ad] OR 
Cookstown[ad] OR Craigavon[ad] OR Derry[ad] OR (Down[ad] AND (district[ad] OR council[ad])) OR Fermanagh[ad] OR 
Dungannon[ad] OR Fermanagh[ad] OR Larne[ad] OR Limavady[ad] OR Lisburn[ad] OR Magherafelt[ad] OR Moyle[ad] OR 
(Newry[ad] AND Mourne[ad]) OR Newtownabbey[ad] OR Omagh[ad] OR Strabane[ad] OR Londonderry[ad] OR Tyrone[ad] 
OR Belfast[ad] OR Aberdeen[ad] OR Aberdeenshire[ad] OR Angus[ad] OR Dundee[ad] OR (Argyll[ad] AND bute[ad]) OR 
Clackmannanshire[ad] OR Fife[ad] OR Ayrshire[ad] OR Dunbartonshire[ad] OR Lothian[ad] OR Renfrewshire[ad] OR 
Edinburgh[ad] OR Falkirk[ad] OR Glasgow[ad] OR Highland*[ad] OR Inverclyde[ad] OR Midlothian[ad] OR Moray[ad] OR 
Lanarkshire[ad] OR (Perth[ad] AND Kinross[ad]) OR Stirling[ad] OR "Orkney Islands"[ad] OR "Eileanan Siar"[ad] OR 
"Shetland Islands"[ad] OR Bridgend[ad] OR "Neath Port Talbot"[ad] OR Cardiff[ad] OR (Vale[ad] AND Glamorgan[ad]) OR 
"Central Valleys"[ad] OR Conwy[ad] OR Denbighshire[ad] OR Flintshire[ad] OR Wrexham[ad] OR "Gwent Valleys"[ad] OR 
Gwynedd[ad] OR (Isle[ad] AND Anglesey[ad]) OR "Monmouthshire"[ad] OR "Newport"[ad] OR Powys[ad] OR Swansea[ad] 
OR Ceredigion[ad] OR Carmarthenshire[ad] OR Pembrokeshire[ad] OR "Merthyr Tydfil"[ad] OR "Rhondda Cynon Taff"[ad] 
OR "Blaenau Gwent"[ad] OR Caerphilly[ad] OR Torfaen[ad] OR Caithness[ad] OR "Sutherland and Ross"[ad] OR 
Cromarty[ad] OR Teeside[ad] OR Tyneside[ad] OR Wearside[ad] OR "West Mercia"[ad] OR Avon[ad] OR Ulster[ad] OR 
Derry[ad] OR Medway[ad] OR "East Riding"[ad] OR "West Riding"[ad] OR "Lake District"[ad] OR "Peak District"[ad] OR 
Cumberland[ad] OR Dartmoor[ad] OR Exmoor[ad])) OR ("United kingdom"[tw] OR Britain[tw] OR British[tw] OR 
(England[tw] NOT ("New England"[tw])) OR English[tw] OR Scotland[tw] OR Scottish[tw] OR Wales[tw] OR Welsh[tw] OR 
"Northen Ireland"[tw] OR London[tw] OR "East midlands"[tw] OR "West midlands"[tw] OR Yorkshire[tw] OR "East 
Anglia"[tw] OR Bedfordshire[tw] OR Hertfordshire[tw] OR Essex[tw] OR Peterborough[tw] OR Cambridgeshire[tw] OR 
Norfolk[tw] OR Suffolk[tw] OR Luton[tw] OR Bedford[tw] OR "Southend on sea"[tw] OR Thurrock[tw] OR Derbyshire[tw] OR 
Nottinghamshire[tw] OR Leicestershire[tw] OR Rutland[tw] OR Northamptonshire[tw] OR Lincolnshire[tw] OR Derby[tw] OR 
Leicester[tw] OR Northamptonshire[tw] OR Nottingham[tw] OR Northumberland[tw] OR "Tyne and Wear"[tw] OR "Tees 
Valley"[tw] OR "Durham"[tw] OR Darlington[tw] OR Hartlepool[tw] OR "Stockton on tees"[tw] OR Northumberland[tw] OR 
Teesside[tw] OR Sunderland[tw] OR Tyneside[tw] OR Cumbria[tw] OR Cheshire[tw] OR Manchester[tw] OR Lancashire[tw] 
OR Merseyside[tw] OR (Blackburn[tw] AND Darwen[tw]) OR Blackpool[tw] OR Chester[tw] OR Liverpool[tw] OR Sefton[tw] 
OR Warrington[tw] OR Wirral[tw] OR Berkshire[tw] OR Buckinghamshire[tw] OR Oxfordshire[tw] OR Hampshire[tw] OR 
"Isle of Wight"[tw] OR Kent[tw] OR Surrey[tw] OR Sussex[tw] OR (Brighton[tw] AND Hove[tw]) OR Medway[tw] OR "Milton 
keynes"[tw] OR Portsmouth[tw] OR Southampton[tw] OR Devon[tw] OR Dorset[tw] OR Somerset[tw] OR 
Gloucestershire[tw] OR Wiltshire[tw] OR Bristol[tw] OR Bath[tw] OR Bournemouth[tw] OR Poole[tw] OR Bristol[tw] OR 
Plymouth[tw] OR Swindon[tw] OR Torbay[tw] OR Herefordshire[tw] OR Worcestershire[tw] OR Warwickshire[tw] OR 
Shropshire[tw] OR Staffordshire[tw] OR Birmingham[tw] OR Coventry[tw] OR Dudley[tw] OR Sandwell[tw] OR 
Shropshire[tw] OR Solihull[tw] OR "stoke on trent"[tw] OR Telford[tw] OR Wrekin[tw] OR Walsall[tw] OR Warwickshire[tw] 
OR Wolverhampton[tw] OR Worcestershire[tw] OR Barnsley[tw] OR Doncaster[tw] OR Rotherham[tw] OR Bradford[tw] OR 
Calderdale[tw] OR Kirklees[tw] OR Kingston[tw] OR Leeds[tw] OR Sheffield[tw] OR Wakefield[tw] OR (York[tw] NOT ("New 
York"[tw])) OR Antrim[tw] OR Ards[tw] OR Armagh[tw] OR Ballymena[tw] OR Ballymoney[tw] OR Banbridge[tw] OR 
Carrickfergus[tw] OR Castlereagh[tw] OR Coleraine[tw] OR Cookstown[tw] OR Craigavon[tw] OR Derry[tw] OR (Down[tw] 

















Limavady[tw] OR Lisburn[tw] OR Magherafelt[tw] OR Moyle[tw] OR (Newry[tw] AND Mourne[tw]) OR Newtownabbey[tw] 
OR Omagh[tw] OR Strabane[tw] OR Londonderry[tw] OR Tyrone[tw] OR Belfast[tw] OR Aberdeen[tw] OR 
Aberdeenshire[tw] OR Angus[tw] OR Dundee[tw] OR (Argyll[tw] AND bute[tw]) OR Clackmannanshire[tw] OR Fife[tw] OR 
Ayrshire[tw] OR Dunbartonshire[tw] OR Lothian[tw] OR Renfrewshire[tw] OR Edinburgh[tw] OR Falkirk[tw] OR Glasgow[tw] 
OR Highland*[tw] OR Inverclyde[tw] OR Midlothian[tw] OR Moray[tw] OR Lanarkshire[tw] OR (Perth[tw] AND Kinross[tw]) 
OR Stirling[tw] OR "Orkney Islands"[tw] OR "Eileanan Siar"[tw] OR "Shetland Islands"[tw] OR Bridgend[tw] OR "Neath Port 
Talbot"[tw] OR Cardiff[tw] OR (Vale[tw] AND Glamorgan[tw]) OR "Central Valleys"[tw] OR Conwy[tw] OR Denbighshire[tw] 
OR Flintshire[tw] OR Wrexham[tw] OR "Gwent Valleys"[tw] OR Gwynedd[tw] OR (Isle[tw] AND Anglesey[tw]) OR 
"Monmouthshire"[tw] OR "Newport"[tw] OR Powys[tw] OR Swansea[tw] OR Ceredigion[tw] OR Carmarthenshire[tw] OR 
Pembrokeshire[tw] OR "Merthyr Tydfil"[tw] OR "Rhondda Cynon Taff"[tw] OR "Blaenau Gwent"[tw] OR Caerphilly[tw] OR 
Torfaen[tw] OR Caithness[tw] OR "Sutherland and Ross"[tw] OR Cromarty[tw] OR Teeside[tw] OR Tyneside[tw] OR 
Wearside[tw] OR "West Mercia"[tw] OR Avon[tw] OR Ulster[tw] OR Derry[tw] OR Medway[tw] OR "East Riding"[tw] OR 
"West Riding"[tw] OR "Lake District"[tw] OR "Peak District"[tw] OR Cumberland[tw] OR Dartmoor[tw] OR Exmoor[tw])) OR 
(((Sweden[ad] OR Sverige[ad] OR Swedish[ad] OR Svenska[ad] OR Stockholm*[ad] OR Norrland[ad] OR Svealand[ad] OR 
Mellansverige[ad] OR Smaland[ad] OR Sydsverige[ad] OR Vastsverige[ad] OR Orebro[ad] OR Ostergotland*[ad] OR 
Vastergotland*[ad] OR Skara*[ad] OR Bohus*[ad] OR Dalsland[ad] OR Narke[ad] OR Sodermanland[ad] OR Uppsala[ad] OR 
Uppland[ad] OR Vastmanland*[ad] OR Jamtland*[ad] OR Harjedalen[ad] OR Vasternorrland*[ad] OR Dalarna[ad] OR 
Kopparberg[ad] OR Gavleborg*[ad] OR Gastrikland[ad] OR Halsingland[ad] OR Varmland*[ad] OR Gotland*[ad] OR 
Oland[ad] OR Jonkoping*[ad] OR Kalmar*[ad] OR Kronoberg*[ad] OR Blekinge[ad] OR Skane*[ad] OR Norrbotten*[ad] OR 
Vasterbotten*[ad] OR Lappland[ad] OR Angermanland[ad] OR Medelpad[ad] OR Halland*[ad] OR Gotaland*[ad] OR 
Gothenburg[ad] OR Goteborg*[ad] OR Malmo*[ad] OR Vasteras[ad] OR Linkoping[ad] OR Helsingborg[ad] OR 
Halsingborg[ad] OR Norrkoping[ad] OR Gavle[ad] OR Umea[ad] OR Lulea[ad] OR Karlstad[ad] OR Kalmar[ad] OR 
Huddinge[ad] OR Solna[ad] OR Ostersjo*[ad] OR Malaren*[ad] OR Malardalen[ad])) OR (Sweden[tw] OR Sverige[tw] OR 
Swedish[tw] OR Svenska[tw] OR Stockholm*[tw] OR Norrland[tw] OR Svealand[tw] OR Mellansverige[tw] OR Smaland[tw] 
OR Sydsverige[tw] OR Vastsverige[tw] OR Orebro[tw] OR Ostergotland*[tw] OR Vastergotland*[tw] OR Skara*[tw] OR 
Bohus*[tw] OR Dalsland[tw] OR Narke[tw] OR Sodermanland[tw] OR Uppsala[tw] OR Uppland[tw] OR Vastmanland*[tw] 
OR Jamtland*[tw] OR Harjedalen[tw] OR Vasternorrland*[tw] OR Dalarna[tw] OR Kopparberg[tw] OR Gavleborg*[tw] OR 
Gastrikland[tw] OR Halsingland[tw] OR Varmland*[tw] OR Gotland*[tw] OR Oland[tw] OR Jonkoping*[tw] OR Kalmar*[tw] 
OR Kronoberg*[tw] OR Blekinge[tw] OR Skane*[tw] OR Norrbotten*[tw] OR Vasterbotten*[tw] OR Lappland[tw] OR 
Angermanland[tw] OR Medelpad[tw] OR Halland*[tw] OR Gotaland*[tw] OR Gothenburg[tw] OR Goteborg*[tw] OR 
Malmo*[tw] OR Vasteras[tw] OR Linkoping[tw] OR Helsingborg[tw] OR Halsingborg[tw] OR Norrkoping[tw] OR Gavle[tw] 
OR Umea[tw] OR Lulea[tw] OR Karlstad[tw] OR Kalmar[tw] OR Huddinge[tw] OR Solna[tw] OR Ostersjo*[tw] OR 
Malaren*[tw] OR Malardalen[tw])) OR (((Spain[ad] OR Espana[ad] OR Spanish[ad] OR Espanol*[ad] OR Spaniard*[ad] OR 
Madrid[ad] OR Andalucia[ad] OR Andalusia[ad] OR Aragon[ad] OR Cantabria[ad] OR Canarias[ad] OR "Canary Islands"[ad] 
OR "Castile and leon"[ad] OR "Castilla y Leon"[ad] OR "Castile La Mancha"[ad] OR "Castilla La Mancha"[ad] OR Cataluna[ad] 
OR Catalonia[ad] OR Ceuta[ad] OR Melilla[ad] OR Navarra[ad] OR Navarre[ad] OR Valencia[ad] OR Valencian[ad] OR 
Extremadura[ad] OR Galicia[ad] OR Balears[ad] OR "Balearic Islands"[ad] OR Baleares[ad] OR "La Rioja"[ad] OR "Pais 
Vasco"[ad] OR "Basque Country"[ad] OR Asturias[ad] OR Murcia[ad] OR Coruna[ad] OR Alava[ad] OR Araba[ad] OR 
Albacete[ad] OR Alicante[ad] OR Alacant[ad] OR Almeria[ad] OR Asturias[ad] OR Avila[ad] OR Badajoz[ad] OR Badajos[ad] 
OR Barcelona[ad] OR Burgos[ad] OR Caceres[ad] OR Cadiz[ad] OR Castellon[ad] OR Castello[ad] OR "Ciudad Real"[ad] OR 
Cordoba[ad] OR Cuenca[ad] OR Eivissa[ad] OR Ibiza[ad] OR Formentera[ad] OR "El Hierro"[ad] OR Fuerteventura[ad] OR 
Girona[ad] OR Gerona[ad] OR "Gran Canaria"[ad] OR Granada[ad] OR Guadalajara[ad] OR Guipuzcoa[ad] OR Gipuzkoa[ad] 
OR Huelva[ad] OR Huesca[ad] OR Jaen[ad] OR "La Gomera"[ad] OR "La Palma"[ad] OR Lanzarote[ad] OR Leon[ad] OR 
Lleida[ad] OR Lerida[ad] OR Lugo[ad] OR Malaga[ad] OR Mallorca[ad] OR Majorca[ad] OR Menorca[ad] OR Minorca[ad] OR 
Murcia[ad] OR Ourense[ad] OR Orense[ad] OR Palencia[ad] OR Pontevedra[ad] OR Salamanca[ad] OR Segovia[ad] OR 
Sevilla[ad] OR Seville[ad] OR Soria[ad] OR Tarragona[ad] OR Tenerife[ad] OR Teruel[ad] OR Toledo[ad] OR Valencia[ad] 
OR Valladolid[ad] OR Vizcaya[ad] OR Biscay[ad] OR Zamora[ad] OR Zaragoza[ad] OR Saragossa[ad] OR Bilbao[ad] OR 
Bilbo[ad] OR Compostela[ad] OR "San Sebastian"[ad] OR Donostia[ad] OR Vitoria[ad] OR Oviedo[ad] OR Pamplona[ad] OR 
Logrono[ad] OR Gasteiz[ad])) OR (Spain[tw] OR Espana[tw] OR Spanish[tw] OR Espanol*[tw] OR Spaniard*[tw] OR 
Madrid[tw] OR Andalucia[tw] OR Andalusia[tw] OR Aragon[tw] OR Cantabria[tw] OR Canarias[tw] OR "Canary Islands"[tw] 
OR "Castile and leon"[tw] OR "Castilla y Leon"[tw] OR "Castile La Mancha"[tw] OR "Castilla La Mancha"[tw] OR Cataluna[tw] 
OR Catalonia[tw] OR Ceuta[tw] OR Melilla[tw] OR Navarra[tw] OR Navarre[tw] OR Valencia[tw] OR Valencian[tw] OR 
Extremadura[tw] OR Galicia[tw] OR Balears[tw] OR "Balearic Islands"[tw] OR Baleares[tw] OR "La Rioja"[tw] OR "Pais 
Vasco"[tw] OR "Basque Country"[tw] OR Asturias[tw] OR Murcia[tw] OR Coruna[tw] OR Alava[tw] OR Araba[tw] OR 
Albacete[tw] OR Alicante[tw] OR Alacant[tw] OR Almeria[tw] OR Asturias[tw] OR Avila[tw] OR Badajoz[tw] OR Badajos[tw] 
OR Barcelona[tw] OR Burgos[tw] OR Caceres[tw] OR Cadiz[tw] OR Castellon[tw] OR Castello[tw] OR "Ciudad Real"[tw] OR 
(Cordoba[tw] NOT Argent*[tw]) OR Cuenca[tw] OR Eivissa[tw] OR Ibiza[tw] OR Formentera[tw] OR "El Hierro"[tw] OR 
Fuerteventura[tw] OR Girona[tw] OR Gerona[tw] OR "Gran Canaria"[tw] OR Granada[tw] OR (Guadalajara[tw] NOT 
Mexic*[tw]) OR Guipuzcoa[tw] OR Gipuzkoa[tw] OR Huelva[tw] OR Huesca[tw] OR Jaen[tw] OR "La Gomera"[tw] OR "La 
Palma"[tw] OR Lanzarote[tw] OR Leon[tw] OR Lleida[tw] OR Lerida[tw] OR Lugo[tw] OR Malaga[tw] OR Mallorca[tw] OR 
Majorca[tw] OR Menorca[tw] OR Minorca[tw] OR Murcia[tw] OR Ourense[tw] OR Orense[tw] OR Palencia[tw] OR 
Pontevedra[tw] OR Salamanca[tw] OR Segovia[tw] OR Sevilla[tw] OR Seville[tw] OR Soria[tw] OR Tarragona[tw] OR 
Tenerife[tw] OR Teruel[tw] OR Toledo[tw] OR Valencia[tw] OR Valladolid[tw] OR Vizcaya[tw] OR Biscay[tw] OR Zamora[tw] 
OR Zaragoza[tw] OR Saragossa[tw] OR Bilbao[tw] OR Bilbo[tw] OR Compostela[tw] OR "San Sebastian"[tw] OR 
Donostia[tw] OR Vitoria[tw] OR Oviedo[tw] OR Pamplona[tw] OR Logrono[tw] OR Gasteiz[tw])) OR (((Slovenia*[ad] OR 
Slovenija[ad] OR slovensk*[ad] OR Ljubljana[ad] OR Gorenjska[ad] OR Carniola[ad] OR Goriska[ad] OR Gorizia[ad] OR 
Koroska[ad] OR Carinthia[ad] OR "Notranjsko kraska"[ad] OR "Obalno kraska"[ad] OR "Coastal krast"[ad] OR Podravska[ad] 
OR Pomurska[ad] OR Savinjska[ad] OR Spodnjeposavska[ad] OR Zasavska[ad] OR Osrednjeslovenska[ad] OR Maribor[ad] 
OR Celje[ad] OR Kranj[ad] OR Velenje[ad] OR Koper[ad] OR Capodistria[ad] OR "Novo mesto"[ad] OR Ptuj[ad] OR 
Trbovlje[ad] OR Kamnik[ad] OR Murska[ad] OR Sobota[ad] OR "Nova Gorica"[ad])) OR (Slovenia*[tw] OR Slovenija[tw] OR 
slovensk*[tw] OR Ljubljana[tw] OR Gorenjska[tw] OR Carniola[tw] OR Goriska[tw] OR Gorizia[tw] OR Koroska[tw] OR 
Carinthia[tw] OR "Notranjsko kraska"[tw] OR "Obalno kraska"[tw] OR "Coastal krast"[tw] OR Podravska[tw] OR 
Pomurska[tw] OR Savinjska[tw] OR Spodnjeposavska[tw] OR Zasavska[tw] OR Osrednjeslovenska[tw] OR Maribor[tw] OR 
Celje[tw] OR Kranj[tw] OR Velenje[tw] OR Koper[tw] OR Capodistria[tw] OR "Novo mesto"[tw] OR Ptuj[tw] OR Trbovlje[tw] 
OR Kamnik[tw] OR Murska[tw] OR Sobota[tw] OR "Nova Gorica"[tw])) OR ((Slovakia[tw] OR Slovensk*[tw] OR Slovak*[tw] 
OR Bratislav*[tw] OR Trnav*[tw] OR Trnava[tw] OR Nitrian*[tw] OR Nitra[tw] OR Trencian*[tw] OR Trencin[tw] OR 
Banskobystri*[tw] OR "Banska Bystrica"[tw] OR Zilina[tw] OR Zilin*[tw] OR Trnava[tw] OR Trnav*[tw] OR Presov[tw] OR 
Presov*[tw] OR Kosic*[tw] OR (Martin[tw] AND (city[tw] OR Svaty[tw])) OR Poprad[tw])) OR (Slovakia[ad] OR 
Slovensk*[ad] OR Slovak*[ad] OR Bratislav*[ad] OR Trnav*[ad] OR Nitrian*[ad] OR Nitra[ad] OR Trencian*[ad] OR 
Trencin[ad] OR Banskobystri*[ad] OR "Banska Bystrica"[ad] OR Zilina[ad] OR Zilin*[ad] OR Trnava[ad] OR Trnav*[ad] OR 
Presov*[ad] OR Kosic*[ad] OR (Martin[ad] AND (city[ad] OR Svaty[ad])) OR Poprad[ad])) OR ((((Romania[tw] OR 
Rumania[tw] OR Roumania[tw] OR Romanian[tw] OR Roman[tw] OR Bucharest[tw] OR Bucuresti[tw] OR Alba[tw] OR 
















Neamt[tw] OR Suceava[tw] OR Vaslui[tw] OR Bihor[tw] OR "Bistrita Nasaud"[tw] OR Cluj[tw] OR Maramures[tw] OR 
Salaj[tw] OR "Satu Mare"[tw] OR Arges[tw] OR Calarasi[tw] OR Dambovita[tw] OR Giurgiu[tw] OR Ialomita[tw] OR 
Prahova[tw] OR Teleorman[tw] OR Braila[tw] OR Buzau[tw] OR Constanta[tw] OR Galati[tw] OR Tulcea[tw] OR Vrancea[tw] 
OR Dolj[tw] OR Gorj[tw] OR Mehedinti[tw] OR (Olt[tw] AND (river[tw] OR county[tw] OR region[tw] OR judetul[tw] OR 
Raul[tw])) OR Valcea[tw] OR Vilcea[tw] OR Arad[tw] OR "Caras-Severin"[tw] OR Hunedoara[tw] OR Timis[tw] OR Ilfov[tw] 
OR Timisoara[tw] OR Constanta[tw] OR Craiova[tw] OR Ploiesti[tw] OR Oradea[tw] OR "Cluj-Napoca"[tw] OR Deva[tw])) OR 
(Romania[ad] OR Rumania[ad] OR Roumania[ad] OR Romanian[ad] OR Roman[ad] OR Bucharest[ad] OR Bucuresti[ad] OR 
Alba[ad] OR Brasov[ad] OR Covasna[ad] OR Harghita[ad] OR Mures[ad] OR Sibiu[ad] OR Bacau[ad] OR Botosani[ad] OR 
Iasi[ad] OR Neamt[ad] OR Suceava[ad] OR Vaslui[ad] OR Bihor[ad] OR "Bistrita Nasaud"[ad] OR Cluj[ad] OR 
Maramures[ad] OR Salaj[ad] OR "Satu Mare"[ad] OR Arges[ad] OR Calarasi[ad] OR Dambovita[ad] OR Giurgiu[ad] OR 
Ialomita[ad] OR Prahova[ad] OR Teleorman[ad] OR Braila[ad] OR Buzau[ad] OR Constanta[ad] OR Galati[ad] OR Tulcea[ad] 
OR Vrancea[ad] OR Dolj[ad] OR Gorj[ad] OR Mehedinti[ad] OR (Olt[ad] AND (river[ad] OR county[ad] OR region[ad] OR 
judetul[ad] OR Raul[ad])) OR Valcea[ad] OR Vilcea[ad] OR Arad[ad] OR "Caras-Severin"[ad] OR Hunedoara[ad] OR 
Timis[ad] OR Ilfov[ad] OR Timisoara[ad] OR Constanta[ad] OR Craiova[ad] OR Ploiesti[ad] OR Oradea[ad] OR "Cluj-
Napoca"[ad] OR Deva[ad])) OR (((Portugal[tw] OR Portugues*[tw] OR Lisboa[tw] OR Lisbon[tw] OR Leira[tw] OR 
Santarem[tw] OR Beja[tw] OR Faro[tw] OR Evora[tw] OR Portalegre[tw] OR "Castelo Branco"[tw] OR Guarda[tw] OR 
Aveiro[tw] OR Viseu[tw] OR Braganca[tw] OR "Vila real"[tw] OR "Viana do Castelo"[tw] OR Alentejo[tw] OR Azores[tw] OR 
Acores[tw] OR Madeira[tw] OR "Os Montes"[tw] OR (Ave[tw] AND (community[tw] OR intermunicipal[tw] OR 
comunidade[tw])) OR Mondego[tw] OR Vouga[tw] OR Beira[tw] OR Cavado[tw] OR Lafoes[tw] OR Douro[tw] OR Porto[tw] 
OR Tejo[tw] OR Minho[tw] OR Setubal[tw] OR Pinhal[tw] OR "Serra da Estrela"[tw] OR Tamega[tw] OR Algarve[tw] OR 
Gaia[tw] OR Amadora[tw] OR Braga[tw] OR (Agualva[tw] AND Cacem[tw]) OR Funchal[tw] OR Coimbra[tw] OR 
Almada[tw])) OR (Portugal[ad] OR Portugues*[ad] OR Lisboa[ad] OR Lisbon[ad] OR Leira[ad] OR Santarem[ad] OR 
Beja[ad] OR Faro[ad] OR Evora[ad] OR Portalegre[ad] OR "Castelo Branco"[ad] OR Guarda[ad] OR Aveiro[ad] OR Viseu[ad] 
OR Braganca[ad] OR "Vila real"[ad] OR "Viana do Castelo"[ad] OR Alentejo[ad] OR Azores[ad] OR Acores[ad] OR 
Madeira[ad] OR "Os Montes"[ad] OR (Ave[ad] AND (community[ad] OR intermunicipal[ad] OR comunidade[ad])) OR 
Mondego[ad] OR Vouga[ad] OR Beira[ad] OR Cavado[ad] OR Lafoes[ad] OR Douro[ad] OR Porto[ad] OR Tejo[ad] OR 
Minho[ad] OR Setubal[ad] OR Pinhal[ad] OR "Serra da Estrela"[ad] OR Tamega[ad] OR Algarve[ad] OR Gaia[ad] OR 
Amadora[ad] OR Braga[ad] OR (Agualva[ad] AND Cacem[ad]) OR Funchal[ad] OR Coimbra[ad] OR Almada[ad])) OR 
(((Poland[ad] OR Polska[ad] OR Polish[ad] OR Polski[ad] OR Pole[ad] OR Poles[ad] OR Polak[ad] OR Polka[ad] OR 
Polacy[ad] OR Polacy[ad] OR Warsaw[ad] OR Warszawa[ad] OR Wielkopolskie[ad] OR Pomerania*[ad] OR Pomorskie[ad] 
OR Kuyavian[ad] OR Kujawsko[ad] OR Malopolskie[ad] OR Lodz[ad] OR Lodzkie[ad] OR Silesia*[ad] OR Slask[ad] OR 
Dolnoslaskie[ad] OR Lublin[ad] OR Lubelskie[ad] OR Lubus[ad] OR Lubusz[ad] OR Lubuskie[ad] OR Masovia[ad] OR 
Mazowske[ad] OR Masovian[ad] OR Mazowieckie[ad] OR Opole[ad] OR Opolskie[ad] OR Podlaskie[ad] OR Podlachia[ad] OR 
Podlasie[ad] OR Subcarpathian*[ad] OR Carpathian*[ad] OR Podkarpackie[ad] OR Swietokrzyskie[ad] OR Slaskie[ad] OR 
Slask[ad] OR "Varmia Mazuria"[ad] OR "Varmian Mazurian"[ad] OR "Varmia Masuria"[ad] OR "Varmian Masurian"[ad] OR 
"Warmia Mazury"[ad] OR "Warminsko Mazurskie"[ad] OR Zachodniopomorskie[ad] OR Krakow[ad] OR Cracow[ad] OR 
Wroclaw[ad] OR Poznan[ad] OR Gdansk[ad] OR Szczecin[ad] OR Bydgoszcz[ad] OR Katowice[ad] OR Bialystok[ad] OR 
Olsztyn[ad] OR Kielce[ad] OR "Zielona Gora"[ad] OR Torun[ad] OR "Gorzow Wielkopolski"[ad])) OR (Poland[tw] OR 
Polska[tw] OR Polish[tw] OR Polski[tw] OR Pole[tw] OR Poles[tw] OR Polak[tw] OR Polka[tw] OR Polacy[tw] OR Polacy[tw] 
OR Warsaw[tw] OR Warszawa[tw] OR Wielkopolskie[tw] OR Pomerania*[tw] OR Pomorskie[tw] OR Kuyavian[tw] OR 
Kujawsko[tw] OR Malopolskie[tw] OR Lodz[tw] OR Lodzkie[tw] OR Silesia*[tw] OR Slask[tw] OR Dolnoslaskie[tw] OR 
Lublin[tw] OR Lubelskie[tw] OR Lubus[tw] OR Lubusz[tw] OR Lubuskie[tw] OR Masovia[tw] OR Mazowske[tw] OR 
Masovian[tw] OR Mazowieckie[tw] OR Opole[tw] OR Opolskie[tw] OR Podlaskie[tw] OR Podlachia[tw] OR Podlasie[tw] OR 
Subcarpathian*[tw] OR Carpathian*[tw] OR Podkarpackie[tw] OR Swietokrzyskie[tw] OR Slaskie[tw] OR Slask[tw] OR 
"Varmia Mazuria"[tw] OR "Varmian Mazurian"[tw] OR "Varmia Masuria"[tw] OR "Varmian Masurian"[tw] OR "Warmia 
Mazury"[tw] OR "Warminsko Mazurskie"[tw] OR Zachodniopomorskie[tw] OR Krakow[tw] OR Cracow[tw] OR Wroclaw[tw] 
OR Poznan[tw] OR Gdansk[tw] OR Szczecin[tw] OR Bydgoszcz[tw] OR Katowice[tw] OR Bialystok[tw] OR Olsztyn[tw] OR 
Kielce[tw] OR "Zielona Gora"[tw] OR Torun[tw] OR "Gorzow Wielkopolski"[tw])) OR (((Netherlands[ad] OR Nederland*[ad] 
OR Dutch*[ad] OR Amsterdam[ad] OR Drenthe[ad] OR Flevoland[ad] OR Friesland[ad] OR Fryslan[ad] OR Gelderland[ad] 
OR Guelders[ad] OR Groningen[ad] OR Limburg[ad] OR "North Brabant"[ad] OR "Noord Brabant"[ad] OR Holland[ad] OR 
Overijssel[ad] OR Overissel[ad] OR Utrecht[ad] OR Zeeland[ad] OR Rotterdam[ad] OR Hague[ad] OR Eindhoven[ad] OR 
Tilburg[ad] OR Almere[ad] OR Breda[ad] OR Nijmegen[ad] OR Nimeguen[ad])) OR (Netherlands[tw] OR Nederland*[tw] OR 
Dutch*[tw] OR Amsterdam[tw] OR Drenthe[tw] OR Flevoland[tw] OR Friesland[tw] OR Fryslan[tw] OR Gelderland[tw] OR 
Guelders[tw] OR Groningen[tw] OR Limburg[tw] OR "North Brabant"[tw] OR "Noord Brabant"[tw] OR Holland[tw] OR 
Overijssel[tw] OR Overissel[tw] OR Utrecht[tw] OR Zeeland[tw] OR Rotterdam[tw] OR Hague[tw] OR Eindhoven[tw] OR 
Tilburg[tw] OR Almere[tw] OR Breda[tw] OR Nijmegen[tw] OR Nimeguen[tw])) OR (Malta[tw] OR Maltese[tw] OR 
Valletta[tw] OR Gozo[tw] OR Ghawdex[tw] OR Malta[ad] OR Maltese[ad] OR Valletta[ad] OR Gozo[ad] OR Ghawdex[ad]) 
OR (Luxembourg*[tw] OR Luxemburg[tw] OR Letzebuerg[tw] OR Diekirch[tw] OR Grevenmacher[tw] OR Luxembourg*[ad] 
OR Luxemburg[ad] OR Letzebuerg[ad] OR Diekirch[ad] OR Grevenmacher[ad]) OR (((Lithuania*[tw] OR "Lietuvos 
Respublika"[tw] OR Lietuva[tw] OR lietuviu[tw] OR Vilnius[tw] OR Vilniaus[tw] OR Kaunas[tw] OR Kauno[tw] OR 
Klaipeda[tw] OR Klaipedos[tw] OR Panevezys[tw] OR Panevezio[tw] OR Siauliai[tw] OR Siauliu[tw] OR Alytus[tw] OR 
Alytaus[tw] OR Taurages[tw] OR Taurage[tw] OR Marijampoles[tw] OR Marijampole[tw] OR Telsiu[tw] OR Telsiai[tw] OR 
Utenos[tw] OR Utena[tw] OR Mazeikiai[tw] OR Jonava[tw] OR Mazeikiu[tw] OR Jonavos[tw])) OR (Lithuania*[ad] OR 
"Lietuvos Respublika"[ad] OR Lietuva[ad] OR lietuviu[ad] OR Vilnius[ad] OR Vilniaus[ad] OR Kaunas[ad] OR Kauno[ad] OR 
Klaipeda[ad] OR Klaipedos[ad] OR Panevezys[ad] OR Panevezio[ad] OR Siauliai[ad] OR Siauliu[ad] OR Alytus[ad] OR 
Alytaus[ad] OR Taurages[ad] OR Taurage[ad] OR Marijampoles[ad] OR Marijampole[ad] OR Telsiu[ad] OR Telsiai[ad] OR 
Utenos[ad] OR Utena[ad] OR Mazeikiai[ad] OR Jonava[ad] OR Mazeikiu[ad] OR Jonavos[ad])) OR (((Latvi*[tw] OR 
Latvija*[tw] OR Riga[tw] OR Courland[tw] OR Kurzeme[tw] OR Kurland[tw] OR Latgale[tw] OR Lettgallia[tw] OR Latgola[tw] 
OR Vidzeme[tw] OR Vidumo[tw] OR Semigallia[tw] OR Semigalia[tw] OR Zemgale[tw] OR Pieriga[tw] OR Daugavpils[tw] OR 
Dinaburg[tw] OR Liepaja[tw] OR Libau[tw] OR Jelgava[tw] OR Jurmala[tw] OR Jekabpils[tw] OR Jakobstadt[tw] OR 
Rezekne[tw] OR Rezne[tw] OR Rositten[tw] OR Valmiera[tw] OR Wolmar[tw] OR Ventspils[tw] OR Windau[tw])) OR 
(Latvi*[ad] OR Latvija*[ad] OR Riga[ad] OR Courland[ad] OR Kurzeme[ad] OR Kurland[ad] OR Latgale[ad] OR Lettgallia[ad] 
OR Latgola[ad] OR Vidzeme[ad] OR Vidumo[ad] OR Semigallia[ad] OR Semigalia[ad] OR Zemgale[ad] OR Pieriga[ad] OR 
Daugavpils[ad] OR Dinaburg[ad] OR Liepaja[ad] OR Libau[ad] OR Jelgava[ad] OR Jurmala[ad] OR Jekabpils[ad] OR 
Jakobstadt[ad] OR Rezekne[ad] OR Rezne[ad] OR Rositten[ad] OR Valmiera[ad] OR Wolmar[ad] OR Ventspils[ad] OR 
Windau[ad]))) OR ((((Italy[tw] OR Italia*[tw] OR Rome[tw] OR Roma[tw] OR Abruzzo[tw] OR Abruzzi[tw] OR Basilicata[tw] 
OR Lucania[tw] OR Calabria[tw] OR Campania[tw] OR "Emilia Romagna"[tw] OR "friuli venezia giulia"[tw] OR Lazio[tw] OR 
Latium[tw] OR Liguria*[tw] OR Lombardy[tw] OR Lombardia[tw] OR Marche[tw] OR Marches[tw] OR Molisano[tw] OR 
Molise[tw] OR Piedmont*[tw] OR Piemonte[tw] OR Sardinia[tw] OR Sardegna[tw] OR Sicily[tw] OR Sicilia[tw] OR 
Toscana[tw] OR Tuscany[tw] OR Trentino[tw] OR Trento[tw] OR Umbria[tw] OR Veneto[tw] OR Triveneto[tw] OR 
Puglia[tw] OR Apulia[tw] OR Bolzano[tw] OR Bozen[tw] OR Milan[tw] OR Milano[tw] OR Naples[tw] OR Napoli[tw] OR 
Turin[tw] OR Torino[tw] OR Palermo[tw] OR Genoa[tw] OR Genova[tw] OR Bologna[tw] OR Florence[tw] OR Firenze[tw] 
















Trieste[tw] OR Urbino[tw] OR Aosta[tw] OR Aoste[tw] OR Perugia[tw] OR Brescia[tw] OR Cagliari[tw] OR Catanzaro[tw] OR 
"L Aquila"[tw] OR Ancona[tw])) OR (Italy[ad] OR Italia*[ad] OR Rome[ad] OR Roma[ad] OR Abruzzo[ad] OR Abruzzi[ad] OR 
Basilicata[ad] OR Lucania[ad] OR Calabria[ad] OR Campania[ad] OR "Emilia Romagna"[ad] OR "friuli venezia giulia"[ad] OR 
Lazio[ad] OR Latium[ad] OR Liguria*[ad] OR Lombardy[ad] OR Lombardia[ad] OR Marche[ad] OR Marches[ad] OR 
Molisano[ad] OR Molise[ad] OR Piedmont*[ad] OR Piemonte[ad] OR Sardinia[ad] OR Sardegna[ad] OR Sicily[ad] OR 
Sicilia[ad] OR Toscana[ad] OR Tuscany[ad] OR Trentino[ad] OR Trento[ad] OR Umbria[ad] OR Veneto[ad] OR Triveneto[ad] 
OR Puglia[ad] OR Apulia[ad] OR Bolzano[ad] OR Bozen[ad] OR Milan[ad] OR Milano[ad] OR Naples[ad] OR Napoli[ad] OR 
Turin[ad] OR Torino[ad] OR Palermo[ad] OR Genoa[ad] OR Genova[ad] OR Bologna[ad] OR Florence[ad] OR Firenze[ad] 
OR Bari[ad] OR Catania[ad] OR Venezia[ad] OR Venice[ad] OR Padova[ad] OR Padua[ad] OR Siena[ad] OR Bologna[ad] OR 
Trieste[ad] OR Urbino[ad] OR Aosta[ad] OR Aoste[ad] OR Perugia[ad] OR Brescia[ad] OR Cagliari[ad] OR Catanzaro[ad] OR 
"L Aquila"[ad] OR Ancona[ad])) OR (((Ireland[tw] OR Eire[tw] OR Irish*[tw] OR Dublin[tw] OR Fingal[tw] OR "Dun 
Laoghaire"[tw] OR Wicklow[tw] OR Wexford[tw] OR Carlow[tw] OR Kildare[tw] OR Meath[tw] OR Louth[tw] OR 
Monaghan[tw] OR Cavan[tw] OR Longford[tw] OR Westmeath[tw] OR Offaly[tw] OR Laois[tw] OR Kilkenny[tw] OR 
Waterford[tw] OR Cork[tw] OR Kerry[tw] OR Limerick[tw] OR Tipperary[tw] OR Clare[tw] OR Galway[tw] OR Mayo[tw] OR 
Roscommon[tw] OR Sligo[tw] OR Leitrim[tw] OR Donegal[tw] OR Drogheda[tw] OR Dundalk[tw] OR Swords[tw] OR 
Bray[tw] OR Navan[tw] OR Munster[tw] OR Leinster[tw] OR Connacht[tw])) OR (Ireland[ad] OR Eire[ad] OR Irish*[ad] OR 
Dublin[ad] OR Fingal[ad] OR "Dun Laoghaire"[ad] OR Wicklow[ad] OR Wexford[ad] OR Carlow[ad] OR Kildare[ad] OR 
Meath[ad] OR Louth[ad] OR Monaghan[ad] OR Cavan[ad] OR Longford[ad] OR Westmeath[ad] OR Offaly[ad] OR Laois[ad] 
OR Kilkenny[ad] OR Waterford[ad] OR Cork[ad] OR Kerry[ad] OR Limerick[ad] OR Tipperary[ad] OR Clare[ad] OR 
Galway[ad] OR Mayo[ad] OR Roscommon[ad] OR Sligo[ad] OR Leitrim[ad] OR Donegal[ad] OR Drogheda[ad] OR 
Dundalk[ad] OR Swords[ad] OR Bray[ad] OR Navan[ad] OR Munster[ad] OR Leinster[ad] OR Connacht[ad])) OR 
(((Hungar*[tw] OR Budapest[tw] OR Transdanubia[tw] OR Magyarorszag[tw] OR magyar[tw] OR Dunantuli[tw] OR 
Dunantul[tw] OR "Great Plain"[tw] OR "Alfold es eszak"[tw] OR "Eszak Alfold"[tw] OR "Del Alfold"[tw] OR Bacs[tw] OR 
Kiskun[tw] OR "Northen Alfold"[tw] OR "Sourthen Alfold"[tw] OR Baranya[tw] OR Bekes[tw] OR borsod[tw] OR Abauj[tw] 
OR Zemplen[tw] OR Fovaros[tw] OR Csongrad[tw] OR Fejer[tw] OR gyor[tw] OR moson[tw] OR sopron[tw] OR hajdu[tw] 
OR bihar[tw] OR Heves[tw] OR "jasz nagykun szolnok"[tw] OR komarom[tw] OR esztergom[tw] OR Nograd[tw] OR Pest[tw] 
OR Somogy[tw] OR szabolcs[tw] OR szatmar[tw] OR bereg[tw] OR Tolna[tw] OR Vas[tw] OR Veszprem[tw] OR Zala[tw] OR 
Zalaegerszeg[tw] OR Debrecen[tw] OR Miskolc[tw] OR Szeged[tw] OR Pecs[tw] OR Gyor[tw] OR Nyiregyhaza[tw] OR 
Kecskemet[tw] OR Szekesfehervar[tw] OR Szombathely[tw] OR Bekescsaba[tw] OR Eger[tw] OR Tatabanya[tw] OR 
Salgotarjan[tw] OR Kaposvar[tw] OR Szekszard[tw])) OR (Hungar*[ad] OR Budapest[ad] OR Transdanubia[ad] OR 
Magyarorszag[ad] OR magyar[ad] OR Dunantuli[ad] OR Dunantul[ad] OR "Great Plain"[ad] OR "Alfold es eszak"[ad] OR 
"Eszak Alfold"[ad] OR "Del Alfold"[ad] OR Bacs[ad] OR Kiskun[ad] OR "Northen Alfold"[ad] OR "Sourthen Alfold"[ad] OR 
Baranya[ad] OR Bekes[ad] OR borsod[ad] OR Abauj[ad] OR Zemplen[ad] OR Fovaros[ad] OR Csongrad[ad] OR Fejer[ad] 
OR gyor[ad] OR moson[ad] OR sopron[ad] OR hajdu[ad] OR bihar[ad] OR Heves[ad] OR "jasz nagykun szolnok"[ad] OR 
komarom[ad] OR esztergom[ad] OR Nograd[ad] OR Pest[ad] OR Somogy[ad] OR szabolcs[ad] OR szatmar[ad] OR 
bereg[ad] OR Tolna[ad] OR Vas[ad] OR Veszprem[ad] OR Zala[ad] OR Zalaegerszeg[ad] OR Debrecen[ad] OR Miskolc[ad] 
OR Szeged[ad] OR Pecs[ad] OR Gyor[ad] OR Nyiregyhaza[ad] OR Kecskemet[ad] OR Szekesfehervar[ad] OR 
Szombathely[ad] OR Bekescsaba[ad] OR Eger[ad] OR Tatabanya[ad] OR Salgotarjan[ad] OR Kaposvar[ad] OR 
Szekszard[ad])) OR (((Greece[ad] OR "Hellenic republic"[ad] OR Greek*[ad] OR Ellada[ad] OR "Elliniki Dimokratia"[ad] OR 
Hellas[ad] OR Hellenes[ad] OR Attica[ad] OR Attiki[ad] OR Makedonia[ad] OR Macedonia[ad] OR Thraki[ad] OR Thrace[ad] 
OR Crete[ad] OR Kriti[ad] OR Epirus[ad] OR Ipeiros[ad] OR "Ionia Nisia"[ad] OR "Ionion neson"[ad] OR "Ionian islands"[ad] 
OR "North aegean"[ad] OR "Aegean islands"[ad] OR "Nisoi Agaiou"[ad] OR "Notio Aigaio"[ad] OR Peloponnese[ad] OR 
Peloponnisos[ad] OR "Voreio Aigaio"[ad] OR "South aegean"[ad] OR Thessaly[ad] OR Thessalia[ad] OR Cycklades[ad] OR 
Kiklades[ad] OR Dodecanese[ad] OR Dodekanisa[ad] OR "Mount athos"[ad] OR "Omicronros Alphathos"[ad] OR Athens[ad] 
OR Athina[ad] OR Thessaloniki[ad] OR Thessalonica[ad] OR Patras[ad] OR Patra[ad] OR Heraklion[ad] OR Heraclion[ad] OR 
Iraklion[ad] OR Irakleion[ad] OR Iraklio[ad] OR Larissa[ad] OR Larisa[ad] OR Volos[ad] OR Rhodes[ad] OR Rodos[ad] OR 
Ioannina[ad] OR Janina[ad] OR Yannena[ad] OR Chania[ad] OR Chalcis[ad] OR Chalkida[ad] OR Alexandroupoli[ad])) OR 
(Greece[tw] OR "Hellenic republic"[tw] OR Greek*[tw] OR Ellada[tw] OR "Elliniki Dimokratia"[tw] OR Hellas[tw] OR 
Hellenes[tw] OR Attica[tw] OR Attiki[tw] OR Makedonia[tw] OR Macedonia[tw] OR Thraki[tw] OR Thrace[tw] OR Crete[tw] 
OR Kriti[tw] OR Epirus[tw] OR Ipeiros[tw] OR "Ionia Nisia"[tw] OR "Ionion neson"[tw] OR "Ionian islands"[tw] OR "North 
aegean"[tw] OR "Aegean islands"[tw] OR "Nisoi Agaiou"[tw] OR "Notio Aigaio"[tw] OR Peloponnese[tw] OR 
Peloponnisos[tw] OR "Voreio Aigaio"[tw] OR "South aegean"[tw] OR Thessaly[tw] OR Thessalia[tw] OR Cycklades[tw] OR 
Kiklades[tw] OR Dodecanese[tw] OR Dodekanisa[tw] OR "Mount athos"[tw] OR "Omicronros Alphathos"[tw] OR Athens[tw] 
OR Athina[tw] OR Thessaloniki[tw] OR Thessalonica[tw] OR Patras[tw] OR Patra[tw] OR Heraklion[tw] OR Heraclion[tw] OR 
Iraklion[tw] OR Irakleion[tw] OR Iraklio[tw] OR Larissa[tw] OR Larisa[tw] OR Volos[tw] OR Rhodes[tw] OR Rodos[tw] OR 
Ioannina[tw] OR Janina[tw] OR Yannena[tw] OR Chania[tw] OR Chalcis[tw] OR Chalkida[tw] OR Alexandroupoli[tw])) OR 
(((German*[ad] OR Deutschland[ad] OR Deutsch*[ad] OR Bundesrepublik[ad] OR Westdeutschland[ad] OR 
Ostdeutschland[ad] OR Baden[ad] OR Wuerttemberg[ad] OR Wurttemberg[ad] OR Bayern[ad] OR Bavaria[ad] OR Berlin[ad] 
OR Brandenburg[ad] OR Bremen[ad] OR Hamburg[ad] OR Hessen[ad] OR Hesse[ad] OR Hessia[ad] OR Mecklenburg[ad] 
OR Vorpommern[ad] OR Pomerania[ad] OR Niedersachsen[ad] OR Neddersassen[ad] OR Saxony[ad] OR Niederbayern[ad] 
OR "North Rhine"[ad] OR Westphalia[ad] OR Westfalen[ad] OR "Rhineland Palatinate"[ad] OR "Rheinland Pfalz"[ad] OR 
Saarland[ad] OR Sachsen[ad] OR "Schleswig Holstein"[ad] OR Thuringia[ad] OR Thuringen[ad] OR Thueringen[ad] OR 
Freiburg[ad] OR Karlsruhe[ad] OR Calsruhe[ad] OR Stuttgart[ad] OR Tubingen[ad] OR Oberbayern[ad] OR "Upper 
palatinate"[ad] OR Oberpfalz[ad] OR Franken[ad] OR Franconia[ad] OR Oberfranken[ad] OR Mittelfranken[ad] OR 
Schwaben[ad] OR Unterfranken[ad] OR Swabia[ad] OR Darmstadt[ad] OR Giessen[ad] OR Giessen[ad] OR Kassel[ad] OR 
Arnsberg[ad] OR Cologne[ad] OR Koln[ad] OR Koeln[ad] OR Detmold[ad] OR Dusseldorf[ad] OR Duesseldorf[ad] OR 
Munster[ad] OR Muenster[ad] OR Munich[ad] OR Munchen[ad] OR Muenchen[ad] OR Frankfurt[ad] OR Dortmund[ad] OR 
Essen[ad] OR Nurnberg[ad] OR Nuernberg[ad] OR Nuremberg[ad] OR Hanover[ad] OR Hannover[ad] OR Leipzig[ad] OR 
Dresden[ad] OR Ruhrgebiet[ad] OR Revier[ad] OR Ruhrpott[ad] OR Pott[ad] OR Ruhr[ad])) OR (German*[tw] OR 
Deutschland[tw] OR Deutsch*[tw] OR Bundesrepublik[tw] OR Westdeutschland[tw] OR Ostdeutschland[tw] OR Baden[tw] 
OR Wuerttemberg[tw] OR Wurttemberg[tw] OR Bayern[tw] OR Bavaria[tw] OR Berlin[tw] OR Brandenburg[tw] OR 
Bremen[tw] OR Hamburg[tw] OR Hessen[tw] OR Hesse[tw] OR Hessia[tw] OR Mecklenburg[tw] OR Vorpommern[tw] OR 
Pomerania[tw] OR Niedersachsen[tw] OR Neddersassen[tw] OR Saxony[tw] OR Niederbayern[tw] OR "North Rhine"[tw] OR 
Westphalia[tw] OR Westfalen[tw] OR "Rhineland Palatinate"[tw] OR "Rheinland Pfalz"[tw] OR Saarland[tw] OR Sachsen[tw] 
OR "Schleswig Holstein"[tw] OR Thuringia[tw] OR Thuringen[tw] OR Thueringen[tw] OR Freiburg[tw] OR Karlsruhe[tw] OR 
Calsruhe[tw] OR Stuttgart[tw] OR Tubingen[tw] OR Oberbayern[tw] OR "Upper palatinate"[tw] OR Oberpfalz[tw] OR 
Franken[tw] OR Franconia[tw] OR Oberfranken[tw] OR Mittelfranken[tw] OR Schwaben[tw] OR Unterfranken[tw] OR 
Swabia[tw] OR Darmstadt[tw] OR Giessen[tw] OR Giessen[tw] OR Kassel[tw] OR Arnsberg[tw] OR Cologne[tw] OR Koln[tw] 
OR Koeln[tw] OR Detmold[tw] OR Dusseldorf[tw] OR Duesseldorf[tw] OR Munster[tw] OR Muenster[tw] OR Munich[tw] OR 
Munchen[tw] OR Muenchen[tw] OR Frankfurt[tw] OR Dortmund[tw] OR Essen[tw] OR Nurnberg[tw] OR Nuernberg[tw] OR 
Nuremberg[tw] OR Hanover[tw] OR Hannover[tw] OR Leipzig[tw] OR Dresden[tw] OR Ruhrgebiet[tw] OR Revier[tw] OR 
Ruhrpott[tw] OR Pott[tw] OR Ruhr[tw])) OR (((France[ad] OR French*[ad] OR Francais[ad] OR Alsace[ad] OR Aquitaine[ad] 
















"Franche Comte"[ad] OR "Ile de France"[ad] OR "Languedoc Roussillon"[ad] OR Limousin[ad] OR Lorraine[ad] OR 
Normandie[ad] OR Normandy[ad] OR "Midi Pyrenees"[ad] OR "Nord Pas de Calais"[ad] OR Loire[ad] OR Picardie[ad] OR 
Picardy[ad] OR "Poitou Charentes"[ad] OR Provence[ad] OR "Rhone Alpes"[ad] OR Corse[ad] OR Corsica[ad] OR Guiana[ad] 
OR Guyane[ad] OR Guadeloupe[ad] OR Martinique[ad] OR Reunion[ad] OR Mayotte[ad] OR Ain[ad] OR Aisne[ad] OR 
Allier[ad] OR "Alpes de Haute Provence"[ad] OR "Haute Alpes"[ad] OR "Alpes Maritimes"[ad] OR Ardeche[ad] OR 
Ardennes[ad] OR Ariege[ad] OR Aube[ad] OR Aude[ad] OR Aveyron[ad] OR "Bas Rhin"[ad] OR "Bouches du Rhone"[ad] OR 
Calvados[ad] OR Cantal[ad] OR Charente[ad] OR Cher[ad] OR Correze[ad] OR "Corse du Sud"[ad] OR "Cote d Or"[ad] OR 
"Cotes d Armor"[ad] OR "Cote d Azur"[ad] OR Creuse[ad] OR "Deux Sevres"[ad] OR Dordogne[ad] OR Doubs[ad] OR 
Drome[ad] OR Essonne[ad] OR Eure[ad] OR Finistere[ad] OR Gard[ad] OR Gers[ad] OR Gironde[ad] OR "Haute Corse"[ad] 
OR "Haute Garonne"[ad] OR "Haute Marne"[ad] OR "Hautes Alpes"[ad] OR "Haute Saone"[ad] OR "Haute Savoie"[ad] OR 
"Hautes Pyrenees"[ad] OR "Haute Vienne"[ad] OR "Haut Rhin"[ad] OR "Hauts de Seine"[ad] OR Herault[ad] OR "Ille et 
Vilaine"[ad] OR Indre[ad] OR Isere[ad] OR Jura[ad] OR Landes[ad] OR Loire[ad] OR Loiret[ad] OR (Lot[ad] AND 
(departement[ad] OR department[ad])) OR "Lot et Garonne"[ad] OR "Loir et Cher"[ad] OR Lozere[ad] OR Manche[ad] OR 
Marne[ad] OR Mayenne[ad] OR "Meurthe et Moselle"[ad] OR Meuse[ad] OR Morbihan[ad] OR Moselle[ad] OR (Nord[ad] 
AND (department[ad] OR departement[ad])) OR Nievre[ad] OR Oise[ad] OR Orne[ad] OR "Pas de calais"[ad] OR Paris[ad] 
OR "Puy de dome"[ad] OR "Pyrenees Atlantiques"[ad] OR "Pyrenees Orientales"[ad] OR Rhone[ad] OR Sarthe[ad] OR 
Savoie[ad] OR "Seine et Marne"[ad] OR "Seine Maritime"[ad] OR Somme[ad] OR Tarn[ad] OR "Territoire de Belfort"[ad] OR 
"Val de Marne"[ad] OR "Val d Oise"[ad] OR Var[ad] OR Vaucluse[ad] OR Vendee[ad] OR Vienne[ad] OR Vosges[ad] OR 
Yonne[ad] OR Yvelines[ad] OR Marseille[ad] OR Lyon[ad] OR Nice[ad] OR Nantes[ad] OR Strasbourg[ad] OR Montpellier[ad] 
OR Bordeaux[ad] OR Lille[ad] OR Toulouse[ad])) OR (France[tw] OR French*[tw] OR Francais[tw] OR Alsace[tw] OR 
Aquitaine[tw] OR Auvergne[tw] OR Brittany[tw] OR Bretagne[tw] OR Bourgogne[tw] OR Burgundy[tw] OR "Champagne 
Ardenne"[tw] OR "Franche Comte"[tw] OR "Ile de France"[tw] OR "Languedoc Roussillon"[tw] OR Limousin[tw] OR 
Lorraine[tw] OR Normandie[tw] OR Normandy[tw] OR "Midi Pyrenees"[tw] OR "Nord Pas de Calais"[tw] OR Loire[tw] OR 
Picardie[tw] OR Picardy[tw] OR "Poitou Charentes"[tw] OR Provence[tw] OR "Rhone Alpes"[tw] OR Corse[tw] OR 
Corsica[tw] OR Guiana[tw] OR Guyane[tw] OR Guadeloupe[tw] OR Martinique[tw] OR Reunion[tw] OR Mayotte[tw] OR 
Ain[tw] OR Aisne[tw] OR Allier[tw] OR "Alpes de Haute Provence"[tw] OR "Haute Alpes"[tw] OR "Alpes Maritimes"[tw] OR 
Ardeche[tw] OR Ardennes[tw] OR Ariege[tw] OR Aube[tw] OR Aude[tw] OR Aveyron[tw] OR "Bas Rhin"[tw] OR "Bouches du 
Rhone"[tw] OR Calvados[tw] OR Cantal[tw] OR Charente[tw] OR Cher[tw] OR Correze[tw] OR "Corse du Sud"[tw] OR "Cote 
d Or"[tw] OR "Cotes d Armor"[tw] OR "Cote d Azur"[tw] OR Creuse[tw] OR "Deux Sevres"[tw] OR Dordogne[tw] OR 
Doubs[tw] OR Drome[tw] OR Essonne[tw] OR Eure[tw] OR Finistere[tw] OR Gard[tw] OR Gers[tw] OR Gironde[tw] OR 
"Haute Corse"[tw] OR "Haute Garonne"[tw] OR "Haute Marne"[tw] OR "Hautes Alpes"[tw] OR "Haute Saone"[tw] OR "Haute 
Savoie"[tw] OR "Hautes Pyrenees"[tw] OR "Haute Vienne"[tw] OR "Haut Rhin"[tw] OR "Hauts de Seine"[tw] OR Herault[tw] 
OR "Ille et Vilaine"[tw] OR Indre[tw] OR Isere[tw] OR Jura[tw] OR Landes[tw] OR Loire[tw] OR Loiret[tw] OR (Lot[tw] AND 
(departement[tw] OR department[tw])) OR "Lot et Garonne"[tw] OR "Loir et Cher"[tw] OR Lozere[tw] OR Manche[tw] OR 
Marne[tw] OR Mayenne[tw] OR "Meurthe et Moselle"[tw] OR Meuse[tw] OR Morbihan[tw] OR Moselle[tw] OR (Nord[tw] 
AND (department[tw] OR departement[tw])) OR Nievre[tw] OR Oise[tw] OR Orne[tw] OR "Pas de calais"[tw] OR Paris[tw] 
OR "Puy de dome"[tw] OR "Pyrenees Atlantiques"[tw] OR "Pyrenees Orientales"[tw] OR Rhone[tw] OR Sarthe[tw] OR 
Savoie[tw] OR "Seine et Marne"[tw] OR "Seine Maritime"[tw] OR Somme[tw] OR Tarn[tw] OR "Territoire de Belfort"[tw] OR 
"Val de Marne"[tw] OR "Val d Oise"[tw] OR Var[tw] OR Vaucluse[tw] OR Vendee[tw] OR Vienne[tw] OR Vosges[tw] OR 
Yonne[tw] OR Yvelines[tw] OR Marseille[tw] OR Lyon[tw] OR Nice[tw] OR Nantes[tw] OR Strasbourg[tw] OR Montpellier[tw] 
OR Bordeaux[tw] OR Lille[tw] OR Toulouse[tw])) OR (((Finland[tw] OR Finnish*[tw] OR Suomi*[tw] OR Lapland[tw] OR 
Lappi[tw] OR Lappland[tw] OR Ostrobothnia[tw] OR Pohjanmaa[tw] OR Osterbotten[tw] OR Kainuu[tw] OR Kajanaland*[tw] 
OR Karelia[tw] OR Karjala[tw] OR Karelen[tw] OR Savonia[tw] OR Savo[tw] OR Savolax[tw] OR Pirkanmaa[tw] OR 
Birkaland[tw] OR Satakunta[tw] OR Satakunda[tw] OR Tavastia[tw] OR Tavastland[tw] OR "Paijat Hame"[tw] OR "Kanta 
Hame"[tw] OR Uusimaa[tw] OR Nyland[tw] OR Kymenlaakso[tw] OR Kymmenedalen[tw] OR Aland[tw] OR Ahvenanmaa[tw] 
OR Helsinki[tw] OR Helsingfors[tw] OR Espoo[tw] OR Esbo[tw] OR Tampere[tw] OR Tammerfors[tw] OR Vantaa[tw] OR 
Vanda[tw] OR Oulu[tw] OR Uleaborg[tw] OR Turku[tw] OR Abo[tw] OR Jyvaskyla[tw] OR Kuopio[tw] OR Lathi[tw] OR 
Lahtis[tw] OR Kouvola[tw])) OR (Finland[ad] OR Finnish*[ad] OR Suomi*[ad] OR Lapland[ad] OR Lappi[ad] OR 
Lappland[ad] OR Ostrobothnia[ad] OR Pohjanmaa[ad] OR Osterbotten[ad] OR Kainuu[ad] OR Kajanaland*[ad] OR 
Karelia[ad] OR Karjala[ad] OR Karelen[ad] OR Savonia[ad] OR Savo[ad] OR Savolax[ad] OR Pirkanmaa[ad] OR 
Birkaland[ad] OR Satakunta[ad] OR Satakunda[ad] OR Tavastia[ad] OR Tavastland[ad] OR "Paijat Hame"[ad] OR "Kanta 
Hame"[ad] OR Uusimaa[ad] OR Nyland[ad] OR Kymenlaakso[ad] OR Kymmenedalen[ad] OR Aland[ad] OR Ahvenanmaa[ad] 
OR Helsinki[ad] OR Helsingfors[ad] OR Espoo[ad] OR Esbo[ad] OR Tampere[ad] OR Tammerfors[ad] OR Vantaa[ad] OR 
Vanda[ad] OR Oulu[ad] OR Uleaborg[ad] OR Turku[ad] OR Abo[ad] OR Jyvaskyla[ad] OR Kuopio[ad] OR Lathi[ad] OR 
Lahtis[ad] OR Kouvola[ad])) OR (((Estonia*[tw] OR Eesti[tw] OR Esti[tw] OR Tallinn[tw] OR Harju[tw] OR Harjumaa[tw] OR 
Hiiu[tw] OR Hiiumaa[tw] OR "Ida Viru"[tw] OR "Ida Virumaa"[tw] OR Jarvamaa[tw] OR Jarva[tw] OR Jogevamaa[tw] OR 
Jogeva[tw] OR Laanemma[tw] OR Laane[tw] OR Parnu[tw] OR Parnumaa[tw] OR Polva[tw] OR Polvamaa[tw] OR Rapla[tw] 
OR Raplamaa[tw] OR Saare[tw] OR Saaremaa[tw] OR Tartu[tw] OR Tartumaa[tw] OR Valga[tw] OR Valgamaa[tw] OR 
Valgamaakond[tw] OR Viljandimaa[tw] OR Viljandi[tw] OR Voru[tw] OR Vorumaa[tw] OR Narva[tw] OR Parnu[tw] OR 
"Kohtla Jarve"[tw] OR Viljandi[tw] OR Rakvere[tw] OR Maardu[tw] OR Sillamae[tw] OR Kuressaare[tw])) OR (Estonia*[ad] 
OR Eesti[ad] OR Esti[ad] OR Tallinn[ad] OR Harju[ad] OR Harjumaa[ad] OR Hiiu[ad] OR Hiiumaa[ad] OR "Ida Viru"[ad] OR 
"Ida Virumaa"[ad] OR Jarvamaa[ad] OR Jarva[ad] OR Jogevamaa[ad] OR Jogeva[ad] OR Laanemma[ad] OR Laane[ad] OR 
Parnu[ad] OR Parnumaa[ad] OR Polva[ad] OR Polvamaa[ad] OR Rapla[ad] OR Raplamaa[ad] OR Saare[ad] OR 
Saaremaa[ad] OR Tartu[ad] OR Tartumaa[ad] OR Valga[ad] OR Valgamaa[ad] OR Valgamaakond[ad] OR Viljandimaa[ad] 
OR Viljandi[ad] OR Voru[ad] OR Vorumaa[ad] OR Narva[ad] OR Parnu[ad] OR "Kohtla Jarve"[ad] OR Viljandi[ad] OR 
Rakvere[ad] OR Maardu[ad] OR Sillamae[ad] OR Kuressaare[ad]))) OR ((((Denmark[tw] OR Danish*[tw] OR Danmark[tw] 
OR dansk*[tw] OR Hovedstaden[tw] OR Midtjylland[tw] OR Nordjylland[tw] OR Sjaelland[tw] OR Sealand[tw] OR 
Syddanmark[tw] OR Jutland[tw] OR Jylland[tw] OR Nordjylland[tw] OR Sonderjyllands[tw] OR "Zealand region"[tw] OR 
"region Zealand"[tw] OR Hillerod[tw] OR Viborg[tw] OR Aalborg[tw] OR Alborg[tw] OR Soro[tw] OR Vejle[tw] OR 
Copenhagen[tw] OR Kobenhavn[tw] OR Arhus[tw] OR Aarhus[tw] OR Roskilde[tw] OR Odense[tw] OR Frederiksberg[tw] OR 
Esbjerg[tw] OR Gentofte[tw] OR Gladsaxe[tw] OR Randers[tw] OR Kolding[tw])) OR (Denmark[ad] OR Danish*[ad] OR 
Danmark[ad] OR dansk*[ad] OR Hovedstaden[ad] OR Midtjylland[ad] OR Nordjylland[ad] OR Sjaelland[ad] OR Sealand[ad] 
OR Syddanmark[ad] OR Jutland[ad] OR Jylland[ad] OR Nordjylland[ad] OR Sonderjyllands[ad] OR "Zealand region"[ad] OR 
"region Zealand"[ad] OR Hillerod[ad] OR Viborg[ad] OR Aalborg[ad] OR Alborg[ad] OR Soro[ad] OR Vejle[ad] OR 
Copenhagen[ad] OR Kobenhavn[ad] OR Arhus[ad] OR Aarhus[ad] OR Roskilde[ad] OR Odense[ad] OR Frederiksberg[ad] OR 
Esbjerg[ad] OR Gentofte[ad] OR Gladsaxe[ad] OR Randers[ad] OR Kolding[ad])) OR ((Czech*[tw] OR Cesk*[tw] OR 
Stredoces*[tw] OR Jihoces*[tw] OR Bohemia[tw] OR "Bohemian region"[tw] OR Kralovehradec*[tw] OR "Hradec 
Kralove"[tw] OR Karlovars*[tw] OR "Karlovy Vary"[tw] OR Liberec*[tw] OR Moravskoslezs*[tw] OR "Moravian Silesian"[tw] 
OR Olomouc*[tw] OR Pardubic*[tw] OR Plzen*[tw] OR Pilsen[tw] OR Prage[tw] OR Praha[tw] OR Prag[tw] OR 
Jihomorav*[tw] OR Moravia[tw] OR Moravian[tw] OR Morava[tw] OR Usteck*[tw] OR Usti[tw] OR Vysocina[tw] OR Zlin[tw] 
OR Zlinsk*[tw] OR "Ceske Budejovice"[tw] OR Budweis[tw] OR Brno[tw] OR Ostrava[tw])) OR (Czech*[ad] OR Cesk*[ad] 
OR Stredoces*[ad] OR Jihoce*[ad] OR Bohemia[ad] OR "Bohemian region"[ad] OR Kralovehradec*[ad] OR "Hradec 
















OR Olomouc*[ad] OR Pardubic*[ad] OR Pardubice[ad] OR Plzen*[ad] OR Pilsen[ad] OR Prage[ad] OR Praha[ad] OR 
Prag[ad] OR Jihomorav*[ad] OR Moravia[ad] OR Moravian[ad] OR Morava[ad] OR Usteck*[ad] OR Usti[ad] OR Vysocina[ad] 
OR Zlin[ad] OR Zlinsk*[ad] OR "Ceske Budejovice"[ad] OR Budweis[ad] OR Brno[ad] OR Ostrava[ad]) OR (((Cyprus[tw] OR 
Cypriot*[tw] OR Kypros[tw] OR Kibris[tw] OR kypriaki*[tw] OR Nicosia[tw] OR Lefkosa[tw] OR Lefkosia[tw] OR 
Famagusta[tw] OR Magusa[tw] OR Ammochostos[tw] OR Gazimagusa[tw] OR Kyrenia[tw] OR Girne[tw] OR Keryneia[tw] 
OR Larnaca[tw] OR Larnaka[tw] OR Limassol[tw] OR Lemesos[tw] OR Limasol[tw] OR Leymosun[tw] OR Paphos[tw] OR 
Pafos[tw] OR Baf[tw] OR Gazibaf[tw] OR Protaras[tw] OR Pergamos[tw] OR Beyarmudu[tw] OR Morfou[tw] OR 
Guzelyurt[tw] OR Omorfo[tw] OR Morphou[tw] OR Aradippou[tw])) OR (Cyprus[ad] OR Cypriot*[ad] OR Kypros[ad] OR 
Kibris[ad] OR kypriaki*[ad] OR Nicosia[ad] OR Lefkosa[ad] OR Lefkosia[ad] OR Famagusta[ad] OR Magusa[ad] OR 
Ammochostos[ad] OR Gazimagusa[ad] OR Kyrenia[ad] OR Girne[ad] OR Keryneia[ad] OR Larnaca[ad] OR Larnaka[ad] OR 
Limassol[ad] OR Lemesos[ad] OR Limasol[ad] OR Leymosun[ad] OR Paphos[ad] OR Pafos[ad] OR Baf[ad] OR Gazibaf[ad] 
OR Protaras[ad] OR Pergamos[ad] OR Beyarmudu[ad] OR Morfou[ad] OR Guzelyurt[ad] OR Omorfo[ad] OR Morphou[ad] 
OR Aradippou[ad])) OR (((Croatia*[tw] OR Hrvatsk*[tw] OR hrvat[tw] OR Bjelovar[tw] OR "Bjelovarsko bilogorska"[tw] OR 
"Brod Posavina"[tw] OR "Brodsko posavska"[tw] OR "Dubrovnik Neretva"[tw] OR "dubrovacko neretvanska"[tw] OR 
Istria[tw] OR Istarska[tw] OR Karlovacka[tw] OR Karlovac[tw] OR "Koprivnicko krizevacka"[tw] OR Koprivnica[tw] OR 
Krizevci[tw] OR "Krapina Zagorje"[tw] OR "Krapinsko zagorska"[tw] OR "Lika Senj"[tw] OR "Licko senjska"[tw] OR 
Medimurska[tw] OR Medimurje[tw] OR Osijek[tw] OR Osjecko[tw] OR Baranja[tw] OR "Osjecko baranjska"[tw] OR "Pozega 
Slavonia"[tw] OR "Pozesko slavonska"[tw] OR "Primorje Gorski Kotar"[tw] OR "Primorsko goranska"[tw] OR "Sibensko 
kninska"[tw] OR "Sibensko kninske"[tw] OR Sibenik[tw] OR Knin[tw] OR Sisak[tw] OR "Sisacko moslavacka"[tw] OR 
Moslavina[tw] OR "Splitsko dalmatinska"[tw] OR Split[tw] OR Dalmatia[tw] OR Varazdin[tw] OR Varazdinska[tw] OR 
"Viroviticko-podravska"[tw] OR Virovitica[tw] OR Podravina[tw] OR "Vukovarsko srijemska"[tw] OR Vukovar[tw] OR 
Srijem[tw] OR Zadar[tw] OR Zadarska[tw] OR Zagreb[tw] OR Zagrebacka[tw] OR Rijeka[tw] OR "Velika gorica"[tw] OR 
"Slavonski brod"[tw] OR Pula[tw])) OR (Croatia*[ad] OR Hrvatsk*[ad] OR hrvat[ad] OR Bjelovar[ad] OR "Bjelovarsko 
bilogorska"[ad] OR "Brod Posavina"[ad] OR "Brodsko posavska"[ad] OR "Dubrovnik Neretva"[ad] OR "dubrovacko 
neretvanska"[ad] OR Istria[ad] OR Istarska[ad] OR Karlovacka[ad] OR Karlovac[ad] OR "Koprivnicko krizevacka"[ad] OR 
Koprivnica[ad] OR Krizevci[ad] OR "Krapina Zagorje"[ad] OR "Krapinsko zagorska"[ad] OR "Lika Senj"[ad] OR "Licko 
senjska"[ad] OR Medimurska[ad] OR Medimurje[ad] OR Osijek[ad] OR Osjecko[ad] OR Baranja[ad] OR "Osjecko 
baranjska"[ad] OR "Pozega Slavonia"[ad] OR "Pozesko slavonska"[ad] OR "Primorje Gorski Kotar"[ad] OR "Primorsko 
goranska"[ad] OR "Sibensko kninska"[ad] OR "Sibensko kninske"[ad] OR Sibenik[ad] OR Knin[ad] OR Sisak[ad] OR "Sisacko 
moslavacka"[ad] OR Moslavina[ad] OR "Splitsko dalmatinska"[ad] OR Split[ad] OR Dalmatia[ad] OR Varazdin[ad] OR 
Varazdinska[ad] OR "Viroviticko-podravska"[ad] OR Virovitica[ad] OR Podravina[ad] OR "Vukovarsko srijemska"[ad] OR 
Vukovar[ad] OR Srijem[ad] OR Zadar[ad] OR Zadarska[ad] OR Zagreb[ad] OR Zagrebacka[ad] OR Rijeka[ad] OR "Velika 
gorica"[ad] OR "Slavonski brod"[ad] OR Pula[ad])) OR (((Bulgaria*[tw] OR Sofia[tw] OR Gabrovo[tw] OR Blagoevgrad[tw] 
OR "Pirin Macedonia"[tw] OR Burgas[tw] OR Dobrich[tw] OR Haskovo[tw] OR Kardzhali[tw] OR Kurdzhali[tw] OR 
Kyustendil[tw] OR Lovech[tw] OR Montana[tw] OR Pazardzhik[tw] OR Pernik[tw] OR Pleven[tw] OR Plovdiv[tw] OR 
Razgrad[tw] OR Rousse[tw] OR Ruse[tw] OR Shumen[tw] OR Sliven[tw] OR Silistra[tw] OR Smolyan[tw] OR "Stara 
Zagora"[tw] OR Targovishte[tw] OR Varna[tw] OR Tarnovo[tw] OR Vidin[tw] OR Vratsa[tw] OR Vratza[tw] OR Yambol[tw])) 
OR (Bulgaria*[ad] OR Sofia[ad] OR Gabrovo[ad] OR Blagoevgrad[ad] OR "Pirin Macedonia"[ad] OR Burgas[ad] OR 
Dobrich[ad] OR Haskovo[ad] OR Kardzhali[ad] OR Kurdzhali[ad] OR Kyustendil[ad] OR Lovech[ad] OR Montana[ad] OR 
Pazardzhik[ad] OR Pernik[ad] OR Pleven[ad] OR Plovdiv[ad] OR Razgrad[ad] OR Rousse[ad] OR Ruse[ad] OR Shumen[ad] 
OR Sliven[ad] OR Silistra[ad] OR Smolyan[ad] OR "Stara Zagora"[ad] OR Targovishte[ad] OR Varna[ad] OR Tarnovo[ad] OR 
Vidin[ad] OR Vratsa[ad] OR Vratza[ad] OR Yambol[ad])) OR (((Belgi*[tw] OR Belge[tw] OR Belgisch[tw] OR Brussel*[tw] 
OR Bruxelles[tw] OR Bruxelloise[tw] OR Flemish[tw] OR Flamand[tw] OR Flemisch[tw] OR Flanders[tw] OR Flandern[tw] OR 
Flandre[tw] OR Vlaanderen[tw] OR Vlaams[tw] OR Flamande[tw] OR Waals[tw] OR Walloon*[tw] OR Wallon*[tw] OR 
Antwerp*[tw] OR Anvers[tw] OR Ostflandern[tw] OR "Vlaams Brabant"[tw] OR Limbourg[tw] OR Limburg[tw] OR 
Hainault[tw] OR Hainaut[tw] OR Henegouwen[tw] OR Hennegau[tw] OR Liege[tw] OR Luik[tw] OR Luttich[tw] OR 
Namur[tw] OR Namen[tw] OR Westflandern[tw] OR "Waals Brabant"[tw] OR Ghent[tw] OR Gent[tw] OR Gand[tw] OR 
Charleroi[tw] OR Bruges[tw] OR Brugge[tw] OR Schaerbeek[tw] OR Schaarbeek[tw] OR Anderlecht[tw] OR Leuven[tw] OR 
Louvain[tw] OR Hasselt[tw] OR Mons[tw] OR Wavre[tw] OR Waver[tw])) OR (Belgi*[ad] OR Belge[ad] OR Belgisch[ad] OR 
Brussel*[ad] OR Bruxelles[ad] OR Bruxelloise[ad] OR Flemish[ad] OR Flamand[ad] OR Flemisch[ad] OR Flanders[ad] OR 
Flandern[ad] OR Flandre[ad] OR Vlaanderen[ad] OR Vlaams[ad] OR Flamande[ad] OR Waals[ad] OR Walloon*[ad] OR 
Wallon*[ad] OR Antwerp*[ad] OR Anvers[ad] OR Ostflandern[ad] OR "Vlaams Brabant"[ad] OR Limbourg[ad] OR 
Limburg[ad] OR Hainault[ad] OR Hainaut[ad] OR Henegouwen[ad] OR Hennegau[ad] OR Liege[ad] OR Luik[ad] OR 
Luttich[ad] OR Namur[ad] OR Namen[ad] OR Westflandern[ad] OR "Waals Brabant"[ad] OR Ghent[ad] OR Gent[ad] OR 
Gand[ad] OR Charleroi[ad] OR Bruges[ad] OR Brugge[ad] OR Schaerbeek[ad] OR Schaarbeek[ad] OR Anderlecht[ad] OR 
Leuven[ad] OR Louvain[ad] OR Hasselt[ad] OR Mons[ad] OR Wavre[ad] OR Waver[ad])) OR (((Austria*[tw] OR Vienna[tw] 
OR Wien[tw] OR Osterreich*[tw] OR Sudosterreich[tw] OR Westosterreich[tw] OR Niederosterreich[tw] OR Burgenland[tw] 
OR Carinthia[tw] OR Karinthia[tw] OR Karnten[tw] OR Oberosterreich[tw] OR Styria[tw] OR Steiermark[tw] OR Salzburg[tw] 
OR Saizburg[tw] OR Tyrol[tw] OR Tirol[tw] OR Becs[tw] OR Vorarlberg[tw] OR Bregenz[tw] OR Linz[tw] OR Eisenstadt[tw] 
OR Innsbruck[tw] OR Graz[tw] OR Klagenfurt[tw] OR Polten[tw] OR Villach[tw] OR Wels[tw] OR Dornbirn[tw] OR 
Feldkirch[tw] OR Steyr[tw])) OR (Austria*[ad] OR Vienna[ad] OR Wien[ad] OR Osterreich*[ad] OR Sudosterreich[ad] OR 
Westosterreich[ad] OR Niederosterreich[ad] OR Burgenland[ad] OR Carinthia[ad] OR Karnten[ad] OR Oberosterreich[ad] OR 
Styria[ad] OR Steiermark[ad] OR Salzburg[ad] OR Saizburg[ad] OR Tyrol[ad] OR Tirol[ad] OR Becs[ad] OR Vorarlberg[ad] 
OR Bregenz[ad] OR Linz[ad] OR Eisenstadt[ad] OR Innsbruck[ad] OR Graz[ad] OR Klagenfurt[ad] OR Polten[ad] OR 
Villach[ad] OR Wels[ad] OR Dornbirn[ad] OR Feldkirch[ad] OR Steyr[ad]))) OR (((((((((Iceland[tw] OR Icelandic*[tw] OR 
islenska*[tw] OR Icelander*[tw] OR islendinga*[tw] OR Reykjavik[tw] OR Reykjavikurborg[tw] OR Hofudborgarsvaedid[tw] 
OR Sudurnes[tw] OR Vesturland[tw] OR Vestfirdir[tw] OR Westfjords[tw] OR Nordurland[tw] OR Austurland[tw] OR 
Sudurland[tw] OR Kopavogur[tw] OR Hafnarfjordur[tw])) OR (Iceland[ad] OR Icelandic*[ad] OR islenska*[ad] OR 
Icelander*[ad] OR islendinga*[ad] OR Reykjavik[ad] OR Reykjavikurborg[ad] OR Hofudborgarsvaedid[ad] OR Sudurnes[ad] 
OR Vesturland[ad] OR Vestfirdir[ad] OR Westfjords[ad] OR Nordurland[ad] OR Austurland[ad] OR Sudurland[ad] OR 
Kopavogur[ad] OR Hafnarfjordur[ad])) OR (Switzerland[tw] OR Schweiz[tw] OR Schweizerische[tw] OR Swiss[tw] OR 
Suisse[tw] OR Aargau[tw] OR Argovia[tw] OR Ausserrhoden[tw] OR "Outer Rhodes"[tw] OR Innerrhoden[tw] OR "Inner 
Rhodes"[tw] OR Basel[tw] OR Bern[tw] OR Berne[tw] OR Fribourg[tw] OR Freiburg[tw] OR Geneva[tw] OR Geneve[tw] OR 
Glarus[tw] OR Graubunden[tw] OR Grisons[tw] OR Grigioni[tw] OR jura[tw] OR Lucerne[tw] OR Luzern[tw] OR 
Neuchatel[tw] OR Zurich[tw] OR (Uri[tw] AND (canton[tw] OR Kanton[tw])) OR Schwyz[tw] OR Obwalden[tw] OR 
Nidwalden[tw] OR Zug[tw] OR Solothurn[tw] OR Schaffhausen[tw] OR Thurgau[tw] OR Thurgovia[tw] OR Ticino[tw] OR 
Tessin[tw] OR Vaud[tw] OR Valais[tw] OR Wallis[tw] OR "St Gallen"[tw] OR Lausanne[tw] OR Winterthur[tw] OR 
Winterthour[tw] OR Lugano[tw] OR Biel[tw] OR Bienne[tw])) OR (Switzerland[ad] OR Schweiz[ad] OR Schweizerische[ad] 
OR Swiss[ad] OR Suisse[ad] OR Aargau[ad] OR Argovia[ad] OR Ausserrhoden[ad] OR "Outer Rhodes"[ad] OR 
Innerrhoden[ad] OR "Inner Rhodes"[ad] OR Basel[ad] OR Bern[ad] OR Berne[ad] OR Fribourg[ad] OR Freiburg[ad] OR 
Geneva[ad] OR Geneve[ad] OR Glarus[ad] OR Graubunden[ad] OR Grisons[ad] OR Grigioni[ad] OR jura[ad] OR Lucerne[ad] 
OR Luzern[ad] OR Neuchatel[ad] OR Zurich[ad] OR (Uri[ad] AND (canton[ad] OR Kanton[ad])) OR Schwyz[ad] OR 
















Ticino[ad] OR Tessin[ad] OR Vaud[ad] OR Valais[ad] OR Wallis[ad] OR "St Gallen"[ad] OR Lausanne[ad] OR Winterthur[ad] 
OR Winterthour[ad] OR Lugano[ad] OR Biel[ad] OR Bienne[ad])) OR (Norway[tw] OR Norwegian*[tw] OR Norge[tw] OR 
Noreg[tw] OR Norgga[tw] OR Ostfold[tw] OR Akershus[tw] OR Oslo[tw] OR Hedmark[tw] OR Oppland[tw] OR Buskerud[tw] 
OR Vestfold[tw] OR Telemark[tw] OR "Aust Agder"[tw] OR "Vest Agder"[tw] OR Rogaland[tw] OR Hordaland[tw] OR "Sogn 
og fjordane"[tw] OR "Sogn and fjordane"[tw] OR "sogn fjordane"[tw] OR "More og Romsdal"[tw] OR "More and 
Romsdal"[tw] OR "More Romsdal"[tw] OR Trondelag[tw] OR Nordland[tw] OR Troms[tw] OR Finnmark[tw] OR Bergen[tw] 
OR Stavanger[tw] OR Sandnes[tw] OR Trondheim[tw] OR Kristiansand[tw] OR Drammen[tw] OR Fredrikstad[tw] OR 
Sarpsborg[tw] OR Porsgrunn[tw] OR Skien[tw] OR Tonsberg[tw] OR Alesund[tw])) OR (Norway[ad] OR Norwegian*[ad] OR 
Norge[ad] OR Noreg[ad] OR Norgga[ad] OR Ostfold[ad] OR Akershus[ad] OR Oslo[ad] OR Hedmark[ad] OR Oppland[ad] OR 
Buskerud[ad] OR Vestfold[ad] OR Telemark[ad] OR "Aust Agder"[ad] OR "Vest Agder"[ad] OR Rogaland[ad] OR 
Hordaland[ad] OR "Sogn og fjordane"[ad] OR "Sogn and fjordane"[ad] OR "sogn fjordane"[ad] OR "More og Romsdal"[ad] 
OR "More and Romsdal"[ad] OR "More Romsdal"[ad] OR Trondelag[ad] OR Nordland[ad] OR Troms[ad] OR Finnmark[ad] 
OR Bergen[ad] OR Stavanger[ad] OR Sandnes[ad] OR Trondheim[ad] OR Kristiansand[ad] OR Drammen[ad] OR 
Fredrikstad[ad] OR Sarpsborg[ad] OR Porsgrunn[ad] OR Skien[ad] OR Tonsberg[ad] OR Alesund[ad])) OR 
(Liechtenstein[tw] OR Vaduz[tw] OR Triesenberg[tw] OR Triesen[tw] OR Schellenberg[tw] OR Schaan[tw] OR Ruggell[tw] 
OR Planken[tw] OR Mauren[tw] OR Gamprin[tw] OR Eschen[tw] OR Balzers[tw])) OR (Liechtenstein[ad] OR Vaduz[ad] OR 
Triesenberg[ad] OR Triesen[ad] OR Schellenberg[ad] OR Schaan[ad] OR Ruggell[ad] OR Planken[ad] OR Mauren[ad] OR 
Gamprin[ad] OR Eschen[ad] OR Balzers[ad])) OR ("European Union"[Mesh] OR "Europe"[MeSH] OR Europa[tw] OR 
Europe*[tw] OR Scandinavia*[tw] OR Scandinavia*[ad] OR Mediterranean[tw] OR "EEA countries"[tw] OR "EU country"[tw] 
OR "EU countries"[tw] OR Mediterranean[ad] OR Europe*[ad] OR Baltic[tw] OR Baltic[ad] OR Yugoslavia[tw] OR 
Jugoslavija[tw] OR Jugoslavija[AD] OR Yugoslavia[ad] OR "EU country"[tw] OR "Eu countries"[tw] OR global*[tw] OR 
world[tw] OR worldwide[tw]) 
 
5.2 Embase search 
Date of the search: 16/03/2015 
Language limit: no limits 
Date limits: from 2005 to 2015 
Number of results: 7801 
No. Query Results 
#9  #1 AND #7 AND [2005–2015]/py 7801 
#8  #1 AND #7 12837 
#7  #4 OR #5 OR #6 24163 
#6  (epidemiolog* NEAR/5 ('hepatitis b' OR 'hepatitis c' OR hepaciviru* OR 'hbv' OR 'hcv' OR hbsag OR 'hbs ag' 
OR 'australia antigen' OR 'australia antigens')):ti 
1146 
#5  (prevalence NEAR/5 ('hepatitis b' OR 'hepatitis c' OR hepaciviru* OR 'hbv' OR 'hcv' OR hbsag OR 'hbs ag' 
OR 'australia antigen' OR 'australia antigens')):ab,ti 
10785 
#4  #2 AND #3 20368 
#3  'hepatitis b'/exp OR 'hepatitis c'/exp OR 'hepatitis b virus'/exp OR 'hepatitis c virus'/exp OR 'hepatitis 
b':ab,ti OR 'hepatitis c':ab,ti OR hepaciviru*:ab,ti OR 'hbv':ab,ti OR 'hcv':ab,ti OR hbsag:ab,ti OR 'hbs ag':ab,ti 
OR 'hepatitis b antibody'/exp OR 'hepatitis b surface antigen'/exp OR 'australia antigen':ab,ti OR 'australia 
antigens':ab,ti OR 'hepatitis c antigen'/exp OR 'hepatitis c antibody'/exp 
201216 
#2  'prevalence'/exp OR 'seroepidemiology'/exp OR 'disease surveillance'/exp OR 'sero epidemiology':ab,ti OR 
'sero epidemiological':ab,ti OR 'sero epidemiologic':ab,ti OR seroepidemiolog*:ab,ti OR surveillance:ti OR 
serolog*:ti OR serosurvey*:ab,ti OR prevalence*:ab,ti OR 'population surveillance':ab,ti 
513612 
#1   11070462 
  #1.8 #1.1 OR #1.3 OR #1.4 OR #1.5 OR #1.6 OR #1.7 11070462 
#1.7 'united kingdom':ad OR britain:ad OR british:ad OR (england:ad NOT 'new england':ad) OR 
english:ad OR scotland:ad OR scottish:ad OR wales:ad OR welsh:ad OR 'northen ireland':ad OR 
london:ad OR 'east midlands':ad OR 'west midlands':ad OR yorkshire:ad OR 'east anglia':ad OR 
bedfordshire:ad OR hertfordshire:ad OR essex:ad OR peterborough:ad OR cambridgeshire:ad OR 
norfolk:ad OR suffolk:ad OR luton:ad OR bedford:ad OR 'southend on sea':ad OR thurrock:ad OR 
derbyshire:ad OR nottinghamshire:ad OR leicestershire:ad OR rutland:ad OR lincolnshire:ad OR 
derby:ad OR leicester:ad OR northamptonshire:ad OR nottingham:ad OR 'tyne and wear':ad OR 
'tees valley':ad OR 'durham':ad OR darlington:ad OR hartlepool:ad OR 'stockton on tees':ad OR 
northumberland:ad OR teesside:ad OR sunderland:ad OR cumbria:ad OR cheshire:ad OR 
manchester:ad OR lancashire:ad OR merseyside:ad OR (blackburn:ad AND darwen:ad) OR 
blackpool:ad OR chester:ad OR liverpool:ad OR sefton:ad OR warrington:ad OR wirral:ad OR 
berkshire:ad OR buckinghamshire:ad OR oxfordshire:ad OR hampshire:ad OR 'isle of wight':ad 
OR kent:ad OR surrey:ad OR sussex:ad OR (brighton:ad AND hove:ad) OR 'milton keynes':ad OR 
portsmouth:ad OR southampton:ad OR devon:ad OR dorset:ad OR somerset:ad OR 
gloucestershire:ad OR wiltshire:ad OR bath:ad OR bournemouth:ad OR poole:ad OR bristol:ad OR 
plymouth:ad OR swindon:ad OR torbay:ad OR herefordshire:ad OR staffordshire:ad OR 
birmingham:ad OR coventry:ad OR dudley:ad OR sandwell:ad OR shropshire:ad OR solihull:ad OR 
'stoke on trent':ad OR telford:ad OR wrekin:ad OR walsall:ad OR warwickshire:ad OR 
wolverhampton:ad OR worcestershire:ad OR barnsley:ad OR doncaster:ad OR rotherham:ad OR 
bradford:ad OR calderdale:ad OR kirklees:ad OR kingston:ad OR leeds:ad OR sheffield:ad OR 
wakefield:ad OR (york:ad NOT 'new york':ad) OR antrim:ad OR ards:ad OR armagh:ad OR 
ballymena:ad OR ballymoney:ad OR banbridge:ad OR carrickfergus:ad OR castlereagh:ad OR 
coleraine:ad OR cookstown:ad OR craigavon:ad OR (down:ad AND (district:ad OR council:ad)) OR 
dungannon:ad OR fermanagh:ad OR larne:ad OR limavady:ad OR lisburn:ad OR magherafelt:ad 
OR moyle:ad OR (newry:ad AND mourne:ad) OR newtownabbey:ad OR omagh:ad OR strabane:ad 
OR londonderry:ad OR tyrone:ad OR belfast:ad OR aberdeen:ad OR aberdeenshire:ad OR 














ayrshire:ad OR dunbartonshire:ad OR lothian:ad OR renfrewshire:ad OR edinburgh:ad OR 
falkirk:ad OR glasgow:ad OR highland*:ad OR inverclyde:ad OR midlothian:ad OR moray:ad OR 
lanarkshire:ad OR (perth:ad AND kinross:ad) OR stirling:ad OR 'orkney islands':ad OR 'eileanan 
siar':ad OR 'shetland islands':ad OR bridgend:ad OR 'neath port talbot':ad OR cardiff:ad OR 
(vale:ad AND glamorgan:ad) OR 'central valleys':ad OR conwy:ad OR denbighshire:ad OR 
flintshire:ad OR wrexham:ad OR 'gwent valleys':ad OR gwynedd:ad OR (isle:ad AND anglesey:ad) 
OR 'monmouthshire':ad OR 'newport':ad OR powys:ad OR swansea:ad OR ceredigion:ad OR 
carmarthenshire:ad OR pembrokeshire:ad OR 'merthyr tydfil':ad OR 'rhondda cynon taff':ad OR 
'blaenau gwent':ad OR caerphilly:ad OR torfaen:ad OR caithness:ad OR 'sutherland and ross':ad 
OR cromarty:ad OR teeside:ad OR tyneside:ad OR wearside:ad OR 'west mercia':ad OR avon:ad 
OR ulster:ad OR derry:ad OR medway:ad OR 'east riding':ad OR 'west riding':ad OR 'lake 
district':ad OR 'peak district':ad OR cumberland:ad OR dartmoor:ad OR exmoor:ad OR 'united 
kingdom':ab,ti OR britain:ab,ti OR british:ab,ti OR (england:ab,ti NOT 'new england':ab,ti) OR 
english:ab,ti OR scotland:ab,ti OR scottish:ab,ti OR wales:ab,ti OR welsh:ab,ti OR 'northen 
ireland':ab,ti OR london:ab,ti OR 'east midlands':ab,ti OR 'west midlands':ab,ti OR yorkshire:ab,ti 
OR 'east anglia':ab,ti OR bedfordshire:ab,ti OR hertfordshire:ab,ti OR essex:ab,ti OR 
peterborough:ab,ti OR cambridgeshire:ab,ti OR norfolk:ab,ti OR suffolk:ab,ti OR luton:ab,ti OR 
bedford:ab,ti OR 'southend on sea':ab,ti OR thurrock:ab,ti OR derbyshire:ab,ti OR 
nottinghamshire:ab,ti OR leicestershire:ab,ti OR rutland:ab,ti OR lincolnshire:ab,ti OR derby:ab,ti 
OR leicester:ab,ti OR northamptonshire:ab,ti OR nottingham:ab,ti OR 'tyne and wear':ab,ti OR 
'tees valley':ab,ti OR 'durham':ab,ti OR darlington:ab,ti OR hartlepool:ab,ti OR 'stockton on 
tees':ab,ti OR northumberland:ab,ti OR teesside:ab,ti OR sunderland:ab,ti OR cumbria:ab,ti OR 
cheshire:ab,ti OR manchester:ab,ti OR lancashire:ab,ti OR merseyside:ab,ti OR (blackburn:ab,ti 
AND darwen:ab,ti) OR blackpool:ab,ti OR chester:ab,ti OR liverpool:ab,ti OR sefton:ab,ti OR 
warrington:ab,ti OR wirral:ab,ti OR berkshire:ab,ti OR buckinghamshire:ab,ti OR oxfordshire:ab,ti 
OR hampshire:ab,ti OR 'isle of wight':ab,ti OR kent:ab,ti OR surrey:ab,ti OR sussex:ab,ti OR 
(brighton:ab,ti AND hove:ab,ti) OR 'milton keynes':ab,ti OR portsmouth:ab,ti OR southampton:ab,ti 
OR devon:ab,ti OR dorset:ab,ti OR somerset:ab,ti OR gloucestershire:ab,ti OR wiltshire:ab,ti OR 
bath:ab,ti OR bournemouth:ab,ti OR poole:ab,ti OR bristol:ab,ti OR plymouth:ab,ti OR 
swindon:ab,ti OR torbay:ab,ti OR herefordshire:ab,ti OR staffordshire:ab,ti OR birmingham:ab,ti 
OR coventry:ab,ti OR dudley:ab,ti OR sandwell:ab,ti OR shropshire:ab,ti OR solihull:ab,ti OR 'stoke 
on trent':ab,ti OR telford:ab,ti OR wrekin:ab,ti OR walsall:ab,ti OR warwickshire:ab,ti OR 
wolverhampton:ab,ti OR worcestershire:ab,ti OR barnsley:ab,ti OR doncaster:ab,ti OR 
rotherham:ab,ti OR bradford:ab,ti OR calderdale:ab,ti OR kirklees:ab,ti OR kingston:ab,ti OR 
leeds:ab,ti OR sheffield:ab,ti OR wakefield:ab,ti OR (york:ab,ti NOT 'new york':ab,ti) OR 
antrim:ab,ti OR ards:ab,ti OR armagh:ab,ti OR ballymena:ab,ti OR ballymoney:ab,ti OR 
banbridge:ab,ti OR carrickfergus:ab,ti OR castlereagh:ab,ti OR coleraine:ab,ti OR cookstown:ab,ti 
OR craigavon:ab,ti OR (down:ab,ti AND (district:ab,ti OR council:ab,ti)) OR dungannon:ab,ti OR 
fermanagh:ab,ti OR larne:ab,ti OR limavady:ab,ti OR lisburn:ab,ti OR magherafelt:ab,ti OR 
moyle:ab,ti OR (newry:ab,ti AND mourne:ab,ti) OR newtownabbey:ab,ti OR omagh:ab,ti OR 
strabane:ab,ti OR londonderry:ab,ti OR tyrone:ab,ti OR belfast:ab,ti OR aberdeen:ab,ti OR 
aberdeenshire:ab,ti OR angus:ab,ti OR dundee:ab,ti OR (argyll:ab,ti AND bute:ab,ti) OR 
clackmannanshire:ab,ti OR fife:ab,ti OR ayrshire:ab,ti OR dunbartonshire:ab,ti OR lothian:ab,ti OR 
renfrewshire:ab,ti OR edinburgh:ab,ti OR falkirk:ab,ti OR glasgow:ab,ti OR highland*:ab,ti OR 
inverclyde:ab,ti OR midlothian:ab,ti OR moray:ab,ti OR lanarkshire:ab,ti OR (perth:ab,ti AND 
kinross:ab,ti) OR stirling:ab,ti OR 'orkney islands':ab,ti OR 'eileanan siar':ab,ti OR 'shetland 
islands':ab,ti OR bridgend:ab,ti OR 'neath port talbot':ab,ti OR cardiff:ab,ti OR (vale:ab,ti AND 
glamorgan:ab,ti) OR 'central valleys':ab,ti OR conwy:ab,ti OR denbighshire:ab,ti OR flintshire:ab,ti 
OR wrexham:ab,ti OR 'gwent valleys':ab,ti OR gwynedd:ab,ti OR (isle:ab,ti AND anglesey:ab,ti) OR 
'monmouthshire':ab,ti OR 'newport':ab,ti OR powys:ab,ti OR swansea:ab,ti OR ceredigion:ab,ti OR 
carmarthenshire:ab,ti OR pembrokeshire:ab,ti OR 'merthyr tydfil':ab,ti OR 'rhondda cynon 
taff':ab,ti OR 'blaenau gwent':ab,ti OR caerphilly:ab,ti OR torfaen:ab,ti OR caithness:ab,ti OR 
'sutherland and ross':ab,ti OR cromarty:ab,ti OR teeside:ab,ti OR tyneside:ab,ti OR wearside:ab,ti 
OR 'west mercia':ab,ti OR avon:ab,ti OR ulster:ab,ti OR derry:ab,ti OR medway:ab,ti OR 'east 
riding':ab,ti OR 'west riding':ab,ti OR 'lake district':ab,ti OR 'peak district':ab,ti OR 
cumberland:ab,ti OR dartmoor:ab,ti OR exmoor:ab,ti OR sweden:ad OR sverige:ad OR swedish:ad 
OR svenska:ad OR stockholm*:ad OR norrland:ad OR svealand:ad OR mellansverige:ad OR 
smaland:ad OR sydsverige:ad OR vastsverige:ad OR orebro:ad OR ostergotland*:ad OR 
vastergotland*:ad OR skara*:ad OR bohus*:ad OR dalsland:ad OR narke:ad OR sodermanland:ad 
OR uppsala:ad OR uppland:ad OR vastmanland*:ad OR jamtland*:ad OR harjedalen:ad OR 
vasternorrland*:ad OR dalarna:ad OR kopparberg:ad OR gavleborg*:ad OR gastrikland:ad OR 
halsingland:ad OR varmland*:ad OR gotland*:ad OR oland:ad OR jonkoping*:ad OR kalmar*:ad 
OR kronoberg*:ad OR blekinge:ad OR skane*:ad OR norrbotten*:ad OR vasterbotten*:ad OR 
lappland:ad OR angermanland:ad OR medelpad:ad OR halland*:ad OR gotaland*:ad OR 
gothenburg:ad OR goteborg*:ad OR malmo*:ad OR vasteras:ad OR linkoping:ad OR 
helsingborg:ad OR halsingborg:ad OR norrkoping:ad OR gavle:ad OR umea:ad OR lulea:ad OR 
karlstad:ad OR kalmar:ad OR huddinge:ad OR solna:ad OR ostersjo*:ad OR malaren*:ad OR 
malardalen:ad OR sweden:ab,ti OR sverige:ab,ti OR swedish:ab,ti OR svenska:ab,ti OR 
stockholm*:ab,ti OR norrland:ab,ti OR svealand:ab,ti OR mellansverige:ab,ti OR smaland:ab,ti OR 
sydsverige:ab,ti OR vastsverige:ab,ti OR orebro:ab,ti OR ostergotland*:ab,ti OR 
vastergotland*:ab,ti OR skara*:ab,ti OR bohus*:ab,ti OR dalsland:ab,ti OR narke:ab,ti OR 
sodermanland:ab,ti OR uppsala:ab,ti OR uppland:ab,ti OR vastmanland*:ab,ti OR jamtland*:ab,ti 
OR harjedalen:ab,ti OR vasternorrland*:ab,ti OR dalarna:ab,ti OR kopparberg:ab,ti OR 
gavleborg*:ab,ti OR gastrikland:ab,ti OR halsingland:ab,ti OR varmland*:ab,ti OR gotland*:ab,ti 
OR oland:ab,ti OR jonkoping*:ab,ti OR kalmar*:ab,ti OR kronoberg*:ab,ti OR blekinge:ab,ti OR 
skane*:ab,ti OR norrbotten*:ab,ti OR vasterbotten*:ab,ti OR lappland:ab,ti OR angermanland:ab,ti 
OR medelpad:ab,ti OR halland*:ab,ti OR gotaland*:ab,ti OR gothenburg:ab,ti OR goteborg*:ab,ti 
OR malmo*:ab,ti OR vasteras:ab,ti OR linkoping:ab,ti OR helsingborg:ab,ti OR halsingborg:ab,ti OR 
norrkoping:ab,ti OR gavle:ab,ti OR umea:ab,ti OR lulea:ab,ti OR karlstad:ab,ti OR kalmar:ab,ti OR 
huddinge:ab,ti OR solna:ab,ti OR ostersjo*:ab,ti OR malaren*:ab,ti OR malardalen:ab,ti OR 
spain:ad OR espana:ad OR spanish:ad OR espanol*:ad OR spaniard*:ad OR madrid:ad OR 
andalucia:ad OR andalusia:ad OR aragon:ad OR cantabria:ad OR canarias:ad OR 'canary 
islands':ad OR 'castile and leon':ad OR 'castilla y leon':ad OR 'castile la mancha':ad OR 'castilla la 
mancha':ad OR cataluna:ad OR catalonia:ad OR ceuta:ad OR melilla:ad OR navarra:ad OR 













islands':ad OR baleares:ad OR 'la rioja':ad OR 'pais vasco':ad OR 'basque country':ad OR 
coruna:ad OR alava:ad OR araba:ad OR albacete:ad OR alicante:ad OR alacant:ad OR almeria:ad 
OR asturias:ad OR avila:ad OR badajoz:ad OR badajos:ad OR barcelona:ad OR burgos:ad OR 
caceres:ad OR cadiz:ad OR castellon:ad OR castello:ad OR 'ciudad real':ad OR cordoba:ad OR 
cuenca:ad OR eivissa:ad OR ibiza:ad OR formentera:ad OR 'el hierro':ad OR fuerteventura:ad OR 
girona:ad OR gerona:ad OR 'gran canaria':ad OR granada:ad OR guadalajara:ad OR guipuzcoa:ad 
OR gipuzkoa:ad OR huelva:ad OR huesca:ad OR jaen:ad OR 'la gomera':ad OR 'la palma':ad OR 
lanzarote:ad OR leon:ad OR lleida:ad OR lerida:ad OR lugo:ad OR malaga:ad OR mallorca:ad OR 
majorca:ad OR menorca:ad OR minorca:ad OR murcia:ad OR ourense:ad OR orense:ad OR 
palencia:ad OR pontevedra:ad OR salamanca:ad OR segovia:ad OR sevilla:ad OR seville:ad OR 
soria:ad OR tarragona:ad OR tenerife:ad OR teruel:ad OR toledo:ad OR valencia:ad OR 
valladolid:ad OR vizcaya:ad OR biscay:ad OR zamora:ad OR zaragoza:ad OR saragossa:ad OR 
bilbao:ad OR bilbo:ad OR compostela:ad OR 'san sebastian':ad OR donostia:ad OR vitoria:ad OR 
oviedo:ad OR pamplona:ad OR logrono:ad OR gasteiz:ad OR spain:ab,ti OR espana:ab,ti OR 
spanish:ab,ti OR espanol*:ab,ti OR spaniard*:ab,ti OR madrid:ab,ti OR andalucia:ab,ti OR 
andalusia:ab,ti OR aragon:ab,ti OR cantabria:ab,ti OR canarias:ab,ti OR 'canary islands':ab,ti OR 
'castile and leon':ab,ti OR 'castilla y leon':ab,ti OR 'castile la mancha':ab,ti OR 'castilla la 
mancha':ab,ti OR cataluna:ab,ti OR catalonia:ab,ti OR ceuta:ab,ti OR melilla:ab,ti OR navarra:ab,ti 
OR navarre:ab,ti OR valencian:ab,ti OR extremadura:ab,ti OR galicia:ab,ti OR balears:ab,ti OR 
'balearic islands':ab,ti OR baleares:ab,ti OR 'la rioja':ab,ti OR 'pais vasco':ab,ti OR 'basque 
country':ab,ti OR coruna:ab,ti OR alava:ab,ti OR araba:ab,ti OR albacete:ab,ti OR alicante:ab,ti OR 
alacant:ab,ti OR almeria:ab,ti OR asturias:ab,ti OR avila:ab,ti OR badajoz:ab,ti OR badajos:ab,ti OR 
barcelona:ab,ti OR burgos:ab,ti OR caceres:ab,ti OR cadiz:ab,ti OR castellon:ab,ti OR castello:ab,ti 
OR 'ciudad real':ab,ti OR (cordoba:ab,ti NOT argent*:ab,ti) OR cuenca:ab,ti OR eivissa:ab,ti OR 
ibiza:ab,ti OR formentera:ab,ti OR 'el hierro':ab,ti OR fuerteventura:ab,ti OR girona:ab,ti OR 
gerona:ab,ti OR 'gran canaria':ab,ti OR granada:ab,ti OR (guadalajara:ab,ti NOT mexic*:ab,ti) OR 
guipuzcoa:ab,ti OR gipuzkoa:ab,ti OR huelva:ab,ti OR huesca:ab,ti OR jaen:ab,ti OR 'la 
gomera':ab,ti OR 'la palma':ab,ti OR lanzarote:ab,ti OR leon:ab,ti OR lleida:ab,ti OR lerida:ab,ti OR 
lugo:ab,ti OR malaga:ab,ti OR mallorca:ab,ti OR majorca:ab,ti OR menorca:ab,ti OR minorca:ab,ti 
OR murcia:ab,ti OR ourense:ab,ti OR orense:ab,ti OR palencia:ab,ti OR pontevedra:ab,ti OR 
salamanca:ab,ti OR segovia:ab,ti OR sevilla:ab,ti OR seville:ab,ti OR soria:ab,ti OR tarragona:ab,ti 
OR tenerife:ab,ti OR teruel:ab,ti OR toledo:ab,ti OR valencia:ab,ti OR valladolid:ab,ti OR 
vizcaya:ab,ti OR biscay:ab,ti OR zamora:ab,ti OR zaragoza:ab,ti OR saragossa:ab,ti OR bilbao:ab,ti 
OR bilbo:ab,ti OR compostela:ab,ti OR 'san sebastian':ab,ti OR donostia:ab,ti OR vitoria:ab,ti OR 
oviedo:ab,ti OR pamplona:ab,ti OR logrono:ab,ti OR gasteiz:ab,ti OR slovenia*:ad OR slovenija:ad 
OR ljubljana:ad OR gorenjska:ad OR carniola:ad OR goriska:ad OR gorizia:ad OR koroska:ad OR 
carinthia:ad OR 'notranjsko kraska':ad OR 'obalno kraska':ad OR 'coastal krast':ad OR 
podravska:ad OR pomurska:ad OR savinjska:ad OR spodnjeposavska:ad OR zasavska:ad OR 
osrednjeslovenska:ad OR maribor:ad OR celje:ad OR kranj:ad OR velenje:ad OR koper:ad OR 
capodistria:ad OR 'novo mesto':ad OR ptuj:ad OR trbovlje:ad OR kamnik:ad OR murska:ad OR 
sobota:ad OR 'nova gorica':ad OR slovenia*:ab,ti OR slovenija:ab,ti OR ljubljana:ab,ti OR 
gorenjska:ab,ti OR carniola:ab,ti OR goriska:ab,ti OR gorizia:ab,ti OR koroska:ab,ti OR 
carinthia:ab,ti OR 'notranjsko kraska':ab,ti OR 'obalno kraska':ab,ti OR 'coastal krast':ab,ti OR 
podravska:ab,ti OR pomurska:ab,ti OR savinjska:ab,ti OR spodnjeposavska:ab,ti OR zasavska:ab,ti 
OR osrednjeslovenska:ab,ti OR maribor:ab,ti OR celje:ab,ti OR kranj:ab,ti OR velenje:ab,ti OR 
koper:ab,ti OR capodistria:ab,ti OR 'novo mesto':ab,ti OR ptuj:ab,ti OR trbovlje:ab,ti OR 
kamnik:ab,ti OR murska:ab,ti OR sobota:ab,ti OR 'nova gorica':ab,ti OR slovakia:ab,ti OR 
slovensk*:ab,ti OR slovak*:ab,ti OR bratislav*:ab,ti OR nitrian*:ab,ti OR nitra:ab,ti OR 
trencian*:ab,ti OR trencin:ab,ti OR banskobystri*:ab,ti OR 'banska bystrica':ab,ti OR zilina:ab,ti OR 
zilin*:ab,ti OR trnava:ab,ti OR trnav*:ab,ti OR presov:ab,ti OR presov*:ab,ti OR kosic*:ab,ti OR 
(martin:ab,ti AND (city:ab,ti OR svaty:ab,ti)) OR poprad:ab,ti OR slovakia:ad OR slovensk*:ad OR 
slovak*:ad OR bratislav*:ad OR nitrian*:ad OR nitra:ad OR trencian*:ad OR trencin:ad OR 
banskobystri*:ad OR 'banska bystrica':ad OR zilina:ad OR zilin*:ad OR trnava:ad OR trnav*:ad OR 
presov*:ad OR kosic*:ad OR (martin:ad AND (city:ad OR svaty:ad)) OR poprad:ad 
#1.6 italy:ab,ti OR italia*:ab,ti OR rome:ab,ti OR roma:ab,ti OR abruzzo:ab,ti OR abruzzi:ab,ti OR 
basilicata:ab,ti OR lucania:ab,ti OR calabria:ab,ti OR campania:ab,ti OR 'emilia romagna':ab,ti OR 
'friuli venezia giulia':ab,ti OR lazio:ab,ti OR latium:ab,ti OR liguria*:ab,ti OR lombardy:ab,ti OR 
lombardia:ab,ti OR marche:ab,ti OR marches:ab,ti OR molisano:ab,ti OR molise:ab,ti OR 
piedmont*:ab,ti OR piemonte:ab,ti OR sardinia:ab,ti OR sardegna:ab,ti OR sicily:ab,ti OR 
sicilia:ab,ti OR toscana:ab,ti OR tuscany:ab,ti OR trentino:ab,ti OR trento:ab,ti OR umbria:ab,ti OR 
veneto:ab,ti OR triveneto:ab,ti OR puglia:ab,ti OR apulia:ab,ti OR bolzano:ab,ti OR bozen:ab,ti OR 
milan:ab,ti OR milano:ab,ti OR naples:ab,ti OR napoli:ab,ti OR turin:ab,ti OR torino:ab,ti OR 
palermo:ab,ti OR genoa:ab,ti OR genova:ab,ti OR florence:ab,ti OR firenze:ab,ti OR bari:ab,ti OR 
catania:ab,ti OR venezia:ab,ti OR venice:ab,ti OR padova:ab,ti OR padua:ab,ti OR siena:ab,ti OR 
bologna:ab,ti OR trieste:ab,ti OR urbino:ab,ti OR aosta:ab,ti OR aoste:ab,ti OR perugia:ab,ti OR 
brescia:ab,ti OR cagliari:ab,ti OR catanzaro:ab,ti OR 'l aquila':ab,ti OR ancona:ab,ti OR italy:ad OR 
italia*:ad OR rome:ad OR roma:ad OR abruzzo:ad OR abruzzi:ad OR basilicata:ad OR lucania:ad 
OR calabria:ad OR campania:ad OR 'emilia romagna':ad OR 'friuli venezia giulia':ad OR lazio:ad 
OR latium:ad OR liguria*:ad OR lombardy:ad OR lombardia:ad OR marche:ad OR marches:ad OR 
molisano:ad OR molise:ad OR piedmont*:ad OR piemonte:ad OR sardinia:ad OR sardegna:ad OR 
sicily:ad OR sicilia:ad OR toscana:ad OR tuscany:ad OR trentino:ad OR trento:ad OR umbria:ad OR 
veneto:ad OR triveneto:ad OR puglia:ad OR apulia:ad OR bolzano:ad OR bozen:ad OR milan:ad OR 
milano:ad OR naples:ad OR napoli:ad OR turin:ad OR torino:ad OR palermo:ad OR genoa:ad OR 
genova:ad OR florence:ad OR firenze:ad OR bari:ad OR catania:ad OR venezia:ad OR venice:ad OR 
padova:ad OR padua:ad OR siena:ad OR bologna:ad OR trieste:ad OR urbino:ad OR aosta:ad OR 
aoste:ad OR perugia:ad OR brescia:ad OR cagliari:ad OR catanzaro:ad OR 'l aquila':ad OR 
ancona:ad OR ireland:ab,ti OR eire:ab,ti OR irish*:ab,ti OR dublin:ab,ti OR fingal:ab,ti OR 'dun 
laoghaire':ab,ti OR wicklow:ab,ti OR wexford:ab,ti OR carlow:ab,ti OR kildare:ab,ti OR meath:ab,ti 
OR louth:ab,ti OR monaghan:ab,ti OR cavan:ab,ti OR longford:ab,ti OR westmeath:ab,ti OR 
offaly:ab,ti OR laois:ab,ti OR kilkenny:ab,ti OR waterford:ab,ti OR cork:ab,ti OR kerry:ab,ti OR 
limerick:ab,ti OR tipperary:ab,ti OR clare:ab,ti OR galway:ab,ti OR mayo:ab,ti OR roscommon:ab,ti 
OR sligo:ab,ti OR leitrim:ab,ti OR donegal:ab,ti OR drogheda:ab,ti OR dundalk:ab,ti OR swords:ab,ti 
OR bray:ab,ti OR navan:ab,ti OR leinster:ab,ti OR connacht:ab,ti OR ireland:ad OR eire:ad OR 
irish*:ad OR dublin:ad OR fingal:ad OR 'dun laoghaire':ad OR wicklow:ad OR wexford:ad OR 














OR westmeath:ad OR offaly:ad OR laois:ad OR kilkenny:ad OR waterford:ad OR cork:ad OR 
kerry:ad OR limerick:ad OR tipperary:ad OR clare:ad OR galway:ad OR mayo:ad OR roscommon:ad 
OR sligo:ad OR leitrim:ad OR donegal:ad OR drogheda:ad OR dundalk:ad OR swords:ad OR 
bray:ad OR navan:ad OR leinster:ad OR connacht:ad OR hungar*:ab,ti OR budapest:ab,ti OR 
transdanubia:ab,ti OR magyarorszag:ab,ti OR magyar:ab,ti OR dunantuli:ab,ti OR dunantul:ab,ti 
OR 'great plain':ab,ti OR 'alfold es eszak':ab,ti OR 'eszak alfold':ab,ti OR 'del alfold':ab,ti OR 
bacs:ab,ti OR kiskun:ab,ti OR 'northen alfold':ab,ti OR 'sourthen alfold':ab,ti OR baranya:ab,ti OR 
bekes:ab,ti OR borsod:ab,ti OR abauj:ab,ti OR zemplen:ab,ti OR fovaros:ab,ti OR csongrad:ab,ti OR 
fejer:ab,ti OR moson:ab,ti OR sopron:ab,ti OR hajdu:ab,ti OR bihar:ab,ti OR heves:ab,ti OR 'jasz 
nagykun szolnok':ab,ti OR komarom:ab,ti OR esztergom:ab,ti OR nograd:ab,ti OR pest:ab,ti OR 
somogy:ab,ti OR szabolcs:ab,ti OR szatmar:ab,ti OR bereg:ab,ti OR tolna:ab,ti OR vas:ab,ti OR 
veszprem:ab,ti OR zala:ab,ti OR zalaegerszeg:ab,ti OR debrecen:ab,ti OR miskolc:ab,ti OR 
szeged:ab,ti OR pecs:ab,ti OR gyor:ab,ti OR nyiregyhaza:ab,ti OR kecskemet:ab,ti OR 
szekesfehervar:ab,ti OR szombathely:ab,ti OR bekescsaba:ab,ti OR eger:ab,ti OR tatabanya:ab,ti 
OR salgotarjan:ab,ti OR kaposvar:ab,ti OR szekszard:ab,ti OR hungar*:ad OR budapest:ad OR 
transdanubia:ad OR magyarorszag:ad OR magyar:ad OR dunantuli:ad OR dunantul:ad OR 'great 
plain':ad OR 'alfold es eszak':ad OR 'eszak alfold':ad OR 'del alfold':ad OR bacs:ad OR kiskun:ad 
OR 'northen alfold':ad OR 'sourthen alfold':ad OR baranya:ad OR bekes:ad OR borsod:ad OR 
abauj:ad OR zemplen:ad OR fovaros:ad OR csongrad:ad OR fejer:ad OR moson:ad OR sopron:ad 
OR hajdu:ad OR bihar:ad OR heves:ad OR 'jasz nagykun szolnok':ad OR komarom:ad OR 
esztergom:ad OR nograd:ad OR pest:ad OR somogy:ad OR szabolcs:ad OR szatmar:ad OR 
bereg:ad OR tolna:ad OR vas:ad OR veszprem:ad OR zala:ad OR zalaegerszeg:ad OR debrecen:ad 
OR miskolc:ad OR szeged:ad OR pecs:ad OR gyor:ad OR nyiregyhaza:ad OR kecskemet:ad OR 
szekesfehervar:ad OR szombathely:ad OR bekescsaba:ad OR eger:ad OR tatabanya:ad OR 
salgotarjan:ad OR kaposvar:ad OR szekszard:ad OR greece:ad OR 'hellenic republic':ad OR 
greek*:ad OR ellada:ad OR 'elliniki dimokratia':ad OR hellas:ad OR hellenes:ad OR attica:ad OR 
attiki:ad OR makedonia:ad OR macedonia:ad OR thraki:ad OR thrace:ad OR crete:ad OR kriti:ad 
OR epirus:ad OR ipeiros:ad OR 'ionia nisia':ad OR 'ionion neson':ad OR 'ionian islands':ad OR 
'north aegean':ad OR 'aegean islands':ad OR 'nisoi agaiou':ad OR 'notio aigaio':ad OR 
peloponnese:ad OR peloponnisos:ad OR 'voreio aigaio':ad OR 'south aegean':ad OR thessaly:ad 
OR thessalia:ad OR cycklades:ad OR kiklades:ad OR dodecanese:ad OR dodekanisa:ad OR 'mount 
athos':ad OR 'omicronros alphathos':ad OR athens:ad OR athina:ad OR thessaloniki:ad OR 
thessalonica:ad OR patras:ad OR patra:ad OR heraklion:ad OR heraclion:ad OR iraklion:ad OR 
irakleion:ad OR iraklio:ad OR larissa:ad OR larisa:ad OR volos:ad OR rhodes:ad OR rodos:ad OR 
ioannina:ad OR janina:ad OR yannena:ad OR chania:ad OR chalcis:ad OR chalkida:ad OR 
alexandroupoli:ad OR greece:ab,ti OR 'hellenic republic':ab,ti OR greek*:ab,ti OR ellada:ab,ti OR 
'elliniki dimokratia':ab,ti OR hellas:ab,ti OR hellenes:ab,ti OR attica:ab,ti OR attiki:ab,ti OR 
makedonia:ab,ti OR macedonia:ab,ti OR thraki:ab,ti OR thrace:ab,ti OR crete:ab,ti OR kriti:ab,ti OR 
epirus:ab,ti OR ipeiros:ab,ti OR 'ionia nisia':ab,ti OR 'ionion neson':ab,ti OR 'ionian islands':ab,ti OR 
'north aegean':ab,ti OR 'aegean islands':ab,ti OR 'nisoi agaiou':ab,ti OR 'notio aigaio':ab,ti OR 
peloponnese:ab,ti OR peloponnisos:ab,ti OR 'voreio aigaio':ab,ti OR 'south aegean':ab,ti OR 
thessaly:ab,ti OR thessalia:ab,ti OR cycklades:ab,ti OR kiklades:ab,ti OR dodecanese:ab,ti OR 
dodekanisa:ab,ti OR 'mount athos':ab,ti OR 'omicronros alphathos':ab,ti OR athens:ab,ti OR 
athina:ab,ti OR thessaloniki:ab,ti OR thessalonica:ab,ti OR patras:ab,ti OR patra:ab,ti OR 
heraklion:ab,ti OR heraclion:ab,ti OR iraklion:ab,ti OR irakleion:ab,ti OR iraklio:ab,ti OR 
larissa:ab,ti OR larisa:ab,ti OR volos:ab,ti OR rhodes:ab,ti OR rodos:ab,ti OR ioannina:ab,ti OR 
janina:ab,ti OR yannena:ab,ti OR chania:ab,ti OR chalcis:ab,ti OR chalkida:ab,ti OR 
alexandroupoli:ab,ti OR german*:ad OR deutschland:ad OR deutsch*:ad OR bundesrepublik:ad 
OR westdeutschland:ad OR ostdeutschland:ad OR baden:ad OR wuerttemberg:ad OR 
wurttemberg:ad OR bayern:ad OR bavaria:ad OR berlin:ad OR brandenburg:ad OR bremen:ad OR 
hamburg:ad OR hessen:ad OR hesse:ad OR hessia:ad OR mecklenburg:ad OR vorpommern:ad OR 
pomerania:ad OR niedersachsen:ad OR neddersassen:ad OR saxony:ad OR niederbayern:ad OR 
'north rhine':ad OR westphalia:ad OR westfalen:ad OR 'rhineland palatinate':ad OR 'rheinland 
pfalz':ad OR saarland:ad OR sachsen:ad OR 'schleswig holstein':ad OR thuringia:ad OR 
thuringen:ad OR thueringen:ad OR freiburg:ad OR karlsruhe:ad OR calsruhe:ad OR stuttgart:ad 
OR tubingen:ad OR oberbayern:ad OR 'upper palatinate':ad OR oberpfalz:ad OR franken:ad OR 
franconia:ad OR oberfranken:ad OR mittelfranken:ad OR schwaben:ad OR unterfranken:ad OR 
swabia:ad OR darmstadt:ad OR giessen:ad OR kassel:ad OR arnsberg:ad OR cologne:ad OR 
koln:ad OR koeln:ad OR detmold:ad OR dusseldorf:ad OR duesseldorf:ad OR munster:ad OR 
muenster:ad OR munich:ad OR munchen:ad OR muenchen:ad OR frankfurt:ad OR dortmund:ad 
OR essen:ad OR nurnberg:ad OR nuernberg:ad OR nuremberg:ad OR hanover:ad OR hannover:ad 
OR leipzig:ad OR dresden:ad OR ruhrgebiet:ad OR revier:ad OR ruhrpott:ad OR pott:ad OR ruhr:ad 
OR german*:ab,ti OR deutschland:ab,ti OR deutsch*:ab,ti OR bundesrepublik:ab,ti OR 
westdeutschland:ab,ti OR ostdeutschland:ab,ti OR baden:ab,ti OR wuerttemberg:ab,ti OR 
wurttemberg:ab,ti OR bayern:ab,ti OR bavaria:ab,ti OR berlin:ab,ti OR brandenburg:ab,ti OR 
bremen:ab,ti OR hamburg:ab,ti OR hessen:ab,ti OR hesse:ab,ti OR hessia:ab,ti OR 
mecklenburg:ab,ti OR vorpommern:ab,ti OR pomerania:ab,ti OR niedersachsen:ab,ti OR 
neddersassen:ab,ti OR saxony:ab,ti OR niederbayern:ab,ti OR 'north rhine':ab,ti OR 
westphalia:ab,ti OR westfalen:ab,ti OR 'rhineland palatinate':ab,ti OR 'rheinland pfalz':ab,ti OR 
saarland:ab,ti OR sachsen:ab,ti OR 'schleswig holstein':ab,ti OR thuringia:ab,ti OR thuringen:ab,ti 
OR thueringen:ab,ti OR freiburg:ab,ti OR karlsruhe:ab,ti OR calsruhe:ab,ti OR stuttgart:ab,ti OR 
tubingen:ab,ti OR oberbayern:ab,ti OR 'upper palatinate':ab,ti OR oberpfalz:ab,ti OR franken:ab,ti 
OR franconia:ab,ti OR oberfranken:ab,ti OR mittelfranken:ab,ti OR schwaben:ab,ti OR 
unterfranken:ab,ti OR swabia:ab,ti OR darmstadt:ab,ti OR giessen:ab,ti OR kassel:ab,ti OR 
arnsberg:ab,ti OR cologne:ab,ti OR koln:ab,ti OR koeln:ab,ti OR detmold:ab,ti OR dusseldorf:ab,ti 
OR duesseldorf:ab,ti OR munster:ab,ti OR muenster:ab,ti OR munich:ab,ti OR munchen:ab,ti OR 
muenchen:ab,ti OR frankfurt:ab,ti OR dortmund:ab,ti OR essen:ab,ti OR nurnberg:ab,ti OR 
nuernberg:ab,ti OR nuremberg:ab,ti OR hanover:ab,ti OR hannover:ab,ti OR leipzig:ab,ti OR 
dresden:ab,ti OR ruhrgebiet:ab,ti OR revier:ab,ti OR ruhrpott:ab,ti OR pott:ab,ti OR ruhr:ab,ti OR 
france:ad OR french*:ad OR francais:ad OR alsace:ad OR aquitaine:ad OR auvergne:ad OR 
brittany:ad OR bretagne:ad OR bourgogne:ad OR burgundy:ad OR 'champagne ardenne':ad OR 
'franche comte':ad OR 'ile de france':ad OR 'languedoc roussillon':ad OR limousin:ad OR 
lorraine:ad OR normandie:ad OR normandy:ad OR 'midi pyrenees':ad OR 'nord pas de calais':ad 
OR picardie:ad OR picardy:ad OR 'poitou charentes':ad OR provence:ad OR 'rhone alpes':ad OR 













reunion:ad OR mayotte:ad OR ain:ad OR aisne:ad OR allier:ad OR 'alpes de haute provence':ad OR 
'haute alpes':ad OR 'alpes maritimes':ad OR ardeche:ad OR ardennes:ad OR ariege:ad OR aube:ad 
OR aude:ad OR aveyron:ad OR 'bas rhin':ad OR 'bouches du rhone':ad OR calvados:ad OR 
cantal:ad OR charente:ad OR cher:ad OR correze:ad OR 'corse du sud':ad OR 'cote d or':ad OR 
'cotes d armor':ad OR 'cote d azur':ad OR creuse:ad OR 'deux sevres':ad OR dordogne:ad OR 
doubs:ad OR drome:ad OR essonne:ad OR eure:ad OR finistere:ad OR gard:ad OR gers:ad OR 
gironde:ad OR 'haute corse':ad OR 'haute garonne':ad OR 'haute marne':ad OR 'hautes alpes':ad 
OR 'haute saone':ad OR 'haute savoie':ad OR 'hautes pyrenees':ad OR 'haute vienne':ad OR 'haut 
rhin':ad OR 'hauts de seine':ad OR herault:ad OR 'ille et vilaine':ad OR indre:ad OR isere:ad OR 
jura:ad OR landes:ad OR loire:ad OR loiret:ad OR (lot:ad AND (departement:ad OR 
department:ad)) OR 'lot et garonne':ad OR 'loir et cher':ad OR lozere:ad OR manche:ad OR 
marne:ad OR mayenne:ad OR 'meurthe et moselle':ad OR meuse:ad OR morbihan:ad OR 
moselle:ad OR (nord:ad AND (department:ad OR departement:ad)) OR nievre:ad OR oise:ad OR 
orne:ad OR 'pas de calais':ad OR paris:ad OR 'puy de dome':ad OR 'pyrenees atlantiques':ad OR 
'pyrenees orientales':ad OR rhone:ad OR sarthe:ad OR savoie:ad OR 'seine et marne':ad OR 'seine 
maritime':ad OR somme:ad OR tarn:ad OR 'territoire de belfort':ad OR 'val de marne':ad OR 'val d 
oise':ad OR var:ad OR vaucluse:ad OR vendee:ad OR vienne:ad OR vosges:ad OR yonne:ad OR 
yvelines:ad OR marseille:ad OR lyon:ad OR nice:ad OR nantes:ad OR strasbourg:ad OR 
montpellier:ad OR bordeaux:ad OR lille:ad OR toulouse:ad OR france:ab,ti OR french*:ab,ti OR 
francais:ab,ti OR alsace:ab,ti OR aquitaine:ab,ti OR auvergne:ab,ti OR brittany:ab,ti OR 
bretagne:ab,ti OR bourgogne:ab,ti OR burgundy:ab,ti OR 'champagne ardenne':ab,ti OR 'franche 
comte':ab,ti OR 'ile de france':ab,ti OR 'languedoc roussillon':ab,ti OR limousin:ab,ti OR 
lorraine:ab,ti OR normandie:ab,ti OR normandy:ab,ti OR 'midi pyrenees':ab,ti OR 'nord pas de 
calais':ab,ti OR picardie:ab,ti OR picardy:ab,ti OR 'poitou charentes':ab,ti OR provence:ab,ti OR 
'rhone alpes':ab,ti OR corse:ab,ti OR corsica:ab,ti OR guiana:ab,ti OR guyane:ab,ti OR 
guadeloupe:ab,ti OR martinique:ab,ti OR reunion:ab,ti OR mayotte:ab,ti OR ain:ab,ti OR aisne:ab,ti 
OR allier:ab,ti OR 'alpes de haute provence':ab,ti OR 'haute alpes':ab,ti OR 'alpes maritimes':ab,ti 
OR ardeche:ab,ti OR ardennes:ab,ti OR ariege:ab,ti OR aube:ab,ti OR aude:ab,ti OR aveyron:ab,ti OR 
'bas rhin':ab,ti OR 'bouches du rhone':ab,ti OR calvados:ab,ti OR cantal:ab,ti OR charente:ab,ti OR 
cher:ab,ti OR correze:ab,ti OR 'corse du sud':ab,ti OR 'cote d or':ab,ti OR 'cotes d armor':ab,ti OR 
'cote d azur':ab,ti OR creuse:ab,ti OR 'deux sevres':ab,ti OR dordogne:ab,ti OR doubs:ab,ti OR 
drome:ab,ti OR essonne:ab,ti OR eure:ab,ti OR finistere:ab,ti OR gard:ab,ti OR gers:ab,ti OR 
gironde:ab,ti OR 'haute corse':ab,ti OR 'haute garonne':ab,ti OR 'haute marne':ab,ti OR 'hautes 
alpes':ab,ti OR 'haute saone':ab,ti OR 'haute savoie':ab,ti OR 'hautes pyrenees':ab,ti OR 'haute 
vienne':ab,ti OR 'haut rhin':ab,ti OR 'hauts de seine':ab,ti OR herault:ab,ti OR 'ille et vilaine':ab,ti 
OR indre:ab,ti OR isere:ab,ti OR jura:ab,ti OR landes:ab,ti OR loire:ab,ti OR loiret:ab,ti OR (lot:ab,ti 
AND (departement:ab,ti OR department:ab,ti)) OR 'lot et garonne':ab,ti OR 'loir et cher':ab,ti OR 
lozere:ab,ti OR manche:ab,ti OR marne:ab,ti OR mayenne:ab,ti OR 'meurthe et moselle':ab,ti OR 
meuse:ab,ti OR morbihan:ab,ti OR moselle:ab,ti OR (nord:ab,ti AND (department:ab,ti OR 
departement:ab,ti)) OR nievre:ab,ti OR oise:ab,ti OR orne:ab,ti OR 'pas de calais':ab,ti OR 
paris:ab,ti OR 'puy de dome':ab,ti OR 'pyrenees atlantiques':ab,ti OR 'pyrenees orientales':ab,ti 
OR rhone:ab,ti OR sarthe:ab,ti OR savoie:ab,ti OR 'seine et marne':ab,ti OR 'seine maritime':ab,ti 
OR somme:ab,ti OR tarn:ab,ti OR 'territoire de belfort':ab,ti OR 'val de marne':ab,ti OR 'val d 
oise':ab,ti OR var:ab,ti OR vaucluse:ab,ti OR vendee:ab,ti OR vienne:ab,ti OR vosges:ab,ti OR 
yonne:ab,ti OR yvelines:ab,ti OR marseille:ab,ti OR lyon:ab,ti OR nice:ab,ti OR nantes:ab,ti OR 
strasbourg:ab,ti OR montpellier:ab,ti OR bordeaux:ab,ti OR lille:ab,ti OR toulouse:ab,ti OR 
finland:ab,ti OR finnish*:ab,ti OR suomi*:ab,ti OR lapland:ab,ti OR lappi:ab,ti OR lappland:ab,ti OR 
ostrobothnia:ab,ti OR pohjanmaa:ab,ti OR osterbotten:ab,ti OR kainuu:ab,ti OR kajanaland*:ab,ti 
OR karelia:ab,ti OR karjala:ab,ti OR karelen:ab,ti OR savonia:ab,ti OR savo:ab,ti OR savolax:ab,ti OR 
pirkanmaa:ab,ti OR birkaland:ab,ti OR satakunta:ab,ti OR satakunda:ab,ti OR tavastia:ab,ti OR 
tavastland:ab,ti OR 'paijat hame':ab,ti OR 'kanta hame':ab,ti OR uusimaa:ab,ti OR nyland:ab,ti OR 
kymenlaakso:ab,ti OR kymmenedalen:ab,ti OR aland:ab,ti OR ahvenanmaa:ab,ti OR helsinki:ab,ti 
OR helsingfors:ab,ti OR espoo:ab,ti OR esbo:ab,ti OR tampere:ab,ti OR tammerfors:ab,ti OR 
vantaa:ab,ti OR vanda:ab,ti OR oulu:ab,ti OR uleaborg:ab,ti OR turku:ab,ti OR abo:ab,ti OR 
jyvaskyla:ab,ti OR kuopio:ab,ti OR lathi:ab,ti OR lahtis:ab,ti OR kouvola:ab,ti OR finland:ad OR 
finnish*:ad OR suomi*:ad OR lapland:ad OR lappi:ad OR lappland:ad OR ostrobothnia:ad OR 
pohjanmaa:ad OR osterbotten:ad OR kainuu:ad OR kajanaland*:ad OR karelia:ad OR karjala:ad 
OR karelen:ad OR savonia:ad OR savo:ad OR savolax:ad OR pirkanmaa:ad OR birkaland:ad OR 
satakunta:ad OR satakunda:ad OR tavastia:ad OR tavastland:ad OR 'paijat hame':ad OR 'kanta 
hame':ad OR uusimaa:ad OR nyland:ad OR kymenlaakso:ad OR kymmenedalen:ad OR aland:ad OR 
ahvenanmaa:ad OR helsinki:ad OR helsingfors:ad OR espoo:ad OR esbo:ad OR tampere:ad OR 
tammerfors:ad OR vantaa:ad OR vanda:ad OR oulu:ad OR uleaborg:ad OR turku:ad OR abo:ad OR 
jyvaskyla:ad OR kuopio:ad OR lathi:ad OR lahtis:ad OR kouvola:ad OR estonia*:ab,ti OR eesti:ab,ti 
OR esti:ab,ti OR tallinn:ab,ti OR harju:ab,ti OR harjumaa:ab,ti OR hiiu:ab,ti OR hiiumaa:ab,ti OR 'ida 
viru':ab,ti OR 'ida virumaa':ab,ti OR jarvamaa:ab,ti OR jarva:ab,ti OR jogevamaa:ab,ti OR 
jogeva:ab,ti OR laanemma:ab,ti OR laane:ab,ti OR parnumaa:ab,ti OR polva:ab,ti OR polvamaa:ab,ti 
OR rapla:ab,ti OR raplamaa:ab,ti OR saare:ab,ti OR saaremaa:ab,ti OR tartu:ab,ti OR tartumaa:ab,ti 
OR valga:ab,ti OR valgamaa:ab,ti OR valgamaakond:ab,ti OR viljandimaa:ab,ti OR voru:ab,ti OR 
vorumaa:ab,ti OR narva:ab,ti OR parnu:ab,ti OR 'kohtla jarve':ab,ti OR viljandi:ab,ti OR 
rakvere:ab,ti OR maardu:ab,ti OR sillamae:ab,ti OR kuressaare:ab,ti OR estonia*:ad OR eesti:ad OR 
esti:ad OR tallinn:ad OR harju:ad OR harjumaa:ad OR hiiu:ad OR hiiumaa:ad OR 'ida viru':ad OR 
'ida virumaa':ad OR jarvamaa:ad OR jarva:ad OR jogevamaa:ad OR jogeva:ad OR laanemma:ad 
OR laane:ad OR parnumaa:ad OR polva:ad OR polvamaa:ad OR rapla:ad OR raplamaa:ad OR 
saare:ad OR saaremaa:ad OR tartu:ad OR tartumaa:ad OR valga:ad OR valgamaa:ad OR 
valgamaakond:ad OR viljandimaa:ad OR voru:ad OR vorumaa:ad OR narva:ad OR parnu:ad OR 
'kohtla jarve':ad OR viljandi:ad OR rakvere:ad OR maardu:ad OR sillamae:ad OR kuressaare:ad 
#1.5 romania:ab,ti OR rumania:ab,ti OR roumania:ab,ti OR romanian:ab,ti OR roman:ab,ti OR 
bucharest:ab,ti OR bucuresti:ab,ti OR alba:ab,ti OR brasov:ab,ti OR covasna:ab,ti OR harghita:ab,ti 
OR mures:ab,ti OR sibiu:ab,ti OR bacau:ab,ti OR botosani:ab,ti OR iasi:ab,ti OR neamt:ab,ti OR 
suceava:ab,ti OR vaslui:ab,ti OR bihor:ab,ti OR 'bistrita nasaud':ab,ti OR cluj:ab,ti OR 
maramures:ab,ti OR salaj:ab,ti OR 'satu mare':ab,ti OR arges:ab,ti OR calarasi:ab,ti OR 
dambovita:ab,ti OR giurgiu:ab,ti OR ialomita:ab,ti OR prahova:ab,ti OR teleorman:ab,ti OR 
braila:ab,ti OR buzau:ab,ti OR galati:ab,ti OR tulcea:ab,ti OR vrancea:ab,ti OR dolj:ab,ti OR 
gorj:ab,ti OR mehedinti:ab,ti OR (olt:ab,ti AND (river:ab,ti OR county:ab,ti OR region:ab,ti OR 














hunedoara:ab,ti OR timis:ab,ti OR ilfov:ab,ti OR timisoara:ab,ti OR constanta:ab,ti OR craiova:ab,ti 
OR ploiesti:ab,ti OR oradea:ab,ti OR 'cluj-napoca':ab,ti OR deva:ab,ti OR romania:ad OR 
rumania:ad OR roumania:ad OR romanian:ad OR roman:ad OR bucharest:ad OR bucuresti:ad OR 
alba:ad OR brasov:ad OR covasna:ad OR harghita:ad OR mures:ad OR sibiu:ad OR bacau:ad OR 
botosani:ad OR iasi:ad OR neamt:ad OR suceava:ad OR vaslui:ad OR bihor:ad OR 'bistrita 
nasaud':ad OR cluj:ad OR maramures:ad OR salaj:ad OR 'satu mare':ad OR arges:ad OR 
calarasi:ad OR dambovita:ad OR giurgiu:ad OR ialomita:ad OR prahova:ad OR teleorman:ad OR 
braila:ad OR buzau:ad OR galati:ad OR tulcea:ad OR vrancea:ad OR dolj:ad OR gorj:ad OR 
mehedinti:ad OR (olt:ad AND (river:ad OR county:ad OR region:ad OR judetul:ad OR raul:ad)) OR 
valcea:ad OR vilcea:ad OR arad:ad OR 'caras-severin':ad OR hunedoara:ad OR timis:ad OR ilfov:ad 
OR timisoara:ad OR constanta:ad OR craiova:ad OR ploiesti:ad OR oradea:ad OR 'cluj-napoca':ad 
OR deva:ad OR portugal:ab,ti OR portugues*:ab,ti OR lisboa:ab,ti OR lisbon:ab,ti OR leira:ab,ti OR 
santarem:ab,ti OR beja:ab,ti OR faro:ab,ti OR evora:ab,ti OR portalegre:ab,ti OR 'castelo 
branco':ab,ti OR guarda:ab,ti OR aveiro:ab,ti OR viseu:ab,ti OR braganca:ab,ti OR 'vila real':ab,ti OR 
'viana do castelo':ab,ti OR alentejo:ab,ti OR azores:ab,ti OR acores:ab,ti OR madeira:ab,ti OR 'os 
montes':ab,ti OR (ave:ab,ti AND (community:ab,ti OR intermunicipal:ab,ti OR comunidade:ab,ti)) 
OR mondego:ab,ti OR vouga:ab,ti OR beira:ab,ti OR cavado:ab,ti OR lafoes:ab,ti OR douro:ab,ti OR 
porto:ab,ti OR tejo:ab,ti OR minho:ab,ti OR setubal:ab,ti OR pinhal:ab,ti OR 'serra da estrela':ab,ti 
OR tamega:ab,ti OR algarve:ab,ti OR gaia:ab,ti OR amadora:ab,ti OR braga:ab,ti OR (agualva:ab,ti 
AND cacem:ab,ti) OR funchal:ab,ti OR coimbra:ab,ti OR almada:ab,ti OR portugal:ad OR 
portugues*:ad OR lisboa:ad OR lisbon:ad OR leira:ad OR santarem:ad OR beja:ad OR faro:ad OR 
evora:ad OR portalegre:ad OR 'castelo branco':ad OR guarda:ad OR aveiro:ad OR viseu:ad OR 
braganca:ad OR 'vila real':ad OR 'viana do castelo':ad OR alentejo:ad OR azores:ad OR acores:ad 
OR madeira:ad OR 'os montes':ad OR (ave:ad AND (community:ad OR intermunicipal:ad OR 
comunidade:ad)) OR mondego:ad OR vouga:ad OR beira:ad OR cavado:ad OR lafoes:ad OR 
douro:ad OR porto:ad OR tejo:ad OR minho:ad OR setubal:ad OR pinhal:ad OR 'serra da 
estrela':ad OR tamega:ad OR algarve:ad OR gaia:ad OR amadora:ad OR braga:ad OR (agualva:ad 
AND cacem:ad) OR funchal:ad OR coimbra:ad OR almada:ad OR poland:ad OR polska:ad OR 
polish:ad OR polski:ad OR pole:ad OR poles:ad OR polak:ad OR polka:ad OR polacy:ad OR 
warsaw:ad OR warszawa:ad OR wielkopolskie:ad OR pomerania*:ad OR pomorskie:ad OR 
kuyavian:ad OR kujawsko:ad OR malopolskie:ad OR lodz:ad OR lodzkie:ad OR silesia*:ad OR 
dolnoslaskie:ad OR lublin:ad OR lubelskie:ad OR lubus:ad OR lubusz:ad OR lubuskie:ad OR 
masovia:ad OR mazowske:ad OR masovian:ad OR mazowieckie:ad OR opole:ad OR opolskie:ad OR 
podlaskie:ad OR podlachia:ad OR podlasie:ad OR subcarpathian*:ad OR carpathian*:ad OR 
podkarpackie:ad OR swietokrzyskie:ad OR slaskie:ad OR slask:ad OR 'varmia mazuria':ad OR 
'varmian mazurian':ad OR 'varmia masuria':ad OR 'varmian masurian':ad OR 'warmia mazury':ad 
OR 'warminsko mazurskie':ad OR zachodniopomorskie:ad OR krakow:ad OR cracow:ad OR 
wroclaw:ad OR poznan:ad OR gdansk:ad OR szczecin:ad OR bydgoszcz:ad OR katowice:ad OR 
bialystok:ad OR olsztyn:ad OR kielce:ad OR 'zielona gora':ad OR torun:ad OR 'gorzow 
wielkopolski':ad OR poland:ab,ti OR polska:ab,ti OR polish:ab,ti OR polski:ab,ti OR pole:ab,ti OR 
poles:ab,ti OR polak:ab,ti OR polka:ab,ti OR polacy:ab,ti OR warsaw:ab,ti OR warszawa:ab,ti OR 
wielkopolskie:ab,ti OR pomerania*:ab,ti OR pomorskie:ab,ti OR kuyavian:ab,ti OR kujawsko:ab,ti 
OR malopolskie:ab,ti OR lodz:ab,ti OR lodzkie:ab,ti OR silesia*:ab,ti OR dolnoslaskie:ab,ti OR 
lublin:ab,ti OR lubelskie:ab,ti OR lubus:ab,ti OR lubusz:ab,ti OR lubuskie:ab,ti OR masovia:ab,ti OR 
mazowske:ab,ti OR masovian:ab,ti OR mazowieckie:ab,ti OR opole:ab,ti OR opolskie:ab,ti OR 
podlaskie:ab,ti OR podlachia:ab,ti OR podlasie:ab,ti OR subcarpathian*:ab,ti OR carpathian*:ab,ti 
OR podkarpackie:ab,ti OR swietokrzyskie:ab,ti OR slaskie:ab,ti OR slask:ab,ti OR 'varmia 
mazuria':ab,ti OR 'varmian mazurian':ab,ti OR 'varmia masuria':ab,ti OR 'varmian masurian':ab,ti 
OR 'warmia mazury':ab,ti OR 'warminsko mazurskie':ab,ti OR zachodniopomorskie:ab,ti OR 
krakow:ab,ti OR cracow:ab,ti OR wroclaw:ab,ti OR poznan:ab,ti OR gdansk:ab,ti OR szczecin:ab,ti 
OR bydgoszcz:ab,ti OR katowice:ab,ti OR bialystok:ab,ti OR olsztyn:ab,ti OR kielce:ab,ti OR 'zielona 
gora':ab,ti OR torun:ab,ti OR 'gorzow wielkopolski':ab,ti OR netherlands:ad OR nederland*:ad OR 
dutch*:ad OR amsterdam:ad OR drenthe:ad OR flevoland:ad OR friesland:ad OR fryslan:ad OR 
gelderland:ad OR guelders:ad OR groningen:ad OR limburg:ad OR 'north brabant':ad OR 'noord 
brabant':ad OR holland:ad OR overijssel:ad OR overissel:ad OR utrecht:ad OR zeeland:ad OR 
rotterdam:ad OR hague:ad OR eindhoven:ad OR tilburg:ad OR almere:ad OR breda:ad OR 
nijmegen:ad OR nimeguen:ad OR netherlands:ab,ti OR nederland*:ab,ti OR dutch*:ab,ti OR 
amsterdam:ab,ti OR drenthe:ab,ti OR flevoland:ab,ti OR friesland:ab,ti OR fryslan:ab,ti OR 
gelderland:ab,ti OR guelders:ab,ti OR groningen:ab,ti OR limburg:ab,ti OR 'north brabant':ab,ti OR 
'noord brabant':ab,ti OR holland:ab,ti OR overijssel:ab,ti OR overissel:ab,ti OR utrecht:ab,ti OR 
zeeland:ab,ti OR rotterdam:ab,ti OR hague:ab,ti OR eindhoven:ab,ti OR tilburg:ab,ti OR 
almere:ab,ti OR breda:ab,ti OR nijmegen:ab,ti OR nimeguen:ab,ti OR malta:ab,ti OR maltese:ab,ti 
OR valletta:ab,ti OR gozo:ab,ti OR ghawdex:ab,ti OR malta:ad OR maltese:ad OR valletta:ad OR 
gozo:ad OR ghawdex:ad OR luxembourg*:ab,ti OR luxemburg:ab,ti OR letzebuerg:ab,ti OR 
diekirch:ab,ti OR grevenmacher:ab,ti OR luxembourg*:ad OR luxemburg:ad OR letzebuerg:ad OR 
diekirch:ad OR grevenmacher:ad OR lithuania*:ab,ti OR 'lietuvos respublika':ab,ti OR lietuva:ab,ti 
OR lietuviu:ab,ti OR vilnius:ab,ti OR vilniaus:ab,ti OR kaunas:ab,ti OR kauno:ab,ti OR klaipeda:ab,ti 
OR klaipedos:ab,ti OR panevezys:ab,ti OR panevezio:ab,ti OR siauliai:ab,ti OR siauliu:ab,ti OR 
alytus:ab,ti OR alytaus:ab,ti OR taurages:ab,ti OR taurage:ab,ti OR marijampoles:ab,ti OR 
marijampole:ab,ti OR telsiu:ab,ti OR telsiai:ab,ti OR utenos:ab,ti OR utena:ab,ti OR mazeikiai:ab,ti 
OR jonava:ab,ti OR mazeikiu:ab,ti OR jonavos:ab,ti OR lithuania*:ad OR 'lietuvos respublika':ad 
OR lietuva:ad OR lietuviu:ad OR vilnius:ad OR vilniaus:ad OR kaunas:ad OR kauno:ad OR 
klaipeda:ad OR klaipedos:ad OR panevezys:ad OR panevezio:ad OR siauliai:ad OR siauliu:ad OR 
alytus:ad OR alytaus:ad OR taurages:ad OR taurage:ad OR marijampoles:ad OR marijampole:ad 
OR telsiu:ad OR telsiai:ad OR utenos:ad OR utena:ad OR mazeikiai:ad OR jonava:ad OR 
mazeikiu:ad OR jonavos:ad OR latvi*:ab,ti OR latvija*:ab,ti OR riga:ab,ti OR courland:ab,ti OR 
kurzeme:ab,ti OR kurland:ab,ti OR latgale:ab,ti OR lettgallia:ab,ti OR latgola:ab,ti OR vidzeme:ab,ti 
OR vidumo:ab,ti OR semigallia:ab,ti OR semigalia:ab,ti OR zemgale:ab,ti OR pieriga:ab,ti OR 
daugavpils:ab,ti OR dinaburg:ab,ti OR liepaja:ab,ti OR libau:ab,ti OR jelgava:ab,ti OR jurmala:ab,ti 
OR jekabpils:ab,ti OR jakobstadt:ab,ti OR rezekne:ab,ti OR rezne:ab,ti OR rositten:ab,ti OR 
valmiera:ab,ti OR wolmar:ab,ti OR ventspils:ab,ti OR windau:ab,ti OR latvi*:ad OR latvija*:ad OR 
riga:ad OR courland:ad OR kurzeme:ad OR kurland:ad OR latgale:ad OR lettgallia:ad OR latgola:ad 
OR vidzeme:ad OR vidumo:ad OR semigallia:ad OR semigalia:ad OR zemgale:ad OR pieriga:ad OR 
daugavpils:ad OR dinaburg:ad OR liepaja:ad OR libau:ad OR jelgava:ad OR jurmala:ad OR 













wolmar:ad OR ventspils:ad OR windau:ad 
#1.4 denmark:ab,ti OR danish*:ab,ti OR danmark:ab,ti OR dansk*:ab,ti OR hovedstaden:ab,ti OR 
midtjylland:ab,ti OR sjaelland:ab,ti OR sealand:ab,ti OR syddanmark:ab,ti OR jutland:ab,ti OR 
jylland:ab,ti OR nordjylland:ab,ti OR sonderjyllands:ab,ti OR 'zealand region':ab,ti OR 'region 
zealand':ab,ti OR hillerod:ab,ti OR viborg:ab,ti OR aalborg:ab,ti OR alborg:ab,ti OR soro:ab,ti OR 
vejle:ab,ti OR copenhagen:ab,ti OR kobenhavn:ab,ti OR arhus:ab,ti OR aarhus:ab,ti OR 
roskilde:ab,ti OR odense:ab,ti OR frederiksberg:ab,ti OR esbjerg:ab,ti OR gentofte:ab,ti OR 
gladsaxe:ab,ti OR randers:ab,ti OR kolding:ab,ti OR denmark:ad OR danish*:ad OR danmark:ad OR 
dansk*:ad OR hovedstaden:ad OR midtjylland:ad OR sjaelland:ad OR sealand:ad OR 
syddanmark:ad OR jutland:ad OR jylland:ad OR nordjylland:ad OR sonderjyllands:ad OR 'zealand 
region':ad OR 'region zealand':ad OR hillerod:ad OR viborg:ad OR aalborg:ad OR alborg:ad OR 
soro:ad OR vejle:ad OR copenhagen:ad OR kobenhavn:ad OR arhus:ad OR aarhus:ad OR 
roskilde:ad OR odense:ad OR frederiksberg:ad OR esbjerg:ad OR gentofte:ad OR gladsaxe:ad OR 
randers:ad OR kolding:ad OR czech*:ab,ti OR cesk*:ab,ti OR stredoces*:ab,ti OR jihoces*:ab,ti OR 
bohemia:ab,ti OR 'bohemian region':ab,ti OR kralovehradec*:ab,ti OR 'hradec kralove':ab,ti OR 
karlovars*:ab,ti OR 'karlovy vary':ab,ti OR liberec*:ab,ti OR moravskoslezs*:ab,ti OR 'moravian 
silesian':ab,ti OR olomouc*:ab,ti OR pardubic*:ab,ti OR plzen*:ab,ti OR pilsen:ab,ti OR prage:ab,ti 
OR praha:ab,ti OR prag:ab,ti OR jihomorav*:ab,ti OR moravia:ab,ti OR moravian:ab,ti OR 
morava:ab,ti OR usteck*:ab,ti OR usti:ab,ti OR vysocina:ab,ti OR zlin:ab,ti OR zlinsk*:ab,ti OR 
'ceske budejovice':ab,ti OR budweis:ab,ti OR brno:ab,ti OR ostrava:ab,ti OR czech*:ad OR cesk*:ad 
OR stredoces*:ad OR jihoce*:ad OR bohemia:ad OR 'bohemian region':ad OR kralovehradec*:ad 
OR 'hradec kralove':ad OR karlovars*:ad OR 'karlovy vary':ad OR liberec*:ad OR 
moravskoslezsk*:ad OR 'moravian silesian':ad OR olomouc*:ad OR pardubic*:ad OR 
pardubice:ad OR plzen*:ad OR pilsen:ad OR prage:ad OR praha:ad OR prag:ad OR jihomorav*:ad 
OR moravia:ad OR moravian:ad OR morava:ad OR usteck*:ad OR usti:ad OR vysocina:ad OR 
zlin:ad OR zlinsk*:ad OR 'ceske budejovice':ad OR budweis:ad OR brno:ad OR ostrava:ad OR 
cyprus:ab,ti OR cypriot*:ab,ti OR kypros:ab,ti OR kibris:ab,ti OR kypriaki*:ab,ti OR nicosia:ab,ti OR 
lefkosa:ab,ti OR lefkosia:ab,ti OR famagusta:ab,ti OR magusa:ab,ti OR ammochostos:ab,ti OR 
gazimagusa:ab,ti OR kyrenia:ab,ti OR girne:ab,ti OR keryneia:ab,ti OR larnaca:ab,ti OR 
larnaka:ab,ti OR limassol:ab,ti OR lemesos:ab,ti OR limasol:ab,ti OR leymosun:ab,ti OR paphos:ab,ti 
OR pafos:ab,ti OR baf:ab,ti OR gazibaf:ab,ti OR protaras:ab,ti OR pergamos:ab,ti OR 
beyarmudu:ab,ti OR morfou:ab,ti OR guzelyurt:ab,ti OR omorfo:ab,ti OR morphou:ab,ti OR 
aradippou:ab,ti OR cyprus:ad OR cypriot*:ad OR kypros:ad OR kibris:ad OR kypriaki*:ad OR 
nicosia:ad OR lefkosa:ad OR lefkosia:ad OR famagusta:ad OR magusa:ad OR ammochostos:ad OR 
gazimagusa:ad OR kyrenia:ad OR girne:ad OR keryneia:ad OR larnaca:ad OR larnaka:ad OR 
limassol:ad OR lemesos:ad OR limasol:ad OR leymosun:ad OR paphos:ad OR pafos:ad OR baf:ad 
OR gazibaf:ad OR protaras:ad OR pergamos:ad OR beyarmudu:ad OR morfou:ad OR guzelyurt:ad 
OR omorfo:ad OR morphou:ad OR aradippou:ad OR croatia*:ab,ti OR hrvatsk*:ab,ti OR hrvat:ab,ti 
OR bjelovar:ab,ti OR 'bjelovarsko bilogorska':ab,ti OR 'brod posavina':ab,ti OR 'brodsko 
posavska':ab,ti OR 'dubrovnik neretva':ab,ti OR 'dubrovacko neretvanska':ab,ti OR istria:ab,ti OR 
istarska:ab,ti OR karlovacka:ab,ti OR karlovac:ab,ti OR 'koprivnicko krizevacka':ab,ti OR 
koprivnica:ab,ti OR krizevci:ab,ti OR 'krapina zagorje':ab,ti OR 'krapinsko zagorska':ab,ti OR 'lika 
senj':ab,ti OR 'licko senjska':ab,ti OR medimurska:ab,ti OR medimurje:ab,ti OR osijek:ab,ti OR 
osjecko:ab,ti OR baranja:ab,ti OR 'osjecko baranjska':ab,ti OR 'pozega slavonia':ab,ti OR 'pozesko 
slavonska':ab,ti OR 'primorje gorski kotar':ab,ti OR 'primorsko goranska':ab,ti OR 'sibensko 
kninska':ab,ti OR 'sibensko kninske':ab,ti OR sibenik:ab,ti OR knin:ab,ti OR sisak:ab,ti OR 'sisacko 
moslavacka':ab,ti OR moslavina:ab,ti OR 'splitsko dalmatinska':ab,ti OR split:ab,ti OR 
dalmatia:ab,ti OR varazdin:ab,ti OR varazdinska:ab,ti OR 'viroviticko-podravska':ab,ti OR 
virovitica:ab,ti OR podravina:ab,ti OR 'vukovarsko srijemska':ab,ti OR vukovar:ab,ti OR 
srijem:ab,ti OR zadar:ab,ti OR zadarska:ab,ti OR zagreb:ab,ti OR zagrebacka:ab,ti OR rijeka:ab,ti 
OR 'velika gorica':ab,ti OR 'slavonski brod':ab,ti OR pula:ab,ti OR croatia*:ad OR hrvatsk*:ad OR 
hrvat:ad OR bjelovar:ad OR 'bjelovarsko bilogorska':ad OR 'brod posavina':ad OR 'brodsko 
posavska':ad OR 'dubrovnik neretva':ad OR 'dubrovacko neretvanska':ad OR istria:ad OR 
istarska:ad OR karlovacka:ad OR karlovac:ad OR 'koprivnicko krizevacka':ad OR koprivnica:ad OR 
krizevci:ad OR 'krapina zagorje':ad OR 'krapinsko zagorska':ad OR 'lika senj':ad OR 'licko 
senjska':ad OR medimurska:ad OR medimurje:ad OR osijek:ad OR osjecko:ad OR baranja:ad OR 
'osjecko baranjska':ad OR 'pozega slavonia':ad OR 'pozesko slavonska':ad OR 'primorje gorski 
kotar':ad OR 'primorsko goranska':ad OR 'sibensko kninska':ad OR 'sibensko kninske':ad OR 
sibenik:ad OR knin:ad OR sisak:ad OR 'sisacko moslavacka':ad OR moslavina:ad OR 'splitsko 
dalmatinska':ad OR split:ad OR dalmatia:ad OR varazdin:ad OR varazdinska:ad OR 'viroviticko-
podravska':ad OR virovitica:ad OR podravina:ad OR 'vukovarsko srijemska':ad OR vukovar:ad OR 
srijem:ad OR zadar:ad OR zadarska:ad OR zagreb:ad OR zagrebacka:ad OR rijeka:ad OR 'velika 
gorica':ad OR 'slavonski brod':ad OR pula:ad OR bulgaria*:ab,ti OR sofia:ab,ti OR gabrovo:ab,ti OR 
blagoevgrad:ab,ti OR 'pirin macedonia':ab,ti OR burgas:ab,ti OR dobrich:ab,ti OR haskovo:ab,ti OR 
kardzhali:ab,ti OR kurdzhali:ab,ti OR kyustendil:ab,ti OR lovech:ab,ti OR montana:ab,ti OR 
pazardzhik:ab,ti OR pernik:ab,ti OR pleven:ab,ti OR plovdiv:ab,ti OR razgrad:ab,ti OR rousse:ab,ti 
OR ruse:ab,ti OR shumen:ab,ti OR sliven:ab,ti OR silistra:ab,ti OR smolyan:ab,ti OR 'stara 
zagora':ab,ti OR targovishte:ab,ti OR varna:ab,ti OR tarnovo:ab,ti OR vidin:ab,ti OR vratsa:ab,ti OR 
vratza:ab,ti OR yambol:ab,ti OR bulgaria*:ad OR sofia:ad OR gabrovo:ad OR blagoevgrad:ad OR 
'pirin macedonia':ad OR burgas:ad OR dobrich:ad OR haskovo:ad OR kardzhali:ad OR kurdzhali:ad 
OR kyustendil:ad OR lovech:ad OR montana:ad OR pazardzhik:ad OR pernik:ad OR pleven:ad OR 
plovdiv:ad OR razgrad:ad OR rousse:ad OR ruse:ad OR shumen:ad OR sliven:ad OR silistra:ad OR 
smolyan:ad OR 'stara zagora':ad OR targovishte:ad OR varna:ad OR tarnovo:ad OR vidin:ad OR 
vratsa:ad OR vratza:ad OR yambol:ad OR belgi*:ab,ti OR belge:ab,ti OR belgisch:ab,ti OR 
brussel*:ab,ti OR bruxelles:ab,ti OR bruxelloise:ab,ti OR flemish:ab,ti OR flamand:ab,ti OR 
flemisch:ab,ti OR flanders:ab,ti OR flandern:ab,ti OR flandre:ab,ti OR vlaanderen:ab,ti OR 
vlaams:ab,ti OR flamande:ab,ti OR waals:ab,ti OR walloon*:ab,ti OR wallon*:ab,ti OR 
antwerp*:ab,ti OR anvers:ab,ti OR ostflandern:ab,ti OR 'vlaams brabant':ab,ti OR limbourg:ab,ti 
OR limburg:ab,ti OR hainault:ab,ti OR hainaut:ab,ti OR henegouwen:ab,ti OR hennegau:ab,ti OR 
liege:ab,ti OR luik:ab,ti OR luttich:ab,ti OR namur:ab,ti OR namen:ab,ti OR westflandern:ab,ti OR 
'waals brabant':ab,ti OR ghent:ab,ti OR gent:ab,ti OR gand:ab,ti OR charleroi:ab,ti OR bruges:ab,ti 
OR brugge:ab,ti OR schaerbeek:ab,ti OR schaarbeek:ab,ti OR anderlecht:ab,ti OR leuven:ab,ti OR 
louvain:ab,ti OR hasselt:ab,ti OR mons:ab,ti OR wavre:ab,ti OR waver:ab,ti OR belgi*:ad OR 
belge:ad OR belgisch:ad OR brussel*:ad OR bruxelles:ad OR bruxelloise:ad OR flemish:ad OR 














vlaams:ad OR flamande:ad OR waals:ad OR walloon*:ad OR wallon*:ad OR antwerp*:ad OR 
anvers:ad OR ostflandern:ad OR 'vlaams brabant':ad OR limbourg:ad OR limburg:ad OR 
hainault:ad OR hainaut:ad OR henegouwen:ad OR hennegau:ad OR liege:ad OR luik:ad OR 
luttich:ad OR namur:ad OR namen:ad OR westflandern:ad OR 'waals brabant':ad OR ghent:ad OR 
gent:ad OR gand:ad OR charleroi:ad OR bruges:ad OR brugge:ad OR schaerbeek:ad OR 
schaarbeek:ad OR anderlecht:ad OR leuven:ad OR louvain:ad OR hasselt:ad OR mons:ad OR 
wavre:ad OR waver:ad OR austria*:ab,ti OR vienna:ab,ti OR wien:ab,ti OR osterreich*:ab,ti OR 
sudosterreich:ab,ti OR westosterreich:ab,ti OR niederosterreich:ab,ti OR burgenland:ab,ti OR 
carinthia:ab,ti OR karinthia:ab,ti OR karnten:ab,ti OR oberosterreich:ab,ti OR styria:ab,ti OR 
steiermark:ab,ti OR salzburg:ab,ti OR saizburg:ab,ti OR tyrol:ab,ti OR tirol:ab,ti OR becs:ab,ti OR 
vorarlberg:ab,ti OR bregenz:ab,ti OR linz:ab,ti OR eisenstadt:ab,ti OR innsbruck:ab,ti OR graz:ab,ti 
OR klagenfurt:ab,ti OR polten:ab,ti OR villach:ab,ti OR wels:ab,ti OR dornbirn:ab,ti OR 
feldkirch:ab,ti OR steyr:ab,ti OR austria*:ad OR vienna:ad OR wien:ad OR osterreich*:ad OR 
sudosterreich:ad OR westosterreich:ad OR niederosterreich:ad OR burgenland:ad OR 
carinthia:ad OR karnten:ad OR oberosterreich:ad OR styria:ad OR steiermark:ad OR salzburg:ad 
OR saizburg:ad OR tyrol:ad OR tirol:ad OR becs:ad OR vorarlberg:ad OR bregenz:ad OR linz:ad OR 
eisenstadt:ad OR innsbruck:ad OR graz:ad OR klagenfurt:ad OR polten:ad OR villach:ad OR 
wels:ad OR dornbirn:ad OR feldkirch:ad OR steyr:ad 
#1.3 iceland:ab,ti OR icelandic*:ab,ti OR islenska*:ab,ti OR icelander*:ab,ti OR islendinga*:ab,ti OR 
reykjavik:ab,ti OR reykjavikurborg:ab,ti OR hofudborgarsvaedid:ab,ti OR sudurnes:ab,ti OR 
vesturland:ab,ti OR vestfirdir:ab,ti OR westfjords:ab,ti OR nordurland:ab,ti OR austurland:ab,ti OR 
sudurland:ab,ti OR kopavogur:ab,ti OR hafnarfjordur:ab,ti OR iceland:ad OR icelandic*:ad OR 
islenska*:ad OR icelander*:ad OR islendinga*:ad OR reykjavik:ad OR reykjavikurborg:ad OR 
hofudborgarsvaedid:ad OR sudurnes:ad OR vesturland:ad OR vestfirdir:ad OR westfjords:ad OR 
nordurland:ad OR austurland:ad OR sudurland:ad OR kopavogur:ad OR hafnarfjordur:ad OR 
switzerland:ab,ti OR schweiz:ab,ti OR schweizerische:ab,ti OR swiss:ab,ti OR suisse:ab,ti OR 
aargau:ab,ti OR argovia:ab,ti OR ausserrhoden:ab,ti OR 'outer rhodes':ab,ti OR innerrhoden:ab,ti 
OR 'inner rhodes':ab,ti OR basel:ab,ti OR bern:ab,ti OR berne:ab,ti OR fribourg:ab,ti OR 
freiburg:ab,ti OR geneva:ab,ti OR geneve:ab,ti OR glarus:ab,ti OR graubunden:ab,ti OR 
grisons:ab,ti OR grigioni:ab,ti OR jura:ab,ti OR lucerne:ab,ti OR luzern:ab,ti OR neuchatel:ab,ti OR 
zurich:ab,ti OR (uri:ab,ti AND (canton:ab,ti OR kanton:ab,ti)) OR schwyz:ab,ti OR obwalden:ab,ti OR 
nidwalden:ab,ti OR zug:ab,ti OR solothurn:ab,ti OR schaffhausen:ab,ti OR thurgau:ab,ti OR 
thurgovia:ab,ti OR ticino:ab,ti OR tessin:ab,ti OR vaud:ab,ti OR valais:ab,ti OR wallis:ab,ti OR 'st 
gallen':ab,ti OR lausanne:ab,ti OR winterthur:ab,ti OR winterthour:ab,ti OR lugano:ab,ti OR 
biel:ab,ti OR bienne:ab,ti OR switzerland:ad OR schweiz:ad OR schweizerische:ad OR swiss:ad OR 
suisse:ad OR aargau:ad OR argovia:ad OR ausserrhoden:ad OR 'outer rhodes':ad OR 
innerrhoden:ad OR 'inner rhodes':ad OR basel:ad OR bern:ad OR berne:ad OR fribourg:ad OR 
freiburg:ad OR geneva:ad OR geneve:ad OR glarus:ad OR graubunden:ad OR grisons:ad OR 
grigioni:ad OR jura:ad OR lucerne:ad OR luzern:ad OR neuchatel:ad OR zurich:ad OR (uri:ad AND 
(canton:ad OR kanton:ad)) OR schwyz:ad OR obwalden:ad OR nidwalden:ad OR zug:ad OR 
solothurn:ad OR schaffhausen:ad OR thurgau:ad OR thurgovia:ad OR ticino:ad OR tessin:ad OR 
vaud:ad OR valais:ad OR wallis:ad OR 'st gallen':ad OR lausanne:ad OR winterthur:ad OR 
winterthour:ad OR lugano:ad OR biel:ad OR bienne:ad OR norway:ab,ti OR norwegian*:ab,ti OR 
norge:ab,ti OR noreg:ab,ti OR norgga:ab,ti OR ostfold:ab,ti OR akershus:ab,ti OR oslo:ab,ti OR 
hedmark:ab,ti OR oppland:ab,ti OR buskerud:ab,ti OR vestfold:ab,ti OR telemark:ab,ti OR 'aust 
agder':ab,ti OR 'vest agder':ab,ti OR rogaland:ab,ti OR hordaland:ab,ti OR 'sogn og fjordane':ab,ti 
OR 'sogn and fjordane':ab,ti OR 'sogn fjordane':ab,ti OR 'more og romsdal':ab,ti OR 'more and 
romsdal':ab,ti OR 'more romsdal':ab,ti OR trondelag:ab,ti OR nordland:ab,ti OR troms:ab,ti OR 
finnmark:ab,ti OR bergen:ab,ti OR stavanger:ab,ti OR sandnes:ab,ti OR trondheim:ab,ti OR 
kristiansand:ab,ti OR drammen:ab,ti OR fredrikstad:ab,ti OR sarpsborg:ab,ti OR porsgrunn:ab,ti 
OR skien:ab,ti OR tonsberg:ab,ti OR alesund:ab,ti OR norway:ad OR norwegian*:ad OR norge:ad 
OR noreg:ad OR norgga:ad OR ostfold:ad OR akershus:ad OR oslo:ad OR hedmark:ad OR 
oppland:ad OR buskerud:ad OR vestfold:ad OR telemark:ad OR 'aust agder':ad OR 'vest agder':ad 
OR rogaland:ad OR hordaland:ad OR 'sogn og fjordane':ad OR 'sogn and fjordane':ad OR 'sogn 
fjordane':ad OR 'more og romsdal':ad OR 'more and romsdal':ad OR 'more romsdal':ad OR 
trondelag:ad OR nordland:ad OR troms:ad OR finnmark:ad OR bergen:ad OR stavanger:ad OR 
sandnes:ad OR trondheim:ad OR kristiansand:ad OR drammen:ad OR fredrikstad:ad OR 
sarpsborg:ad OR porsgrunn:ad OR skien:ad OR tonsberg:ad OR alesund:ad OR liechtenstein:ab,ti 
OR vaduz:ab,ti OR triesenberg:ab,ti OR triesen:ab,ti OR schellenberg:ab,ti OR schaan:ab,ti OR 
ruggell:ab,ti OR planken:ab,ti OR mauren:ab,ti OR gamprin:ab,ti OR eschen:ab,ti OR balzers:ab,ti 
OR liechtenstein:ad OR vaduz:ad OR triesenberg:ad OR triesen:ad OR schellenberg:ad OR 
schaan:ad OR ruggell:ad OR planken:ad OR mauren:ad OR gamprin:ad OR eschen:ad OR 
balzers:ad 
 
#1.2 'turkey (republic)'/exp OR turkey:ab,ti OR turkiye:ab,ti OR turkish:ab,ti OR istanbul:ab,ti OR 
marmara:ab,ti OR aegean:ab,ti OR anatolia:ab,ti OR 'black sea':ab,ti OR tekirdag:ab,ti OR 
balikesir:ab,ti OR izmir:ab,ti OR aydin:ab,ti OR manisa:ab,ti OR bursa:ab,ti OR kocaeli:ab,ti OR 
ankara:ab,ti OR konya:ab,ti OR antalya:ab,ti OR adana:ab,ti OR hatay:ab,ti OR kirikkale:ab,ti OR 
kayseri:ab,ti OR zonguldak:ab,ti OR kastamonu:ab,ti OR samsun:ab,ti OR trabzon:ab,ti OR 
erzurum:ab,ti OR agri:ab,ti OR malatya:ab,ti OR (van:ab,ti AND (region:ab,ti OR subregion:ab,ti OR 
bolgesi:ab,ti)) OR gaziantep:ab,ti OR sanliurfa:ab,ti OR mardin:ab,ti OR mersin:ab,ti OR turkey:ad 
OR turkiye:ad OR turkish:ad OR istanbul:ad OR marmara:ad OR aegean:ad OR anatolia:ad OR 
'black sea':ad OR tekirdag:ad OR balikesir:ad OR izmir:ad OR aydin:ad OR manisa:ad OR bursa:ad 
OR kocaeli:ad OR ankara:ad OR konya:ad OR antalya:ad OR adana:ad OR hatay:ad OR kirikkale:ad 
OR kayseri:ad OR zonguldak:ad OR kastamonu:ad OR samsun:ad OR trabzon:ad OR erzurum:ad 
OR agri:ad OR malatya:ad OR (van:ad AND (region:ad OR subregion:ad OR bolgesi:ad)) OR 
gaziantep:ad OR sanliurfa:ad OR mardin:ad OR mersin:ad 
292777 
#1.1 'europe'/exp OR 'european union'/exp OR europa:ab,ti OR europe*:ab,ti OR scandinavia*:ab,ti OR 
scandinavia*:ad OR mediterranean:ab,ti OR 'eea countries':ab,ti OR mediterranean:ad OR 
europe*:ad OR baltic:ab,ti OR baltic:ad OR yugoslavia:ab,ti OR jugoslavija:ab,ti OR jugoslavija:ad 

















5.3 Cochrane library (CDSR, DARE, HTA, EED)  
Date of search: 12/03/2015 
Language limits: no limits 
Date limits: 2005–2015 
Number of results: CDSR: 3; DARE: 7; HTA: 2; EED: 25 
ID Search           Hits 
#1 MeSH descriptor: [Prevalence] explode all trees      3943 
#2 MeSH descriptor: [Population Surveillance] explode all trees     585 
#3 MeSH descriptor: [Seroepidemiologic Studies] explode all trees    134 
#4 prevalence* or seroepidemiolog* or "sero epidemiologic" or "sero epidemiological"  15921  
or "sero epidemiology" or serosurvey* or serolog* or epidemiolog* or surveillance:ti,ab,kw  
#5 #1 or #2 or #3 or #4          19532 
#6 MeSH descriptor: [Hepatitis B] explode all trees      1939 
#7 MeSH descriptor: [Hepatitis B Antibodies] explode all trees     555 
#8 MeSH descriptor: [Hepatitis B Antigens] explode all trees     940 
#9 MeSH descriptor: [Hepatitis B virus] explode all trees      671 
#10 MeSH descriptor: [Hepatitis C] explode all trees      2287 
#11 MeSH descriptor: [Hepatitis C Antigens] explode all trees     15 
#12 MeSH descriptor: [Hepatitis C Antibodies] explode all trees     112 
#13 MeSH descriptor: [Hepacivirus] explode all trees      1001 
#14 "hepatitis b" or "hepatitis c" or hepaciviru* or "hbv" or "hcv" or "hbsag" or "hbs ag"   6994 
or "Australia Antigen" or "Australia Antigens":ti,ab,kw Publication 
#15 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14      8380 














Annex 6. Data extraction  
Table A20. Variables: data extraction 
Variable Description Values 
PMID  PubMed identifier, accession number Numerical 
Study ID The ID links each study to the source article Alphanumerical (PMID plus a, b, c…. 
for each study) 
First author Surname of first author of the article  
Year of publication Year of publication of the article Year: yyyy 
Type of publication Type of publication Original article; review; report; 
abstract; commentary; erratum 
Exclusion If required, reason for exclusion  
Disease Disease for which the study report prevalence estimates HBV; HCV; both 
Country Country for which the study report prevalence estimates Country name 
Period of sampling Year/s during which study sampling was conducted Year: yyyy 
Population coverage Coverage of the population by the sampling design in 
geographic/demographic terms 
National; regional; multicentre; single 
centre/local 
Population Target population sampled in the study General population; pregnant women; 
MSM; prisoner 
Study population details Narrative field for any further relevant information on the study 
population 
 
Sampling approach Description of sampling approach Random sampling; convenience 
sampling; respondent-driven (i.e. 
snowballing); exhaustive (screening); 
not specified; other 
Sample size Total sample size (for all estimates) Numerical 
Response rate Percentage of respondents % 
Type of sample Description of sample type Serum, saliva; dry blood spot 
Type of test Description of laboratory test used HBsAg; HBV DNA; HBV rapid test; Anti-
HCV; anti-HCV immunoblot; HCV RNA; 
HCV rapid test 
Age group Description of age group 0-17 (children); >17 (adults); all 
Mean/median age Mean or median age of study population Numerical 
Age range Minimum and maximum age of study population Numerical 
Prevalence number per estimate Number screened and number positive (HBsAg, HBV DNA, anti-
HCV, HCV RNA) 
Numerical 
Prevalence % per estimate Prevalence estimate (HBsAg, HBV DNA, anti-HCV, HCV) % 
95% CI per estimate Calculated using Fisher method for 95% CI % 
Standardized Weighted/standardied prevalence estimate available Yes/No 















Annex 7. Excluded references 




Scientific journal Study population 
Alazawi et al. 2014 Br J Gen Pract General population 
Allstaff et al. 2014 HIV Med MSM 
Almasio et al.  2011 Dig Liver Dis Prisoners 
Anderson et al. 2009 Scott Med J General population 
Aniszewska et al. 2009 Przegl Epidemiol Pregnant women 
Aniszewska et al. 2009 Przegl Epidemiol Pregnant women 
Ansaldi et al. 2005 J Med Virol General population 
Armstrong et al. 2010 Gut General population 
Armstrong et al. 2010 Hepatology General population 
Aurich et al. 2014 Transfus Med Hemother Pregnant women 
Barclay et al. 2010 Scott Med J General population 
Blystad et al. 2005 Euro Surveill General population 
Bottero et al. 2012 J Hepatol General population 
Bottero et al. 2014 PloS One General population 
Caley et al. 2012 Euro Surveill Pregnant women 
Carbonara et al. 2005 Eur Respir J Prisoners 
Cesa et al. 2006 Arch Pediatr Pregnant women 
Chlibek et al. 2006 Epidemiol Mikrobiol Imunol General population 
Christensen et al. 2012 BMC Infect Dis General population 
Cowan et al. 2006 Euro Surveill Pregnant women 
Cozzolongo et al. 2009 J Hepatol General population 
Craine et al. 2014 Eur J Public Health Prisoners 
Czarkowski et al. 2005 Przegl Epidemiol General population 
Czarkowski et al. 2008 Przegl Epidemiol General population 
Czerwinski et al. 2007 Refuat Hapeh Vehashinayim General population 
daCosta DiBonaventura et al. 2012 Eur J Gastroenterol Hepatol General population 
Dall'Aglio et al. 2012 Dig Liver Dis General population 
D'Amelio et al. 2006 Dig Liver Dis General population 
Datta et al. 2014 Br J Gen Pract General population 
De Angelis et al. 2009 Stat Methods Med Res General population 
de Jong et al. 2008 Neth J Med General population 
de Ory Manchon et al. 2009 Rev Esp Salud Publica General population 
Delarocque-Astagneau et al. 2010 J Viral Hepat General population 
Dhairyawan et al. 2011 HIV Med General population 
Dibonaventura et al. 2014 PloS One General population 
Dibonaventura et al. 2011 J Med Econ General population 
Dibonaventura et al. 2012 Value Health General population 
Dopico et al. 2013 Trop Med Int Health. Pregnant women 
Duberg et al. 2008 J Viral Hepat General population 
Duffell et al. 2014 J Viral Hepat General population 
Duncan et al. 2013 Int J STD AIDS Prisoners 
Elefsiniotis et al. 2005 J Clin Virol General population 
Elefsiniotis et al. 2007 Eur J Obstet Gynecol Reprod Bio General population 
Elefsiniotis et al. 2010 Int J Gynaecol Obstet Pregnant women 
Elefsiniotis et al. 2010 Hepatol Int Pregnant women 
Elefsiniotis et al. 2009 Euro Surveill Pregnant women 
Faustini et al. 2010 BMC Infect Dis General population 
Fiore et al. 2006 Eur J Inflamm General population 
FitzSimons et al. 2013 Int J Circumpolar Health General population 
Fitzsimons et al. 2011 Vaccine General population 
Flisiak et al. 2015 Eur J Gastroenterol Hepatol General population 
Folch et al. 2014 Med Clin (Barc). MSM 
Folch et al.  2015 Med Clin (Barc). MSM 
Ganczak 2011 Clin Microbiol Infect General population 
Geckova et al. 2014 Cent Eur J Public Health General population 
Giacomoni et al. 2010 J Hepatol General population 
Giraudon et al. 2009 Euro Surveill Pregnant women 
















Scientific journal Study population 
Godzik et al. 2012 Przegl Epidemiol General population 
Goldberg et al. 2008 Euro Surveill General population 
Grgic-Vitek et al. 2006 Croat Med J General population 
Guadagnino et al. 2012 J Hepatol General population 
Hansen et al. 2013 Euro Surveill General population 
Harris et al. 2012 Eur J Public Health General population 
Hope et al. 2007 J Viral Hepat Prisoners 
Hutchinson et al. 2006 Scott Med J General population 
Iliescu 2013 J Gastroenterol Hepatol General population 
Janicko et al. 2014 Cent Eur J Public Health General population 
Julkunen et al. 2009 Clin Microbiol Infect Pregnant women 
Kaic et al. 2013 Acta Med Croatica General population 
Kirwan et al. 2011 J Public Health (Oxf) Prisoners 
Knorr et al. 2008 J Clin Virol Pregnant women 
Kolaric et al. 2010 Cent Eur J Public Health Prisoners 
Lambert et al. 2010 HIV Med Pregnant women 
Lavanchy 2012 Hepat Mon General population 
Lesnikar 2005 Acta Med Croatica General population 
Magdzik et al. 2006 Przegl Epidemiol General population 
Mariolis et al. 2006 Public Health General population 
Marques et al. 2009 Clin Microbiol Infect Prisoners 
Martin et al. 2013 BMJ Open Prisoners 
Matthews et al. 2012 Gut Pregnant women 
Mazuelas et al. 2010 J Matern Fetal Neonatal Med Pregnant women 
McDonald et al. 2010 Euro Surveill General population 
Meara et al. 2007 Ir Med J General population 
Mena et al. 2014 PloS One General population 
Mena et al. 2013 Hepatology General population 
Merkinaite et al. 2008 Cent Eur J Public Health General population 
Michel et al. 2008 Harm Reduct J Prisoners 
Monnet et al. 2006 J Hepatol General population 
Montella et al. (erratum) 2005 Infection General population 
Montenegro et al. 2013 Am J Gastroenterol General population 
Mossner et al. 2010 J Med Virol General population 
Mossong et al. 2006 Epidemiol Infect General population 
Mukhopadhya 2014 Gut General population 
Mulic et al. 2006 Lijec Vjesn General population 
Niederau et al. 2006 Med Klin (Munich) General population 
Oakes 2014 Nurs Times General population 
O'Grady et al. 2011 The Lancet Prisoners 
Op de Coul et al. 2010 Ned Tijdschr Geneeskd Pregnant women 
Ortigosa Gomez et al. 2011 Medicina Clinica Pregnant women 
Paat et al. 2009 Cent Eur J Public Health General population 
Paat et al. 2009 Cent Eur J Public Health Prisoners 
Papatheodoridis et al. 2015 J Viral Hepat General population 
Parda et al. 2014 Przegl Epidemiol General population 
Pawlowska et al. 2011 Hepatol Int General population 
Payne-James et al. 2005 J Clin Forensic Med Prisoners 
Picardi et al. 2007 J Clin Virol General population 
Pitigoi et al. 2008 Euro Surveill General population 
Popov et al. 2011 Clin Microbiol Infect Prisoners 
Popovic 2014 MS ppt presentation General population 
Portman et al. 2014 HIV Med MSM 
Rautanen 2010 Schizophr Res Prisoners 
Remy 2007 Gastroenterologie Clinique et Biologique Prisoners 
Rimseliene et al. 2011 BMC Infect Dis General population 
Rosinska et al. 2013 Przegl Epidemiol General population 
Roudot-Thoraval et al. 2015 Hepatology General population 
Roux et al. 2014 BMJ Open General population 
Ruf et al. 2008 Euro Surveill MSM 
Ruffini et al. 2014 Infez Med Pregnant women 
Saiz de la Hoya et al. 2005 Enferm Infecc Microbiol Clin Prisoners 
















Scientific journal Study population 
Sarmati et al. 2007 J Med Virol Prisoners 
Sauvage et al. 2015 Bull Epidemiol Hebd (Paris Prisoners 
Schlosser et al. 2009 J Hepatol General population 
Schnier et al. 2014 Epidemiol Infect General population 
Schulte et al. 2009 Int J Prison Health Prisoners 
Semaille et al. 2013 Euro Surveill Prisoners 
Shalabi et al.  2013 Gut Prisoners 
Shalabi et al.  2013 Hepatol Int Prisoners 
Shanmugaratnam et al. 2012 Int J STD AIDS General population 
Sillanpaa et al. 2013 J Viral Hepat General population 
Soriano et al. 2005 Enferm Infecc Microbiol Clin Prisoners 
Stanekova et al. 2006 Cent Eur J Public Health Pregnant women 
Sutton et al. 2008 J Viral Hepat Prisoners 
Sweeting et al. 2008 Biostatistics General population 
Swiderek et al. 2008 Clin Exp Med Lett General population 
Taylor et al. 2013 Addiction Prisoners 
Thornton et al. 2012 Epidemiol Infect General population 
Tolmane et al. 2009 Hepatol Int General population 
Tsovili et al. 2014 Infez Med General population 
Urbanus et al. 2011 PloS One General population 
Urbanus et al. 2011 J Hepatol General population 
Urbanus et al. 2013 PloS One Pregnant women 
Urbanus et al. 2011 Hepatology MSM 
van Vlierberghe 2008 Neth J Med General population 
Voiculescu et al. 2010 J Gastrointestin Liver Dis General population 
Vriend et al. 2012 Eur J Public Health General population 
Wainwright et al. 2013 Sex Transm Infect MSM 
Wiegand et al. 2014 J Hepatol General population 
Wiessing et al. 2008 Euro Surveill General population 
Williams et al. 2012 Sex Transm Infect Prisoners 
Yates et al. 2012 Thorax Prisoners 
Zani et al. 2009 Hepatology General population 
Zani et al. 2011 Dig Liver Dis General population 
Zavitsanou et al. 2007 J Med Virol General population 
Zielinski et al. 2009 Przegl Epidemiol General population 
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